SUSMP Feb 21 F2021C00098

Poisons Standard February 2021
made under subsection 52D(2) of the
Therapeutic Goods Act 1989
Compilation No. 1
Compilation date: 1 February 2021
Includes amendments up to: F2021L00070
Prepared by the Department of Health, Canberra
Authorised Version F2021C00098 registered 01/02/2021

About this compilation
This compilation
This is a compilation of the Poisons Standard February 2021 that shows the text of the law as
amended and in force on 1 February 2021 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending
laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any
uncommenced amendments affecting the law are accessible on the Legislation Register
(www.legislation.gov.au). The details of amendments made up to, but not commenced at, the
compilation date are underlined in the endnotes. For more information on any uncommenced
amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application,

saving or transitional provision that is not included in this compilation, details are included in
the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the
modification does not amend the text of the law. Accordingly, this compilation does not show
the text of the compiled law as modified. For more information on any modifications, see the
series page on the Legislation Register for the compiled law.
Self-repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law,
details are included in the endnotes.

1 Name
This instrument is the Poisons Standard February 2021.
3 Authority
This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act
1989.
4 Current Poisons Standard

Schedule 1 to this instrument contains the Standard for the Uniform Scheduling of
Medicines and Poisons No. 32, otherwise known as the current Poisons Standard.
Poisons Standard February 2021 i
Compilation No. 1 Compilation date: 1/2/21

Schedule 1—Standard for the Uniform Scheduling of
Medicines and Poisons No. 32
Poisons Standard February 2021 ii

STANDARD FOR THE UNIFORM
SCHEDULING OF MEDICINES AND POISONS
No. 32
February 2021
Poisons Standard February 2021 iii

Reasons for scheduling delegates’ final decisions can be accessed from the TGA website, at
https://www.tga.gov.au/reasons-scheduling-delegates-final-decisions
Further inquiries in relation to this document should be directed to:
The Secretary
Chemicals and Medicines SchedulingSecretariat (MD122)
Scheduling and Committee Governance
Therapeutic Goods Administration
PO Box 100
WODEN ACT 2606
or by email to
[email protected]
[email protected]
Media Liaison Unit

Australian Government Department of Health
Poisons Standard February 2021 iv

Table of Contents
Table of Contents v
INTRODUCTION viii
PART 1 1
INTERPRETATION ______________________________________________1
PART 2 11
CONTROL ON MEDICINES AND POISONS _______________________ 11
SECTION ONE LABELS __________________________________________ 11
SECTION TWO CONTAINERS _____________________________________ 23
SECTION THREE STORAGE ______________________________________ 29
SECTION FOUR DISPOSAL _________________________________________ 30
SECTION FIVE RECORD KEEPING ________________________________ 30
SECTION SIX SALE, SUPPLY, POSSESSION, or USE __________________ 31
SECTION SEVEN/Appendix I PAINT OR TINTERS ____________________ 32
PART 3 34
MISCELLANEOUS REGULATIONS ______________________________ 34
SECTION ONE ADVERTISING ____________________________________ 34
SECTION TWO SALE OR SUPPLY _________________________________ 34
SECTION THREE STORAGE ______________________________________ 35
PART 4 36
THE SCHEDULES ______________________________________________36
SCHEDULE 1 _____________________________________________________ 36
SCHEDULE 2 _____________________________________________________ 36
SCHEDULE 3 _____________________________________________________ 55
SCHEDULE 4 _____________________________________________________ 64
SCHEDULE 5 ____________________________________________________ 165
Poisons Standard February 2021 v

SCHEDULE 6 ____________________________________________________ 201
SCHEDULE 7 ____________________________________________________ 259
SCHEDULE 8 ____________________________________________________ 273
SCHEDULE 9 ____________________________________________________ 278
SCHEDULE 10 ___________________________________________________ 286
PART 5 292
THE APPENDICES _____________________________________________292
APPENDIX A – GENERAL EXEMPTIONS ____________________________ 292
APPENDIX B – SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL

BY SCHEDULING ________________________________________________ 295
APPENDIX C (see SCHEDULE 10) __________________________________ 316
APPENDIX D – ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF

POISONS INCLUDED IN SCHEDULE 4 OR 8 _________________________ 317
APPENDIX E – FIRST AID INSTRUCTIONS FOR POISONS _____________ 324
APPENDIX F – WARNING STATEMENTS AND GENERAL SAFETY

DIRECTIONS FOR POISONS _______________________________________ 352
APPENDIX G – DILUTE PREPARATIONS____________________________ 393
APPENDIX H – SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED396
APPENDIX I _____________________________________________________ 399
APPENDIX J – SCHEDULE 7 POISONS REQUIRING ADDITIONAL

CONTROLS ON AVAILABILITY AND USE __________________________ 400
APPENDIX K – DRUGS REQUIRED TO BE LABELLED WITH A SEDATION

WARNING ______________________________________________________ 406
APPENDIX L – REQUIREMENTS FOR DISPENSING LABELS FOR HUMAN

AND VETERINARY MEDICINES ___________________________________ 416
APPENDIX M – ADDITIONAL CONTROLS OR SUPPLY REQUIREMENTS

FOR POISONS INCLUDED IN SCHEDULE 3 TO ALLOW THEM TO BE
PROVIDED BY A PHARMACIST ___________________________________ 420
INDEX 421
Endnotes ______________________________________________________ 769
Poisons Standard February 2021 vi

Endnote 1—About the endnotes _____________________________________ 769
Endnote 2—Abbreviation key ______________________________________ 770
Endnote 3—Legislation history _____________________________________ 771
Endnote 4—Amendment history ____________________________________ 772
Poisons Standard February 2021 vii

INTRODUCTION
The Poisons Standard February 2021, which, under section 4 above contains the Standard for
the Uniform Scheduling of Medicines and Poisons No. 32 (“the Standard” or “the SUSMP”), is
made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989, and is a compilation of
decisions made under section 52D of the same Act. The SUSMP should be read in conjunction
with the Scheduling Policy Framework (“SPF”) of the Australian Health Ministers' Advisory
Council. Further information on the scheduling amendments and the SPF can be accessed at
www.tga.gov.au. Refer to Part 1, Interpretation, on page 2 below for definitions of specific
terms used in this document including “medicine” and “poison” (noting that the definition of
poison includes medicine).
The SUSMP serves two key purposes.
Firstly, the SUSMP contains the decisions of the Secretary of the Department of Health or the
Secretary's delegates regarding the classification of poisons into Schedules, as recommendations
to Australian States and Territories. The scheduling classification sets the level of control on the
availability of poisons. The scheduling of poisons is implemented through relevant State and
Territory legislation. Certain advertising, labelling and packaging requirements may also be a
consequence of scheduling, but are the subject of other Commonwealth registration schemes.
Secondly, the SUSMP includes provisions for labelling, containers, storage, disposal, record-
keeping, sale, supply and possession of poisons in general which are intended to be adopted for
use in each jurisdiction of Australia. Other government agencies may also impose controls on
certain products.
The requirements for labelling and containers in the SUSMP are intended to integrate with
existing legislative instruments for labelling and containers. Advertising, labelling and
packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with
through the respective product registration schemes provided for in Commonwealth legislation.
Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary
use are exempt from all labelling requirements included in the SUSMP as they are covered by
labelling requirements under applicable jurisdictional Work Health and Safety laws, as amended
from time to time. Note, however that this exemption does not extend to controls on supply of
these poisons.
The SUSMP is presented with a view to promoting uniform:
 scheduling of poisons throughout Australia;
 signal headings on labels for poisons throughout Australia;
 labelling and packaging requirements for poisons throughout Australia;
 additional controls on the availability and use of poisons in Australia.
The various Commonwealth Acts, legislative instruments and other documents, which integrate
with the SUSMP include:
Poisons Standard February 2021 viii

 the Agricultural and Veterinary Chemicals Code Act 1994;
 the Agricultural and Veterinary Chemicals Code Regulations 1995;
 the Therapeutic Goods Act 1989;
 the Therapeutic Goods Order No. 91 – Standard for labels of prescription and related
medicines (Compilation No. 2);
 the Therapeutic Goods Order No. 92 – Standard for labels of non-prescription medicines
(Compilation No. 1);
 the Therapeutic Goods Order No. 95 – Child-resistant packaging requirements for

medicines 2017 (TGO 95);
 the Therapeutic Goods (Medicines Advisory Statements) Specification 2019 – Schedule 1

Required Advisory Statements for Medicine Labels (RASML).
CLASSIFICATION
Poisons are classified according to the Schedules in which they are included. The following is a
general description of the Schedules. For the legal definitions, however, it is necessary to check
with each relevant State or Territory authority.
Schedule 1 This Schedule is intentionally blank.
Schedule 2 Pharmacy Medicine – Substances, the safe use of which may require advice
from a pharmacist and which should be available from a pharmacy or, where a
pharmacy service is not available, from a licensed person.
Schedule 3 Pharmacist Only Medicine – Substances, the safe use of which requires
professional advice but which should be available to the public from a
pharmacist without a prescription.
Schedule 4 Prescription Only Medicine, or Prescription Animal Remedy – Substances,

the use or supply of which should be by or on the order of persons permitted by
State or Territory legislation to prescribe and should be available from a
pharmacist on prescription.
Schedule 5 Caution – Substances with a low potential for causing harm, the extent of which
can be reduced through the use of appropriate packaging with simple warnings
and safety directions on the label.
Schedule 6 Poison – Substances with a moderate potential for causing harm, the extent of
which can be reduced through the use of distinctive packaging with strong
Poisons Standard February 2021 ix

warnings and safety directions on the label.
Schedule 7 Dangerous Poison – Substances with a high potential for causing harm at low
exposure and which require special precautions during manufacture, handling or
use. These poisons should be available only to specialised or authorised users
who have the skills necessary to handle them safely. Special regulations
restricting their availability, possession, storage or use may apply.
Schedule 8 Controlled Drug – Substances which should be available for use but require
restriction of manufacture, supply, distribution, possession and use to reduce
abuse, misuse and physical or psychological dependence.
Schedule 9 Prohibited Substance – Substances which may be abused or misused, the

manufacture, possession, sale or use of which should be prohibited by law
except when required for medical or scientific research, or for analytical,
teaching or training purposes with approval of Commonwealth and/or State or
Territory Health Authorities.
Schedule 10 Substances of such danger to health as to warrant prohibition of sale,

(previously supply and use - Substances which are prohibited for the purpose or purposes
Appendix C) listed for each poison.
PRINCIPLES OF SCHEDULING
Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one
of the factors considered, and is itself a complex of factors, the decision to include a substance
in a particular Schedule also takes into account many other criteria such as the purpose of use,
potential for abuse, safety in use and the need for the substance.
This Standard lists poisons in ten Schedules according to the degree of control recommended to
be exercised over their availability to the public.
Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with
progression through these Schedules signifying increasingly restrictive regulatory controls.
For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7
represent increasingly stricter container and labelling requirements with special regulatory
controls over the availability of the poisons listed in Schedule 7. Products for domestic use must
not include poisons listed in Schedule 7.
Schedule 9 contains substances that should be available only for teaching, training, medical or
scientific research including clinical trials conducted with the approval of Commonwealth
and/or State and Territory health authorities. Although appearing as a Schedule in this Standard,
the method by which it is implemented in the States and Territories may vary.
Poisons Standard February 2021 x

Schedule 10 (previously Appendix C) contains a list of substances or preparations, the sale,
supply or use of which should be prohibited because of their known dangerous properties.
Substances in products which have been considered for scheduling, but have been exempted
from this Standard, may be listed in either Appendix A (general exemptions) or Appendix B
(substances considered not to require control by scheduling).
READING THE SCHEDULES
Schedule entries have been designed to be as simple as possible while retaining readability,
legal integrity and as much freedom from ambiguity and contradiction as possible. As a result,
they are expressed in a number of ways, though this number has been kept to a minimum. It is
necessary to keep this variety of expression in mind when searching or interpreting Schedule
entries.
Firstly, poisons are scheduled individually using their approved names wherever practicable
although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older
group entries are revised and replaced by individual entries as time permits, although in some of
these cases a group term has also been retained to deal with any members of the group or class
that may have escaped attention but should be scheduled.
Secondly, Schedule entries have been expressed in either positive or negative terms and care
must be taken to distinguish between the two different forms of expression. Thus, selenium is in
Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in
Schedule 6 unless one of the exempting clauses applies.
Where exceptions are included in an entry, these have been emphasised by printing the word
“except” in bold type.
Where the Schedule entries for a poison make a specific exclusion or exemption, the
requirements of this Standard do not apply to that poison within the constraints of that exclusion
or exemption although controls under other legislation, such as pesticide registration, may
apply.
Where a Schedule entry for a poison requires a specific statement to be included on a label as a
condition for a product to qualify for an exemption (“reverse scheduling”), then in cases where
it is impracticable for a supplier to use the exact wording of such a statement, its wording may
be varied provided that the full intent and meaning of the statement is not changed.
Where a poison has been included in more than one Schedule, the principal entry, where
practicable, has been included in the most restrictive Schedule with references to the other
Schedule(s) involved.
It is important to remember that a Schedule entry includes preparations containing the poison in
any concentration and all salts and derivatives of the poison unless it specifically states
otherwise (see Part 1, Interpretation, subparagraph 1(2)).
It is important to note that a substance is not classed as a derivative on the basis of a single,
prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison
relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g.
structurally, pharmacologically, and toxicologically) to a scheduled poison or is readily
Poisons Standard February 2021 xi

converted (either physically or chemically) to a scheduled poison. However, a substance is only
considered a derivative of a scheduled poison if it is not individually listed elsewhere in the
Schedules, or captured by a more restrictive group or class entry. Additionally, some entries
specifically exclude derivatives. Once a substance is determined to be a derivative of a
scheduled poison, the same scheduling requirements as the scheduled poison, including limits
on access, supply and availability, will apply.
Finally, when using this Standard to determine the scheduling status of a poison, it may be
necessary to search each relevant Schedule as well as Appendices A, B and the Index. In this
process, if the poison is not found under its “approved name” it may be shown under a group
term such as:
Group Example
the parent acid of salts “oxalic acid” to find sodium oxalate
the radical of a salt “chromates” to find potassium chromate
the element “arsenic” to find arsenic trioxide
a chemical group with similar toxicological or “hydrocarbons, liquid” to find kerosene

pharmacological activity
a pharmacological group “anabolic steroidal agents” to find “androsterone”
AVAILABILITY OF POISONS
The purpose of classification is to group substances into Schedules that require similar
regulatory controls over their availability.
These Schedules have been developed over a long period and contain poisons that may be
obsolete for various reasons. Also, as part of the move to harmonise the Australian and New
Zealand classifications, many substances have been added to the Schedules for that purpose,
irrespective of their availability in either country.
Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It

does not indicate:
 that the poison is available; nor
 that is has been approved or is efficacious for any use that may be specified in a Schedule;
nor
Poisons Standard February 2021 xii

 does it negate any obligation for registration of a therapeutic good, or agricultural or
veterinary chemical product containing that poison.
PREPARATIONS CONTAINING POISONS LISTED IN TWO OR MORE

SCHEDULES
If a preparation contains two or more poisons, the provisions relating to each of the Schedules in
which those poisons are included apply.
Where it is not possible to comply both with a provision relating to one of those Schedules and
with a provision relating to another of those Schedules, the provision of the more restrictive
Schedule applies, unless a contrary intention is indicated in the Schedules or relevant
legislation.
The Schedules listed in order of greatest to least restriction on access and availability are 9, 10,
8, 4, 7, 3, 2, 6, 5.
Schedule 1 is not currently in use.
Some substances in certain circumstances are also subject to exemptions or additional

restrictions as described in the Appendices of this Standard. The table below summarises the
purpose of each of the Appendices and the controls imposed on substances included in them.
Appendix Title Purpose/ controls imposed
Appendix A General exemptions List of classes of products or uses exempted from this
Standard.
Appendix B Substances considered List of poisons exempted from scheduling.

not to require control by
scheduling
Appendix C Appendix is See Schedule 10.

intentionally left blank
Appendix D Additional controls on List of poisons included in Schedule 4 or 8 where

possession or supply of additional specified controls apply on possession or
poisons included in supply.
Schedule 4 or 8
Appendix E First aid instructions for First aid instructions for poisons (other than agricultural
poisons and veterinary chemicals and chemicals packed and sold
solely for industrial, dispensary, manufacturing or
laboratory use).
Poisons Standard February 2021 xiii

Appendix F Warning statements and Warning statements and general safety directions for
general safety directions poisons (other than human medicines, agricultural and
for poisons veterinary chemicals and chemicals packed and sold
solely for industrial, dispensary, manufacturing or
laboratory use).
Appendix G Dilute preparations Concentration cut-offs for specified poisons, below

which the requirements of the Standard do not apply
Appendix H Schedule 3 medicines List of medicines included in Schedule 3 that are

permitted to be permitted to be advertised to the public.
advertised
Appendix I Appendix is
intentionally left blank
Appendix J Conditions for List of poisons included in Schedule 7 where additional

availability and use of specified conditions apply to their availability and use.
Schedule 7 poisons
Appendix K Human medicines List of human medicines required to be labelled with a

required to be labelled warning regarding their sedation potential.
with a sedation warning
Appendix L Requirements for Requirements applying to labels attached to medicines at

dispensing labels for the time of dispensing.
medicines
Appendix M Additional controls or The substance and proposed intervention/additional

supply requirements for requirement(s).
Poisons included in
Schedule 3 to allow
them to be provided by a
pharmacist
Poisons Standard February 2021 xiv

PART 1 - INTERPRETATION
PART 1
INTERPRETATION
1. (1) In this Standard, unless the contrary intention appears —
“Agricultural chemical” means a substance that is represented, imported, manufactured,

supplied or used as a means of directly or indirectly:
a) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation

by or attacks of, any pest in relation to a plant, a place or a thing;
b) destroying a plant;
c) modifying the physiology of a plant or pest so as to alter its natural development,
productivity, quality or reproductive capacity;
d) modifying an effect of another agricultural chemical;
e) attracting a pest for the purpose of destroying it; or
f) any active ingredient included in a product declared by regulation under the
Agricultural and Veterinary Chemicals Code Act 1994 to be an agricultural chemical
product;
but does not include:
g) a veterinary chemical.
“Agricultural chemical product” has the meaning defined in the Agricultural and Veterinary
Chemicals Code Act 1994.
“Animal” means any animal (other than a human being), whether vertebrate or not, and whether
a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians,
fish, crustaceans and molluscs.
“Animal feed premix” means a concentrated preparation, containing one or more poisons, for
mixing with food ingredients to produce a bulk feed for a group of animals (including fish
or birds), but does not include a preparation for mixing with an individual animal’s food.
“Appropriate authority” means:
a) in the Australian Capital Territory, ACT Government Health Directorate;

b) for the purpose of providing an exemption from all or part of Section 1.1 to Section
1.5.3 in Part 2 of this Standard by the Australian Pesticides and Veterinary Medicines
Authority, the Chief Executive Officer or their delegate;
c) in New South Wales, the Director-General of the NSW Ministry of Health;
d) in the Northern Territory, the Chief Health Officer of the Department of Health;
e) in Queensland, the Chief Executive of Queensland Health;
Poisons Standard February 2021 1

f) in South Australia, the Chief Executive of the Department for Health and Ageing;
g) in Tasmania, the Secretary of the Department of Health and Human Services;
h) for the purpose of providing an exemption from all or part of Section 1.1 to Section
1.5.3 of this Standard, the Deputy Secretary of the Australian Government
Department of Health with responsibility for the Therapeutic Goods Administration,
or their delegate;
i) in Victoria, the Secretary to the Department of Health;
j) in Western Australia, the Chief Executive Officer of the Department of Health.
“Approved name” means:
a) in relation to a poison that is for human therapeutic use, the name approved for use by
the Therapeutic Goods Administration;
b) in relation to a poison that is for animal or agricultural use, the name approved for use
by the Australian Pesticides and Veterinary Medicines Authority;
c) in relation to all other poisons:
i) the name used in an entry in these Schedules; or, if no such name is given,
ii) the English name recommended by Standards Australia as the common name for
the poison; or, if no such name is given,
iii) the English name given to the poison by the International Organization for
Standardization; or, if no such name is given,
iv) the English name given to the poison by the British Standards Institution; or, if no
such name is given,
v) the name that would comply with the requirements of part (a) or (b) of this
definition, or, if no such name is given,
vi) the English name given to the poison by the European Committee for
Standardization (CEN); or, if no such name is given,
vii) the international non-proprietary name recommended for the poison by the World
Health Organization; or, if no such name is given,
viii) the International Nomenclature Cosmetic Ingredient name for the poison listed
in the International Cosmetic Ingredient Dictionary & Handbook published by
the Personal Care Products Council of America; or, if no such name is given,
ix) the accepted scientific name or the name descriptive of the true nature and origin
of the poison.
“Australian Code for the Transport of Dangerous Goods by Road and Rail” means the
seventh edition of the document of that name.
“Authorised prescriber” means a registered medical, dental or veterinary practitioner or such

other person authorised by the appropriate authority.
“Blood” means whole blood extracted from human donors.

“Blood components” means therapeutic components that have been manufactured from blood
(including red cells, white cells, stem cells, platelets and plasma), except for products
derived through fractionation of plasma.
“Child-resistant closure” means:
a) a closure that complies with the requirements for a child-resistant closure in the
Australian Standard AS 1928-2007 entitled Child-resistant packaging –
Requirements and testing procedures for reclosable packages (ISO 8317:2015,
MOD);
b) a closure approved by an order made under subsection 10(3) of the Commonwealth
Therapeutic Goods Act 1989; or
c) in the case of a can fitted with a press-on lid, a lid of the design known as “double
tight” or “triple tight”.
See also "Non-access packaging”.
“Child-resistant packaging” means packaging that:
a) complies with the requirements of the Australian Standard AS 1928-2007 entitled

Child resistant packaging – Requirements and testing procedures for reclosable
packages (ISO 8317:2015, MOD);
b) is reclosable and complies with the requirements of at least one of the following
Standards:
i) the International Organization for Standardization Standard ISO
8317:2015entitled Child-resistant packaging – Requirements and testing
procedures for reclosable packages;
ii) the British Standards Institution Standard BS EN ISO 8317:2004 entitled Child-
resistant packaging. Requirements and testing procedures for reclosable
packages;
iii) the Canadian Standards Association Standard CSA Z76.1-06 entitled Reclosable
Child-Resistant Packages;
iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, entitled
Poison prevention packaging standards and Section 1700.20, entitled Testing
procedure for special packaging;
c) is approved as child-resistant by any order made under subsection 10(3) of the
Commonwealth Therapeutic Goods Act 1989; or
d) is in the form of blister or strip packaging in which a unit of use is individually
protected until the time of release and that complies with Section 3 (Requirements for
non-reclosable packages) of Australian Standard AS 1928-2001 entitled Child-
resistant packages.
See also "Non-access packaging".

“Compounded” in relation to a substance means combined with one or more other

therapeutically active substances in such a way that it cannot be separated from them by
simple dissolution or other simple physical means.
“Cosmetic” means:
a) a substance or preparation intended for placement in contact with any external part of
the human body, including:
i) the mucous membranes of the oral cavity; and
ii) the teeth;
with a view to:
iii) altering the odours of the body; or

iv) changing its appearance; or
v) cleansing it; or
vi) maintaining it in good condition; or
vii) perfuming it; or
viii) protecting it.
“Debitterised neem seed oil” means highly purified oil from the neem seed containing only
fatty acids and glycerides of fatty acids.
“Dermal use” means application to the skin primarily for localised effect.
“Designated solvent” means the following:
acetone
dimethylformamide
N-(N-dodecyl)-2-pyrrolidone
hydrocarbons, liquid
methanol when included in Schedule 5
methyl ethyl ketone
methyl isoamyl ketone
methyl isobutyl ketone
N-methyl-2-pyrrolidone
N-(N-octyl)-2- pyrrolidone

phenyl methyl ketone
styrene
tetrachloroethylene
1,1,1-trichloroethane
"Dispensing label” means the label attached to the immediate container of a substance for
therapeutic use at the time of dispensing.
“Distributor” means a person who imports, sells or otherwise supplies a poison.
“Divided preparation” means a preparation manufactured and packed as discrete pre-measured

dosage units prior to sale or supply, and includes tablets, capsules, cachets, single dose
powders or single dose sachets of powders or granules.
“Dosage unit” means an individual dose of a poison for therapeutic use and includes a tablet,
capsule, cachet, single dose powder or single dose sachet of powders or granules.
“Drug” means a poison intended for human or animal therapeutic use.
“Essential oils” means products obtained from natural raw materials either by distillation with
water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry
distillation. For scheduling purposes it also means:
a) oils of equivalent composition derived through synthetic means; or

b) prepared mixtures of oils of equivalent composition comprising a mixture of
synthetic and natural components.
“External” in relation to the use of a poison means application in the ears, eyes or nose or to a
body surface other than in the mouth, rectum, vagina, urethra or other body orifice.
“First Group Paint” means a paint containing the specified proportion of any substance in the
First Group to Part 2 Section 7 of this Standard.
“Free formaldehyde” includes all hydrated and non-hydrated formaldehyde present in aqueous
solution, including methylene glycol and formaldehyde released from formaldehyde
donors.
“Graphic material” means the material which is to be deposited on another material by a

graphic instrument during writing, drawing or marking and includes cores of pencils,
school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and
watercolour blocks.
“Hawking” means to sell or supply (including peddle or distribute or cause to be distributed) in

a public place.
“Height” in relation to letters used for words, expressions or statements on labels means the
height of capital letters or lower case letters having an ascender or a descender.

“Hemp seed oil” means the oil obtained by cold expression from the ripened fruits (seeds) of
Cannabis sativa.
“Immediate container” includes all forms of containers in which a poison is directly packed
but does not include any such container intended for consumption or any immediate
wrapper.
“Immediate wrapper” means metal foil, plastic foil, waxed paper, or any other such material
not intended for consumption, when used as the first wrapper for a dosage unit or dressing.
“Internal use” means administration:
a) orally, except for topical effect in the mouth; or

b) for absorption and the production of a systemic effect;
i) by way of a body orifice other than the mouth; or
ii) parenterally, other than by application to unbroken skin.
“Label” means:
a) a written statement on a container of a poison; and

b) in relation to a therapeutic good, includes a display of printed information about the
product:
i) on, or attached to, the good;
ii) on, or attached to, a container or primary pack in which the good is supplied; or
iii) supplied with such a container or pack.
“Main label” means, where there are two or more labels on a container or a label is divided into
two or more portions:
a) the part of a label that is most likely to be displayed, presented, shown, or examined
under ordinary or customary conditions of display; and
b) where there are two or more labels or two or more portions of a single label – that
label or portion of the label where the product name is more or most conspicuously
shown; or
c) where the product name is equally conspicuous on two or more labels or portions of a
label – each such label or portion.
“Manufacturer” means a person who manufactures, produces, or packs a poison.
“Marker dyes or pigments” means any product that is added to a liquid used in agricultural or
veterinary chemicals to identify or distinguish treated from untreated objects, land or
organisms by temporarily imparting colour on the relevant object, land or organism
through, for example, spot – or boom-spraying.

“Measure pack” means a sealed container which contains a measured quantity of poison for
use on one occasion as a pesticide or domestic product and one or more of which is
enclosed in a primary pack.
“Medicine” means any poison for therapeutic use.

Note: To be preceded by “human” or “veterinary” where restriction of the “medicine” to
human or animal use is intended.
“Name and address” means the name and address, in Australia, of the manufacturer or
distributor of a poison but does not include a post office, cable, telegraphic or code address.
Where such manufacturer or distributor is a company incorporated in accordance with the
appropriate law of any State or Territory of the Commonwealth of Australia or a firm
registered under the Business Names Act of any State or Territory, the inclusion in the label
of the registered name of the corporation or firm or its branch or its division and the city or
town in which a registered office is situated shall be deemed to comply with the
requirements.
“Non-access packaging” is packaging that complies with the requirements of Australian

Standard AS4710-2001 entitled Packages for chemicals not intended for access or contact
with their contents by humans, in relation to products that are not intended for human
therapeutic use.
See also "Child-resistant closure" and "Child-resistant packaging”.
“Non-volatile content” in relation to a paint or tinter means that portion of a paint or tinter
determined to be the non-volatile content by Method 301.1 of Australian Standard AS
1580-301.1-2005 entitled Paints and related materials – Methods of test – Non-volatile
content by mass.
“Oromucosal use” means administration to the oral mucosa, specifically the oral cavity and/or
the pharynx.
“Paint”, without limiting the ordinary meaning, includes any substance used or intended to be
used for application as a colouring or protective coating to any surface but does not include
graphic material or paints for therapeutic use.
“Pesticide” means any substance or mixture of substances used or intended to be used:
a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects,

rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life
or viruses, which are pests; or
b) as a plant regulator, promoter, defoliant or desiccant for food storage, household,
industrial, commercial, agricultural and non-agricultural application, but does not
include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for
human use, food additives or fertilisers.
“Poison” means any substance or preparation included in a Schedule to this Standard.
“Primary pack” means the pack in which a poison and its immediate container or immediate
wrapper or measure pack are presented for sale or supply.

“Product sample” means a packed poison supplied directly to the consumer free of charge or a
nominal charge as a mechanism to promote the sale of the product and may be small packs
produced specifically for the purposes of promotion or normal commercial packs which in
other circumstances a consumer would need to purchase.
“Public Place” means any place where members of the public are lawfully entitled, invited or
permitted to be present in their capacity as members of the public. For example a street,
road, footway, court, alley or through-fare that the public are allowed to use, in any
residential premises, door to door, place to place or house to house.
“Required Advisory Statements for Medicine Labels” means the document made under
subsection 3(5A) of the Therapeutic Goods Act 1989 by the Therapeutic Goods
Administration.
“Restricted flow insert” means a restriction fitted, or moulded, in the neck of a container
which:
a) cannot readily be removed from the container by manual force; and

b) limits the delivery of the contents to drops each of which is not more than 200
microlitres.
“Second Group Paint” means a paint containing the specified proportion of any substance in
the Second Group to Part 2 Section 7 of this Standard.
“Selected container” means:
a) an injection vial having a nominal capacity of ten millilitres or less;

b) a single use syringe; or
c) any other container for substances for therapeutic use having a nominal capacity of
ten millilitres or less.
“Solid” is considered to include “powder” for the purposes of scheduling.
“Therapeutic good” has the meaning defined in the Commonwealth Therapeutic Goods Act
1989.
“Therapeutic use” means use in or in connection with:
a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in

human beings or animals;
b) influencing, inhibiting or modifying a physiological process in human beings or
animals;
c) testing the susceptibility of human beings or animals to a disease or ailment;
d) influencing, controlling or preventing conception in human beings or animals;
e) testing for pregnancy in human beings or animals; or
f) the replacement or modification of parts of the anatomy in human beings or animals.

“Tinter” means any pigment or admixture of pigment with other substances, in powder, semi-
solid or liquid form, sold or supplied for the purpose of adding to paint in order to change
the colour of the paint.
“Topical use” means application of a poison for the purpose of producing a localised effect on
the surface of the organ or within the tissue to which it is applied.
“Toy” means an object or number of objects manufactured, designed, labelled or marketed as a

plaything for a child or children up to the age of 14 years.
“Transdermal use” means application to the skin primarily for systemic effect.
“Veterinary chemical” means a substance that is represented as being suitable for, or is

manufactured, supplied or used for, administration or application to an animal by any
means, or consumption by an animal, as a way of directly or indirectly:
a) preventing, diagnosing, curing or alleviating a disease or condition in the animal or

an infestation of the animal by a pest;
b) curing or alleviating an injury suffered by the animal;
c) modifying the physiology of the animal:
i) so as to alter its natural development, productivity, quality or reproductive
capacity; or
ii) so as to make it more manageable;
d) modifying the effect of another veterinary chemical
e) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or
additive is used for a purpose mentioned in paragraph (a), (b), (c) or (d); or
f) any active ingredient included in a product declared by regulation under the
Agricultural and Veterinary Chemicals Code Act 1994 to be an veterinary chemical
product;
g) an agricultural chemical.
“Veterinary chemical product” has the meaning defined in the Agricultural and Veterinary
Chemicals Code Act 1994.
“Writing” includes the visible representation or reproduction of words or figures in any form,
and “to write” and “written” have corresponding meanings.
(2) Unless the contrary intention appears a reference to a substance in a Schedule or an

Appendix to this Standard includes:
a) that substance prepared from natural sources or artificially; and

b) where the substance is a plant (other than a plant included in Schedule 8 or 9), that
plant or any part of that plant when packed or prepared for therapeutic use; and

c) every salt, active principle or derivative of the substance, including esters and ethers,
and every salt of such an active principle or derivative; and
d) every alkaloid of the substance and every salt of such an alkaloid; and
e) every stereoisomer of the substance and every salt of such a stereoisomer; and
f) every recombinant form of the substance; and
g) a preparation or admixture containing any proportion of the substance,
h) a preparation or product included in Appendix A, or a substance and the reason for its
entry in Appendix B; or
i) a substance included in Appendix G at a concentration not exceeding the
concentration specified in column 2 of that Appendix in respect of that substance; or
j) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10
mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule
7 or 8; or
k) any substance present as an impurity in a pesticide, at a concentration at or below the
maximum content for that substance, specified for the pesticide in the Standards for
Active Constituents, as published by the Australian Pesticides and Veterinary
Medicines Authority.
(3) Unless the contrary intention appears where a concentration, strength or quantity is specified
in a Schedule or an Appendix to this Standard in respect of a substance:
a) if the substance is present as a salt, active principle or derivative (including an ester

or ether), the concentration, strength or quantity is calculated as the equivalent
amount of the substance that is listed in the Schedule or Appendix; and
b) the expression “one per cent” means:
i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of
the preparation; or
ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 gram
of the substance per 100 grams of the preparation; and
iii) any expression of greater or lesser percentages shall have a corresponding
meaning; and
c) in the case of codeine, such concentration, strength or quantity is calculated as
anhydrous codeine.
(4) A reference to a boiling or distillation temperature in the Schedules means that temperature
at an atmospheric pressure of 101.325 kPa (760 millimetres of mercury).

PART 2 – CONTROL ON MEDICINES AND POISONS
PART 2
CONTROL ON MEDICINES AND POISONS

SECTION ONE LABELS
1.1 General requirements
(1) A person must not sell or supply a poison unless it is labelled in accordance with Part 2
Section 1 of this Standard.
(2) Any word, expression or statement required by this Standard to be written on a label or
container must be written:
a) on the outside face of the label or container; and

b) in the English language; and
c) in durable characters; and
d) in a colour or colours to provide a distinct contrast to the background colour; and
e) in letters at least 1.5 millimetres in height.
(3) Section 1.1(2)(e) does not apply to a word, expression or statement on a container which has
a capacity of 20 millilitres or less, or on the label of such a container if:
a) an appropriate authority approves the use of smaller letters; and

b) the letters are at least 1 millimetre in height.
(4) The label must be printed on, or securely attached to:
a) the outside of the immediate container; and

b) if the immediate container is enclosed in a primary pack, the outside of that primary
pack.
1.2 Immediate wrapper
(1) A poison enclosed in an immediate wrapper must be contained in a primary pack labelled in
accordance with Section 1.3 of this Standard; and
(2) the immediate wrapper must be conspicuously labelled with:
a) the name of the manufacturer or distributor or the brand name or trade name used
exclusively by the manufacturer or distributor for that poison; and
b) the approved name of the poison; and
c) a statement of the quantity or strength of the poison in accordance with Section 1.4 of
this Standard.

1.3 Primary packs and immediate containers
(1) The primary pack and immediate container of a poison must be labelled as follows:
a) with the signal word or words relating to the Schedule in which the poison is included
and the purpose for which it is to be used, as shown in the following table:
Schedule Purpose Signal words required
2 for any purpose PHARMACY MEDICINE
3 for any purpose PHARMACIST ONLY MEDICINE
4 for human use PRESCRIPTION ONLY MEDICINE
4 for animal use PRESCRIPTION ANIMAL REMEDY
5 for any purpose CAUTION
6 for any purpose POISON
7 for any purpose DANGEROUS POISON
8 for any purpose CONTROLLED DRUG
written:
i) on the first line or lines of the main label; and

ii) in bold-face sans serif capital letters of uniform thickness; and
iii) in letters at least half the height of the largest letter or numeral on the label but
need not be larger than:
A) 6 millimetres on labels for packages having a nominal capacity of 2 litres or
less; or
B) 15 millimetres on labels for packages having a nominal capacity of more
than 2 litres; and
iv) if the poison:
A) is a Schedule 5 poison, with nothing, other than a Class label as specified in
the Australian Code for the Transport of Dangerous Goods by Road and

Rail or a statement of the principal hazard of the poison, written on that line;
or
B) is not a Schedule 5 poison, with nothing, other than a Class label as specified
in the Australian Code for the Transport of Dangerous Goods by Road and
Rail, written on that line;
b) if the poison is a Schedule 8 poison, with the cautionary statement –
POSSESSION WITHOUT AUTHORITY ILLEGAL
written:
i) on a separate line or lines immediately below the signal words required by

Section1.3(1)(a); and
iii) in letters at least four-tenths the height of the letters used for the signal words;
and
iv) with no other statement written on the same line;
c) with the cautionary statement –
KEEP OUT OF REACH OF CHILDREN
written:
i) on a separate line or lines:

A) immediately below the signal word or words required by Section 1.3(1)(a);
or
B) where the cautionary statement “POSSESSION WITHOUT AUTHORITY
ILLEGAL” is required by Section 1.3(1)(b), on the line immediately below
that statement; and
iii) in letters at least four-tenths the height of the letters used for the signal word or
words; and
iv) with nothing, other than a Class label as specified in the Australian Code for the
Transport of Dangerous Goods by Road and Rail, written on the same line;
d) if the poison is a dry chlorinating compound containing more than 10 per cent of
available chlorine, except for preparations certified by a relevant State or Territory
authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising
substances, as specified in the Australian Code for the Transport of Dangerous
Goods by Road and Rail, with the cautionary statement –
FIRE AND EXPLOSION HAZARD
written:

i) on a separate line or lines immediately below the cautionary statement “KEEP

OUT OF REACH OF CHILDREN” as required by Section 1.3(1)(c); and
words; and
e) if the poison is an alkaline salt in a dishwashing machine product, with the cautionary
statement –
BURNS SKIN AND THROAT
written:
i) on a separate line or lines immediately below the cautionary statement “KEEP

OUT OF REACH OF CHILDREN” as required by Section 1.3(1)(c); and
iii) in letters at least four-tenths the height of the letters used for the signal word; and
Transport of Dangerous Goods by Road and Rail, written on the same line of the
main label;
f) if the poison is an aqueous solution of paraquat, with the cautionary statements –
CAN KILL IF SWALLOWED

DO NOT PUT IN DRINK BOTTLES
KEEP LOCKED UP
written:
i) on separate lines immediately below the cautionary statement “KEEP OUT OF

REACH OF CHILDREN” as required by Section1.3(1)(c); and
iii) in letters at least four-tenths the height of the letters used for the signal words;
and
Transport of Dangerous Goods by Road and Rail, written on the same lines of
the main label;
g) for any poison other than a poison for human therapeutic use labelled in accordance
with the Required Advisory Statements for Medicine Labels, if safety directions are
required on the label by Section 1.3(1)(n), with the cautionary statement –
READ SAFETY DIRECTIONS BEFORE OPENING

OR USING

or with the cautionary statement –
READ SAFETY DIRECTIONS
written:
i) on a separate line or lines;

A) immediately below the cautionary statement “KEEP OUT OF REACH OF
CHILDREN” as required by Section (1)(c); or
B) if one or more other cautionary statements is required to be on the line
immediately below “KEEP OUT OF REACH OF CHILDREN”,
immediately below that statement or those statements; and
words; and
h) if the poison meets the criteria for a ‘flammable liquid’ in the Australian Code for the
Transport of Dangerous Goods by Road and Rail, with the cautionary statement –
FLAMMABLE
written on the main label in bold-face sans serif capital letters of uniform thickness,
unless already present in accordance with the requirements of the Australian Code for
the Transport of Dangerous Goods by Road and Rail;
i) if the poison is for the treatment of animals, with the cautionary statement –
FOR ANIMAL TREATMENT ONLY
written on the main label in bold-face sans serif capital letters of uniform thickness;
j) if the poison is a Schedule 5 poison intended for any purpose other than internal or
pesticidal use, with the cautionary statement –
DO NOT SWALLOW
written in sans serif capital letters on the main label or as part of the directions for use;
k) with the approved name of the poison and a statement of the quantity, proportion or
strength of the poison in accordance with Section 1.4:
i) if the poison is for human therapeutic use, written in accordance with orders
made under subsection 10(3) of the Commonwealth Therapeutic Goods Act,
1989; or
ii) if the poison is not for human therapeutic use, written in bold-face sans serif
capital letters on the main label, unless:

A) list of approved names is required; and

B) it is impractical to include the list on the main label; and
C) an appropriate authority has authorised its inclusion on another part of the
label; or
iii) if the poison is a Schedule 5 poison referred to in column 1 of the following table
the appropriate name opposite thereto in column 2 may be used as the approved
name:
TABLE
Column 1 Column 2
Alkaline salts Alkaline salts
Amines for use as curing agents for Aliphatic amines or aromatic amines
epoxy resins (unless separately specified
in the Schedules)
Epoxy resins, liquid Liquid epoxy resins
Hydrocarbons, liquid Liquid hydrocarbons
Quaternary ammonium compounds Quaternary ammonium compound(s)
iv) if a poison contains a mixture of designated solvents in excess of 25 per cent of

the total volume of the poison but the proportion of one or more individual
designated solvents in the mixture is equal to or less than 25 per cent, the
approved names of those solvents may be expressed as follows:
A) where the designated solvent is a liquid hydrocarbon as “liquid
hydrocarbons”; or
B) where the designated solvent is a ketone as “ketones”; or
C) in any other case as “solvents” or “other solvents”;
l) if the poison is an organophosphorus compound or carbamate for pesticidal use or for
the treatment of animals, with the following expression written immediately below
the approved name or the list of declared contents –
AN ANTICHOLINESTERASE COMPOUND
i) the requirements of Section 1.3(1)(l) do not apply to:

A) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or

B) an organophosphorus compound or carbamate contained in impregnated

plastic resin strips, medallions or granules; or
C) an organophosphorus compound or carbamate contained in a pressurised
spray pack for household use;
m) for any poison other than a poison for human therapeutic use labelled in accordance
with Therapeutic Goods Order 91 Standard for labels of prescription and related
medicines or Therapeutic Goods Order 92 Standard for labels of non-prescription
medicines or in an agricultural or veterinary chemical product labelled in compliance
with the Agricultural and Veterinary Chemicals Code Act 1994, if the poison is
prepared, packed or sold for a specific purpose, with clear and adequate directions for
use unless:
i) the poison is included in Schedule 4 or Schedule 8; or
ii) it is impractical to include such directions on the label and:
A) the primary pack and the immediate container are labelled with the
statement “DIRECTIONS FOR USE: See package insert”; and
B) an appropriate authority has authorised the directions for use to be
written on a package insert instead of the label; and
C) the insert is enclosed in the primary pack;
n) for any poison other than a poison for human therapeutic use labelled in accordance
with the Required Advisory Statements for Medicine Labels, if use of the poison may
be harmful to the user, with appropriate safety directions (see Appendix F), grouped
together as a distinct section of the label and prefaced by the words –
SAFETY DIRECTIONS
written in bold-face capital letters;
o) for any poison other than a poison for human therapeutic use labelled in accordance
with the Required Advisory Statements for Medicine Labels, if any warning statement
or statements are required for the poison (see Appendix F), with that warning
statement or those statements grouped together:
i) if safety directions are included on the label, immediately after the words
“SAFETY DIRECTIONS”; or
ii) if there are no safety directions, immediately preceding the directions for use;
p) if the poison is not for human internal use and is not a Schedule 3, Schedule 4 or
Schedule 8 poison, with appropriate first aid instructions (see Appendix E):
i) grouped together and prefaced by the words –
FIRST AID
written in bold-face capital letters; or

ii) if a primary pack contains two or more immediate containers of poisons each
requiring different first aid instructions:
A) written on each immediate container as specified in Section 1.3(1)(p)(i); and
B) replaced on the primary pack with the statement –
FIRST AID: See inner packs;
q) with the name and address of the manufacturer or distributor.
(2) For the purposes of Section 1.3(1)(a)(iii) the term “largest letter or numeral” does not
include:
a) a single letter or numeral which is larger than other lettering on the label; or
b) an affix forming part of the trade name; or
c) in the case of a poison for therapeutic use, numerals used to distinguish the strength
of a preparation from the strengths of other preparations of the same poison.
1.4 Statements of quantity, proportion or strength
(1) The statement of the quantity, proportion or strength of a poison must be expressed in the
most appropriate of the following forms:
a) if the poison is for human therapeutic use, in the manner prescribed by orders made
under subsection 10(3) of the Commonwealth Therapeutic Goods Act 1989;
b) if the poison is for a purpose or purposes other than human therapeutic use and:
i) if the poison is in a pressurised spray aerosol preparation, as the mass of the
poison per stated mass of the preparation;
ii) if the poison is a liquid in a liquid preparation, as the mass or volume of the
poison per stated volume of the preparation;
iii) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume
of the poison per stated mass of the preparation;
iv) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the
poison per stated volume of the preparation;
v) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the
mass of the poison per stated mass of the preparation;
vi) if the poison is a gas in a liquid preparation, as the mass of the poison per stated
volume of the preparation;
vii) if the poison is a gas in a solid or semi-solid preparation, as the mass of the
poison per stated mass of the preparation;
viii) if the poison is a gas in a gaseous preparation, as the mass of the poison per
stated mass of the preparation;
c) if the poison is a solution of a mineral acid, the proportion of the acid (un-neutralised
by any bases present in the preparation) in a preparation may be expressed as the un-
neutralised mass of the acid per stated mass of the preparation;

d) if the poison is an inorganic pigment, the proportion may be expressed as a

percentage of the metal present using one of the following expressions as appropriate:
contains not more than 10 per cent of (insert name of the metal); or
contains not more than 30 per cent of (insert name of the metal); or
contains more than 30 per cent of (insert name of the metal);
e) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use,
the proportion may be expressed as a range provided that the limits of the range do
not differ by more than 5 per cent of the product;
f) if the poison is a lead-based pigment included in automotive paint, the proportion
may be expressed as the maximum content of the lead that may be present in the non-
volatile content of the paint;
g) if a preparation contains more than one derivative of a poison, the quantity or
proportion of the poison may be expressed as the equivalent quantity or proportion of
one of the derivatives present which it would contain if all of the derivatives were
that derivative.
h) for the purposes of Section 1.4(1)(g) “derivative” includes alkaloid.
1.5 Exemptions
1.5.1 Selected containers and measure packs
(1) The requirements of Section 1.3 do not apply to an immediate container that is a measure
pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial
to which Section 1.5.2 (1) and (2) apply) when:
a) the immediate container is for a therapeutic good and is labelled in the manner
prescribed by orders made under subsection 10(3) of the Commonwealth Therapeutic
Goods Act 1989; or
b) the immediate container is:
i) packed in a primary pack labelled in accordance with Section 1.3; and
ii) labelled with:
A) the signal word or words relating to the Schedule in which the poison is
included and the purpose for which it is to be used, as shown in the table to
Section 1.3(1)(a); and
B) the approved name of the poison and the quantity, proportion or strength of
the poison in accordance with Section 1.4; and
C) the name of the manufacturer or distributor or the brand name or trade name
used exclusively by the manufacturer or distributor for the poison; and
D) if the poison is for the treatment of animals, with the cautionary statement –

written in sans serif capital letters.
1.5.2 Ampoules, pre-filled syringes and injection vials
(1) The requirements of Section 1.3 do not apply to a selected container, or an ampoule (other
than an ampoule to which Section 1.5.2(2) applies) when:
a) the selected container or ampoule is for a therapeutic good and is labelled in the
manner prescribed by orders made under subsection 10(3) of the Commonwealth
Therapeutic Goods Act 1989; or
b) the selected container or ampoule is:
ii) labelled with:
A) the approved name of the poison and the quantity, proportion or strength of
the poison in accordance with Section 1.4; and
B) with the name of the manufacturer or distributor or the brand name or trade
name used exclusively by the manufacturer or distributor for the poison; and
C) if the poison is for the treatment of animals, with the cautionary statement –
written in sans serif capital letters.
(2) The requirements of Section 1.3 do not apply to a selected container that is a plastic ampoule
that is continuous with a strip of the same material and opens as it is detached from the strip
when:
a) the selected container is a plastic ampoule that is continuous with a strip of the same
material and opens as it is detached from the strip, is for a therapeutic good and is
labelled in the manner prescribed by orders made under subsection 10(3) of the
Commonwealth Therapeutic Goods Act 1989; or
b) the selected container is a plastic ampoule that is continuous with a strip of the same
material and opens as it is detached from the strip, is:
ii) the strip is labelled in accordance with Section 1.5.2; and
iii) the ampoule is labelled with:
A) the approved name of the poison or the trade name of the product; and
B) the quantity, proportion or strength of the poison in accordance with Section
1.4.

1.5.3 Transport containers and wrappings
(1) The labelling requirements of this Standard do not apply to a transparent cover, or to any
wrapper, hamper, packing case, crate or other cover used solely for the purposes of
transport or delivery.
1.5.4 Dispensary, industrial, laboratory and manufacturing poisons
(1) The labelling requirements of this Standard do not apply to a poison that:
a) is packed and sold solely for dispensary, industrial, laboratory or manufacturing

purposes; and
b) is labelled in accordance with requirements under applicable jurisdictional Work
Health and Safety laws, as amended from time to time.
1.5.5 Exemptions from label requirements in certain circumstances
(1) the labelling requirements of Sections 1.3 to 1.5.3 do not apply to a poison where an
appropriate authority has granted a labelling exemption in whole or in part for these
sections for a specified product; and
(2) the labelling exemption from an appropriate authority referred to in Section 1.5.5(1) is
limited to no more than 12 months from the effective date of the decision for retail supply
of the product; and
(3) for the avoidance of doubt this paragraph does not apply to exemptions issued under Section
1.3(1)(m)(ii)(B) of this Standard.
1.5.6 Dispensed medicines
(1) Unless otherwise specified by regulation:
a) The labelling requirements of this Standard do not apply to a medicine that:

i) is supplied by an authorised prescriber or other person authorised to supply and is
labelled in accordance with the requirements of Appendix L Part 1 of this
Standard; or
ii) is supplied on and in accordance with a prescription written by an authorised
prescriber and is labelled in accordance with the requirements of Appendix L Part
1 of this Standard; or
iii) is prepared and supplied by a pharmacist for an individual patient and is labelled
in accordance with the requirements of Appendix L Part 1 of this Standard.
b) A person must not supply a dispensed medicine for human use containing:
i) a poison listed in column 1 of the table at Appendix L Part 2 of this Standard
unless it is clearly labelled with the warning statement(s) specified in column 2 of
that table; or
ii) a poison listed in Appendix K unless it is clearly labelled with a sedation warning
(being statement 39, 40 or 90 as specified in Appendix F Part 1 of this Standard).

1.5.7 Gas cylinders
(1) The requirements of Sections 1.3(1)(a)(iv), 1.3(1)(c)(iv), and 1.3(1)(g)(iv) do not apply to a
cylinder containing a poison that is a compressed gas.
1.5.8 Paints
(1) The requirements of Section 1.3 do not apply to:
a) paint (other than a paint for therapeutic or cosmetic use) which:

i) contains only Schedule 5 poisons; or
ii) is a First Group or Second Group paint that is labelled with:
A) the word “WARNING”, written in bold-face sans serif capital letters, the
height of which is not less than 5 mm, on the first line of the main label with
no other words written on that line; and
B) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-
face sans serif capital letters, the height of which is not less than 2.5 mm, on
a separate line immediately below the word “WARNING”; and
C) the appropriate warnings specified for the paint in Appendix F, written
immediately below the expression “KEEP OUT OF REACH OF
CHILDREN”; and
D) the name and proportion of the First Group or Second Group poisons it
contains, provided that where the substance is a metal or metal salt the
proportion is expressed as the metallic element present “calculated on the
non-volatile content” or “in the dried film” of the paint; or
b) a tinter which contains:
i) only Schedule 5 poisons; or
ii) a poison included in the First Group or Second Group in Part 2 Section 7,
provided that it is labelled with the name and proportion of that poison, and
where the poison is a metal or metal salt, the proportion is expressed as the
metallic element present as “calculated on the non-volatile content” or “in the
dried film”.
1.5.9 Camphor and naphthalene
(1) The labelling requirements of Section1.1(2)(d) and Section 1.3 do not apply to a device that
contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:
a) complies with Section 2.7; and

b) is sold or supplied in a primary pack labelled in accordance with Section 1.1 and
Section 1.3.
1.6 Prohibitions
(1) A label used in connection with any poison must not include:

a) any reference to this Standard, or any comment on, reference to, or explanation of
any expression required by this Standard that directly or by implication contradicts,
qualifies or modifies such expression; or
b) any expression or device suggesting or implying that the poison is safe, harmless,
non-toxic, non-poisonous, or is recommended or approved by the Government or any
government authority unless required by legislation; or
c) any expression or device which is false or misleading in any particular concerning the
safety of the poison or any of its ingredients; or
d) any trade name or description that:
i) represents any single constituent of a compound preparation; or
ii) misrepresents the composition or any property or quality of the poison; or
iii) gives any false or misleading indication of origin or place of manufacture of the
poison.
(2) A label must not be attached to the immediate container or primary pack used in connection
with any poison in such a manner as to obscure:
a) any expression required by this Standard to be written or embossed on the container

or pack; or
b) any of the ribs or embossed or printed words required by paragraph 21, 22 or 23 as
appropriate.
SECTION TWO CONTAINERS

2.1 Containers for poisons other than Schedule 5 poisons
(1) A person must not sell or supply a poison unless the immediate container complies with
the requirements of Sections 2.1 and 2.3 to 2.7 of this Standard.
(2) If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal
capacity of 2 litres or less, the container must comply with Australian Standard AS 2216-
1997, entitled Packaging for poisonous substances.
(3) Notwithstanding Section 2.1(2), a poison which is in Schedule 6 and is an essential oil may
be packed in an amber glass container which does not comply with the tactile identification
requirements of Australian Standard AS 2216-1997, entitled Packaging for poisonous
substances, if:
a) the other safety factors are not diminished; and

b) the container has a restricted flow insert and a child-resistant closure.
(4) If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal
capacity of more than 2 litres, the container must:
a) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-

1997 entitled Packaging for poisonous substances; and

b) have the word “POISON”:

i) in sans serif capital letters the height of which is at least one thirty second part of
the length, height or width of the container, whichever is the greatest:
A) embossed; or
B) indelibly written in a colour in distinct contrast to the background colour;
ii) on the side or shoulder of the container.
2.2 Containers for Schedule 5 poisons
(1) The container in which any Schedule 5 poison is sold or supplied must:
a) comply with the container requirements of Sections 2.1(2) or 2.1(4); or

b) be readily distinguishable from a container in which food, wine or other beverage is
sold; and
i) comply with subsection 1.4 (General Requirements) of Australian Standard AS
2216-1997 entitled Packaging for poisonous substances, excluding paragraph
1.4.3;
ii) be securely closed and, except when containing a preparation for use on one
occasion only, be capable of being re-closed to prevent spillage of its contents;
and
iii) have the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED
AS A FOOD CONTAINER” embossed or indelibly written thereon, or printed on
a permanent adhesive label designed to adhere to a substrate without lifting and
which cannot be removed without damaging either the label or the substrate.
(2) Notwithstanding Section 2.2(1), the following Schedule 5 poisons namely:
a) methylated spirit(s);
b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners,
reducers, white petroleum spirit or dry cleaning fluid;
c) petrol;
d) toluene; or
e) xylene,
must not be sold or supplied in a bottle or jar having a nominal capacity of 2 litres or less,
unless the immediate container complies with the container requirements specified in
Section 2.1(2).
2.3 Approved containers
(1) Notwithstanding section 2.1(2), 2.1(4) and 2.2 a poison may be packed in a container that
does not comply with the tactile identification requirements of Australian Standard
AS2216-1997 entitled Packaging for poisonous substances or the requirements of Section
2.1(4)(b) or Section 2.2(1)(b)(iii) if:

a) the other safety factors are not diminished;

b) the container is for a specific purpose; and
c) an appropriate authority has approved the use of the container for that purpose.
2.4 Child-resistant closures
(1) If a poison, other than a poison included in a therapeutic good packaged in a manner
compliant with orders made under subsection 10(3) of the Commonwealth Therapeutic
Goods Act 1989, listed in column 1 of the following table is sold or supplied in a container
having a nominal capacity specified for that poison in column 2, it must be closed with a
child-resistant closure.
Column 1 Column 2
Name of the poison Nominal capacity
Alkaline salts included in Schedule 5, when All sizes

packed and labelled as dishwashing machine
tablets.
Alkaline salts included in Schedule 5, when 5 litres /kilograms or less

packed and labelled as dishwashing machine
liquids, solids or gels.
Alkaline salts included in Schedule 5, when 2.5 litres or less

packed and labelled as a food additive.
Anise oil when included in Schedule 5. 200 millilitres or less
Basil oil when included in Schedule 5. 200 millilitres or less
Bay oil when included in Schedule 6. 200 millilitres or less
Cajuput oil when included in Schedule 6. 200 millilitres or less
Cassia oil when included in Schedule 5. 200 millilitres or less
Cineole when included in Schedule 6. 2 litres or less

Cinnamon bark oil when included in 200 millilitres or less

Schedule 5.
Cinnamon leaf oil when included in 200 millilitres or less

Schedule 6.
Clove oil when included in Schedule 6. 200 millilitres or less
CYCLOSILAZANES, DI-ME, ME All sizes

HYDROGEN, POLYMERS WITH DI-ME,
ME HYDROGEN SILAZANES,
REACTION PRODUCTS WITH 3-
(TRIETHOXYSILYL)-1-PROPANAMINE
(CAS 475645-84-2) when included in
Schedule 6, when presented in a wipe.
Essential oils when included in Schedule 6 200 millilitres or less

because of their natural camphor
component.
Ethylene glycol when included in 5 litres or less

Schedule 6.
Ethylene glycol when included in Schedule 5 litres or less

5 in preparations containing more than 50
per cent of ethylene glycol.
Eucalyptus oil when included in Schedule 6. 2 litres or less
Eugenol when included in Schedule 6. 200 millilitres or less
Fennel oil when included in Schedule 5. 200 millilitres or less
Hydrocarbons, liquid, when packed as 5 litres or less

kerosene, lamp oil, mineral turpentine,
thinners, reducers, white petroleum spirit or
dry cleaning fluid.

Hydrochloric acid when included in 5 litres or less

Schedule 6.
Leptospermum scoparium oil (manuka oil) 200 millilitres or less

when included in Schedule 6
Marjoram oil when included in Schedule 5. 200 millilitres or less
Melaleuca oil (tea-tree oil) when included in 200 millilitres or less

Schedule 6.
Methylated spirit excluding preparations or 5 litres or less

admixtures.
Methyl salicylate and preparations 200 millilitres or less

containing more than 50 per cent of methyl
salicylate.
Nutmeg oil when included in Schedule 5. 200 millilitres or less
Oil of turpentine. 5 litres or less
Paracetamol included in Schedule 4, when All sizes

packed and labelled for the treatment of
animals.
Pennyroyal oil when included in Schedule 6. 200 millilitres or less
Potassium hydroxide as such. 2.5 litres or less
Potassium hydroxide in oven, hot plate or 5 litres or less

drain cleaners when included in Schedule 6
except when in pressurised spray packs.
D-Pulegone when included in Schedule 6. 200 millilitres or less

Sage oil (Dalmatian) when included in 200 millilitres or less

Schedule 6.
Sodium hydroxide as such. 2.5 litres or less
Sodium hydroxide in oven, hot plate or 5 litres or less

drain cleaners when included in Schedule 6
except when in pressurised spray packs.
Thujone when included in Schedule 6. 200 millilitres or less
Thyme oil when included in Schedule 5. 200 millilitres or less
(2) The manufacturer or packer of a poison must ensure that the child-resistant closure is
appropriate for the container and the poison and that it retains its child-resistant properties
for the expected life of the poison.
2.5 Schedule 8 poisons
(1) A person who supplies any Schedule 8 poison must ensure that the Schedule 8 poison is
packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is
readily distinguishable from other sealed primary packs.
(2) This paragraph does not apply to the supply of a Schedule 8 poison by an:
a) authorised prescriber or other authorised supplier;

b) pharmacist on the prescription of an authorised prescriber;
c) pharmacist employed at a hospital, on the written requisition of a medical
practitioner, a dentist or the nurse or midwife in charge of the ward in which the
Schedule 8 poison is to be used or stored; or
d) nurse or midwife on the direction in writing of an authorised prescriber.
2.6 Exemptions
(1) Section 2.1(2), Section 2.1(4) and Section 2.2 do not apply to the immediate container of a
poison prepared, packed and sold:
a) for human internal or animal internal use; or

b) as a solid or semi-solid preparation for human external or animal external use; or
c) as a paint, other than a paint for therapeutic or cosmetic use; or
d) in containers having a nominal capacity of 15 millilitres or less; or

e) for use in automatic photographic or photocopy processing machines if the container

is specifically designed to fit into the machines; or
f) solely for dispensary, industrial, laboratory or manufacturing purposes.
(2) Section 2.4 does not apply to a poison prepared, packed and sold solely for dispensary,
industrial, laboratory or manufacturing purposes.
(3) The tactile identification or embossing required by Section 2.1(2), Section 2.1(4) and
Section (2.2) of this Standard or Australian Standard AS 2216-1997 entitled Packaging for
poisonous substances do not apply to a container that is an aerosol container, a collapsible
tube, or a measure pack which is a flexible sachet.
2.7 Camphor and naphthalene
(1) The container requirements of Section 2.1(2) do not apply to a device that contains only
camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the
device:
a) in normal use, prevents removal or ingestion of its contents; and

b) is incapable of reacting with the poison; and
c) is sufficiently strong to withstand the ordinary risks of handling, storage or transport;
and
d) has the word “POISON” and the approved name of the poison embossed or indelibly
printed on it.
(2) A person must not sell or supply camphor or naphthalene in ball, block, disc, pellet or flake
form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a
device which prevents removal or ingestion of its contents.
2.8 Prohibitions
(1) A person must not sell or supply a poison in a container which has the name of another
poison embossed or indelibly marked thereon.
(2) A person must not sell any poison which is for internal use or any food, drink or condiment
in a container prescribed by Sections 2.1(2), 2.1(4) and Section 2.2 of this Standard.
(3) A person must not sell any poison in a container that is not readily distinguishable from a
container in which food, alcohol, other beverage or condiment is sold.
SECTION THREE STORAGE

(1) A person who sells or supplies Schedule 6 poisons by way of retail sale must keep those
poisons in such a way as to prevent access by children.

(2) A person who sells or supplies Schedule 7 poisons must not keep those poisons for retail
sale in any areas or in any area or in any manner that allows physical access by any person
unless they are:
a) the owner of the retail establishment; or

b) an employee of the owner; or
c) legally permitted to purchase the substance and are under the supervision of the
owner or an employee of the owner.
(3) Controls on storage of Schedule 2, 3, 4 and 8 poisons require referral to Part 3 of this
Standard and relevant legislation.
SECTION FOUR DISPOSAL

(1) A person must not dispose of or cause to be disposed of a Schedule 5, Schedule 6 or

Schedule 7 poison in any place or manner that constitutes or is likely to constitute a risk to
public health or safety.
(2) Controls on disposal of Schedule 2, 3, 4 and 8 poisons require referral to relevant legislation.
SECTION FIVE RECORD KEEPING

5.1 General Requirements
(1) A person who sells or supplies Schedule 7 poisons must keep a record of:
a) Name and address of seller or supplier and purchaser; and

b) Date of order and supply; and
c) Approved name or trade name that identifies the poison to be supplied or sold; and
d) Quantity supplied or sold; and
e) Proof of purchaser authorisation must be recorded in jurisdictions where an
authorisation is required for purchase.
(2) Records for sale or supply of Schedule 7 poisons must be kept for a minimum period of five
years.
(3) Controls on record keeping for sale or supply of Schedule 2, 3, 4 and 8 poisons require
referral to relevant legislation.

SECTION SIX SALE, SUPPLY, POSSESSION, or USE

6.1 General Requirements for Schedule 5 and Schedule 6 Product samples
(1) A person must not sell or supply or distribute free a product sample containing a Schedule 5
or Schedule 6 poison in any manner unless the recipient has the opportunity to refuse at the
time of sale or supply.
(2) A person must not sell or supply or distribute free a product sample containing a Schedule 5
or Schedule 6 poison in an unsolicited manner for example via the post / mailbox or
attached to any other product.
(3) A person must not sell or supply a Schedule 5 or Schedule 6 poison product sample in a
manner that does not promote disposal in accordance with section four.
6.2 Schedule 7 Poisons
(1) A person must not possess or use a Schedule 7 poison for domestic or domestic garden
purposes.
(2) A person must not sell or supply:
a) a Schedule 7 poison for domestic or domestic garden purposes; or

b) a Schedule 7 poison being a liquid preparation containing paraquat unless it is
coloured blue or green and contains sufficient stenching agent to produce an
offensive smell; or
c) a Schedule 7 poison for which an authorisation to purchase, possess or use is required
by the appropriate authority unless the purchaser produces his or her authorisation.
(3) A person must not sell, supply or distribute free product samples containing Schedule 7
poisons.
6.3 Schedule 10 (previously Appendix C) poisons
(1) A person must not knowingly have in his or her possession or sell, supply or use a poison
listed in Schedule 10 of this Standard for the purpose or purposes indicated in relation to
that poison in Schedule 10.
6.4 Hawking
(1) A person must not sell by way of hawking a Schedule 7 poison.
(2) Controls on sale or supply or sale by way of hawking of Schedule 2, 3, 4 and 8 poisons
require referral to Part 3 of this Standard and relevant legislation.

SECTION SEVEN/Appendix I PAINT OR TINTERS

7.1 General Requirements
(1) A person must not manufacture, sell, supply or use a First Group Paint for application to:
a) a roof or any surface to be used for the collection or storage of potable water; or
b) furniture; or
c) any fence, wall, post, gate or building (interior or exterior) other than a building
which is used exclusively for industrial purposes or mining or any oil terminal; or
d) any premises used for the manufacture, processing, preparation, packing or serving of
products intended for human or animal consumption.
(2) A person must not manufacture, sell, supply or use a paint or tinter containing more than
0.1% Lead (the proportion of Lead for the purposes of this section is calculated as a
percentage of the element present in the non-volatile content of the paint).
(3) A person must not manufacture, sell, supply or use a paint for application to toys unless the
paint complies with the specification for coating materials contained in Australian/New
Zealand Standard AS/NZS ISO 8124.3:2012 entitled Safety of toys Part 3: Migration of
certain elements (ISO 8124-03:2010, MOD).
(4) A person must not manufacture, sell, supply, or use a paint or tinter containing a pesticide
except a fungicide, algaecide, bactericide or antifouling agent.
The First Group
The proportion of a substance for the purposes of this Group is calculated as a percentage of the
element present in the non-volatile content of the paint.
Substance Proportion
ANTIMONY or antimony compounds other more than 5 per cent

than antimony titanate pigments
BARIUM salts except barium sulfate or more than 5 per cent

barium metaborate
CADMIUM or cadmium compounds more than 0.1 per cent
CHROMIUM as chromates of ammonia, more than 5 per cent

barium, potassium sodium, strontium or zinc

SELENIUM or selenium compounds more than 0.1 per cent
The Second Group
Substance Proportion
DICHLOROMETHANE (methylene chloride) more than 5 per cent by wt
ETHYLENE GLYCOL MONOALKYL more than 10 per cent by vol

ETHERS and their acetates
HEXYLOXYETHANOL more than 10 per cent by vol
TOLUENE more than 50 per cent by vol
XYLENE more than 50 per cent by vol

PART 3 – MISCELLANEOUS REGULATIONS
PART 3
MISCELLANEOUS REGULATIONS
(It is recommended that the States and Territories implement regulations which provide controls
similar to those included in this Part of the Standard.)
SECTION ONE ADVERTISING

(1) A person must not include any reference to a poison included in:
a) Schedule 3 unless included in Appendix H; or

b) Schedule 4 or Schedule 8,
of this Standard in any advertisement except in genuine professional or trade

journals or other publications intended for circulation only within the medical,
nursing, veterinary, dental or pharmaceutical professions or the wholesale drug
industry.
(2) A person must not include any reference to a poison included in Schedule 9 or Schedule 10
(previously Appendix C) of this Standard in any advertisement.
SECTION TWO SALE OR SUPPLY

(1) A person, other than a pharmacist (or an assistant under the direction of a pharmacist) or a
medical, dental or veterinary practitioner in the lawful practice of their professions, must
not sell or supply a Schedule 2 poison unless licensed to do so.
(2) A person is not eligible to be granted a licence to sell a Schedule 2 poison by way of retail
sale unless:
a) he or she is carrying on the business of selling goods by retail; and

b) the premises from which the poison will be sold is more than 25 kilometres by the
shortest practical route from the nearest pharmacy; and
c) he or she produces such evidence, as may be required, that he or she is a fit and
proper person to be so licensed.
(1) A person, other than a pharmacist, or a medical, dental or veterinary practitioner, in the
lawful practice of his or her profession, must not sell or supply a Schedule 3 poison.

PART 3 – MISCELLANEOUS REGULATIONS
(2) The person who sells or supplies a Schedule 3 poison must:
a) provide adequate instructions for use, either written or verbal, at the time of supply or
sale; and
b) label the container with his or her name or the name of the pharmacy and the address
from which it was sold or supplied; and
c) if required by regulation, make a record of the transaction in a prescription book or
other approved recording system.
(1) A person, other than a medical, dental or veterinary practitioner in the ordinary course of
their professions or a pharmacist dispensing a legal prescription must not sell or supply a
Schedule 4 poison.
(2) Section 3.4(1) does not apply to a pharmacist who sells or supplies a Schedule 4 poison,
other than a poison excepted by regulation from this provision, without a prescription if:
a) the patient is under medical treatment with the poison and continuation of medication
is essential; and
b) the quantity sold or supplied does not exceed 3 days' medication; and
c) the pharmacist is satisfied that an emergency exists.
(3) Section 3.2(1), Sections 3.3(1) and (2) and Section 3.4(1) do not apply to sale by way of
wholesale dealing to a pharmacist, medical practitioner, veterinary practitioner, dentist or a
person licensed or otherwise authorised to possess, sell or supply such poisons.
3.5 Prohibitions on sale, prescribing and possession
(1) A person must not:
a) sell or supply, other than by way of wholesale dealing, or prescribe a poison listed in
Appendix D paragraphs 1, 2, 3, 4, 6 and 7 except in accordance with the provisions
indicated for that poison in Appendix D; or
b) knowingly have in his or her possession a poison listed in Appendix D paragraph 5
without authority.
SECTION THREE STORAGE

(1) A person who sells or supplies Schedule 2 poisons must keep those poisons in such a way
that public access to advice from a pharmacist is available if required.
(2) A person who sells or supplies Schedule 3 or Schedule 4 poisons must keep those poisons in
a part of the premises to which the public does not have access.

PART 4 – THE SCHEDULES
SCHEDULE 2
PART 4
THE SCHEDULES
SCHEDULE 1
This Schedule is intentionally blank.
SCHEDULE 2
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80
per cent of acetic acid (CH3COOH) for therapeutic use.
ACETYLCYSTEINE in preparations for oral use except when labelled with a recommended
daily dose of 1 g or less of acetylcysteine.
ACONITUM spp. for therapeutic use in adults:
a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids
except in packs containing 0.02 mg or less of total alkaloids; or
b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in
packs each containing 0.2 mg or less of total alkaloids except in packs containing
0.02 mg or less of total alkaloids.
ALIMEMAZINE when combined with one or more other therapeutically active substances in
solid oral preparations when:
a) at least one of the other therapeutically active substances is a sympathomimetic

decongestant; or
b) in a day-night pack containing alimemazine in the bed-time dose where the day and
night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
ALOXIPRIN.
AMOROLFINE in preparations for topical use except in preparations for the treatment of tinea
pedis.
ANTAZOLINE in eye drops.
ASPIRIN except:

SCHEDULE 2
a) when included in Schedule 4, 5 or 6;

b) in individually wrapped powders or sachets of granules each containing 650 mg or
less of aspirin as the only therapeutically active constituent other than an effervescent
agent when:
i) enclosed in a primary pack that contains 12 or less such powders or sachets of
granules; and
ii) compliant with the requirements of the Required Advisory Statements for
Medicine Labels;
c) in tablets or capsules each containing no other therapeutically active constituent other
than an effervescent agent when:
i) packed in blister or strip packaging or in a container with a child-resistant
closure;
ii) in a primary pack of not more than 25 tablets or capsules, each containing 325
mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules,
each containing 500 mg or less of aspirin; and
iii) compliant with the requirements of the Required Advisory Statements for
Medicine Labels;
d) in tablets or capsules each containing no other therapeutically active constituent other
than an effervescent agent when:
i) packed in blister or strip packaging or in a container with a child-resistant
closure;
ii) in a primary pack containing 100 or less tablets or capsules, each containing 100
mg or less of aspirin when packed and labelled for the prevention of
cardiovascular disease or for the inhibition of platelet aggregation; and
iii) compliant with the requirements of the Required Advisory Statements for
Medicine Labels.
ATROPA BELLADONNA (belladonna):
a) for external use in preparations containing 0.03 per cent or less of total solanaceous
alkaloids; or
b) for oral use:
i) in undivided preparations containing 0.03 per cent or less of total solanaceous
alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous
alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous
alkaloids; or
ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids
per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less
of total solanaceous alkaloids.
ATROPINE (excluding atropine methonitrate) for oral use:

SCHEDULE 2
a) in undivided preparations containing 0.03 per cent or less of total solanaceous

alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids
and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per
dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total
solanaceous alkaloids.
AZELAIC ACID in dermal preparations.
AZELASTINE:
a) in preparations for nasal use; or

b) in topical eye preparations containing 0.05 per cent or less of azelastine.
BECLOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of

beclometasone per actuation when the maximum recommended daily dose is no greater
than 400 micrograms and when packed in a primary pack containing 200 actuations or less,
for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children
12 years of age and over.
BENZOCAINE in preparations for topical use other than eye drops:
a) containing 10 per cent or less of total local anaesthetic substances, except in dermal
preparations containing 2 per cent or less of total local anaesthetic substances; or
b) in divided preparations containing 200 mg or less of total local anaesthetic substances
per dosage unit, except in lozenges containing 30 mg or less of total local anaesthetic
substances per dosage unit.
BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per
cent or less of benzoyl peroxide except in preparations containing 5 per cent or less of
benzoyl peroxide.
BENZYDAMINE in preparations for topical use, except:
a) in preparations for dermal use;

b) in divided topical oral preparations containing 3 mg or less of benzydamine; or
c) in undivided topical oral preparations containing 0.3 per cent or less of benzydamine
in a primary pack containing not more than 50 mL.
BEPHENIUM SALTS.
BIFONAZOLE in preparations for dermal use except:
a) in preparations containing 1 per cent or less of bifonazole for the treatment of the
scalp; or
b) in preparations for the treatment of tinea pedis.

SCHEDULE 2
BROMHEXINE.
BROMPHENIRAMINE when combined with one or more other therapeutically active

substances in oral preparations when:

decongestant; or
b) in a day-night pack containing brompheniramine in the bed-time dose where the day
and night doses are in the same immediate container or immediate wrapper,
BUDESONIDE in aqueous nasal sprays delivering 64 micrograms or less of budesonide per

actuation when the maximum recommended daily dose is no greater than 400 micrograms,
for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children
12 years of age and over.
CARBETAPENTANE except in preparations containing 0.5 per cent or less of carbetapentane.
CARBOCISTEINE.
CETIRIZINE in preparations for oral use except in divided preparations for the treatment of
seasonal allergic rhinitis in adults and children 12 years of age and over when:
a) in a primary pack containing not more than 10 days’ supply; and

b) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
CHLOPHEDIANOL.
CHLORBUTANOL for human use in topical preparations containing 5 per cent or less of
chlorbutanol except in preparations containing 0.5 per cent or less of chlorbutanol.
CHLOROFORM in preparations for therapeutic use except:
a) when included in Schedule 4; or

b) in preparations containing 0.5 per cent or less of chloroform.
CHLORPHENAMINE when combined with one or more other therapeutically active


decongestant; or
b) in a day-night pack containing chlorphenamine in the bed-time dose where the day
CICLOPIROX:

SCHEDULE 2
a) in preparations for dermal use containing 2 per cent or less of ciclopirox except in
preparations for the treatment of tinea pedis; or
b) in preparations for application to the nails containing 8 per cent or less of ciclopirox.
CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or
less of total local anaesthetic substances.
CINNAMEDRINE.
CLOTRIMAZOLE for human use in dermal preparations and for application to the nails except
in preparations for the treatment of tinea pedis.
CREOSOTE derived from wood other than beechwood for human therapeutic use, except in
preparations containing 10 per cent or less of creosote derived from wood other than
beechwood.
DATURA spp. for oral use:

and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or
solanaceous alkaloids,
except when separately specified in these Schedules.
DATURA STRAMONIUM (stramonium) for oral use when:

except for smoking or burning.
DATURA TATULA (stramonium) for oral use:

except for smoking or burning.

SCHEDULE 2
DELPHINIUM STAPHISAGRIA except in preparations containing 0.2 per cent or less of

Delphinium staphisagria.
DESLORATADINE in preparations for oral use.
DEXCHLORPHENAMINE when combined with one or more other therapeutically active


decongestant; or
b) in a day-night pack containing dexchlorphenamine in the bed-time dose where the
day and night doses are in the same immediate container or immediate wrapper,
DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing

600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less
of dextromethorphan.
DIBROMOPROPAMIDINE for ophthalmic use.
DICLOFENAC when:
a) in divided preparations for oral use containing 12.5 mg or less of diclofenac per
dosage unit in a pack containing 20 or less dosage units and labelled with a
recommended daily dose of 75 mg or less of diclofenac;
b) in preparations for dermal use containing 4 per cent or less of diclofenac except in
preparations for dermal use containing 2 per cent or less of diclofenac or for the
treatment of solar keratosis; or
c) in transdermal preparations for topical use containing 140 mg or less of diclofenac.
DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of

motion sickness, except in preparations for the treatment of children under 2 years of age.
DIPHENHYDRAMINE in oral preparations:
a) in a primary pack containing 10 dosage units or less for the prevention or treatment of
motion sickness; or
b) when combined with one or more other therapeutically active substances when:
i) at least one of the other therapeutically active substances is a sympathomimetic
decongestant; or
ii) in a day-night pack containing diphenhydramine in the bed-time dose where the
day and night doses are in the same immediate container or immediate wrapper,

SCHEDULE 2
DOXYLAMINE when combined with one or more other therapeutically active substances in
oral preparations when:

decongestant; or
b) in a day-night pack containing doxylamine in the bed-time dose where the day and
DUBOISIA LEICHHARDTII for oral use:

DUBOISIA MYOPOROIDES for oral use:

ECONAZOLE for human use in dermal preparations except in preparations for the treatment of
tinea pedis.
ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief
of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing
not more than 14 days supply.
ETAFEDRINE.
ETHER for therapeutic use except:

b) in preparations containing 10 per cent or less of ether.
ETHYLMORPHINE when:
a) compounded with one or more other therapeutically active substances:

i) in divided preparations containing 10 mg or less of ethylmorphine per dosage
unit; or

SCHEDULE 2
ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine;

b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.
ETOFENAMATE in preparations for external use.
FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days'
supply.
FELBINAC in preparations for external use.
FEXOFENADINE in preparations for oral use except in divided preparations:
a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age
and over when:
i) in a primary pack containing 20 dosage units or less and not more than 10
days’ supply; and
ii) labelled with a recommended daily dose not exceeding 120 mg of
fexofenadine;
b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age
and over when:
days’ supply; and
fexofenadine; or
c) for the treatment of seasonal allergic rhinitis and children 6 years of age and over
when:
days’ supply; and
fexofenadine.
FLUORIDES for human use:
a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit;
or
b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in
a container with a child-resistant closure:
i) for therapeutic use when compliant with the requirements of the Required
Advisory Statements for Medicine Labels except in preparations containing 220
mg/kg or less of fluoride ion, in packs containing not more than 120 mg total
fluoride when fitted with a child-resistant closure and compliant with the
requirements of Required Advisory Statements for Medicine Labels; or
ii) for non-therapeutic use when labelled with warnings to the following effect:

SCHEDULE 2
A) Do not swallow; and

B) Do not use (this product/insert name of product) in children 6 years of
age or less,
except in preparations containing 220 mg/kg or less of fluoride ion, in packs

containing not more than 120 mg total fluoride, when fitted with a child-
resistant closure and labelled with warnings to the following effect:

B) Do not use (this product/insert name of product) in children 6 years of
age or less,
except in preparations containing 15 mg/kg or less of fluoride ion or preparations for

supply to registered dental professionals or by approval of an appropriate authority.
FLURBIPROFEN in preparations for topical oral use when:
a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit

except when:
i) in a primary pack containing not more than 16 dosage units; and
ii) labelled only for the treatment of adults and children over 12 years.
b) in undivided preparations containing 0.25 percent or less or 10 mg or less per dose of
flurbiprofen.
FLUTICASONE PROPIONATE (excluding derivatives) in aqueous nasal sprays delivering 50

micrograms or less of fluticasone per actuation when the maximum recommended daily
dose is no greater than 400 micrograms, for the prophylaxis or treatment of allergic rhinitis
for up to 6 months in adults and children 12 years of age and over.
FOLIC ACID for human therapeutic use except:

b) in preparations containing 500 micrograms or less of folic acid per recommended
daily dose.
FOLINIC ACID for human therapeutic use except:

b) in preparations containing 500 micrograms or less of folinic acid per recommended
daily dose.
FORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
b) in other preparations containing 0.2 per cent or less of free formaldehyde.

SCHEDULE 2
GELSEMIUM SEMPERVIRENS.
GLUTARAL for human therapeutic use.
GUAIFENESIN in a modified release dosage form of 1200 mg or less of guaifenesin with a

recommended daily dose of 2400 mg or less when not labelled for the treatment of children
under 12 years of age.
HEXACHLOROPHENE in preparations for human use containing 3 per cent or less of

hexachlorophene except:
a) in preparations for use on infants, as specified in Schedule 4; or

b) in preparations for cosmetic use, as specified in Schedule 6; or
c) in other preparations containing 0.75 per cent or less of hexachlorophene.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and

derivatives, in preparations for human therapeutic use:
a) for dermal use in preparations containing 0.5 per cent or less of hydrocortisone, in
packs containing 30 g or less of such preparations, containing no other therapeutically
active constituent other than an antifungal substance; or
b) for dermal use in preparations containing 1 per cent or less of hydrocortisone, in
packs containing 15 g or less of such preparations, containing an antifungal substance
and no other therapeutically active constituent:
i) for the treatment of tinea (tinea pedis, tinea cruris, tinea corporis) and other
fungal skin infections; and
ii) not labelled for the treatment of children under 12 years of age; or
c) for rectal use in preparations containing 0.5 per cent or less of hydrocortisone, when
combined with a local anaesthetic substance but no other therapeutically active
constituent except unscheduled astringents:
iii) in undivided preparations in packs of 35 g or less; or
iv) in packs containing 12 or less suppositories.
HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in

Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per
cent or less of hydroquinone except:
a) in hair preparations containing 0.3 per cent or less of hydroquinone; or

b) in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.
HYOSCINE:
a) for transdermal use in preparations containing 2 mg or less of total solanaceous

alkaloids per dosage unit; or
b) for oral use:

SCHEDULE 2

alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous
alkaloids; or
per dosage unit when labelled with a recommended daily dose of 1.2 mg or less
of total solanaceous alkaloids.
HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided

preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage
unit in a pack containing 200 mg or less of hyoscine butylbromide.
HYOSCYAMINE:
a) for external use in preparations containing 0.03 per cent or less of total solanaceous
alkaloids; or
b) for oral use:
alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous
alkaloids; or
per dosage unit when labelled with a recommended daily dose of 1.2 mg or less
total solanaceous alkaloids.
HYOSCYAMUS NIGER for oral use:

b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per
except in a pack containing 0.03 mg or less of total solanaceous alkaloids.
IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of
1200 mg or less of ibuprofen:
a) in liquid preparations when sold in the manufacturer’s original pack containing 8 g or

less of ibuprofen; or
b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not
more than 100 dosage units except when:
i) as the only therapeutically active constituent (other than phenylephrine or when
combined with an effervescent agent);

SCHEDULE 2
ii) packed in blister or strip packaging or in a container with a child-resistant

closure;
iii) in a primary pack containing not more than 25 dosage units;
iv) compliant with the requirements of the Required Advisory Statements for
Medicine Labels;
v) not labelled for the treatment of children 6 years of age or less; and
vi) not labelled for the treatment of children under 12 years of age when combined
with phenylephrine; or
c) in divided immediate release preparations, each containing 400 mg or less of
ibuprofen in a primary pack containing not more than 12 dosage units, when labelled
not for the treatment of children under 12 years of age.
INDANAZOLINE.
INDOMETACIN in preparations for external use containing 1 per cent or less of indometacin.
IODINE:
a) in preparations for human internal therapeutic use containing 300 micrograms or

more of iodine per recommended daily dose; or
b) in preparations for human external therapeutic use containing more than 2.5 per cent
of available iodine (excluding salts, derivatives or iodophors),
except in oral preparations for use in prophylaxis and treatment in the event of radioactive
iodine exposure under an emergency plan approved by an appropriate authority.
IPRATROPIUM in preparations for nasal use.
IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided

preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided
preparations containing 1 per cent or less of total iron oxides) for human internal use
except:

b) when labelled with a recommended daily dose of 24 mg or less of iron:
i) in undivided preparations supplied in packs each containing 750 mg or less of
iron; or
ii) in divided preparations:
A) containing more than 5 mg of iron per dosage unit in packs each
containing 750 mg or less of iron; or
B) containing 5 mg or less of iron per dosage unit.
ISOCONAZOLE for human use in dermal preparations.
ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.

SCHEDULE 2
KETOCONAZOLE in preparations for dermal use except:
a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the
scalp; or
KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.
LANSOPRAZOLE in oral preparations 15 mg or less of lansoprazole per dosage unit for the
relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs
containing not more than 7 days’ supply.
LEVOCABASTINE in topical eye or nasal preparations.
LEVOCETIRIZINE in preparations for oral use except in divided preparations for the treatment
of seasonal allergic rhinitis in adults and children 12 years of age and over when:
a) in a primary pack containing not more than 5 days’ supply; and

b) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
LIDOCAINE in preparations for topical use other than eye drops:
a) containing 10 per cent or less of total local anaesthetic substances, except:

i) in dermal preparations containing 2 per cent or less of total local anaesthetic
substances; or
ii) in aqueous sprays for oromucosal use containing 0.6 per cent or less of total
local anaeasthetic substances; or
b) in divided preparations containing 200 mg or less of total local anaesthetic
substances, except in lozenges containing 30 mg or less of total local anaesthetic
substances per dosage unit.
LINDANE in preparations for human external therapeutic use containing 2 per cent or less of
lindane.
LITHIUM in preparations for dermal use containing 1 per cent or less of lithium except:
a) when present as an excipient at 0.25 per cent or less of lithium; or

b) in preparations containing 0.01 per cent or less of lithium.
LOBELIA INFLATA except for smoking or burning.
LOBELINE except in preparations for smoking or burning.
LODOXAMIDE in preparations for ophthalmic use.

SCHEDULE 2
LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less except
in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack
containing 8 dosage units or less.
LORATADINE in preparations for oral use except in divided preparations for the treatment of
seasonal allergic rhinitis when:
a) in a primary pack containing 10 dosage units or less when labelled for adults and
children 6 years and over; and
b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
MACROGOLS in preparations for oral use as a liquid concentrate for laxative use.
MEBENDAZOLE for human therapeutic use.
MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the
prevention or treatment of motion sickness, except in preparations for the treatment of
children under 2 years of age.
MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for
the treatment of dysmenorrhoea.
MEPYRAMINE for dermal use.
MERCUROCHROME in preparations for external use containing 2 per cent or less of

mercurochrome except when included in Schedule 6.
MERCURY for external use in preparations containing 0.5 per cent or less of mercury.
METHOXAMINE in preparations for external use except in preparations containing 1 per cent
or less of methoxamine.
METHOXYPHENAMINE.
METHYLEPHEDRINE.
MICONAZOLE for human use in dermal preparations and for application to the nails except in
preparations for the treatment of tinea pedis.
MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.
MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per

actuation when the maximum recommended daily dose is no greater than 200 micrograms
for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and
children 12 years of age and over.
NAPHAZOLINE.
NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in
packs of 30 or less dosage units.

SCHEDULE 2
NICLOSAMIDE for human therapeutic use.
NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days'
supply.
NOSCAPINE.
NYSTATIN in dermal preparations.
OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for
the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs
containing not more than 7 days’ supply.
OXETACAINE (oxethazaine) in preparations for internal use.
OXICONAZOLE for dermal use except in preparations for the treatment of tinea pedis.
OXYMETAZOLINE.
OXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, except in
preparations for external use containing 1 per cent or less of such substances.
PAPAVERINE except when included in Schedule 4.
PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage

unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in
packs containing not more than 7days’ supply.
PARACETAMOL for therapeutic use:
a) in liquid preparations for oral use containing a maximum of 10 g of paracetamol per

container; or
b) when combined with ibuprofen in preparations for oral use when labelled with a
recommended daily dose of 1200 mg or less of ibuprofen in divided doses in a
primary pack containing no more than 12 dosage units per pack; or
c) in tablets or capsules enclosed in a primary pack containing not more than 100 tablets
or capsules; or
d) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or
capsules intended only as a bulk medicine pack and labelled ‘For dispensing only’
and ‘This pack is not to be supplied to a patient’; or
e) in individually wrapped powders or sachets of granules enclosed in a primary pack
containing not more than 50 wrapped powders or sachets of granules; or
f) in individually wrapped powders or sachets of granules enclosed in a primary pack
containing more than 50 wrapped powders or sachets of granules intended only as a
bulk medicine pack and labelled ‘For dispensing only’ and ‘This pack is not to be
supplied to a patient’; or
g) in other preparations except:

SCHEDULE 2
i) when included in Schedule 3 or 4; or

ii) in individually wrapped powders or sachets of granules each containing 1000 mg
or less of paracetamol as the only therapeutically active constituent (other than
caffeine, phenylephrine and/or guaifenesin or when combined with effervescent
agents) when:
(A) enclosed in a primary pack that contains not more than 10 such
powders or sachets of granules,
(B) compliant with the requirements of the Required Advisory
Statements for Medicine Labels,
(C) not labelled for the treatment of children 6 years of age or less, and
(D) not labelled for the treatment of children under 12 years of age when
combined with caffeine, phenylephrine and/or guaifenesin; or
iii) in tablets or capsules each containing 500 mg or less of paracetamol as the only
therapeutically active constituent (other than caffeine, phenylephrine and/or
guaifenesin or when combined with effervescent agents) when:
(A) packed in blister or strip packaging or in a container with a child-
resistant closure,
(B) in a primary pack containing not more than 20 tablets or capsules,
(C) compliant with the requirements of the Required Advisory
Statements for Medicine Labels,
(D) not labelled for the treatment of children 6 years of age or less, and
(E) not labelled for the treatment of children under 12 years of age when
combined with caffeine, phenylephrine and/or guaifenesin.
PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use except:
a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
b) in other preparations containing 0.2 per cent or less of free formaldehyde.
PHEDRAZINE.
PHENAZONE for human external use.
PHENIRAMINE:
a) in eye drops; or
b) when combined with one or more other therapeutically active substances in oral
preparations when:
decongestant; or
ii) in a day-night pack containing pheniramine in the bed-time dose where the day

SCHEDULE 2
PHENOL, or any homologue boiling below 220°C, for human therapeutic use except:

b) in preparations for external use containing 1 per cent or less of phenol and in
preparations for external use containing 3 per cent or less of cresols and xylenols and
other homologues of phenol.
PHENYLEPHRINE except:
a) when included in Schedule 4;

b) in oral preparations containing 50 mg or less of phenylephrine per recommended
daily dose in packs containing 250 mg or less of phenylephrine; or
c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.
PHOLCODINE:
a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a
recommended dose not exceeding 25 mg of pholcodine; or
b) when compounded with one or more other therapeutically active substances in
divided preparations containing 10 mg or less of pholcodine per dosage unit and with
a recommended dose not exceeding 25 mg of pholcodine.
PIPERAZINE for human therapeutic use.
PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for

human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of

podophyllin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of

podophyllin for human use for the treatment of warts other than anogenital warts.
POTASSIUM CHLORATE for therapeutic use except in preparations containing 10 per cent or
less of potassium chlorate.
PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local
anaesthetic substances.
PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.
PROMETHAZINE in oral preparations:
a) in a primary pack containing 10 dosage units or less for the prevention or treatment of
motion sickness; or
b) when combined with one or more other therapeutically active substances when:

SCHEDULE 2

decongestant; or
ii) in a day-night pack containing promethazine in the bed-time dose where the day
PROPAMIDINE for ophthalmic use.
PYRANTEL for human therapeutic use.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of

chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing
more than 10 per cent of such substances.
PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the
scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements
of the Required Advisory Statements for Medicine Labels.
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit

for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in
packs containing not more than 7 days’ supply.
RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more
than 14 days' supply except:
a) in divided preparations for oral use containing 150 mg or less of ranitidine per dosage
unit in the manufacturer’s original pack containing not more than 14 dosage units; or
b) in divided preparations for oral use containing 300 mg or less of ranitidine per dosage
unit in the manufacturer’s original pack containing not more than 7 dosage units.
SALICYLAMIDE except when included in Schedule 4.
SELENIUM in preparations for human therapeutic use except:
a) for topical use containing 3.5 per cent or less of selenium sulfide;
b) when included in Schedule 4; or
c) for oral use with a recommended daily dose of 150 micrograms or less.
SILVER for therapeutic use except:
a) in solutions for human oral use containing 0.3 per cent or less of silver when
compliant with the requirements of the Required Advisory Statements for Medicine
Labels; or
b) in other preparations containing 1 per cent or less of silver.
SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

SCHEDULE 2
SODIUM NITRITE for therapeutic use (excluding when present as an excipient).
SQUILL except in preparations containing 1 per cent or less of squill.
SULCONAZOLE in preparations for dermal use.
TERBINAFINE for dermal use except in preparations for the treatment of tinea pedis.
TETRACAINE in preparations for topical use other than eye drops, containing 10 per cent or
less of total local anaesthetic substances except in dermal preparations containing 2 per
cent or less of total local anaesthetic substances.
TETRACHLOROETHYLENE for human therapeutic use.
TETRYZOLINE.
THIABENDAZOLE for human therapeutic use.
TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of
tinea pedis.
TRAMAZOLINE.
TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone

per actuation when the maximum recommended daily dose is no greater than 220
micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults
and children 12 years of age and over.
TRIPROLIDINE when combined with one or more other therapeutically active substances in
oral preparations when:

decongestant; or
b) in a day-night pack containing triprolidine in the bed-time dose where the day and
TUAMINOHEPTANE.
TYMAZOLINE.
XYLOMETAZOLINE.
ZINC CHLORIDE for human dermal use except in preparations containing 5 per cent or less of
zinc chloride.

SCHEDULE 3
SCHEDULE 3
ADRENALINE in preparations containing 1 per cent or less of adrenaline except in
preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for
injection.
ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use
containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the
preparation.
ALIMEMAZINE:
a) in solid oral preparations except when included in Schedule 2; or

b) in liquid oral preparations containing 10 mg or less of alimemazine per 5 mL,
AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.
AMYL NITRITE when in preparations for human therapeutic use and packaged in containers
with child-resistant closures.
ASTODRIMER SODIUM except in a condom lubricant.
AZATADINE in oral preparations.
BROMPHENIRAMINE in oral preparations except:

b) for the treatment of children under 2 years of age.
BUCLIZINE in oral preparations.
BUTOCONAZOLE in preparations for vaginal use.
CANNABIDIOL in oral, oromucosal and sublingual preparations included in the Australian

Register of Therapeutic Goods when:
a) the cannabidiol is either plant derived or, when synthetic, only contains the (-)-CBD
enantiomer; and
b) the cannabidiol comprises 98 per cent or more of the total cannabinoid content of the
preparation; and
c) any cannabinoids, other than cannabidiol, must be only those naturally found in
cannabis and comprise 2 per cent or less of the total cannabinoid content of the
preparation and of which tetrahydrocannabinol (THC) can only comprise 1 per cent
of the total cannabinoid content; and
d) the maximum recommended daily dose is 150 mg or less of cannabidiol; and

SCHEDULE 3
e) packed in blister or strip packaging or in a container fitted with a child-resistant

closure; and
f) in packs containing not more than 30 days supply; and
g) for persons aged 18 years and over.
CHLORAMPHENICOL for ophthalmic use only.
CHLORBUTANOL in preparations for human use except:

b) in preparations containing 0.5 per cent or less of chlorbutanol.
CHLORPHENAMINE in oral preparations except:

CICLOPIROX in preparations for dermal use and for application to the nails except:

CIMETIDINE in a primary pack containing not more than 14 days' supply.
CLEMASTINE in preparations for oral use.
CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in

preparations for dermal use containing 0.05 per cent or less of clobetasone in packs
containing 30 g or less of the preparation.
CLOTRIMAZOLE in preparations for vaginal use.
CYCLIZINE in divided preparations for oral use in primary packs containing 6 dosage units or
less.
CYPROHEPTADINE in oral preparations.
DEXCHLORPHENAMINE in oral preparations except:

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per
dosage unit in a pack containing 30 or less dosage units except when included in
Schedule 2.

SCHEDULE 3
DIHYDROCODEINE when indicated for cough suppression and compounded with one or more
other therapeutically active substances:
a) in divided preparations containing 10 mg or less of dihydrocodeine per dosage unit

and with a recommended dose not exceeding 15 mg of dihydrocodeine; or
b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a
recommended dose not exceeding 15 mg of dihydrocodeine.
DIIODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.
DIMENHYDRINATE in oral preparations except when included in Schedule 2.
DIMETHINDENE in oral preparations.
DIPHENHYDRAMINE in oral preparations except:

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or
less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of
the dose of diphenoxylate.
DITHRANOL for therapeutic use.
DOXYLAMINE in oral preparations except:

ECONAZOLE in preparations for vaginal use.
ELETRIPTAN for oral use in tablets containing 40 mg or less per tablet and when in a pack
containing not more than 2 dosage units for the acute relief of migraine in patients who
have a stable, well-established pattern of symptoms.
ERYTHRITYL TETRANITRATE for therapeutic use.
FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less
of famciclovir for the treatment of herpes labialis (cold sores).
FLAVOXATE.
FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for

the treatment of vaginal candidiasis.
FLUORIDES for human topical use:

SCHEDULE 3
a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container

with a child-resistant closure except when included in or expressly excluded from
Schedule 2; or
b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion except:
i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion
and, when containing more than 1000 mg/kg fluoride ion, compliant with the
requirements of the Required Advisory Statements for Medicine Labels;
ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride
ion and, when containing more than 1000 mg/kg fluoride ion, labelled with
warnings to the following effect:
B) Do not use [this product/name of product] in children six years of age
or less; or
iii) in preparations for supply to registered dental professionals or by approval of an
appropriate authority.
GLUCAGON.
GLYCERYL TRINITRATE:
a) in preparations for oral use; or

b) in preparations for rectal use.
GLYCOPYRRONIUM except when included in Schedule 4.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and

derivatives, in preparations for human therapeutic use containing 1 per cent or less of
hydrocortisone:
a) for dermal use, in packs containing 30 g or less of such preparations, containing no

other therapeutically active constituent other than an antifungal substance; or
b) for dermal use, in packs containing 2 g or less of such preparations, containing no
other therapeutically active constituent other than aciclovir (5% w/w or less) in adults
and adolescents (12 years of age and older); or
c) for rectal use when combined with a local anaesthetic substance but no other
therapeutically active constituent except unscheduled astringents:
i) in undivided preparations, in packs of 35 g or less; or
ii) in packs containing 12 or less suppositories;
except when included in Schedule 2.
HYOSCINE BUTYLBROMIDE in undivided preparations for oral use with a recommended

single dose not exceeding 20 mg of hyoscine butylbromide in a pack containing 100 mg or
less of hyoscine butylbromide when labelled for adults and children 6 years and over.

SCHEDULE 3
IBUPROFEN:
a) in divided preparations, each containing 400 mg or less of ibuprofen in a primary

pack containing not more than 50 dosage units, when labelled:
i) with a recommended daily dose of 1200 mg or less of ibuprofen; and
ii) not for the treatment of children under 12 years of age; or
b) in a modified release dosage form, each containing 600 mg of ibuprofen in a primary
pack containing not more than 32 dosage units, when labelled:
i) with a recommended daily dose of 1200 mg or less of ibuprofen; and
ii) not for the treatment of children under 12 years of age;
except when included in or expressly excluded from Schedule 2.
INOSITOL NICOTINATE.
ISOCONAZOLE in preparations for vaginal use.
ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate

per dosage unit.
KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per
dosage unit in a pack containing 30 or less dosage units.
LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage

packs containing not more than 14 days' supply except when included in Schedule 2.
LEVONORGESTREL for emergency post-coital contraception.
MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or
surgical procedures.
MAGNESIUM SULFATE for human therapeutic use in divided oral preparations except when
containing 1.5 g or less of magnesium sulfate per recommended daily dose.
MALATHION in preparations for human external use except in preparations containing 2 per
cent or less of malathion.
MANNITYL HEXANITRATE for therapeutic use.
MEPYRAMINE in oral preparations.
METHDILAZINE in oral preparations.
METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and

labelled only for the treatment of nausea associated with migraine, in packs containing not
more than 10 dosage units.

SCHEDULE 3
MICONAZOLE for human use in topical preparations:
a) for the treatment of oral candidiasis; or

b) for vaginal use.
MOMETASONE as the only therapeutically active substance in preparations for dermal use
containing 0.1 per cent or less of mometasone in packs containing 15 g or less.
NALOXONE when used for the treatment of opioid overdose.
NAPROXEN in a modified release dosage form of 600 mg or less of naproxen per dosage unit
in packs of 16 or less dosage units when labelled not for the treatment of children under 12
years of age.
NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less
of nicotinic acid per dosage unit except:
a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

b) nicotinamide.
NICOTINYL ALCOHOL except in preparations containing 100 mg or less of nicotinyl alcohol

per dosage unit.
NYSTATIN in preparations for topical use except when included in Schedule 2.
OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for
the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs
containing not more than 14 days' supply except when included in Schedule 2.
ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of

orlistat per dosage unit.
OXICONAZOLE in preparations for vaginal use.
PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage

PARACETAMOL:
a) when combined with ibuprofen in a primary pack containing 30 dosage units or less
except when included in Schedule 2; or
b) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed

in a primary pack containing not more than 100 tablets or capsules; or
c) in modified release tablets or capsules containing 665 mg or less paracetamol enclosed

in a primary pack containing more than 100 tablets or capsules intended only as a bulk

SCHEDULE 3
medicine and labelled 'For dispensing only' and 'This pack is not to be supplied to a
patient'; or
d) in liquid preparations for oral use except when in Schedule 2.
PHENIRAMINE in oral preparations except:

PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for

human use for the treatment of warts other than anogenital warts except when included in
Schedule 2.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of

podophyllin for human use for the treatment of warts other than anogenital warts except
when included in Schedule 2.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of

podophyllin for human use for the treatment of warts other than anogenital warts except
PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than
10 dosage units for the treatment of nausea associated with migraine.
PROMETHAZINE in oral preparations except:

b) in preparations for the treatment of children under 2 years of age.
PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-

control purposes) when supplied in a primary pack:
a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride

(or its equivalent); or
b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or
its equivalent).
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit

for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in
RIZATRIPTAN when in divided oral preparations containing 5 mg or less per dosage unit and
when sold in a pack containing not more than 2 dosage units for the acute relief of migraine
in patients who have a stable, well-established pattern of migraine symptoms.
SALBUTAMOL as the only therapeutically active substance:

SCHEDULE 3
a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered

dose; or
b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per
dose; and
where supply is limited:
c) for the relief of bronchospasm in patients with asthma or chronic obstructive
pulmonary disease, and for acute prophylaxis against exercise-induced asthma and
other stimuli known to induce bronchospasm; or
d) for the treatment of a person with a record of previous supply from a pharmacy; or
e) to persons authorised under a law of a State or Territory to use or supply salbutamol
in the practice of their profession; or
f) for use in institutional first aid; and
where paragraph (c) or (d) applies—supply is limited to one primary pack of salbutamol
per person being treated.
SALICYLIC ACID in preparations for dermal use except in preparations containing 40 per cent
or less of salicylic acid.
SANTONIN.
SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic
medical and surgical procedures.
SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic
medical or surgical procedures.
SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of

sulfacetamide.
SUMATRIPTAN when in divided oral preparations containing 50 mg or less per dosage unit
and when sold in a pack containing not more than 2 dosage units for the acute relief of
migraine in patients who have a stable, well-established pattern of symptoms.
TERBUTALINE as the only therapeutically active substance:
a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered

dose; or
b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per
dose.
THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.
TIOCONAZOLE in preparations for vaginal use.
TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of
triamcinolone in a pack of 5 g or less.

SCHEDULE 3
TRIPROLIDINE in oral preparations except:

ULIPRISTAL for emergency post-coital contraception.
VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or
less of vitamin D per recommended single weekly dose except in preparations containing
25 micrograms or less of vitamin D per recommended daily dose.
ZOLMITRIPTAN when in divided oral preparations containing 2.5 mg or less per dosage unit
and when sold in a pack containing not more than 2 dosage units for the acute relief of
migraine in patients who have a stable, well-established pattern of symptoms.

SCHEDULE 4
(Substances marked # are listed in Appendix D)
SCHEDULE 4
ABACAVIR.
ABATACEPT.
ABIRATERONE ACETATE.
ABCIXIMAB.
ABEMACICLIB.
ACALABRUTINIB.
ACAMPROSATE CALCIUM.
ACARBOSE.
ACEBUTOLOL.
ACEPROMAZINE.
ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human
therapeutic use.
ACETARSOL.
ACETAZOLAMIDE.
ACETOHEXAMIDE.
ACETYL ISOVALERYLTYLOSIN.
ACETYLCARBROMAL.
ACETYLCHOLINE.
ACETYLCYSTEINE except:

b) in preparations for oral use when labelled with a recommended daily dose of 1 g or
less of acetylcysteine.
ACETYLDIGITOXIN.
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.
ACETYLSTROPHANTHIDIN.

SCHEDULE 4
ACICLOVIR except in preparations containing 5 per cent or less of aciclovir for the treatment
of herpes labialis in packs containing 10 g or less.
ACIPIMOX.
# ACITRETIN.
ACLIDINIUM BROMIDE.
ACOKANTHERA OUABAIO.
ACOKANTHERA SCHIMPERI.
ACONITUM spp. except:

b) in preparations for oral use in adults in packs containing 0.02 mg or less of total
alkaloids; or
c) in preparations for dermal use in adults containing 0.02 per cent or less of total
alkaloids in packs containing 0.02 mg or less of total alkaloids.
ACRIVASTINE.
ADALIMUMAB.
ADAPALENE.
ADEFOVIR.
ADENOSINE for human therapeutic use in preparations for injection.
ADIPHENINE.
ADONIS VERNALIS.
ADRAFINIL.
ADRENALINE except:

b) in preparations containing 0.02 per cent or less of adrenaline unless packed and
labelled for injection.
ADRENOCORTICAL HORMONES except when separately specified in these Schedules.
AFAMELANOTIDE.
AFATINIB DIMALEATE.

SCHEDULE 4
AFLIBERCEPT.
AGALSIDASE.
AGLEPRISTONE.
AGOMELATINE.
ALANYLGLUTAMINE.
ALATROFLOXACIN MESILATE.
ALBENDAZOLE except:
a) when included in Schedule 5 or 6; or

b) in intraruminal implants each containing 3.85 g or less of albendazole for the
treatment of animals.
ALCLOFENAC.
ALCLOMETASONE except when included in Schedule 3.
ALCURONIUM.
ALDESLEUKIN.
ALDOSTERONE.
ALECTINIB.
# ALEFACEPT.
ALEMTUZUMAB.
ALENDRONIC ACID.
ALFACALCIDOL.
ALFUZOSIN.
ALGLUCERASE.
ALGLUCOSIDASE.
ALIMEMAZINE except when included in Schedule 2 or 3.
ALIROCUMAB.
ALISKIREN.

SCHEDULE 4
ALKYL NITRITES except when separately specified in these schedules.
ALLERGENS for therapeutic use.
ALLOPURINOL.
ALLYLESTRENOL.
ALOGLIPTIN.
ALOSETRON.
ALPELISIB.
ALPHA1-PROTEINASE INHIBITOR (HUMAN).
ALPHADOLONE.
ALPHAXALONE.
ALPRENOLOL.
ALPROSTADIL.
ALSEROXYLON.
ALTEPLASE.
ALTRENOGEST.
ALTRETAMINE (hexamethylmelamine).
AMANTADINE.
AMBENONIUM CHLORIDE.
# AMBRISENTAN.
AMBUCETAMIDE.
AMBUTONIUM BROMIDE.
AMCINONIDE.
AMIFOSTINE.
AMIKACIN.
AMILORIDE.

SCHEDULE 4
AMINOCAPROIC ACID.
AMINOGLUTETHIMIDE.
5-AMINOLEVULINIC ACID.
AMINOMETRADINE.
AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.
AMINOPHYLLINE except when included in Schedule 3.
AMINOPTERIN.
4-AMINOPYRIDINE for therapeutic use.
AMINOREX.
AMINOSALICYLIC ACID.
AMIODARONE.
AMIPHENAZOLE.
AMISOMETRADINE.
AMISULPRIDE.
AMITRIPTYLINE.
AMLODIPINE.
AMMI VISNAGA.
AMMONIUM BROMIDE for therapeutic use.
AMOBARBITAL when packed and labelled for injection.
AMODIAQUINE.
AMOROLFINE except:

AMOXAPINE.
AMOXICILLIN.

SCHEDULE 4
AMPHOMYCIN.
AMPHOTERICIN B.
AMPICILLIN.
AMPRENAVIR.
AMRINONE.
AMSACRINE.
AMYL NITRITE except when included in Schedule 3.
AMYLOCAINE.
# ANABOLIC STEROIDAL AGENTS.
ANAGRELIDE.
ANAKINRA.
ANASTROZOLE.
ANCESTIM.
ANCROD and its immunoglobulin antidote.
ANECORTAVE.
# ANDROGENIC STEROIDAL AGENTS.
# ANDROISOXAZOLE.
# ANDROSTANOLONE.
# ANDROSTENEDIOL.
# ANDROSTENEDIONE.
ANGIOTENSIN AMIDE.
ANIDULAFUNGIN.
ANIRACETAM.
ANISTREPLASE.
ANTAZOLINE except when included in Schedule 2.

SCHEDULE 4
ANTIBIOTIC SUBSTANCES except:
a) when separately specified in these Schedules; or

b) nisin.
ANTIGENS for human therapeutic use except when separately specified in this Schedule.
ANTIHISTAMINES except:

b) when separately specified in this Schedule.
ANTIMONY for therapeutic use except when separately specified in these Schedules.
ANTISERA (immunosera) for human use by injection except when separately specified in
these Schedules.
# AOD-9604 (CAS No. 221231-10-3).
APALUTAMIDE.
APIXABAN.
APOCYNUM spp.
APOMORPHINE.
APRACLONIDINE.
APRAMYCIN.
APREMILAST.
APREPITANT.
APRONAL.
APROTININ.
ARBUTIN (BETA) in oral preparations except herbal preparations containing 500 mg or less
beta-arbutin per recommended daily dose.
ARECOLINE.
ARIPIPRAZOLE.
ARMODAFINIL.
ARSENIC for human therapeutic use except when separately specified in these Schedules.

SCHEDULE 4
ARTEMETHER.
ARTICAINE.
ASENAPINE.
ASFOTASE ALFA.
ASPARAGINASE.
ASPIRIN:
a) when combined with caffeine, paracetamol or salicylamide or any derivative of these

substances; or
b) for injection.
ASTEMIZOLE.
ASUNAPREVIR.
# ATAMESTANE.
ATAZANAVIR.
ATENOLOL.
ATEZOLIZUMAB.
ATIPAMEZOLE.
ATOMOXETINE.
ATORVASTATIN.
ATOSIBAN.
ATOVAQUONE.
ATRACURIUM BESILATE.
ATROPA BELLADONNA (belladonna) except when included in Schedule 2.
ATROPINE except when included in Schedule 2.
ATROPINE METHONITRATE.
AURANOFIN.
AUROTHIOMALATE SODIUM.

SCHEDULE 4
AVELUMAB.
AVILAMYCIN except:
a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or

b) in animal feeds containing 50 mg/kg or less of avilamycin activity.
AVIPTADIL.
AXITINIB.
AVOPARCIN.
AZACITIDINE.
AZACYCLONOL.
AZAPERONE.
AZAPROPAZONE.
AZARIBINE.
AZATADINE except when included in Schedule 3.
AZATHIOPRINE.
AZELAIC ACID except:

b) in preparations containing 1 per cent or less of azelaic acid for non-human use.
AZELASTINE except when included in Schedule 2.
AZITHROMYCIN.
AZLOCILLIN.
AZTREONAM.
BACAMPICILLIN.
BACITRACIN.
BACLOFEN.
BALOXAVIR MARBOXIL.
BALSALAZIDE.

SCHEDULE 4
BAMBERMYCIN (flavophospholipol) except:

b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic
substances.
BAMBUTEROL.
BAMETHAN.
BAMIPINE.
BARBITURATES except when separately specified in these Schedules.
BARICITINIB.
BASILIXIMAB.
BAZEDOXIFENE.
BECAPLERMIN.
BECLAMIDE.
BECLOMETASONE except when included in Schedule 2.
BELATACEPT.
BELIMUMAB.
BEMEGRIDE.
BENACTYZINE.
BENAZEPRIL.
BENDAMUSTINE.
BENDROFLUAZIDE.
BENETHAMINE PENICILLIN.
BENORYLATE.
BENOXAPROFEN.
BENPERIDOL.
BENRALIZUMAB.

SCHEDULE 4
BENSERAZIDE.
BENZATHINE PENICILLIN.
BENZILONIUM.
BENZOCAINE except:

b) in dermal preparations containing 2 per cent or less of total local anaesthetic
substances; or
c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage
unit.
# BENZODIAZEPINE derivatives except when separately specified in these Schedules.
BENZOYL PEROXIDE in preparations for human therapeutic use except:

b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.
BENZPHETAMINE.
BENZTHIAZIDE.
BENZATROPINE.
BENZYDAMINE except:

b) in preparations for dermal use;
c) in divided topical oral preparations containing 3 mg or less of benzydamine; or
d) in undivided topical oral preparations containing 0.3 per cent or less of benzydamine
in a primary pack containing not more than 50 mL.
BENZYLPENICILLIN.
BEPRIDIL.
BERACTANT.
BESIFLOXACIN.
BETAHISTINE.
BETAMETHASONE.

SCHEDULE 4
BETAXOLOL.
BETHANECHOL CHLORIDE.
BETHANIDINE.
BEVACIZUMAB.
BEVANTOLOL.
# BEXAROTENE.
BEZAFIBRATE.
BEZLOTOXUMAB.
BICALUTAMIDE.
BICTEGRAVIR.
BIFONAZOLE except:

b) in preparations for dermal use containing 1 per cent or less of bifonazole for the
treatment of the scalp; or
c) in preparations for dermal use for the treatment of tinea pedis.
BILASTINE.
BIMATOPROST.
BINIMETINIB.
BIPERIDEN.
BISMUTH COMPOUNDS for cosmetic use, except:
a) bismuth citrate when incorporated in hair colourant preparations in concentrations of

0.5 per or less; or
b) bismuth oxychloride.
BISMUTH COMPOUNDS for human therapeutic use, except bismuth formic iodide or bismuth
subiodide in dusting powders containing 3 per cent or less of bismuth.
BISOPROLOL.
BIVALIRUDIN.

SCHEDULE 4
BLEOMYCIN.
BLINATUMOMAB.
BOCEPREVIR.
# BOLANDIOL.
# BOLASTERONE.
# BOLAZINE.
# BOLDENONE (dehydrotestosterone).
# BOLENOL.
# BOLMANTALATE.
BORON, including boric acid and borax, for human therapeutic use except:
a) in preparations for internal use containing 6 mg or less of boron per recommended

daily dose;
b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not
for paediatric or antifungal use; or
c) when present as an excipient.
BORTEZOMIB.
# BOSENTAN.
BOSUTINIB.
BOTULINUM TOXINS for human use except when separately specified in these Schedules.
BRENTUXIMAB VEDOTIN.
BRETYLIUM TOSILATE.
BREXPIPRAZOLE.
BRIGATINIB.
BRIMONIDINE.
BRINZOLAMIDE.
BRIVARACETAM.
# BROMAZEPAM.

SCHEDULE 4
BROMIDES, inorganic, for therapeutic use except when separately specified in these
Schedules.
BROMOCRIPTINE.
BROMOFORM for therapeutic use.
BROMPHENIRAMINE except when included in Schedule 2 or 3.
BROMVALETONE.
BRUGMANSIA spp.
BUCLIZINE except when included in Schedule 3.
BUDESONIDE except when included in Schedule 2.
BUFEXAMAC except:
a) in preparations for dermal use containing 5 per cent or less of bufexamac; or

b) in suppositories.
BUMETANIDE.
BUPHENINE.
BUPIVACAINE except when included in Schedule 5.
BUPROPION.
BUSERELIN.
BUSPIRONE.
BUSULPHAN.
BUTACAINE.
BUTAMBEN except in dermal preparations containing 2 per cent or less of total local
anaesthetic substances.
BUTOCONAZOLE except when included in Schedule 3.
BUTRACONAZOLE.
BUTYLCHLORAL HYDRATE.
BUTYL NITRITE.

SCHEDULE 4
CABAZITAXEL.
CABERGOLINE.
CABOTEGRAVIR.
CABOZANTINIB.
CADMIUM COMPOUNDS for human therapeutic use.
CAFFEINE for internal therapeutic use except:
a) in divided preparations when labelled with a maximum recommended daily dose of

no greater than 600 mg of total caffeine; or
b) in undivided preparations with a concentration of less than 5 per cent of caffeine and
when labelled with a maximum recommended daily dose of no greater than 600 mg
of total caffeine.
CALCIFEDIOL for human internal therapeutic use except in preparations containing 10

micograms or less of calcifediol per recommended daily dose.
CALCIPOTRIOL.
CALCITONIN.
CALCITONIN SALMON.
CALCITRIOL.
CALCIUM CARBIMIDE for therapeutic use.
CALCIUM HYDROXYLAPATITE in preparations for injection or implantation:
a) for tissue augmentation; or

b) for cosmetic use.
CALCIUM POLYSTYRENE SULPHONATE.
CALOTROPIS GIGANTEA.
CALOTROPIS PROCERA.
# CALUSTERONE.
CAMPHORATED OIL for therapeutic use.
CAMPHOTAMIDE.

SCHEDULE 4
CANAGLIFLOZIN.
CANAKINUMAB.
CANDESARTAN CILEXETIL.
CANDICIDIN.
CANINE TICK ANTI-SERUM.
CANNABIDIOL in preparations for therapeutic use or analytical and scientific research where:
a) cannabidiol comprises 98 per cent or more of the total cannabinoid content of the
preparation; and
b) any cannabinoids, other than cannabidiol, must be only those naturally found in
cannabis and comprise 2 per cent or less of the total cannabinoid content of the
preparation;
CANTHARIDIN.
CAPECITABINE.
CAPREOMYCIN.
CAPTODIAME.
CAPTOPRIL.
CAPURIDE.
CARAMIPHEN.
CARBACHOL.
CARBAMAZEPINE.
CARBARYL for human therapeutic use.
CARBAZOCHROME.
CARBENICILLIN.
CARBENOXOLONE for internal use.
CARBETOCIN.
CARBIDOPA.

SCHEDULE 4
CARBIMAZOLE.
CARBOCROMEN.
CARBOPLATIN.
CARBOPROST.
CARBROMAL.
CARBUTAMIDE.
CARBUTEROL.
CARFILZOMIB.
CARGLUMIC ACID (N-carbamoyl-L-glutamic acid).
CARINDACILLIN.
CARIPRAZINE.
CARISOPRODOL.
CARMUSTINE.
CARNIDAZOLE.
CARPROFEN.
CARVEDILOL.
CASPOFUNGIN.
CATHINE.
CATUMAXOMAB.
CEDAZURIDINE.
CEFACETRILE.
CEFACLOR.
CEFADROXIL.
CEFALEXIN.
CEFALORIDINE.

SCHEDULE 4
CEFALOTIN.
CEFAMANDOLE.
CEFAPIRIN.
CEFAZOLIN.
CEFEPIME.
CEFETAMET.
CEFIXIME.
CEFODIZIME.
CEFONICID.
CEFOPERAZONE.
CEFOTAXIME.
CEFOTETAN.
CEFOTIAM.
CEFOVECIN for veterinary use.
CEFOXITIN.
CEFPIROME.
CEFPODOXIME.
CEFQUINOME.
CEFTAROLINE FOSAMIL.
CEFSULODIN.
CEFTAZIDIME.
CEFTIBUTEN.
CEFTIOFUR.
CEFTRIAXONE.
CEFUROXIME.

SCHEDULE 4
CELECOXIB.
CELIPROLOL.
CENEGERMIN.
CEPHAELIS ACUMINATA (ipecacuanha) except in preparations containing 0.2 per cent or

less of emetine.
CEPHAELIS IPECACUANHA except in preparations containing 0.2 per cent or less of

emetine.
CEPHALONIUM.
CEPHRADINE.
CERITINIB.
CERIVASTATIN.
CERLIPONASE ALFA.
CERTOLIZUMAB PEGOL.
CERULETIDE.
CETIRIZINE except

b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in
adults and children 12 years of age and over when:
i) in a primary pack containing not more than 10 days’ supply; and
ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.
CETRORELIX.
CETUXIMAB.
CHENODEOXYCHOLIC ACID.
CHLORAL FORMAMIDE.
CHLORAL HYDRATE except in preparations for topical use containing 2 per cent or less of
chloral hydrate.
CHLORALOSE except when included in Schedule 6.
CHLORAMBUCIL.

SCHEDULE 4
CHLORAMPHENICOL except when included in Schedule 3.
# CHLORANDROSTENOLONE.
CHLORAZANIL.
CHLORCYCLIZINE.
# CHLORDIAZEPOXIDE.
CHLORMERODRIN.
CHLORMETHIAZOLE.
CHLORMEZANONE.
CHLOROFORM for use in anaesthesia.
# 4-CHLOROMETHANDIENONE.
2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.
CHLOROQUINE.
CHLOROTHIAZIDE.
CHLOROTRIANISENE.
# CHLOROXYDIENONE.
CHLORPHENAMINE except when included in Schedule 2 or 3.
CHLORPHENTERMINE.
CHLORPROMAZINE.
CHLORPROPAMIDE.
CHLORPROTHIXENE.
CHLORQUINALDOL for human topical use.
CHLORTALIDONE.
CHLORTETRACYCLINE except when included in Schedule 5.
CHLORZOXAZONE.
CHOLERA VACCINE.

SCHEDULE 4
CHOLIC ACID.
CHYMOPAPAIN for human therapeutic use.
CICLACILLIN.
CICLESONIDE.
CICLOPIROX except:

CICLOSPORIN.
CIDOFOVIR.
CILASTATIN.
CILAZAPRIL.
CILOSTAZOL.
CIMETIDINE except when included in Schedule 3.
CIMICOXIB.
CINACALCET.
CINCHOCAINE except when included in Schedule 2.
CINNARIZINE.
CINOXACIN.
CIPROFLOXACIN.
CISAPRIDE.
CISATRACURIUM BESILATE.
CISPLATIN.
CITALOPRAM.
# CJC-1295 (CAS No. 863288-34-0).
CLADRIBINE.

SCHEDULE 4
CLANOBUTIN.
CLARITHROMYCIN.
CLAVULANIC ACID.
CLEMASTINE except when included in Schedule 3.
CLEMIZOLE.
CLENBUTEROL.
CLEVIDIPINE.
CLIDINIUM BROMIDE.
CLINDAMYCIN.
CLIOQUINOL and other halogenated derivatives of oxyquinoline for human topical use except
when separately specified in this Schedule.
CLOBAZAM.
CLOBETASOL.
CLOBETASONE (clobetasone-17-butyrate) except when included in Schedule 3.
CLOCORTOLONE.
CLODRONIC ACID (includes sodium clodronate).
CLOFARABINE.
CLOFAZIMINE.
CLOFENAMIDE.
CLOFIBRATE.
# CLOMIFENE.
CLOMIPRAMINE.
CLOMOCYCLINE.
# CLONAZEPAM.
CLONIDINE.
CLOPAMIDE.

SCHEDULE 4
CLOPIDOGREL.
CLOPROSTENOL.
# CLORAZEPATE.
CLOREXOLONE.
CLORPRENALINE.
# CLOSTEBOL (4-chlorotestosterone).
CLOTRIMAZOLE except:
a) when included in Schedule 2, 3 or 6; or

b) in preparations for dermal use for the treatment of tinea pedis.
CLOXACILLIN.
# CLOZAPINE.
COBALT for human therapeutic use except as dicobalt edetate in preparations for the treatment
of cyanide poisoning.
COBICISTAT.
COBIMETINIB.
CODEINE when compounded with one or more other therapeutically active substances:
a) in divided preparations containing 30 mg or less of codeine per dosage unit; or

b) in undivided preparations containing 1 per cent or less of codeine.
CO-DERGOCRINE.
COLCHICINE.
COLCHICUM AUTUMNALE.
COLESTIPOL.
COLESTYRAMINE for human therapeutic use.
COLFOSCERIL PALMITATE for human therapeutic use.
COLISTIN.
COLLAGEN in preparations for injection or implantation:

SCHEDULE 4

COLLAGENASE CLOSTRIDIUM HISTOLYTICUM.
COLURACETAM.
CONVALLARIA KEISKI.
CONVALLARIA MAJALIS.
COPPER COMPOUNDS for human use except:
a) when separately specified in these Schedules;

b) in preparations for human internal use containing 5 mg or less of copper per
recommended daily dose; or
c) in other preparations containing 5 per cent or less of copper compounds.
# CORIFOLLITROPIN ALFA.
CORONILLA spp.
CORTICOSTERONE.
CORTICOTROPHIN.
CORTISONE.
CO-TRIMOXAZOLE.
COUMARIN for therapeutic use (excluding when present as an excipient).
CRISABOROLE.
CRIZOTINIB.
CROFELEMER.
CUPRIMYXIN.
CURARE.
CYCLANDELATE.
CYCLIZINE except when included in Schedule 3.
CYCLOBENZAPRINE.

SCHEDULE 4
# CYCLOFENIL.
CYCLOHEXIMIDE.
CYCLOPENTHIAZIDE.
CYCLOPENTOLATE.
CYCLOPHOSPHAMIDE.
CYCLOPROPANE for therapeutic use.
CYCLOSERINE.
CYCLOTHIAZIDE.
CYCRIMINE.
CYMARIN.
CYPROHEPTADINE except when included in Schedule 3.
CYPROTERONE.
CYTARABINE.
DABRAFENIB MESILATE.
DABIGATRAN.
DACARBAZINE.
DACLATASVIR.
DACLIZUMAB.
DACTINOMYCIN.
DALFOPRISTIN.
DALTEPARIN (includes dalteparin sodium).
DANAPAROID (includes danaparoid sodium).
# DANAZOL.
DANTHRON for human use.
DANTROLENE.

SCHEDULE 4
DAPAGLIFLOZIN.
DAPOXETINE.
DAPSONE.
DAPTOMYCIN.
DARATUMUMAB.
# DARBEPOETIN.
DARIFENACIN.
DAROLUTAMIDE.
DARUNAVIR.
DATURA spp. except:

DASABUVIR.
DASATINIB.
DATURA STRAMONIUM (stramonium) except:

b) for smoking or burning.
DATURA TATULA (stramonium) except:

b) for smoking or burning.
DAUNORUBICIN.
DEANOL for therapeutic use.
DEBRISOQUINE.
DECAMETHONIUM.
DECITABINE.
DEFERASIROX.

SCHEDULE 4
DEFERIPRONE.
DEFIBROTIDE.
DEFLAZACORT.
DEGARELIX.
# DEHYDROCHLOROMETHYLTESTOSTERONE.
DEHYDROCORTICOSTERONE.
DELAVIRDINE MESILATE.
DEMBREXINE except when included in Schedule 5.
DEMECARIUM.
DEMECLOCYCLINE.
DENGUE VACCINE.
DENOSUMAB.
DEOXYCHOLIC ACID.
DEOXYCORTONE.
DEOXYRIBONUCLEASE except:
a) when separately specified in this Schedule; or

b) for external use.
DERACOXIB.
DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE

EXTRACT.
DESFERRIOXAMINE.
DESFLURANE.
DESIPRAMINE.
DESIRUDIN.
DESLANOSIDE.
DESLORATADINE except when included in Schedule 2.

SCHEDULE 4
DESLORELIN.
DESMOPRESSIN (D.D.A.V.P.).
DESOGESTREL.
DESONIDE.
DESOXYMETHASONE.
DESVENLAFAXINE.
DETOMIDINE.
DEXAMETHASONE.
DEXCHLORPHENAMINE except when included in Schedule 2 or 3.
DEXFENFLURAMINE.
DEXMEDETOMIDINE.
DEXTROMETHORPHAN (excluding its stereoisomers) except when included in Schedule 2.
# DEXTROPROPOXYPHENE:
a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage

unit; or
b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.
DEXTRORPHAN (excluding its stereoisomers).
DIAMTHAZOLE.
DIAVERIDINE.
# DIAZEPAM.
DIAZOXIDE.
DIBENZEPIN.
DIBOTERMIN.
DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.
DICHLORALPHENAZONE.
DICHLOROPHEN for human therapeutic use.

SCHEDULE 4
DICHLORPHENAMIDE.
DICLOFENAC except:

b) in preparations for dermal use unless:
i) for the treatment of solar keratosis; or
ii) containing more than 4 per cent of diclofenac.
DICLOXACILLIN.
DICYCLOMINE.
DIDANOSINE.
DIENESTROL.
DIENOGEST.
DIETHAZINE.
DIETHYLCARBAMAZINE for human therapeutic use.
DIETHYLPROPION.
DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a
quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.
DIFLORASONE.
DIFLOXACIN.
DIFLUCORTOLONE.
DIFLUNISAL.
DIGITALIS LANATA.
DIGITALIS PURPUREA.
DIGITOXIN.
DIGOXIN.
DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).
DIHYDRALAZINE.

SCHEDULE 4
DIHYDROCODEINE when compounded with one or more other therapeutically active

substances:
a) in divided preparations containing not more than 100 mg of dihydrocodeine per

dosage unit; or
b) in undivided preparations with a concentration of not more than 2.5 per cent of
dihydrocodeine,
DIHYDROERGOTOXINE.
# DIHYDROLONE.
DIHYDROSTREPTOMYCIN.
DIHYDROTACHYSTEROL.
DIIODOHYDROXYQUINOLINE (iodoquinol) except:

b) for human internal use.
DIISOPROPYLAMINE DICHLOROACETATE.
DILTIAZEM.
DIMENHYDRINATE except when included in Schedule 2 or 3.
DIMERCAPROL.
# DIMETHANDROSTANOLONE.
# DIMETHAZINE.
DIMETHINDENE except when included in Schedule 3.
DIMETHOTHIAZINE.
DIMETHOXANATE.
DIMETHYL FUMARATE.
DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use except:

b) in in vitro test kits; or

SCHEDULE 4
c) when used as a flavour component in compliance with the current Therapeutic Goods
(Permissible Ingredients) determination for listed medicines.
DIMETRIDAZOLE.
DIMIRACETAM.
2,4-DINITROCHLOROBENZENE for therapeutic use.
DINITROCRESOLS for therapeutic use except when separately specified in these Schedules.
DINITRONAPHTHOLS for therapeutic use except when separately specified in these

Schedules.
DINITROPHENOLS for therapeutic use.
DINITROTHYMOLS for therapeutic use except when separately specified in these Schedules.
# DINOPROST.
# DINOPROSTONE.
DIPERODON.
DIPHEMANIL except in preparations for dermal use.
DIPHENHYDRAMINE except when included in Schedule 2 or 3.
DIPHENIDOL.
DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of

diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose
of diphenoxylate except when included in Schedule 3.
DIPHENYLPYRALINE.
DIPHTHERIA TOXOID.
DIPIVEFRIN.
DIPYRIDAMOLE.
DIRITHROMYCIN.
DIRLOTAPIDE.
DISOPHENOL.
DISOPYRAMIDE.

SCHEDULE 4
DISTIGMINE.
DISULFIRAM for therapeutic use.
DISULPHAMIDE.
DITHIAZANINE except when included in Schedule 6.
DITIOCARB.
DOBUTAMINE.
DOCETAXEL.
DOFETILIDE.
DOLASETRON.
DOLUTEGRAVIR.
DOMPERIDONE.
DONEPEZIL.
DOPAMINE.
DOPEXAMINE.
DORAVIRINE.
DORIPENEM.
DORNASE.
DORZOLAMIDE.
DOSULEPIN.
DOXANTRAZOLE.
DOXAPRAM.
DOXAZOSIN.
DOXEPIN.
DOXORUBICIN.
DOXYCYCLINE.

SCHEDULE 4
DOXYLAMINE except when included in Schedule 2 or 3.
DRONEDARONE.
DROPERIDOL.
DROSPIRENONE.
# DROSTANOLONE.
DROTRECOGIN.
DUBOISIA LEICHHARDTII except when included in Schedule 2.
DUBOISIA MYOPOROIDES except when included in Schedule 2.
DULAGLUTIDE.
DULOXETINE.
DUPILUMAB.
DURVALUMAB.
DUTASTERIDE.
DYDROGESTERONE.
ECONAZOLE except:

ECOTHIOPATE (includes ecothiopate iodide).
ECTYLUREA.
ECULIZUMAB.
EDETIC ACID for human therapeutic use except:
a) in preparations containing 0.25 per cent or less of edetic acid;

b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or
c) in contact lens preparations.
EDOXUDINE.
EDROPHONIUM.

SCHEDULE 4
EFALIZUMAB.
EFAVIRENZ.
EFLORNITHINE.
ELBASVIR.
ELETRIPTAN except when included in Schedule 3.
ELEXACAFTOR.
ELOSULFASE ALFA.
ELOTUZUMAB.
ELTENAC.
ELTROMBOPAG.
ELUXADOLINE.
ELVITEGRAVIR.
EMEPRONIUM.
EMETINE except in preparations containing 0.2 per cent or less of emetine.
EMPAGLIFLOZIN.
EMTRICITABINE.
ENALAPRIL.
ENASIDENIB.
ENCORAFENIB.
# ENESTEBOL.
ENFLURANE for therapeutic use.
ENFUVIRTIDE.
# ENOBOSARM.
ENOXACIN.
ENOXAPARIN.

SCHEDULE 4
ENOXIMONE.
ENPROSTIL.
ENROFLOXACIN.
ENTACAPONE.
ENTECAVIR.
ENTRECTINIB.
ENZALUTAMIDE.
EPHEDRA spp. except in preparations containing 0.001 per cent or less of ephedrine.
# EPHEDRINE.
EPICILLIN.
EPINASTINE.
EPIRUBICIN.
# EPITIOSTANOL.
EPLERENONE.
# EPOETINS.
EPOPROSTENOL.
EPROSARTAN.
EPTIFIBATIDE.
ERENUMAB.
ERGOMETRINE.
ERGOT.
ERGOTAMINE.
ERGOTOXINE.
ERIBULIN MESILATE.
ERLOTINIB.

SCHEDULE 4
ERTAPENEM.
ERTUGLIFLOZIN.
ERYSIMUM spp.
ERYTHROMYCIN.
# ERYTHROPOIETIN.
# ERYTHROPOIETINS except when separately specified in these Schedules.
ESCITALOPRAM.
ESMOLOL.
ESOMEPRAZOLE except when included in Schedule 2.
ESTRADIOL except when included in Schedule 5.
ESTRIOL.
ESTRAMUSTINE.
ESTROGENS except when separately specified in these Schedules.
ESTRONE.
ESTROPIPATE (piperazine estrone sulfate).
ETACRYNIC ACID.
ETANERCEPT.
ETHAMBUTOL.
ETHAMIVAN.
ETHCHLORVYNOL.
ETHER for use in anaesthesia.
ETHINAMATE.
ETHINYLESTRADIOL.
ETHIONAMIDE.
# ETHISTERONE.

SCHEDULE 4
ETHOGLUCID.
ETHOHEPTAZINE.
ETHOPROPAZINE.
ETHOSUXIMIDE.
ETHOTOIN.
ETHOXZOLAMIDE.
ETHYL CHLORIDE for human therapeutic use.
# ETHYLDIENOLONE.
ETHYLMORPHINE when compounded with one or more other therapeutically active

substances:
a) in divided preparations containing not more than 100 mg of ethylmorphine per

dosage unit; or
b) in undivided preparations with a concentration of not more than 2.5 per cent of
ethylmorphine;
# ETHYLESTRENOL.
ETIDOCAINE.
ETIDRONIC ACID (includes etidronate disodium):
a) for internal use; or

b) in topical preparations except in preparations containing 1 per cent or less of
etidronic acid.
ETILEFRIN.
ETIPROSTON.
ETODOLAC.
ETOFENAMATE except when included in Schedule 2.
ETONOGESTREL.
ETOPOSIDE.
ETORICOXIB.

SCHEDULE 4
ETRAVIRINE.
# ETRETINATE.
ETYNODIOL.
EVEROLIMUS.
EXEMESTANE.
EXENATIDE.
EZETIMIBE.
FAMCICLOVIR except when included in Schedule 3.
FAMOTIDINE except when included in Schedule 2.
FASORACETAM.
FEBUXOSTAT.
FELBINAC except when included in Schedule 2.
FELODIPINE.
FELYPRESSIN.
FENBUFEN.
FENCAMFAMIN.
FENCLOFENAC.
FENFLURAMINE.
FENOFIBRATE.
FENOLDOPAM.
FENOPROFEN.
FENOTEROL.
FENPIPRAMIDE.
FENPIPRANE.
FENPROPOREX.

SCHEDULE 4
FENPROSTALENE.
FERRIC DERISOMALTOSE.
FEXOFENADINE except:

b) in divided preparations for the treatment of seasonal allergic rhinitis in adults and
children 12 years of age and over when:
days’ supply; and
fexofenadine;
c) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age
and over when:
days’ supply; and
fexofenadine; or
d) for the treatment of seasonal allergic rhinitis and children 6 years of age and over
when:
days’ supply; and
fexofenadine.
FIBRINOLYSIN except for external use.
# FIBROBLAST GROWTH FACTORS.
FIDAXOMICIN.
FILGOTINIB.
FILGRASTIM.
FINASTERIDE.
FINGOLIMOD.
FIROCOXIB.
FLECAINIDE.

SCHEDULE 4
FLEROXACIN.
FLOCTAFENINE.
FLORFENICOL.
FLUANISONE.
FLUCLOROLONE.
FLUCLOXACILLIN.
FLUCONAZOLE except when included in Schedule 3.
FLUCYTOSINE.
FLUDARABINE.
FLUDROCORTISONE.
FLUFENAMIC ACID.
FLUMAZENIL.
FLUMETASONE.
FLUMETHIAZIDE.
FLUNISOLIDE.
FLUNIXIN MEGLUMINE.
FLUOCINOLONE.
FLUOCINONIDE.
FLUOCORTIN.
FLUOCORTOLONE.
FLUORESCEIN in preparations for injection.
FLUORIDES in preparations for human use except when included in or expressly excluded
from Schedule 2 or 3.
FLUOROMETHOLONE.
FLUOROURACIL.
FLUOXETINE.

SCHEDULE 4
# FLUOXYMESTERONE.
FLUPENTIXOL.
FLUPHENAZINE.
FLUPROSTENOL.
FLURANDRENOLONE.
# FLURAZEPAM.
FLURBIPROFEN except when included in or expressly excluded from Schedule 2.
FLUROXENE for human therapeutic use.
FLUSPIRILENE.
FLUTAMIDE.
FLUTICASONE except when included in Schedule 2.
FLUVASTATIN.
FLUVOXAMINE.
FOLIC ACID in preparations for human use for injection.
FOLINIC ACID in preparations for human use for injection.
FOLLICLE-STIMULATING HORMONE except when separately specified in this Schedule.
# FOLLISTATIN.
# FOLLITROPIN ALFA.
# FOLLITROPIN BETA.
# FOLLITROPIN DELTA.
FOMEPIZOLE.
FOMIVIRSEN.
FONDAPARINUX.
# FORMEBOLONE.
FORMESTANE.

SCHEDULE 4
FORMOTEROL
FOSAMPRENAVIR.
FOSAPREPITANT.
FOSCARNET.
FOSFESTROL (diethylstilbestrol diphosphate).
FOSFOMYCIN.
FOSINOPRIL.
FOSNETUPITANT.
FOSPHENYTOIN.
FOTEMUSTINE.
FRAMYCETIN.
FULVESTRANT.
FURALTADONE.
# FURAZABOL.
FURAZOLIDONE.
FUROSEMIDE (frusemide).
FUSIDIC ACID.
GABAPENTIN.
GALANTAMINE.
GALANTHUS spp.
GALCANEZUMAB.
GALLAMINE.
GALSULFASE.
GANCICLOVIR.
GANIRELIX.

SCHEDULE 4
GATIFLOXACIN.
GRAZOPREVIR.
GEFITINIB.
GEMCITABINE.
GEMEPROST.
GEMFIBROZIL.
GEMIFLOXACIN.
GEMTUZUMAB OZOGAMICIN.
GENTAMICIN.
GESTODENE.
GESTONORONE.
# GESTRINONE.
GHRH INJECTABLE PLASMID.
GILTERITINIB.
GITALIN.
GLATIRAMER ACETATE.
GLECAPREVIR.
GLIBENCLAMIDE.
GLIBORNURIDE.
GLICLAZIDE.
GLIMEPIRIDE.
GLIPIZIDE.
GLISOXEPIDE.
GLUTATHIONE for parenteral use.
# GLUTETHIMIDE.

SCHEDULE 4
GLYCERYL TRINITRATE except when included in Schedule 3.
GLYCOPYRRONIUM in preparations for injection.
GLYMIDINE.
GnRH VACCINE.
GOLIMUMAB.
GONADORELIN.
GONADOTROPHIC HORMONES except when separately specified in this Schedule.
GOSERELIN.
GRAMICIDIN.
GRANISETRON.
GRAPIPRANT.
GREPAFLOXACIN.
GRISEOFULVIN.
# GROWTH HORMONE RELEASING HORMONES* (GHRHs).
# GROWTH HORMONE RELEASING PEPTIDES (GHRPs).
# GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6).
# GROWTH HORMONE SECRETAGOGUES* (GHSs).
GUAIFENESIN for human therapeutic use except:

b) in oral liquid preparations containing 2 per cent or less of guaifenesin; or
c) in divided preparations containing 200 mg or less of guaifenesin per dosage unit.
GUANABENZ.
GUANACLINE.
GUANETHIDINE.
GUANFACINE.
GUANIDINE for therapeutic use.

SCHEDULE 4
GUSELKUMAB.
HACHIMYCIN.
HAEMATIN.
HAEMOPHILUS INFLUENZAE VACCINE.
HALCINONIDE.
HALOFANTRINE.
HALOFENATE.
HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the
HALOPERIDOL.
HALOTHANE for therapeutic use.
HEMEROCALLIS (Hemerocallis flava).
HEPARINS for internal use except when separately specified in this Schedule.
HEPATITIS A VACCINE.
HEPATITIS B VACCINE.
HETACILLIN.
HEXACHLOROPHENE:
a) in preparations for use on infants; or

b) in other preparations except:
i) when included in Schedule 2 or 6; or
ii) in preparations containing 0.75 per cent or less of hexachlorophene.
HEXAMETHONIUM.
# HEXARELIN.
HEXETIDINE for human internal use.
HEXOBENDINE.
HEXOCYCLIUM.

SCHEDULE 4
HEXOPRENALINE.
HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE).
HISTAMINE for therapeutic use except in preparations containing 0.5 per cent or less of
histamine.
HMG-CoA REDUCTASE INHIBITORS (including "statins") except when separately specified

in these Schedules.
HOMATROPINE.
HUMAN CHORIONIC GONADATROPHIN except in pregnancy test kits.
HUMAN PAPILLOMAVIRUS VACCINE.
HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation.
HYDRALAZINE.
HYDRARGAPHEN.
HYDROCHLOROTHIAZIDE.
HYDROCORTISONE:
a) for human use except when included in Schedule 2 or 3; or

b) for the treatment of animals.
HYDROCYANIC ACID for therapeutic use.
HYDROFLUMETHIAZIDE.
HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in
preparations for human therapeutic or cosmetic use except:

b) in hair preparations containing 0.3 per cent or less of hydroquinone; or
c) in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.
HYDROXYCARBAMIDE.
# HYDROXYCHLOROQUINE.
HYDROXYEPHEDRINE.
HYDROXYPHENAMATE.

SCHEDULE 4
HYDROXYPROGESTERONE.
# HYDROXYSTENOZOL.
HYDROXYZINE.
HYGROMYCIN.
HYOSCINE except when included in Schedule 2.
HYOSCYAMINE except when included in Schedule 2.
HYOSCINE BUTYLBROMIDE except when included in Schedule 2 or Schedule 3.
HYOSCYAMUS NIGER except:

b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.
HYPOTHALAMIC RELEASING FACTORS except when separately specified in this

Schedule.
HYPROMELLOSE in preparations for injection.
IBAFLOXACIN for veterinary use.
IBANDRONIC ACID.
IBOGAINE.
IBRITUMOMAB.
IBRUTINIB.
IBUFENAC.
IBUPROFEN except:
a) when included in or expressly excluded from Schedule 2 or 3; or

b) in preparations for dermal use.
# IBUTAMOREN.
IBUTEROL.
IBUTILIDE.
ICATIBANT.

SCHEDULE 4
IDARUBICIN.
IDARUCIZUMAB
IDEBENONE.
IDOXURIDINE except in preparations containing 0.5 per cent or less of idoxuridine for dermal
use.
IDURSULFASE.
IFOSFAMIDE.
ILOPROST.
IMATINIB.
IMEPITOIN.
IMIDAPRIL.
IMIGLUCERASE.
IMIPENIM.
IMIPRAMINE.
IMIQUIMOD.
IMMUNOGLOBULINS for human parenteral use except when separately specified in these
Schedules.
INDACATEROL.
INDAPAMIDE.
INDINAVIR.
INDOMETACIN except when included in Schedule 2.
INDOPROFEN.
INDORAMIN.
INFLIXIMAB.
INFLUENZA AND CORYZA VACCINES:
a) for parenteral use; or

SCHEDULE 4
b) for nasal administration.
INGENOL MEBUTATE.
INOTUZUMAB OZOGAMICIN.
INSULIN DEGLUDEC.
INSULIN GLARGINE.
# INSULIN-LIKE GROWTH FACTOR I.
# INSULIN-LIKE GROWTH FACTORS except when separately specified in this Schedule.
INSULINS.
INTERFERONS.
INTERLEUKINS except when separately specified in these Schedules.
IODOTHIOURACIL.
# IPAMORELIN.
IPILIMUMAB.
IPRATROPIUM except when included in Schedule 2.
IPRIFLAVONE.
IPRINDOLE.
IPRONIAZID.
IRBESARTAN.
IRINOTECAN.
IRON COMPOUNDS in injectable preparations for human use.
ISAVUCONAZOLE.
ISOAMINILE.
ISOAMYL NITRITE.
ISOBUTYL NITRITE.
ISOCARBOXAZID.

SCHEDULE 4
ISOCONAZOLE except when included in Schedule 2, 3 or 6.
ISOETARINE.
ISOFLURANE for therapeutic use.
ISOMETHEPTENE.
ISONIAZID.
ISOPRENALINE.
ISOPRINOSINE.
ISOPROPAMIDE except when included in Schedule 2.
ISOSORBIDE DINITRATE except when included in Schedule 3.
ISOSORBIDE MONONITRATE.
# ISOTRETINOIN.
ISOXICAM.
ISOXSUPRINE.
ISRADIPINE.
ITRACONAZOLE.
IVABRADINE.
IVACAFTOR.
IVERMECTIN:
a) for human use; or

b) for the treatment of mange in dogs.
IXABEPILONE.
IXAZOMIB.
IXEKIZUMAB.
JAPANESE ENCEPHALITIS VACCINE.
KANAMYCIN.

SCHEDULE 4
KETANSERIN except in topical veterinary preparations containing 0.5 per cent or less of
ketanserin.
# KETAZOLAM.
KETOCONAZOLE except:

b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the
treatment of the scalp; or
c) in preparations for dermal use for the treatment of tinea pedis.
KETOPROFEN except:
a) in preparations for dermal use; or

b) when included in Schedule 3.
KETOROLAC (includes ketoralac trometamol).
KETOTIFEN except when included in Schedule 2.
KHELLIN.
KITASAMYCIN except:
a) when included in Schedule 5 ; or

substances.
LABETALOL.
LACIDIPINE.
LACOSAMIDE.
LAMIVUDINE.
LAMOTRIGINE.
LANADELUMAB.
LANATOSIDES.
LANREOTIDE.
LANSOPRAZOLE except when included in Schedule 2 or 3.
LANTHANUM for therapeutic use.

SCHEDULE 4
LAPATINIB.
LARONIDASE.
LAROPIPRANT.
LAROTRECTINIB.
LATAMOXEF.
LATANOPROST.
LAUDEXIUM.
LAUROMACROGOLS in preparations for injection except:
a) when present as an excipient; or

b) when separately specified in these Schedules.
LEAD for human therapeutic use.
LEDIPASVIR.
LEFETAMINE.
LEFLUNOMIDE.
# LENALIDOMIDE.
LENOGRASTIM.
LENVATINIB.
LEPIRUDIN.
LEPTAZOL.
LERCANIDIPINE.
LESINURAD.
LETERMOVIR.
LETROZOLE.
LEUPRORELIN.
LEVALLORPHAN.

SCHEDULE 4
LEVAMISOLE:
a) for human therapeutic use; or

b) in preparations for the prevention or treatment of heartworm in dogs.
LEVETIRACETAM.
LEVOBUNOLOL.
LEVOBUPIVACAINE.
LEVOCABASTINE except when included in Schedule 2.
LEVOCETIRIZINE except:

adults and children 12 years of age and over when:
i) in a primary pack containing not more than 5 days’ supply; and
ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
LEVODOPA.
LEVOMEPROMAZINE.
LEVOMILNACIPRAN.
LEVONORGESTREL except when included in Schedule 3.
LEVOSIMENDAN.
LIDOCAINE except:
a) when included in Schedules 2 or 5;

substances per dosage unit; or
c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.
LIDOFLAZINE.
LIFITEGRAST.
LINACLOTIDE.
LINAGLIPTIN.
LINCOMYCIN.

SCHEDULE 4
LINDANE for human therapeutic use except when included in Schedule 2.
LINEZOLID.
LIOTHYRONINE.
LIPEGFILGRASTIM.
LIRAGLUTIDE.
LISINOPRIL.
LISURIDE.
LITHIUM for therapeutic use except:

b) when present as an excipient in preparations for dermal use containing 0.25 per cent
or less of lithium; or
c) in preparations containing 0.01 per cent or less of lithium.
LIXISENATIDE.
LODOXAMIDE except when included in Schedule 2.
LOFEXIDINE.
LOGIPARIN for internal use.
LOMEFLOXACIN.
LOMUSTINE.
LOPERAMIDE except:

b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in
a primary pack containing 8 dosage units or less.
LOPINAVIR.
# LOPRAZOLAM.
LORACARBEF.
LORATADINE except:

SCHEDULE 4
adults and children 6 years of age and over, when:
i) in a primary pack containing 10 dosage units or less; and
ii) labelled with a recommended daily dose not exceeding 10 mg of loratadine.
# LORAZEPAM.
LORLATINIB.
# LORMETAZEPAM.
LOSARTAN.
LOTEPREDNOL.
LOXAPINE.
LUMACAFTOR.
LUMEFANTRINE.
LUMIRACOXIB.
LURASIDONE.
# LUTEINISING HORMONE except in ovulation test kits.
LYMECYCLINE.
MACITENTAN for human use.
MAFENIDE except when included in Schedule 6.
MANDRAGORA OFFICINARUM.
MANNOMUSTINE.
MAPROTILINE.
MARAVIROC.
MARBOFLOXACIN.
MAROPITANT.
MAVACOXIB.
MAZINDOL.

SCHEDULE 4
MEASLES VACCINE.
MEBANAZINE.
MEBEVERINE.
MEBHYDROLIN.
# MEBOLAZINE.
MEBUTAMATE.
MECAMYLAMINE.
MECASERMIN.
MECILLINAM.
MECLOCYCLINE.
MECLOFENAMATE.
MECLOFENOXATE.
MECLOZINE except when included in Schedule 2.
# MEDAZEPAM.
MEDETOMIDINE.
MEDIGOXIN (methyldigoxin).
MEDROXYPROGESTERONE.
MEDRYSONE.
MEFENAMIC ACID except when included in Schedule 2.
MEFENOREX.
MEFLOQUINE.
MEFRUSIDE.
MEGESTROL.
MELAGATRAN.
MELANOTAN II.

SCHEDULE 4
MELATONIN for human use.
MELENGESTROL except when included in Schedule 6.
MELOXICAM.
MELPHALAN.
MEMANTINE.
MENINGOCOCCAL VACCINE.
MENINGOCOCCAL GROUP B VACCINE.
MENOTROPHIN.
MEPACRINE.
MEPENZOLATE.
MEPHENESIN.
MEPHENTERMINE.
MEPINDOLOL.
# MEPITIOSTANE.
MEPIVACAINE.
MEPROBAMATE.
MEPTAZINOL.
MEPYRAMINE except when included in Schedule 2 or 3.
MEQUITAZINE.
MERCAPTAMINE for human therapeutic use.
MERCAPTOMERIN.
MERCAPTOPURINE.
MERCUROCHROME except when included in Schedule 2 or 6.
MERCURY for cosmetic or therapeutic use except:

SCHEDULE 4
b) in a sealed device which prevents access to the mercury.
MEROPENEM.
MERSALYL.
# MESABOLONE.
MESALAZINE.
MESNA.
# MESTANOLONE (androstalone).
# MESTEROLONE.
MESTRANOL.
# METANDIENONE.
METARAMINOL.
# METENOLONE.
METERGOLINE.
METFORMIN.
METHACHOLINE.
METHACYCLINE.
METHALLENESTRIL.
# METHANDRIOL.
METHANTHELINIUM.
METHAZOLAMIDE.
METHDILAZINE except when included in Schedule 3.
# METHENOLONE.
METHICILLIN.
METHIMAZOLE.
METHISAZONE.

SCHEDULE 4
METHIXENE.
METHOCARBAMOL.
METHOHEXITONE.
METHOIN.
METHOTREXATE.
METHOXAMINE except:

b) in preparations for external use containing 1 per cent or less of methoxamine.
METHOXSALEN.
METHOXYFLURANE.
METHSUXIMIDE.
METHYCLOTHIAZIDE.
METHYL AMINOLEVULINATE.
#METHYLANDROSTANOLONE.
# METHYLCLOSTEBOL.
METHYLDOPA.
METHYLENE BLUE in preparations for injection.
METHYLERGOMETRINE.
METHYLMERCURY for therapeutic use.
METHYLNALTREXONE.
METHYLPENTYNOL.
METHYLPHENOBARBITAL.
METHYLPHENYLPIRACETAM.
METHYLPREDNISOLONE.
METHYLROSANILINIUM CHLORIDE for human use except when used as a dermal marker.

SCHEDULE 4
METHYL SALICYLATE in preparations for internal therapeutic use.
# METHYLTESTOSTERONE.
METHYLTHIOURACIL.
# METHYLTRIENOLONE.
METHYPRYLONE.
METHYSERGIDE.
METOCLOPRAMIDE except when included in Schedule 3.
METOLAZONE.
METOPROLOL.
# METRIBOLONE.
METRIFONATE (trichlorfon) for human therapeutic use.
METRONIDAZOLE.
METYRAPONE.
MEXILETINE.
MEZLOCILLIN.
MIANSERIN.
MIBEFRADIL.
# MIBOLERONE.
MICAFUNGIN.
MICONAZOLE except:

# MIDAZOLAM.
MIDOSTAURIN.
MIDODRINE.

SCHEDULE 4
MIFEPRISTONE.
MIGALASTAT.
MIGLITOL.
MIGLUSTAT.
MILBEMYCIN OXIME except when included in Schedule 5.
MILNACIPRAN.
MILRINONE.
MINOCYCLINE.
MINOXIDIL except when included in Schedule 2.
MIRABEGRON.
MIRTAZAPINE.
MISOPROSTOL.
MITOBRONITOL.
MITOMYCIN.
MITOTANE.
MITOXANTRONE.
MITRATAPIDE.
MIVACURIUM CHLORIDE.
MOCLOBEMIDE.
MODAFINIL.
MOLGRAMOSTIM.
MOLINDONE.
MOMETASONE except when included in Schedule 2 or Schedule 3.
MONENSIN except:

SCHEDULE 4
b) in animal feeds containing 360 mg/kg or less of antibiotic substances.
MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use
except in cosmetic nail preparations containing 0.02 per cent or less of monobenzone or alkyl
ethers of hydroquinone.
MONOCLONAL ANTIBODIES for therapeutic use except:
a) in diagnostic test kits; or

MONOETHANOLAMINE in preparations for injection.
MONTELUKAST.
MOPERONE.
MORAZONE.
MORICIZINE.
MOTRAZEPAM.
MOTRETINIDE.
MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin except
when included in Schedule 5 or 6.
MOXIFLOXACIN.
MOXONIDINE.
MUMPS VACCINE.
MUPIROCIN.
MURAGLITAZAR.
MUROMONAB.
MUSTINE (nitrogen mustard).
MYCOPHENOLIC ACID (includes mycophenolate mofetil).
NABUMETONE.
NADOLOL.
NADROPARIN.

SCHEDULE 4
NAFARELIN.
NAFTIDROFURYL.
NALBUPHINE.
NALIDIXIC ACID.
NALMEFENE.
NALORPHINE.
NALOXEGOL.
NALOXONE except when in Schedule 3.
NALTREXONE.
# NANDROLONE.
NAPROXEN except when included in Schedule 2 or 3.
NARASIN except:

NARATRIPTAN.
NATALIZUMAB.
NATAMYCIN except for use as a food additive.
NATEGLINIDE.
NEBACUMAB.
NEBIVOLOL.
NEBRACETAM.
NEDOCROMIL.
NEFAZODONE.
NEFIRACETAM.
NEFOPAM.

SCHEDULE 4
NELFINAVIR (includes nelfinavir mesilate).
NEOMYCIN.
NEOSTIGMINE.
NEPAFENAC.
NERATINIB.
NERIUM OLEANDER.
NESIRITIDE.
NETILMICIN.
NETUPITANT.
NEVIRAPINE.
NIALAMIDE.
NICARDIPINE.
NICERGOLINE.
NICOFURANOSE.
NICORANDIL.
NICOTINE in preparations for human therapeutic use except for use as an aid in withdrawal
from tobacco smoking in preparations for oromucosal or transdermal use.
NICOTINIC ACID for human therapeutic use except:

b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
c) nicotinamide.
NICOUMALONE.
NIFEDIPINE.
NIFENAZONE.
NIKETHAMIDE.
NILOTINIB.

SCHEDULE 4
NILUTAMIDE.
NIMESULIDE.
NIMODIPINE.
NIMORAZOLE.
NINTEDANIB.
NIRAPARIB.
NIRIDAZOLE.
NISOLDIPINE.
NITISINONE.
# NITRAZEPAM.
NITRENDIPINE.
NITRIC OXIDE for human therapeutic use.
NITROFURANTOIN.
NITROFURAZONE.
NITROUS OXIDE for therapeutic use.
NITROXOLINE.
NIVOLUMAB.
NIZATIDINE except when included in Schedule 2.
NOMEGESTROL.
NOMIFENSINE.
NORADRENALINE.
# 19-NORANDROSTENEDIOL.
# 19-NORANDROSTENEDIONE.
# NORANDROSTENOLONE.
# NORBOLETHONE.

SCHEDULE 4
# NORCLOSTEBOL.
NORELGESTROMIN.
# NORETHANDROLONE.
NORETHISTERONE.
NORFLOXACIN.
NORGESTREL.
NORIBOGAINE.
NORMAL HUMAN IMMUNOGLOBULIN.
# NORMETHANDRONE.
NORTRIPTYLINE.
NOVOBIOCIN.
NOXIPTYLINE.
NUSINERSEN.
NYSTATIN except when included in Schedule 2 or 3.
OBETICHOLIC ACID.
OCLACITINIB.
OCRELIZUMAB.
OCRIPLASMIN.
OCTAMYLAMINE.
OCTATROPINE.
OCTREOTIDE.
OCTYL NITRITE.
OFATUMUMAB.
OFLOXACIN.
OLANZAPINE.

SCHEDULE 4
OLAPARIB.
OLARATUMAB.
OLEANDOMYCIN except:

substances.
OLEANDRIN.
OLMESARTAN.
OLODATEROL.
OLOPATADINE.
OLSALAZINE.
OMALIZUMAB.
OMBERACETAM.
OMBITASVIR.
OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic
use, for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.
OMEPRAZOLE except when included in Schedule 2 or 3.
ONASEMNOGENE ABEPARVOVEC.
ONDANSETRON.
OPICAPONE.
OPIPRAMOL.
ORBIFLOXACIN.
ORCIPRENALINE.
ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human

therapeutic use except:

b) in preparations containing 2 per cent or less of malathion for external use.

SCHEDULE 4
ORLISTAT except when included in Schedule 3.
ORNIDAZOLE.
ORNIPRESSIN.
ORPHENADRINE.
ORTHOPTERIN.
OSELTAMIVIR.
OSIMERTINIB.
OUABAIN.
# OVANDROTONE.
# OXABOLONE.
OXACILLIN.
OXALIPLATIN.
# OXANDROLONE.
OXAPROZIN.
# OXAZEPAM.
OXCARBAZEPINE.
OXEDRINE for human internal use except in preparations labelled with a recommended daily
dose of 30 mg or less of oxedrine.
OXETACAINE (oxethazaine) except when included in Schedule 2.
OXICONAZOLE except:

OXIRACETAM.
OXITROPIUM.
OXOLAMINE.
OXOLINIC ACID.

SCHEDULE 4
OXPRENOLOL.
OXYBUPROCAINE.
OXYBUTYNIN.
# OXYMESTERONE.
# OXYMETHOLONE.
OXYPHENBUTAZONE.
OXYPHENCYCLIMINE.
OXYPHENONIUM.
OXYTETRACYCLINE except when included in Schedule 5.
OXYTOCIN.
OZANIMOD.
PACLITAXEL.
PALBOCICLIB.
PALIFERMIN.
PALIPERIDONE.
PALIVIZUMAB.
PALONOSETRON.
PAMAQUIN.
PAMIDRONIC ACID (includes pamidronate disodium).
PANCREATIC ENZYMES except:
a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit;
or
PANCURONIUM.
PANITUMUMAB.
PANOBINOSTAT.

SCHEDULE 4
PANTOPRAZOLE except when included in Schedule 2 or 3.
PAPAVERINE in preparations for injection.
PARACETAMOL:
a) when combined with aspirin or salicylamide or any derivative of these substances

except when separately specified in these Schedules;
b) when combined with ibuprofen in a primary pack containing more than 30 dosage
units;
c) in modified release tablets or capsules containing more than 665 mg paracetamol;
d) in non-modified release tablets or capsules containing more than 500 mg
paracetamol;
e) in individually wrapped powders or sachets of granules each containing more than
1000 mg paracetamol;
f) in tablets or capsules enclosed in a primary pack containing more than 100 tablets or
capsules except in Schedule 2 or Schedule 3;
g) in individually wrapped powders or sachets of granules enclosed in a primary pack
containing more than 50 wrapped powders or sachets of granules except when
included in Schedule 2;
h) for injection;
i) for the treatment of animals.
PARALDEHYDE.
PARAMETHADIONE.
PARAMETHASONE.
PARECOXIB.
PARICALCITOL.
PARITAPREVIR.
PAROMOMYCIN.
PAROXETINE.
PASIREOTIDE.
PATIROMER SORBITEX CALCIUM.
PAZOPANIB.
PECAZINE.

SCHEDULE 4
PEFLOXACIN.
PEGAPTANIB.
PEGASPARGASE.
PEGFILGRASTIM.
PEGINTERFERON.
PEGVISOMANT.
PEMBROLIZUMAB.
PEMETREXED.
PEMOLINE.
PEMPIDINE.
PENBUTOLOL.
PENCICLOVIR except in preparations containing 1 per cent or less of penciclovir for the
treatment of herpes labialis in packs containing 10 g or less.
PENETHAMATE.
PENICILLAMINE.
PENTAERYTHRITYL TETRANITRATE.
PENTAGASTRIN.
PENTAMETHONIUM.
PENTAMIDINE (includes pentamidine isetionate).
PENTHIENATE.
PENTOBARBITAL when packed and labelled for injection.
PENTOLINIUM.
PENTOSAN POLYSULFATE SODIUM.
PENTOXIFYLLINE.
PERAMIVIR.
# PERAMPANEL.

SCHEDULE 4
PERGOLIDE.
PERHEXILINE.
PERICIAZINE.
PERINDOPRIL.
PERMETHRIN for human therapeutic use except in preparations containing 5 per cent or less
of permethrin.
PERPHENAZINE.
PERTUSSIS ANTIGEN.
PERTUZUMAB.
PHENACEMIDE.
PHENACETIN for therapeutic use (excluding when present as an excipient).
PHENAGLYCODOL.
PHENAZONE except when included in Schedule 2 or 5.
PHENAZOPYRIDINE.
PHENELZINE.
PHENETICILLIN.
PHENFORMIN.
PHENGLUTARIMIDE.
PHENINDIONE.
PHENIRAMINE except when included in Schedule 2 or 3.
PHENISATIN.
PHENOBARBITAL.
PHENOL in preparations for injection.
PHENOLPHTHALEIN for human therapeutic use.
PHENOXYBENZAMINE.
PHENOXYMETHYLPENICILLIN.

SCHEDULE 4
PHENSUXIMIDE.
# PHENTERMINE.
PHENTHIMENTONIUM.
PHENTOLAMINE.
PHENYLBUTAZONE.
PHENYLEPHRINE:
a) in preparations for injection; or

b) in preparations for human ophthalmic use containing 5 per cent or more of
phenylephrine.
PHENYLPIRACETAM.
PHENYLPROPANOLAMINE.
PHENYLTOLOXAMINE.
PHENYTOIN.
PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract).
PHOLCODINE:
a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

b) in undivided preparations containing 2.5 per cent or less of pholcodine,
PHOSPHODIESTERASE TYPE 5 INHIBITORS except:

b) when present as an unmodified, naturally occurring substance.
PHTHALYLSULFATHIAZOLE.
PHYSOSTIGMINE.
PIBRENTASVIR.
PICROTOXIN.
PILOCARPINE except in preparations containing 0.025 per cent or less of pilocarpine.
PIMECROLIMUS.

SCHEDULE 4
PIMOBENDAN.
PIMOZIDE.
PINACIDIL.
PINDOLOL.
PIOGLITAZONE.
PIPECURONIUM.
PIPEMIDIC ACID.
PIPENZOLATE.
PIPER METHYSTICUM (kava) in preparations for human use except when included on the
Australian Register of Therapeutic Goods in preparations:
a) for oral use when present in tablet, capsule or teabag form that is labelled with a
recommended maximum daily dose of 250 mg or less of kavalactones and:
i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet or
capsule; or
ii) the amount of dried whole or peeled rhizome and/or root in the teabag does not
exceed 3 g;
and, where containing more than 25 mg of kavalactones per dose, compliant with the
b) in topical preparations for use on the rectum, vagina or throat containing dried whole
or peeled rhizome and/or root or containing aqueous dispersions or aqueous extracts
of whole or peeled rhizome and/or root; or
c) in dermal preparations.
PIPERACILLIN.
PIPERIDINE.
PIPERIDOLATE.
PIPOBROMAN.
PIPOTHIAZINE.
PIPRADROL.
PIRACETAM.

SCHEDULE 4
PIRBUTEROL.
PIRENOXINE (catalin).
PIRENZEPINE.
PIRETANIDE.
PIRFENIDONE.
PIROXICAM except in preparations for dermal use.
PIRPROFEN.
PITAVASTATIN.
PITUITARY HORMONES except when separately specified in these Schedules.
PIVAMPICILLIN.
PIZOTIFEN.
PLICAMYCIN.
PLITIDEPSIN.
PLERIXAFOR.
PNEUMOCOCCAL VACCINE.
PODOPHYLLOTOXIN for human use:
a) internally;
b) in preparations for the treatment of anogenital warts; or
c) in other preparations except when included in Schedule 2 or 3.
PODOPHYLLUM EMODI (podophyllin) for human use:
a) internally;
PODOPHYLLUM PELTATUM (podophyllin) for human use:
a) internally;

SCHEDULE 4
POLIDEXIDE.
POLIOMYELITIS VACCINE.
POLYACRYLAMIDE in preparations for injection or implantation:

b) for cosmetic use; or
c) for veterinary use.
POLYCAPROLACTONE in preparations for injection or implantation:

POLYESTRADIOL.
POLYLACTIC ACID in preparations for injection or implantation:

POLYMYXIN.
POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, except when

separately specified in these Schedules.
POLYTHIAZIDE.
POMALIDOMIDE.
PORACTANT.
POSACONAZOLE.
POTASSIUM BROMIDE for therapeutic use.
POTASSIUM CHLORIDE in oral preparations for human therapeutic use except:
a) when containing less than 550 mg of potassium chloride per dosage unit;
b) in preparations for oral rehydration therapy;
c) in preparations for oral use for bowel cleansing prior to diagnostic medical and
surgical procedures; or
d) in preparations for enteral feeding.
POTASSIUM PERCHLORATE for therapeutic use.

SCHEDULE 4
PRACTOLOL.
PRADOFLOXACIN.
PRALATREXATE.
PRALIDOXIME.
PRAMIPEXOLE.
PRAMIRACETAM.
PRAMOCAINE.
# PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2 (GHRP-2)).
PRAMPINE.
# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).
PRASUGREL.
PRAVASTATIN.
# PRAZEPAM.
PRAZIQUANTEL for human therapeutic use.
PRAZOSIN.
PREDNISOLONE.
PREDNISONE.
PREGABALIN.
PREGNENOLONE.
PRENALTEROL.
PRENYLAMINE.
PRILOCAINE except when included in Schedule 2.
PRIMAQUINE.
PRIMIDONE.
PROBENECID.

SCHEDULE 4
PROBUCOL.
PROCAINAMIDE.
PROCAINE.
PROCAINE BENZYLPENICILLIN.
PROCARBAZINE.
PROCHLORPERAZINE except when included in Schedule 3.
PROCYCLIDINE except when included in Schedule 2.
PROGESTERONE except when included in Schedule 5.
PROGESTOGENS except when separately specified in these Schedules.
PROGLUMIDE.
PROGUANIL.
PROLINTANE.
PROMAZINE.
PROMETHAZINE except when included in Schedule 2 or 3.
PROMOXOLANE.
PROPAFENONE.
PROPAMIDINE for therapeutic use except when included in Schedule 2.
PROPANIDID.
PROPANTHELINE.
PROPENTOFYLLINE.
# PROPETANDROL.
PROPIONIBACTERIUM ACNES for therapeutic use.
PROPOFOL.
PROPRANOLOL.
PROPYLHEXEDRINE.

SCHEDULE 4
PROPYLTHIOURACIL.
PROPYPHENAZONE.
PROQUAZONE.
PROSCILLARIDIN.
PROSTAGLANDINS except when separately specified in this Schedule.
PROSTIANOL.
PROTAMINE.
PROTHIONAMIDE.
PROTHIPENDYL.
PROTIRELIN.
PROTOVERATRINES.
PROTRIPTYLINE.
PROXYMETACAINE.
PRUCALOPRIDE.
PSEUDOEPHEDRINE except when included in Schedule 3.
PYRAZINAMIDE.
PYRIDINOLCARBAMATE.
PYRIDOSTIGMINE.
PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use except:
a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine,

pyridoxal or pyridoxamine per recommended daily dose when compliant with the
requirements of the Required Advisory Statements for Medicine Labels; or
b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or
pyridoxamine per recommended daily dose.
PYRIMETHAMINE.
PYROVALERONE.
PYRVINIUM.

SCHEDULE 4
# QUAZEPAM.
QUETIAPINE.
QUINAGOLIDE.
QUINAPRIL.
# QUINBOLONE.
QUINETHAZONE.
QUINIDINE.
QUININE for human therapeutic use except when the maximum recommended daily dose is
50 mg or less of quinine.
QUINISOCAINE (dimethisoquin).
QUINUPRISTIN.
RABEPRAZOLE except when included in Schedule 2 or 3.
RABIES VACCINE.
RACETAMS except when separately specified in these Schedules.
RACTOPAMINE except when included in Schedule 5.
RALOXIFENE.
RALTEGRAVIR.
RALTITREXED.
RAMIPRIL.
RAMUCIRUMAB.
RANIBIZUMAB.
RANITIDINE except:

b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage
unit when supplied in the manufacturer’s original pack containing not more than
14 dosage units;
c) in divided preparations for oral use containing 300mg or less of ranitidine per dosage
unit in the manufacturer’s original pack containing not more than 7 dosage units.

SCHEDULE 4
RANOLAZINE.
RAPACURONIUM.
RASAGILINE.
RASBURICASE.
RAUWOLFIA SERPENTINA.
RAUWOLFIA VOMITORIA.
RAZOXANE.
REBOXETINE.
RED YEAST RICE for human therapeutic use.
REMDESIVIR.
REGORAFENIB.
REMOXIPRIDE.
REPAGLINIDE.
RESERPINE.
RESLIZUMAB.
RETAPAMULIN.
RETEPLASE.
RETIGABINE.
RIBAVIRIN.
RIBOCICLIB.
RIDAFOROLIMUS.
RIFABUTIN.
RIFAMPICIN.
RIFAMYCIN.
RIFAPENTINE.

SCHEDULE 4
RIFAXIMIN.
RILPIVIRINE.
RILUZOLE.
RIMEXOLONE.
RIMITEROL.
RIMONABANT.
RIOCIGUAT.
RIPRETINIB.
RISANKIZUMAB.
RISEDRONIC ACID.
RISPERIDONE.
RITODRINE.
RITONAVIR.
RITUXIMAB.
RIVAROXABAN.
RIVASTIGMINE.
RIZATRIPTAN except when included in Schedule 3.
ROBENACOXIB.
ROCURONIUM.
ROFECOXIB.
ROFLUMILAST.
ROLITETRACYCLINE.
ROLZIRACETAM.
ROMIDEPSIN.
ROMIFIDINE.

SCHEDULE 4
ROMIPLOSTIM.
ROMOSOZUMAB.
RONIDAZOLE.
ROPINIROLE.
ROPIVACAINE.
ROSIGLITAZONE.
ROSOXACIN.
ROSUVASTATIN.
ROTIGOTINE.
# ROXIBOLONE.
ROXITHROMYCIN.
RUBELLA VACCINE.
RUBOXISTAURIN.
RUFINAMIDE.
RUPATADINE.
RUXOLITINIB.
SACUBITRIL.
SAFINAMIDE
SALBUTAMOL except when included in Schedule 3.
SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of

these substances.
SALINOMYCIN except:

SALMETEROL.
SAPROPTERIN.

SCHEDULE 4
SAQUINAVIR.
SARILUMAB.
SARS-COV-2 (COVID-19) VACCINE.
SAXAGLIPTIN.
SCHOENOCAULON OFFICINALE (sabadilla) except in preparations containing 10 mg/kg or

10 mg/L or less of total alkaloids of Schoenocaulon officinale.
SCOPOLIA CARNIOLICA for therapeutic use.
SEBELIPASE ALFA.
SECUKINUMAB.
# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).
SELEGILINE.
SELENIUM:
a) for human oral use with a recommended daily dose of more than 300 micrograms; or
b) for the treatment of animals except:
i) when included in Schedule 6 or 7;
ii) in solid, slow release bolus preparations containing 300 mg or less of selenium
per dosage unit;
iii) in other divided preparations containing 30 micrograms or less of selenium per
dosage unit;
iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
v) in feeds containing 1 g/tonne or less of selenium.
SELETRACETAM.
SELEXIPAG.
SEMAGLUTIDE.
SERELAXIN.
SERMORELIN.
SERTINDOLE.
SERTRALINE.

SCHEDULE 4
SEVELAMER.
SEVOFLURANE.
SEX HORMONES and all substances having sex hormonal activity except when separately
specified in these Schedules.
SIBUTRAMINE.
# SILANDRONE.
SILDENAFIL.
SILICONES for intra-ocular use.
SILODOSIN.
SILTUXIMAB.
SILVER SULFADIAZINE.
SIMEPREVIR.
SIMVASTATIN.
SIPONIMOD.
SIROLIMUS.
SISOMICIN (sisomycin).
SITAGLIPTIN.
# SITAXENTAN.
SODIUM BROMIDE for therapeutic use.
SODIUM CELLULOSE PHOSPHATE for human internal use.
SODIUM CROMOGLYCATE except when included in Schedule 2.
SODIUM GLYCEROPHOSPHATE HYDRATE.
SODIUM MORRHUATE in preparations for injection.
SODIUM NITROPRUSSIDE for human therapeutic use.
SODIUM PHENYLBUTYRATE.
SODIUM PHOSPHATE in preparations for oral laxative use.

SCHEDULE 4
SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.
SODIUM SALICYLATE in preparations for internal use for the treatment of animals.
SODIUM TETRADECYLSULFATE in preparations for injection.
SODIUM ZIRCONIUM CYCLOSILICATE.
SOFOSBUVIR.
SOLASODINE.
SOLIFENACIN.
SOMATOSTATIN.
SOMATOTROPIN EQUINE.
# SOMATROPIN (human growth hormone).
SONIDEGIB.
SONTOQUINE.
SORAFENIB.
SOTALOL.
SPARFLOXACIN.
SPARTEINE.
SPECTINOMYCIN.
SPIRAMYCIN.
SPIRAPRIL.
SPIRONOLACTONE.
# STANOLONE.
# STANOZOLOL.
STAVUDINE.
# STENABOLIC (SR9009) and other synthetic REV-ERB agonists.
# STENBOLONE.

SCHEDULE 4
STEROID HORMONES except when separately specified in these Schedules.
STILBESTROL (diethylstilbestrol).
STIRIPENTOL.
STREPTODORNASE.
STREPTOKINASE.
STREPTOMYCIN.
STRONTIUM RANELATE.
STROPHANTHINS.
STROPHANTHUS spp.
STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of
animals.
STRYCHNOS spp. except in preparations containing 1 mg or less per litre or per kilogram of
strychnine.
STYRAMATE.
SUCCIMER.
SUCROFERRIC OXYHYDROXIDE.
SUGAMMADEX.
SULBACTAM.
SULCONAZOLE except when included in Schedule 2.
SULFACETAMIDE except when included in Schedule 3 or 5.
SULFADIAZINE except when included in Schedule 5.
SULFADIMETHOXINE.
SULFADIMIDINE except when included in Schedule 5.
SULFADOXINE.
SULFAFURAZOLE.
SULFAGUANIDINE.

SCHEDULE 4
SULFAMERAZINE except when included in Schedule 5.
SULFAMETHIZOLE.
SULFAMETHOXAZOLE.
SULFAMETHOXYDIAZINE.
SULFAMETHOXYPYRIDAZINE.
SULFAMETROLE.
SULFAMONOMETHOXINE.
SULFAMOXOLE.
SULFAPHENAZOLE.
SULFAPYRIDINE.
SULFAQUINOXALINE.
SULFASALAZINE.
SULFATHIAZOLE except when included in Schedule 5.
SULFATROXAZOLE.
SULFINPYRAZONE.
SULFOMYXIN.
SULFONAMIDES except:
a) when separately specified in this Schedule;

b) when included in Schedule 3, 5 or 6; or
c) when packed and labelled solely for use as a herbicide.
SULFONMETHANE (sulfonal) and alkyl sulfonals.
SULINDAC.
SULTAMICILLIN.
SULTHIAME.
SUMATRIPTAN except when included in Schedule 3.
SUNIFIRAM.

SCHEDULE 4
SUNITINIB.
SUPROFEN.
SUTILAINS.
SUXAMETHONIUM.
SUXETHONIUM.
SUVOREXANT.
TACRINE.
TACROLIMUS.
TADALAFIL.
TAFAMIDIS.
TAFENOQUINE SUCCINATE.
TAFLUPROST.
TALAZOPARIB.
TALIGLUCERASE ALFA.
TALIMOGENE LAHERPAREPVEC.
TAMOXIFEN.
TAMSULOSIN.
TANACETUM VULGARE except in preparations containing 0.8 per cent or less of oil of
tansy.
TASONERMIN.
TAZAROTENE.
TAZOBACTAM.
# TB-500.
T-CELL RECEPTOR ANTIBODY.
TEDUGLUTIDE.
TEGAFUR.

SCHEDULE 4
TEGASEROD.
TELAPREVIR.
TELITHROMYCIN.
TEICOPLANIN.
TELBIVUDINE.
TELMISARTAN.
TELOTRISTAT ETHYL.
# TEMAZEPAM.
TEMOZOLOMIDE.
TEMSIROLIMUS.
TENECTEPLASE.
TENIPOSIDE.
TENOFOVIR.
TENOXICAM.
TEPOXALIN.
TERAZOSIN.
TERBINAFINE except:

TERBUTALINE except when included in Schedule 3.
TERFENADINE.
TERIFLUNOMIDE.
# TERIPARATIDE.
TERLIPRESSIN.
TERODILINE.

SCHEDULE 4
TEROPTERIN.
# TESTOLACTONE.
# TESTOSTERONE except when included in Schedule 6.
TETANUS ANTITOXIN except when used for short-term protection or treatment of tetanus in
animals.
TETANUS TOXOID for human use.
TETRABENAZINE.
TETRACAINE except:

substances.
TETRACOSACTIDE.
TETRACYCLINE except when included in Schedule 5.
TETRAETHYLAMMONIUM.
TETROXOPRIM.
TEZACAFTOR.
# THALIDOMIDE.
THENYLDIAMINE.
THEOPHYLLINE except when included in Schedule 3.
THEVETIA PERUVIANA.
THEVETIN.
THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.
THIAMBUTOSINE.
THIAZOSULFONE.
THIETHYLPERAZINE.
THIOACETAZONE.

SCHEDULE 4
THIOCARLIDE.
# THIOMESTERONE (tiomesterone).
THIOPENTAL.
THIOPROPAZATE.
THIOPROPERAZINE.
THIORIDAZINE.
THIOSTREPTON.
THIOTEPA.
THIOTHIXENE.
THIOURACIL.
THIOUREA for therapeutic use except in preparations containing 0.1 per cent or less of
thiourea.
# THYMOSIN BETA 4 (THYMOSIN β4).
THYMOXAMINE (includes thymoxamine hydrochloride).
THYROID except when separately specified in this Schedule.
THYROTROPHIN.
THYROXINE (includes thyroxine sodium).
TIAGABINE.
TIAMULIN.
# TIANEPTINE.
TIAPROFENIC ACID.
TIARAMIDE.
TIBOLONE.
TICAGRELOR.
TICARCILLIN.
TICLOPIDINE.

SCHEDULE 4
TIEMONIUM.
TIENILIC ACID.
TIGECYCLINE.
TIGILANOL TIGLATE.
TIGLOIDINE.
TILDIPIROSIN.
TILETAMINE.
TILMANOCEPT
TILMICOSIN.
TILUDRONIC ACID (includes disodium tiludronate).
TIMOLOL.
TINIDAZOLE.
TINZAPARIN (includes tinzaparin sodium).
TIOCONAZOLE except:

TIOGUANINE.
TIOTROPIUM.
TIPEPIDINE.
TIPIRACIL.
TIPRANAVIR.
TIRILAZAD.
TIROFIBAN.
TOBRAMYCIN.
TOCAINIDE.

SCHEDULE 4
TOCERANIB.
TOCILIZUMAB.
TOFACITINIB.
TOLAZAMIDE.
TOLAZOLINE.
TOLBUTAMIDE.
TOLCAPONE.
TOLFENAMIC ACID.
TOLMETIN.
TOLONIUM.
TOLPROPAMINE.
TOLRESTAT.
TOLTERODINE.
TOLVAPTAN.
TOPIRAMATE.
TOPOTECAN.
TORASEMIDE.
TOREMIFENE.
TOXOIDS for human parenteral use except when separately specified in these Schedules.
TRAMADOL.
TRANDOLAPRIL.
TRAMETINIB DIMETHYL SULFOXIDE.
TRANEXAMIC ACID except in preparations containing 3 per cent or less of cetyl tranexamate
hydrochloride for dermal cosmetic use.
TRANYLCYPROMINE.
TRASTUZUMAB.

SCHEDULE 4
TRASTUZUMAB EMTANSINE.
TRAVOPROST.
TRAZODONE.
# TRENBOLONE (trienbolone, trienolone) except when included in Schedule 5.
TREOSULPHAN.
TREPROSTINIL.
# TRESTOLONE.
TRETAMINE.
# TRETINOIN.
TRIACETYLOLEANDOMYCIN.
TRIAMCINOLONE except when included in Schedule 2 or 3.
TRIAMTERENE.
TRIAZIQUONE.
# TRIAZOLAM.
TRICHLORMETHIAZIDE.
TRICHLOROACETIC ACID for human dermal use except when in preparations containing
12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital
warts.
TRICHLOROETHYLENE for therapeutic use.
TRICLOFOS.
TRICYCLAMOL.
TRIDIHEXETHYL.
TRIENTINE.
TRIFAROTENE.
TRIFLUOPERAZINE.
TRIFLUPERIDOL.

SCHEDULE 4
TRIFLUPROMAZINE.
TRIFLURIDINE.
TRIHEXYPHENIDYL.
TRILOSTANE.
TRIMETAPHAN.
TRIMETHOPRIM.
TRIMIPRAMINE.
TRIMUSTINE.
TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.
TRIOXYSALEN.
TRIPELENNAMINE.
TRIPLE ANTIGEN VACCINE.
TRIPROLIDINE except when included in Schedule 2 or 3.
TRIPTORELIN.
TROGLITAZONE.
TROLAMINE when in preparations for tattoo removal.
TROMETAMOL in preparations for injection except in preparations containing 3 per cent or

less of trometamol.
TROPICAMIDE.
TROPISETRON.
TROVAFLOXACIN.
TROXIDONE.
TRYPTOPHAN for human therapeutic use except in preparations labelled with a recommended
daily dose of 100 mg or less of tryptophan.
TUBERCULIN.
TUBOCURARINE.

SCHEDULE 4
TUCATINIB.
TULATHROMYCIN.
TULOBUTEROL.
TYLOSIN.
TYPHOID VACCINE.
ULIPRISTAL except when included in Schedule 3.
UMECLIDINIUM.
UNIFIRAM.
UNOPROSTONE.
UPADACITINIB.
URACIL.
URAPIDIL.
URETHANE (excluding its derivatives) for therapeutic use.
# UROFOLLITROPIN.
UROKINASE.
URSODEOXYCHOLIC ACID.
USTEKINUMAB.
VACCINES for human therapeutic use except when separately specified in this Schedule.
VACCINES for veterinary live virus except:
a) poultry vaccines;
b) pigeon pox vaccine;
c) scabby mouth vaccine; or
d) bovine ephemeral fever vaccine.
VACCINES – PLASMID DNA for animal use except when separately specified in these
Schedules.
VACCINIA VIRUS VACCINE.

SCHEDULE 4
VALACICLOVIR.
VALDECOXIB.
VALGANCICLOVIR.
VALNOCTAMIDE.
VALPROIC ACID.
VALSARTAN.
VANCOMYCIN.
VANDETANIB.
VARDENAFIL.
VARENICLINE.
VARICELLA VACCINE.
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN.
VASOPRESSIN.
VECURONIUM.
VEDAPROFEN.
VEDOLIZUMAB.
VELAGLUCERASE ALFA.
VELPATASVIR.
VEMURAFENIB.
VENETOCLAX.
VENLAFAXINE.
VERAPAMIL.
VERATRUM spp. except when separately specified in this Schedule.
VERNAKALANT.
VERTEPORFIN.

SCHEDULE 4
VIDARABINE.
VIGABATRIN.
VILANTEROL.
VILDAGLIPTIN.
VILOXAZINE.
VINBLASTINE.
VINCAMINE.
VINCRISTINE.
VINDESINE.
VINFLUNINE.
VINORELBINE.
VINYL ETHER for therapeutic use.
VIRGINIAMYCIN except when included in Schedule 5.
VISMODEGIB.
VISNADINE.
VITAMIN A for human therapeutic or cosmetic use except:
a) in preparations for topical use containing 1 per cent or less of Vitamin A;

b) in preparations for internal use containing 3000 micrograms retinol equivalents or
less of Vitamin A per daily dose; or
c) in preparations for parenteral nutrition replacement.
VITAMIN D for human internal therapeutic use except:
a) in preparations containing 25 micrograms or less of vitamin D per recommended

daily dose ; or
b) when included in Schedule 3.
VORAPAXAR.
VORETIGENE NEPARVOVEC.
VORICONAZOLE.

SCHEDULE 4
VORINOSTAT.
VORTIOXETINE.
VOXILAPREVIR.
WARFARIN for therapeutic use.
XAMOTEROL.
XANTHINOL NICOTINATE.
XIMELAGATRAN.
XIPAMIDE.
XYLAZINE.
YOHIMBINE.
ZAFIRLUKAST.
ZALCITABINE.
ZALEPLON.
ZANAMIVIR.
ZERANOL except when included in Schedule 6.
ZIDOVUDINE.
ZILPATEROL.
ZIMELDINE.
ZINC COMPOUNDS for human internal use except:
a) in preparations with a recommended daily dose of 25 mg or less of zinc; or

b) in preparations with a recommended daily dose of more than 25 mg but not more than
50 mg of zinc when compliant with the requirements of the Required Advisory
Statements for Medicine Labels.
ZIPRASIDONE.
ZOLAZEPAM.
ZOLEDRONIC ACID.

SCHEDULE 4
ZOLMITRIPTAN except when included in Schedule 3.
ZOLPIDEM.
ZONISAMIDE.
ZOPICLONE.
ZOXAZOLAMINE.
ZUCLOPENTHIXOL.

SCHEDULE 5
SCHEDULE 5
ABAMECTIN
a) in preparations, for internal use for the treatment of animals, containing 1 per cent or
less of abamectin; or
b) in gel formulations containing 0.05 per cent or less of abamectin in applicators
containing 50 mg or less of abamectin.
ABSCISIC ACID.
ACEQUINOCYL.
ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per
cent of acetic acid (CH3COOH) except:

b) for therapeutic use.
ACETONE except in preparations containing 25 per cent or less of designated solvents.
ACRIFLAVINIUM CHLORIDE in preparations for veterinary use containing 2.5 per cent or
less of acriflavinium chloride.
AFOXOLANER in oral divided preparations each containing 150 mg or less of afoxolaner per
dosage unit
a) for the treatment and prevention of flea infestations and control of ticks in dogs; or
b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal
nematodes and heartworm in dogs, when combined with milbemycin oxime.
AKLOMIDE.
ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less
of albendazole except in intraruminal implants each containing 3.85 g or less of
albendazole.
ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium
alone or in any combination:
a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use”

aqueous solution is more than 11.5;
b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous
solution or mixture is more than 11.5 but less than or equal to 12.5;
c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than
11.5; or

SCHEDULE 5
d) in liquid or semi-solid preparations, the pH of which is more than 11.5, unless:

i) in food additive preparations for domestic use; or
ii) in automatic dish washing preparations for domestic use with a pH of more than
12.5,
except when separately specified in these Schedules.
ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent

or less of alkoxylated fatty alkylamine polymer except in preparations containing 20 per
cent or less of alkoxylated fatty alkylamine polymer.
ALLETHRIN in preparations containing 10 per cent or less of allethrin except:
a) in insecticidal mats; or
b) in other preparations containing 1 per cent or less of allethrin.
ALLOXYDIM.
ALPHA-CYPERMETHRIN:
a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or

b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.
AMETRYN.
AMINES for use as curing agents for epoxy resins except when separately specified in these
Schedules.
AMINOACRIDINE in preparations for veterinary use containing 2.5 per cent or less of
aminoacridine.
AMINOPYRALID in preparations containing 22 per cent or less of aminopyralid.
AMITROLE.
AMINOCYCLOPYRACHLOR.
AMISULBROM.
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in
preparations containing 5 per cent or less of ammonia except:
a) in preparations for human internal therapeutic use;

b) in preparations for inhalation when absorbed in an inert solid material; or
c) in preparations containing 0.5 per cent or less of free ammonia.

SCHEDULE 5
AMMONIUM THIOCYANATE except in preparations containing 10 per cent or less of

ammonium thiocyanate.
ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins except when
ANISE OIL except:
a) in medicines for human therapeutic use, when packed in containers having a nominal
capacity of 50 mL or less fitted with a restricted flow insert and compliant with the
b) in preparations other than medicines for human therapeutic use, when packed in
containers having a nominal capacity of 50 mL or less fitted with a restricted flow
insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
c) in preparations containing 50 per cent or less of anise oil.
ASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip
packaging or in a container with a child-resistant closure.
ATRAZINE.
AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels
using water, methanol or ethanol, in preparations containing 5 per cent or less of total
limonoids, for agricultural use.
AZOXYSTROBIN.
BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed Pseudomonas

fluorescens.
BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of

barium silicofluoride per sq. cm.
BASIL OIL except:
c) in preparations containing 5 per cent or less of methyl chavicol.

SCHEDULE 5
BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFU)/mL

or less of Beauveria bassiana.
BENALAXYL.
BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.
BENTAZONE.
BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium

chloride except in preparations containing 5 per cent or less of benzalkonium chloride.
BENZOFENAP.
BENZOYL PEROXIDE except:

b) in preparations containing 5 per cent or less of benzoyl peroxide.
BERGAMOT OIL except:
a) when steam distilled or rectified;

b) in preparations for internal use;
c) in preparations containing 0.4 per cent or less of bergamot oil;
d) in soaps or bath or shower gels that are washed off the skin;
e) in medicines for human therapeutic use when compliant with the requirements of the
Required Advisory Statements for Medicine Labels; or
f) in other preparations when packed in containers labelled with the statement:
Application to the skin may increase sensitivity to sunlight.
BETACYFLUTHRIN:
a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or

b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.
BICYCLOPYRONE in preparations containing 20 per cent or less of bicyclopyrone.
BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing

0.3 per cent or less of total bifluorides.
BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin except in

preparations containing 1 per cent or less of bioallethrin.
BIORESMETHRIN except in preparations containing 10 per cent or less of bioresmethrin.
BISPYRIBAC except in preparations containing 10 per cent or less of bispyribac.

SCHEDULE 5
BIXAFEN.
BORIC ACID except:

b) in cosmetic hand cleaning preparations when labelled with a warning to the following
effect:
NOT TO BE USED FOR CHILDREN UNDER 3 YEARS OF AGE; and if the
concentration of free soluble borates exceeds 1.5 per cent (as boric acid), with the
words: NOT TO BE USED ON PEELING OR IRRITATED SKIN; or
c) in cosmetic talc preparations containing 5 per cent or less calculated as boric acid
when labelled with a warning to the following effect:
d) in cosmetic oral hygiene preparations containing 0.1 per cent or less calculated as
boric acid when labelled with a warning to the following effect:
NOT TO BE SWALLOWED. NOT TO BE USED FOR CHILDREN UNDER 3
YEARS OF AGE; or
e) in other cosmetic preparations containing 3 per cent or less calculated as boric acid
when labelled with a warning to the following effect:
f) in preparations, other than insect baits, containing 6 per cent or less calculated as
boric acid.
BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron

trifluoride (BF3).
BROFLANILIDE in preparations containing 0.3 per cent or less of broflanilide.
BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.
BUPIVACAINE in aqueous gel preparations containing 0.5 per cent or less of bupivacaine, for
the dermal spray-on administration to the wounds of animals.
BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin.
BUTHIDAZOLE.
BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.
BUTRALIN.
BUTROXYDIM.

SCHEDULE 5
n-BUTYL ALCOHOL in preparations containing 10 per cent or less of n-butyl alcohol except:
a) in preparations containing 5 per cent or less of n-butyl alcohol; or

b) in preparations for cosmetic or therapeutic use other than spray form.
CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor
except:
a) in medicines for human therapeutic use, in essential oils when packed in containers
having a nominal capacity of 25 mL or less fitted with a restricted flow insert and
compliant with the requirements of the Required Advisory Statements for Medicine
Labels;
b) in preparations other than medicines for human therapeutic use, in essential oils when
packed in containers having a nominal capacity of 25 mL or less fitted with a
restricted flow insert, and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN;
c) in rosemary oil, sage oil (Spanish), or lavandin oils; or

d) in preparations containing 2.5 per cent or less of camphor.
CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide

peroxide except in preparations containing 9 per cent or less of carbamide peroxide.
CARBARYL:
a) in preparations containing 10 per cent or less of carbaryl except when included in

Schedule 4; or
b) when impregnated into plastic resin material containing 20 per cent or less of
carbaryl.
CASSIA OIL except:
a) in food additives;
b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia
oil; or
c) in other preparations containing 2 per cent or less of cassia oil.
CHLORFENAC.
CHLORFENAPYR. in preparations containing 0.5 per cent or less of chlorfenapyr.
CHLORFENSON.
CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine except:

SCHEDULE 5
a) in preparations containing 1 per cent or less of chlorhexidine; or

b) when in solid preparations.
CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, except:

b) sodium hypochlorite preparations with a pH of less than 11.5;
c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of
available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful.

May give off dangerous gas if mixed with other products;
d) liquid preparations containing less than 2 per cent of available chlorine; or

e) other preparations containing 4 per cent or less of available chlorine.
CHLORNIDINE.
CHLOROCRESOL except in preparations containing 3 per cent or less of chlorocresol.
CHLORPROPHAM.
CHLORPYRIFOS:
a) in aqueous preparations containing 20 per cent or less of microencapsulated

chlorpyrifos;
b) in controlled release granular preparations containing 10 per cent or less of
chlorpyrifos; or
c) in other preparations containing 5 per cent or less of chlorpyrifos,
except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic
metre.
CHLORSULFURON.
CHLORTETRACYCLINE in preparations:
a) for topical application to animals for ocular use only; or

b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the
treatment of ornamental caged birds or ornamental fish only.
CHLORTHAL-DIMETHYL.
CINMETHYLIN.
CINNAMON BARK OIL except:

SCHEDULE 5
a) in food additives; or
b) in preparations containing 2 per cent or less of cinnamon bark oil.
CLETHODIM.
CLIMBAZOLE in preparations containing 40 per cent or less of climbazole except:
a) in leave-on hair, face and foot cosmetic preparations containing 0.5 per cent or less of
climbazole; or
b) in other preparations (that are not leave-on cosmetic preparations) containing 2 per
cent or less of climbazole.
CLOFENTEZINE.
CLOPYRALID.
CLOQUINTOCET.
CLORSULON.
CLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin except in gel

preparations dispensed in sealed cartridges containing 1 per cent or less of clothianidin.
CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil except
in preparations containing 25 per cent or less of clove oil.
COPPER ACETATE in preparations containing 20 per cent or less of copper acetate except in
preparations containing 5 per cent or less of copper acetate.
COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper
except in preparations containing 1 per cent or less of copper.
COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide

except in preparations containing 12.5 per cent or less of copper hydroxide.
COPPER OXIDES in preparations containing 25 per cent or less of copper oxides except:
a) in preparations for internal use;

b) in marine paints; or
c) in other preparations containing 5 per cent or less of copper oxides.
COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride

except in preparations containing 12.5 per cent or less of copper oxychloride.
COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate except:
a) in preparations for internal use; or

b) in other preparations containing 5 per cent or less of copper sulfate.

SCHEDULE 5
COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.
4-CPA.
CYANATRYN.
CYANOACRYLATE ESTERS in contact adhesives except:
a) when labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes
and avoid breathing vapour. Bonds on contact. Should fingers stick together
apply a solvent such as acetone to contact areas then wash off with water. Do
not use solvents near eyes or open wounds. In case of eye contact immediately
flush with water; or
b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate
esters:
i) labelled with the approved name or trade name of the poison, the quantity and the
warning:
Can cause eye injury. Instantly bonds skin; and
ii) enclosed in a primary pack labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and
avoid breathing vapour. Bonds on contact. Should fingers stick together apply a
solvent such as acetone to contact areas then wash off with water. Do not use
solvents near eyes or open wounds. In case of eye contact immediately flush with
water.
CYANTRANILIPROLE.
CYANURIC ACID (excluding its salts and derivatives).
CYAZOFAMID.
CYCLOHEXANONE PEROXIDE.
CYCLOPROTHRIN except in preparations containing 10 per cent or less of cycloprothrin.
CYCLOXYDIM.
CYFLUFENAMID.
CYFLUTHRIN:
a) in wettable powders containing 10 per cent or less of cyfluthrin;

b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or
c) in emulsions containing 5 per cent or less of cyfluthrin.

SCHEDULE 5
CYHALOFOP-BUTYL.
CYMIAZOLE.
CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.
CYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin.
CYPROCONAZOLE except in preparations containing 10 per cent or less of cyproconazole.
CYPRODINIL.
CYTHIOATE for the treatment of animals:
a) in divided preparations containing 30 mg or less of cythioate per dosage unit when

packed in blister or strip packaging or in a container with a child-resistant closure; or
b) in undivided preparations containing 5 per cent or less of cythioate.
2,4-D in preparations containing 20 per cent or less of 2,4-D.
DAMINOZIDE.
2,4-DB.
DECOQUINATE:
DELTAMETHRIN:
a) when impregnated in plastic resin strip material containing 4 per cent or less of
deltamethrin;
b) in aqueous preparations containing 5 per cent or less of deltamethrin when no organic
solvent other than a glycol is present;
c) in wettable granular preparations containing 25 per cent or less of deltamethrin when
packed in child-resistant packaging each containing 3 g or less of the formulation;
d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-
resistant packaging; or
e) in other preparations containing 0.5 per cent or less of deltamethrin,
except:
a) in factory prepared mosquito nets containing 1 per cent or less deltamethrin; or

b) in preparations containing 0.1 per cent or less of deltamethrin.
DEMBREXINE in oral preparations for the treatment of animals.
2,4-DES.

SCHEDULE 5
DIAFENTHIURON.
N,N-DIALLYLDICHLOROACETAMIDE except in preparations containing 10 per cent or less

of N,N-diallyldichloroacetamide.
DIAZINON in dust preparations containing 2 per cent or less of diazinon.
DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of
dicamba.
DICHLONE.
p-DICHLOROBENZENE.
DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, except

in:
a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of
available chlorine when labelled with the statements:

b) liquid preparations containing less than 2 per cent of available chlorine; or

c) other preparations containing 4 per cent or less of available chlorine.
DICHLOROMETHANE (methylene chloride) except:
a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or

paint strippers and containing 10 per cent or less of dichloromethane;
b) in other preparations in pressurised spray packs; or
c) in paints and tinters containing 5 per cent or less of dichloromethane.
DICHLOROPHEN for the treatment of animals.
DICHLORVOS:
dichlorvos;
b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the
treatment of animals; or
c) in pressurised spray packs containing 10 grams or less of dichlorvos.
DICLOBUTRAZOL.
DICLORAN.
DICOFOL.

SCHEDULE 5
DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per

cent or less of diethanolamine except in preparations containing 5 per cent or less of
diethanolamine.
DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not
less than 10 mg/kg of denatonium benzoate as a bittering agent except:
a) in paints or paint tinters;

b) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene
glycol; or
c) in other preparations containing 2.5 per cent or less of diethylene glycol.
DIETHYLENE GLYCOL MONOBUTYL ETHER except in preparations containing 10 per

cent or less of diethylene glycol monobutyl ether.
DIETHYLTOLUAMIDE (DEET) except:
a) in medicines for human therapeutic use containing 20 per cent or less of

diethyltoluamide, when compliant with the requirements of the Required Advisory
Statements for Medicine Labels;
b) in preparations for human use, other than medicines, containing 20 per cent or less of
diethyltoluamide, when labelled with the warning statement:
WARNING: May be dangerous, particularly to children, if you use large

amounts on the skin, clothes or bedding or on large areas of the body, especially
if you keep using it for a long time; or
c) in preparations other than for human use containing 20 per cent or less of
diethyltoluamide.
DIFENOCONAZOLE.
DIFLUBENZURON.
DIMETHICODIETHYLBENZALMALONATE except when included in preparations

containing 10 per cent or less of dimethicodiethylbenzalmalonate.
DIMETHIRIMOL.
DIMETHOMORPH except in preparations containing 10 per cent or less of dimethomorph.
DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.
DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of

dimethylformamide except in silicone rubber mastic containing 2 per cent or less of
dimethylformamide.

SCHEDULE 5
3,7-DIMETHYL-2,6-OCTADIENAL and its isomers in cosmetic and household cleaning

preparations except in preparations containing 5 per cent or less of 3,7-dimethyl-2,6,-
octadienal isomers.
DINICONAZOLE.
DINOTEFURAN except in preparations containing 1 per cent or less of dinotefuran.
DI-n-PROPYL ISOCINCHOMERONATE except in preparations containing 25 per cent or less

of di-n-propyl isocinchomeronate.
DIPHENAMID.
DIRECT RED 254 in preparations containing 30 per cent or less of Direct Red 254 calculated
as free acid.
DITHIOPYR.
N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-

dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any
two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-
pyrrolidone except in preparations containing 25 per cent or less of designated solvents.
DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per
cent or less of doramectin.
EMAMECTIN in preparations containing 2 per cent or less of emamectin.
EMODEPSIDE in preparations:
a) containing 2.5 per cent or less of emodepside for the external treatment of animals; or
b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of
animals.
EPOXICONAZOLE.
EPOXY RESINS, LIQUID.
EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.
ESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin except in pressurised

spray packs containing 1 per cent or less of esbiothrin.
ESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.
ESTRADIOL in implant preparations for growth promotion in animals.
1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL) OXIRANE AND N-

METHYLMETHANAMINE.

SCHEDULE 5
ETHER in preparations containing more than 10 per cent of ether for use in internal combustion
engines.
ETHOFUMESATE.
ETHOXYQUIN except in preparations containing 10 per cent or less of ethoxyquin.
ETHOXYSULFURON.
ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less
than 10 mg/kg of denatonium benzoate as a bittering agent except:
a) in paints or paint tinters;

b) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol;
or
c) in other preparations containing 2.5 per cent or less of ethylene glycol.
ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use except in preparations
containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.
ETRIDIAZOLE.
EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol except in
preparations containing 25 per cent or less of eugenol.
EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus

(Corymbia citriodora) , except in preparations containing 40 per cent or less of extract of
lemon eucalyptus.
FENARIMOL.
FENBENDAZOLE for the treatment of animals.
FENBUCONAZOLE.
FENCHLORAZOLE-ETHYL.
FENNEL OIL except:
requirements of the Medicines Advisory Statements Specification;
c) in preparations containing 5 per cent or less of methyl chavicol.

SCHEDULE 5
FENOPROP.
FENOXAPROP-ETHYL.
FENOXAPROP-p-ETHYL.
FENPYRAZAMINE except in preparations containing 40 per cent or less of fenpyrazamine.
FENSON.
FENTHION:
a) in preparations containing 25 per cent or less of fenthion when packed in single-use

containers having a capacity of 2 mL or less; or
b) in preparations containing 10 per cent or less of fenthion.
FIPRONIL in preparations containing 10 per cent or less of fipronil except in preparations

containing 0.05 per cent or less of fipronil.
FLAMPROP-METHYL.
FLAMPROP-M-METHYL.
FLAZASULFURON.
FLORASULAM.
FLUAZAINDOLIZINE in preparations containing 50 per cent or less fluazaindolizine.
FLUAZURON.
FLUBENDAZOLE for the treatment of animals.
FLUBENDIAMIDE.
FLUCHLORALIN.
FLUDIOXONIL except in preparations containing 10 per cent or less of fludioxonil.
FLUMETHRIN:
flumethrin; or
b) in oil based preparations containing 1 per cent or less of flumethrin.
FLUMICLORAC PENTYL.
FLUOPYRAM except in preparations containing 50 per cent or less of fluopyram.
FLUORIDES in preparations containing 3 per cent or less of fluoride ion except:

SCHEDULE 5
a) in preparations for human use; or

b) in preparations containing 15 mg/kg or less of fluoride ion.
FLURALANER.
FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.
FLUXAPYROXAD.
FORAMSULFURON.
FORMIC ACID (excluding its salts and derivatives) except in preparations containing 0.5 per
cent or less of formic acid.
FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of
fospirate.
FURALAXYL.
FURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of

furathiocarb.
GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of

microencapsulated gamma-cyhalothrin.
GLUFOSINATE-AMMONIUM.
GLUTARAL in preparations containing 5 per cent or less of glutaral except:

b) in preparations containing 0.5 per cent or less of glutaral when labelled with the
statements:
IRRITANT; and
Avoid contact with eyes.
GLYPHOSATE.
HALOSULFURON-METHYL.
HEXACONAZOLE except in preparations containing 5 per cent or less of hexaconazole.
HEXAZINONE in preparations containing 25 per cent or less of hexazinone.
HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in

welded plastic labyrinths.

SCHEDULE 5
HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white

petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their
derivatives), except:
a) toluene and xylene when included in Schedule 6;

b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;
c) food grade and pharmaceutical grade white mineral oils;
d) in solid or semi-solid preparations;
e) in preparations containing 25 per cent or less of designated solvents;
f) in preparations packed in pressurised spray packs;
g) in adhesives packed in containers each containing 50 grams or less of adhesive;
h) in writing correction fluids and thinners for writing correction fluids packed in
containers having a capacity of 20 mL or less; or
i) in other preparations when packed in containers with a capacity of 2 mL or less.
HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per
cent or less of hydrochloric acid (HCl) except:
a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate
hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.
HYDROGEN PEROXIDE (excluding its salts and derivatives):
a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide except in
hair dyes containing 6 per cent or less of hydrogen peroxide; or
b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide
except in preparations containing 3 per cent (10 volume) or less of hydrogen
peroxide.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations

containing 0.1 per cent or less of hydrosilicofluoric acid (H2SiF6).
2-HYDROXYETHYL METHACRYLATE except when included in dental restorative

preparations for therapeutic use or in nail preparations when labelled “Avoid contact with
skin”.
2-HYDROXYPROPYL METHACRYLATE in nail preparations except when labelled 'avoid

contact with skin'.
IMAZALIL.
IMAZAMOX except in preparations containing 25 per cent or less of imazamox.

SCHEDULE 5
IMAZAPIC except in preparations containing 25 per cent or less of imazapic.
IMAZAPYR except in preparations containing 25 per cent or less of imazapyr.
IMAZETHAPYR except in preparations containing 25 per cent or less of imazethapyr.
IMIDACLOPRID in preparations containing 20 per cent or less of imidacloprid except in

preparations containing 5 per cent or less of imidacloprid.
IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin except in

preparations containing 10 per cent or less of imiprothrin.
INDOXACARB (includes the R and S enantiomers) in preparations containing 1 per cent or

less of indoxacarb.
3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10 per

cent or less of 3-iodo-2-propynyl butyl carbamate except:
a) in aqueous preparations not for cosmetic use containing 10 per cent or less 3-iodo-2-
propynyl butyl carbamate; or
b) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent
or less of 3-iodo-2-propynyl butyl carbamate.
IODOSULFURON-METHYL-SODIUM.
IPCONAZOLE in preparations containing 2 per cent or less of ipconazole.
IRON COMPOUNDS:
a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present
as an excipient):
i) in preparations for injection containing 20 per cent or less of iron except in
preparations containing 0.1 per cent or less of iron; or
ii) in other preparations containing 4 per cent or less of iron except:
A) in liquid or gel preparations containing 0.1 per cent or less of iron; or
B) in animal feeds or feed premixes; or
b) in garden preparations except in preparations containing 4 per cent or less of iron.
ISOEUGENOL in preparations not intended for skin contact containing 25 per cent or less of
isoeugenol except in preparations containing 10 per cent or less of isoeugenol.
ISOPHORONE.
ISOXABEN.
ISOXAFLUTOLE.

SCHEDULE 5
IVERMECTIN for use in animals:
a) in preparations for the prophylaxis of heartworm in cats and dogs;

b) in intraruminal implants containing 160 mg or less of ivermectin;
c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-
resistant packaging or in packaging approved by the relevant registration authority; or
d) in other preparations containing 2 per cent or less of ivermectin.
KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of
antibiotic substances.
LAMBDA-CYHALOTHRIN:
a) in aqueous preparations containing 1 per cent or less of lambda- cyhalothrin; or

b) in aqueous preparations containing 10 per cent or less of microencapsulated lambda-
cyhalothrin.
LASIODIPLODIA PSEUDOTHEOBROMAE except when used as a herbicide in capsule

preparations at a concentration of 16 CFU or less per capsule.
LEAD COMPOUNDS in preparations for use as hair cosmetics.
LEMON OIL except:

c) in preparations containing 0.05 per cent or less of lemon oil;
e) in medicines for human therapeutic use, when compliant with the requirements of the
LEMONGRASS OIL in cosmetic and household cleaning preparations except in preparations

containing 5 per cent or less of 3,7-dimethyl-2,6-octadienal.
LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of
animals except:

b) in preparations for the treatment of ornamental birds or ornamental fish, in packs
containing 10 mg or less of levamisole.

SCHEDULE 5
LIDOCAINE in aqueous gel preparations containing 4.5 per cent or less of lidocaine, for the
dermal spray-on administration to the wounds of animals.
LIME OIL except:

c) in preparations containing 0.5 per cent or less of lime oil;
LINDANE in preparations containing 10 per cent or less of lindane except when included in
Schedule 2 or 4.
LOTILANER.
LUFENURON except:
a) in divided preparations each containing 500 mg or less of lufenuron for the treatment
of animals; or
b) in single use syringes each containing 500 mg or less of lufenuron for the treatment
of animals.
MACROPHOMINA PHASEOLINA except when used as a herbicide in capsule preparations at

a concentration of 16 CFU or less per capsule.
MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic

substances.
MAGNESIUM CHLORATE except in preparations containing 10 per cent or less of

magnesium chlorate.
MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of
malachite green.
MALATHION in preparations containing 10 per cent or less of malathion except:
a) for human therapeutic use; or

b) in dust preparations containing 2 per cent or less of malathion.
MANCOZEB.
MANDESTROBIN except in preparations containing 25 per cent or less of mandestrobin.

SCHEDULE 5
MANDIPROPAMID.
MARJORAM OIL except:
c) in preparations containing 50 per cent or less of marjoram oil.
MCPA:
a) in preparations containing 25 per cent or less of MCPA (acid); or

b) in preparations containing 50 per cent or less of the salts and esters of MCPA.
MEBENDAZOLE for the treatment of animals:
a) in divided preparations each containing 300 mg or less of mebendazole per dosage

unit; or
b) in undivided preparations containing 25 per cent or less of mebendazole.
MECLOFENAMIC ACID for the treatment of animals.
MECOPROP in preparations containing 2 per cent or less of mecoprop.
MEFENPYR-DIETHYL.
MEFENTRIFLUCONAZOLE except in preparations containing 7.5 per cent or less of

mefentrifluconazole.
MEPIQUAT.
MERCAPTAMINE in cosmetic preparations containing 6 per cent or less of mercaptamine

except in preparations containing 1 per cent or less of mercaptamine.
MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic
preparations containing 20 per cent or less of mercaptoacetic acid or its salts (as
mercapturic acid), except in preparations containing 5 per cent or less of mercaptoacetic
acid or its salts (as mercapturic acid)
MESOTRIONE.
METAFLUMIZONE.

SCHEDULE 5
METALAXYL in preparations containing 35 per cent or less of metalaxyl.
METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.
METAZACHLOR.
METHABENZTHIAZURON.
METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of

methanol except in preparations containing 2 per cent or less of methanol.
METHENAMINE in cosmetic preparations, except in preparations containing 0.15 per cent or

less of methenamine.
METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.
METHIOZOLIN.
METHOXYCHLOR.
METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl

isobutyl ketone and fluorescein) except:
a) when included in preparations or admixtures; or

b) when packed in containers having a capacity of more than 5 litres.
METHYLATED SPIRIT(S) when packed and labelled as a 'biofuel' suitable for use in 'spirit
burners'.
METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of
methylene blue.
METHYL ETHYL KETONE except in preparations containing 25 per cent or less of

designated solvents.
METHYL ETHYL KETONE PEROXIDE.
METHYL ISOAMYL KETONE except in preparations containing 25 per cent or less of

METHYL ISOBUTYL KETONE except in preparations containing 25 per cent or less of

N-METHYL-2-PYRROLIDONE:
a) when packed in single use containers having a capacity of 2 mL or less; or

b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or
preparations containing 50 per cent or less of a mixture of any two or more of N-

SCHEDULE 5
methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone

except in preparations containing 25 per cent or less of designated solvents.
METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate

except:
a) in preparations for therapeutic use; or

b) in preparations containing 5 per cent or less of methyl salicylate.
2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5-
TRIAZINE.
METIRAM.
METOFLUTHRIN:
a) in impregnated fabric mosquito repellent preparations for use in a vaporiser

containing 15 mg or less of metofluthrin per disk; or
b) when impregnated into a polyethylene slow release matrix containing 250 mg or less
of metofluthrin.
METOLACHLOR.
METRAFENONE in preparations containing 50 per cent or less of metrafenone.
MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.
MILBEMYCIN OXIME
a) for the prophylaxis of heartworm in dogs and cats; or

b) for the treatment and prevention of flea infestations, control of ticks, gastrointestinal
nematodes and heartworm in dogs, when combined with afoxolaner, in oral divided
preparations each containing 150 mg or less of afoxolaner per dosage unit.
MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.
MONEPANTEL.
MONOETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20

per cent or less of monoethanolamine except:

b) in preparations containing 5 per cent or less of monoethanolamine.
MORANTEL in preparations containing 25 per cent or less of morantel except in preparations

containing 10 per cent or less of morantel.
MOXIDECTIN:

SCHEDULE 5
a) in preparations for external use for the treatment of animals other than cats and dogs,
containing 0.5 per cent or less of moxidectin;
b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per
cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less;
or
c) for internal use for the treatment of animals:
i) in divided preparations for dogs, containing 250 micrograms or less of
moxidectin per dosage unit in a pack containing six or less dosage units; or
ii) in other preparations containing 2 per cent or less of moxidectin.
MYCLOBUTANIL.
NAA except in preparations containing 25 per cent or less of NAA.
NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.
NAPTALAM.
NEOSCYTALIDIUM NOVAEHOLLANDIAE except when used as a herbicide in capsule

preparations at a concentration of 16 CFU or less per capsule.
NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of
netobimin.
NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or
less of nitric acid (HNO3) except in preparations containing 0.5 per cent or less of nitric
acid.
NITROSCANATE for the treatment of animals.
NONANOIC ACID:
a) when used in a pesticide; or
b) in other preparations except in preparations containing 10 per cent or less of nonanoic

acid.
NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 except:
a) when labelled with the statements:
IRRITANT; and
Avoid contact with eyes;
b) in preparations containing 12.5 per cent or less of nonoxinol 9; or

c) in preparations for human use.

SCHEDULE 5
NORBORMIDE.
NUTMEG OIL except:
c) in preparations containing 50 per cent or less of nutmeg oil.
N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE except in preparations containing 10 per

cent or less of N-octyl bicycloheptene dicarboximide.
N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of:
a) N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture

of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or
b) N-(N-dodecyl)-2-pyrrolidone except in preparations containing 25 per cent or less of
OLEANDOMYCIN in animal feed premixes for growth promotion.
OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.
ORANGE OIL (BITTER) except:

c) in preparations containing 1.4 per cent or less of orange oil (bitter);
OXADIARGYL.
OXADIXYL.
OXANTEL EMBONATE for the treatment of animals.

SCHEDULE 5
OXFENDAZOLE for the treatment of animals.
OXIBENDAZOLE for the treatment of animals.
OXYCARBOXIN.
OXYTETRACYCLINE in preparations:

b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled
for the treatment of ornamental caged birds or ornamental fish only.
OXYTHIOQUINOX.
PACLOBUTRAZOL.
PENCONAZOLE.
PENDIMETHALIN.
PENFLUFEN.
PENTHIOPYRAD except in preparations containing 20 per cent or less of penthiopyrad.
PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.
PERMETHRIN (excluding preparations for human therapeutic use):
a) in preparations containing 25 per cent or less of permethrin; or

b) in preparations for external use, for the treatment of dogs, containing 50 per cent or
less of permethrin when packed in single use containers having a capacity of 4 mL or
less,
except in preparations containing 2 per cent or less of permethrin.
PETROL except preparations containing 25 per cent or less of petrol.
PHENAZONE for the external treatment of animals.
PHENISOPHAM.
PHENOL, including cresols and xylenols and any other homologue of phenol boiling below
220°C, when in animal feed additives containing 15 per cent or less of such substances,
except in preparations containing 1 per cent or less of phenol and in preparations
containing 3 per cent or less of cresols and xylenols and other homologues of phenol.
PHENYL METHYL KETONE except in preparations containing 25 per cent or less of


SCHEDULE 5
o-PHENYLPHENOL except in preparations containing 5 per cent or less of o-phenylphenol.
PHOSPHONIC ACID (excluding its salts and derivatives) except in preparations containing 10
per cent or less of phosphonic acid (H3PO3).
PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per
cent or less of phosphoric acid (H3PO4) except:
a) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);

b) in solid or semi-solid preparations; or
c) in professional dental kits.
o-PHTHALALDEHYDE in preparations containing 1 per cent or less of o-phthalaldehyde.
PICARIDIN except in preparations containing 20 per cent or less of picaridin.
PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled
as a herbicide.
PINOXADEN in preparations containing 10 per cent or less of pinoxaden.
PIPERAZINE for animal use.
PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.
POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts

except in preparations containing 1 per cent or less of polixetonium salts.
POLYETHANOXY (15) TALLOW AMINE.
POLYOXIN D ZINC SALT.
POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α
-HYDROXY-,MONO-C13-15-ALKYL ETHERS.
POTASSIUM CHLORATE except:

b) in preparations containing 10 per cent or less of potassium chlorate.
POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5

per cent or less of potassium hydroxide being:
a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food
additive preparations for domestic use.

SCHEDULE 5
POTASSIUM METABISULPHITE when packed for domestic use except in preparations

containing 10 per cent or less of potassium metabisulphite.
POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite

except:
a) in preparations containing 0.5 per cent or less of potassium nitrite;

b) when present as an excipient in preparations for therapeutic use; or
c) in aerosols.
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent

or less of potassium peroxomonosulfate triple salt being:
a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or
b) liquid or semi-solid preparations, the pH of which is less than 2.5.
POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g

or less of potassium sulfide.
PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin

except in insecticidal mats containing 1 per cent or less of prallethrin.
PROFOXYDIM except in preparations containing 20 per cent or less of profoxydim.
PROGESTERONE:
a) in implant preparations or controlled release pessaries for synchronisation of oestrus

in cattle, sheep or goats; or
b) in implant preparations for growth promotion in cattle.
PROHEXADIONE CALCIUM.
PROMETRYN.
PROPAMOCARB.
PROPANIL.
PROPAQUIZAFOP.
PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.
PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent
or less of propionic acid, except:
a) in preparations containing 30 per cent or less of propionic acid; or


SCHEDULE 5
PROPOXUR:
propoxur;
b) in dust preparations containing 3 per cent or less of propoxur;
c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark
colouring agent and a separate bittering agent;
d) in pressurised spray packs containing 2 per cent or less of propoxur; or
e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and
in any case not more than 100 mg of propoxur per sheet.
n-PROPYL ALCOHOL in preparations containing 10 per cent or less of n-propyl alcohol

except:
a) in preparations containing 5 per cent or less of n-propyl alcohol; or

b) in preparations for cosmetic or therapeutic use other than in spray form.
PROPYZAMIDE.
PROTHIOCONAZOLE-DESCHLORO except in preparations containing 0.5 per cent or less of

prothioconazole-deschloro.
PROTHIOCONAZOLE-TRIAZOLIDINETHIONE except in preparations containing 0.5 per

cent or less of prothioconazole-triazolidinethione.
PYMETROZINE.
PYRACLOSTROBIN.
PYRAFLUFEN-ETHYL.
PYRASULFOTOLE.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of

chrysanthemic or pyrethric acids except:
a) in preparations for human therapeutic use; or

b) in preparations containing 10 per cent or less of such substances.
PYRIDABEN in preparations containing 25 per cent or less of pyridaben.
PYRIFENOX.
PYRITHIOBAC SODIUM.

SCHEDULE 5
PYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on
the non-volatile content of the paint except in paints containing 0.1 per cent or less of
pyrithione zinc calculated on the non-volatile content of the paint.
PYRIOFENONE in preparations containing 30 per cent or less of pyriofenone.
QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less

of quaternary ammonium compounds except:

b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl
groups are derived from tallow or hydrogenated tallow or similar chain length
(C16/C18) sources; or
c) in preparations containing 5 per cent or less of such quaternary ammonium
compounds.
QUINCLORAC.
QUININE in preparations for veterinary use containing 1 per cent or less of quinine.
QUINTOZENE.
QUIZALOFOP-p-ETHYL in aqueous preparations containing 40 per cent or less of

quizalofop-p-ethyl.
RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.
RESMETHRIN in preparations containing 10 per cent or less of resmethrin.
RIMSULFURON.
ROBENIDINE except in preparations containing 20 per cent or less of robenidine.
ROSIN when packaged for use as a soldering flux or in flux-cored solder.
SAFLUFENACIL in water dispersible granules or a water-based suspension concentrate.
SALICYLANILIDE.
SAROLANER for veterinary use in divided preparations each containing 120 mg or less of
sarolaner per dosage unit.
SEDAXANE.
SELAMECTIN except in preparations containing 12 per cent or less of selamectin.
SETHOXYDIM.
SIDURON.

SCHEDULE 5
SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion except:
a) barium silicofluoride when separately specified in this Schedule; or

SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin except in

preparations containing 1 per cent or less of sinbioallethrin.
SODIUM BROMIDE except when included in Schedule 4.
SODIUM CHLORATE except in preparations containing 10 per cent or less of sodium

chlorate.
SODIUM DIACETATE except in preparations containing 60 per cent or less of sodium

diacetate.
SODIUM DODECYLBENZENE SULFONATE except in preparations containing 30 per cent

or less of sodium dodecylbenzene sulfonate.
SODIUM HYDROGEN SULFATE except in preparations containing 10 per cent or less of

sodium hydrogen sulfate.
SODIUM HYDROSULFITE when packed for domestic use except in preparations containing
10 per cent or less of sodium hydrosulfite.
SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per
cent or less of sodium hydroxide being:
a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or
b) liquid or semi-solid preparations, the pH of which is more than 11.5 except in food
additive preparations for domestic use.
SODIUM LAURETH-6 CARBOXYLATE except in preparations containing 1 per cent or less

of sodium laureth-6 carboxylate.
SODIUM METABISULPHITE when packed for domestic use except in preparations

containing 10 per cent or less of sodium metabisulphite.
SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite except:
a) in preparations containing 0.5 per cent or less of sodium nitrite;

b) when present as an excipient in preparations for therapeutic use; or
c) in aerosols.
SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or

less of sodium percarbonate except in preparations containing 15 per cent or less of sodium
percarbonate.

SCHEDULE 5
SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use except in

preparations containing 10 per cent or less of sodium polystyrene sulphonate.
SODIUM STANNATE except in preparations for cosmetic use containing 1 per cent or less of
sodium stannate.
SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or

less of sodium sulfide.
SPINETORAM.
SPINOSAD except in aqueous suspensions containing 25 per cent or less of spinosad.
STAR ANISE OIL except:
c) in preparations containing 50 per cent or less of star anise oil.
STYRENE (excluding its derivatives).
SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or
ornamental fish only.
SULFADIAZINE when packed and labelled for the treatment of ornamental caged birds or
SULFADIMIDINE when packed and labelled for the treatment of ornamental caged birds or
SULFAMERAZINE when packed and labelled for the treatment of ornamental caged birds or
SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or
less of sulfamic acid (H3NO3S).
SULFATHIAZOLE when packed and labelled for the treatment of ornamental caged birds or
SULFOMETURON-METHYL.
SULFOXAFLOR in preparations containing 25 per cent or less of sulfoxaflor.
SYMPHYTUM spp. (Comfrey) for dermal therapeutic or dermal cosmetic use.

SCHEDULE 5
2,3,6-TBA.
TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10 per cent or less

of TDE.
TEBUCONAZOLE.
TEBUFENOZIDE.
TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.
TEMEPHOS:
a) in liquid preparations containing 10 per cent or less of temephos;

b) in powders containing 2 per cent or less of temephos; or
c) in preparations containing 40 per cent or less of temephos when packed in single use
containers having a capacity of 2 mL or less.
TEPRALOXYDIM.
TERBUTRYN.
TETRACHLOROETHYLENE in preparations containing 5 per cent or less of

tetrachloroethylene except:

b) in preparations for the treatment of animals; or
c) when absorbed into an inert solid.
TETRACHLORVINPHOS except in animal feeds containing 0.2 per cent or less of

tetrachlorvinphos.
TETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole.
TETRACYCLINE in preparations:

b) containing 40 per cent or less of tetracycline when packed and labelled for the
treatment of ornamental caged birds or ornamental fish only.
TETRAMETHRIN [(R, cis): (R, trans) = 20:80] except in pressurised spray packs.
TETRANILIPROLE except in preparations containing 20 per cent or less tetraniliprole.
THIABENDAZOLE:
a) for the treatment of animals; or

SCHEDULE 5
b) when packed and labelled for use as a fungicide except in preparations containing 50
per cent or less of thiabendazole.
THIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.
THIAZOPYR.
THIFENSULFURON.
THIOBENCARB.
THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.
THIOPHANATE-METHYL in preparations containing 25 per cent or less of thiophanate-

methyl.
THYME OIL except:
c) in preparations containing 50 per cent or less of thyme oil.
TIOCARBAZIL.
TOLCLOFOS-METHYL.
TOLTRAZURIL.
TOPRAMEZONE
TRALKOXYDIM.
TRENBOLONE in implant preparations for growth promotion in animals.
TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.
TRIADIMENOL.
TRI-ALLATE.
TRIBENURON-METHYL.
TRICHLOROACETIC ACID, alkali salts of.

SCHEDULE 5
1,1,1-TRICHLOROETHANE except:
a) in preparations packed in pressurised spray packs;

b) in preparations containing 25 per cent or less of designated solvents;
c) in preparations, other than writing correction fluids or thinners for writing correction
fluidsin containers having a capacity of 50 mL or less; or
d) in writing correction fluids or thinners for writing correction fluids, in containers
having a capacity of 50 mL or less labelled with:
i) the word “Trichloroethane” written in letters not less than 1 mm in height and in
distinct contrast to the background; and
ii) the expression:
WARNING – DO NOT DELIBERATELY SNIFF THIS PRODUCT.

SNIFFING MIGHT HARM OR KILL YOU;
written in bold face sans serif capital letters not less than 1 mm in height
and in distinct contrast to the background.
TRIDIPHANE.
TRIETAZINE.
TRIFLOXYSTROBIN.
TRIFLUDIMOXAZIN except in preparations containing 12.5 per cent or less.
TRIFLUMIZOLE.
TRIFLUMURON.
TRIISOPROPANOLAMINE LAURYL ETHER SULFATE except in preparations containing

30 per cent or less of triisopropanolamine lauryl ether sulfate when labelled with the
statements:
Avoid contact with eyes and skin; and
Wash hands after handling.
TRINEXAPAC-ETHYL except:
a) when packed in a sealed water-soluble measure pack; or

b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50
g or less.
3,6,9-TRIOXAUNDECANEDIOIC ACID except in preparations containing 5 per cent or less

of 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.

SCHEDULE 5
TRITICONAZOLE.
TROLAMINE (excluding its salts and derivatives) except:
a) when in Schedule 4;or

b) in preparations containing 5 per cent or less of trolamine.
TURPENTINE OIL except in preparations containing 25 per cent or less of turpentine oil.
VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for
the prevention of laminitis in horses when in a pack of 5 kg or less.
VERNOLATE.
WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.
ZINEB.

SCHEDULE 6
SCHEDULE 6
ABAMECTIN:
a) in preparations for pesticidal use containing 4 per cent or less of abamectin except
when included in Schedule 5; or
b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of
abamectin.
ACEPHATE.
ACETAMIPRID except in preparations containing 1 per cent or less of acetamiprid.
ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80
per cent of acetic acid (CH3COOH) except when included in Schedule 2.
ACETIC ANHYDRIDE excluding its derivatives.
ACIFLUORFEN.
ACINITRAZOLE except in preparations containing 20 per cent or less of acinitrazole.
ACLONIFEN.
ALBENDAZOLE for the treatment of animals except:

b) in intraruminal implants each containing 3.85 g or less of albendazole.
ALDRIN.
alone or in any combination for non-domestic use:
a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous

solution or mixture is more than 12.5; or
b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more
than 12.5.
ALKOXYLATED FATTY ALKYLAMINE POLYMER except:

b) in preparations containing 20 per cent or less of alkoxylated fatty alkylamine
polymer.
ALLETHRIN except:

SCHEDULE 6

b) in insecticidal mats containing 20 per cent or less of allethrin; or
c) in other preparations containing 1 per cent or less of allethrin.
ALLYL ESTERS (excluding derivatives) being:
ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9)
ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5)
ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8)
ALLYL HEXANOATE (CAS No. 123-68-2)
ALLYL ISOVALERATE (CAS No. 2835-39-4)
ALLYL NONANOATE (CAS No. 7493-72-3)
ALLYL OCTANOATE (CAS No. 4230-97-1)
ALLYL PHENYLACETATE (CAS No. 1797-74-6)
ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9)
in preparations containing 0.1 per cent or less of free allyl alcohol by weight of allyl
ester except in preparations containing 5 per cent or less of allyl esters with 0.1 per cent
or less of free allyl alcohol by weight of allyl esters.
ALPHA-CYPERMETHRIN:
a) in aqueous preparations containing 30 per cent or less of alpha-cypermethrin; or

b) in other preparations containing 10 per cent or less of alpha-cypermethrin,
AMICARBAZONE.
AMIDITHION.
AMIDOPROPYL BETAINES except:
a) in cosmetic wash-off preparations containing 30 per cent or less of amidopropyl

betaines and, if containing more than 5 per cent of amidopropyl betaines when
labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER;

SCHEDULE 6
b) in cosmetic leave-on preparations containing 1.5 per cent or less of amidopropyl

betaines; or
c) in other preparations containing 30 per cent or less of amidopropyl betaines and, if
containing more than 5 per cent of amidopropyl betaines, when labelled with
IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and
IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED

CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER
2-AMINO-6-CHLORO-4-NITROPHENOL in hair dye and eyebrow/eyelash colouring

preparations, except:
a) in preparations containing 2 per cent or less of 2-amino-6-chloro-4-nitrophenol when

applied directly to the hair, or containing 2 per cent or less of 2-amino-6-chloro-4-
nitrophenol after mixing and when the immediate container and primary pack are
labelled with the following statements:
WARNING – This product contains ingredients which may cause skin

sensitisation to certain individuals. A preliminary test according to the
accompanying directions should be made before use. This product must not be
used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
b) in eyelash and eyebrow tinting products containing 1.5 per cent or less of 2-amino-6-
chloro-4-nitrophenol after mixing for use when the immediate container and primary
pack are labelled with the following statement:

sensitisation to certain individuals, and when used for eyelash or eyebrow
tinting may cause injury to the eye. A preliminary test according to the
accompanying directions should be made before use.
written in letters not less than 1.5mm in height.
4-AMINO-m-CRESOL in hair dyes and eyebrow/eyelash colouring preparations except:
a) in hair dye preparations containing 1.5 per cent or less of 4-amino-m-cresol after
mixing for use when the immediate container and primary pack are labelled with the
following statements:
KEEP OUT OF REACH OF CHILDREN, and


SCHEDULE 6
written in letters not less than 1.5mm in height; or
b) in eyelash and eyebrow tinting products containing 1.5 per cent or less of 4-amino-m-
cresol after mixing for use when the immediate container and primary pack are
labelled with the following statement:

2-AMINO-5-ETHYLPHENOL in hair dye preparations except in preparations containing 1 per

cent or less of 2-amino-5-ethylphenol when the immediate container and primary pack are
WARNING – This product contains ingredients which may cause skin irritation to
certain individuals. A preliminary test according to the accompanying directions should
be made before use. This product must not be used for dyeing eyelashes and eyebrows;
to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
4-AMINO-2-HYDROXYTOLUENE in hair dyes and eyebrow/eyelash colouring products

except:
a) in hair dye preparations containing 1.5 per cent or less of 4-amino-2-hydroxytoluene

after mixing for use when the immediate container and primary pack are labelled with
the following statements:

written in letters not less than 1.5mm in height; or
b) in eyelash and eyebrow tinting products containing 1.5 per cent or less of 4-amino-2-
hydroxytoluene after mixing for use when the immediate container and primary pack
are labelled with the following statement:


SCHEDULE 6
AMINOCARB in preparations containing 25 per cent or less of aminocarb.
AMINOETHOXYVINYLGLYCINE except in preparations containing 15 per cent or less of

aminoethoxyvinylglycine.
1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.
4-AMINO-3-NITROPHENOL except:
a) in non-oxidative hair dye preparations and eyebrow/eyelash colouring products

containing 1 per cent or less of 4-amino-3-nitrophenol when the immediate container
and primary pack are labelled with the following statements:
WARNING - This product contains ingredients which may cause skin

written in letters not less than 1.5 mm in height; or
b) in oxidative hair dye preparations and eyebrow/eyelash colouring products containing

1 per cent or less of 4-amino-3-nitrophenol after mixing under oxidative conditions
when the immediate container and primary pack are labelled with the following
statements:

2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL (including its salts) except:
a) in non-oxidative hair dye preparations containing 2.5 per cent or less of 2,2'-[(4-
amino-3-nitrophenyl)imino]bisethanol after mixing when the immediate container


SCHEDULE 6
b) in oxidative hair dye preparations containing 1.25 per cent or less of 2,2'-[(4-amino-
3-nitrophenyl)imino]bisethanol after mixing under oxidative conditions when the
immediate container and primary pack are labelled with the following statements:

m-AMINOPHENOL except when used in hair dye and eyebrow/eyelash preparations at a

concentration of 1.2 per cent or less of m-aminophenol after mixing for use when the

p- AMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring products at a
concentration of 1 per cent or less of p-aminophenol after mixing for use when the

AMINOPYRALID except when included in Schedule 5.
AMITRAZ.
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) except:

b) in preparations for human internal therapeutic use;
c) in preparations for inhalation when absorbed in an inert solid material; or
d) in preparations containing 0.5 per cent or less of ammonia.

SCHEDULE 6
AMMONIUM COCOYL ISETHIONATE, except in cosmetic rinse-off preparations containing

30 per cent or less of ammonium cocoyl isethionate and, if containing more than 5 per cent
of ammonium cocoyl isethionate, when labelled with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER
AMMONIUM PERSULFATE in hair preparations.
ANILINE (excluding its salts and derivatives) except in preparations containing 1 per cent or
less of aniline.
ANTIMONY COMPOUNDS except:

b) antimony chloride in polishes;
c) antimony titanate pigments in paint; or
d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-
volatile content of the paint or tinter.
ARBUTIN (ALPHA) except:
a) in preparations for application to the face containing 2 per cent or less alpha-arbutin
with hydroquinone levels of 10mg/kg or less; or
b) in preparations for application to the body containing 0.5 per cent or less alpha-
arbutin with hydroquinone levels of 10mg/kg or less.
ARBUTIN (BETA) except:

b) oral herbal preparations containing 500 mg or less beta-arbutin per recommended
daily dose; or
c) in preparations for application to the face containing 7 per cent or less beta-arbutin
with hydroquinone levels of 10mg/kg or less.
ARBUTIN (DEOXY OR OTHER DERIVATIVES).
ARSENIC:
a) in ant poisons containing 0.4 per cent or less of arsenic;

b) in animal feed premixes containing 4 per cent or less of arsenic; or
c) in preparations for the treatment of animals except thiacetarsamide when included in
Schedule 4,
except when separately specified in this Schedule.
ASPIRIN for the treatment of animals except when included in Schedule 4 or 5.

SCHEDULE 6
AZACONAZOLE except in preparations containing 1 per cent or less of azaconazole.
AZADIRACHTA INDICA (Neem) including its extracts and derivatives except:

b) in preparations for human internal use;
c) debitterised neem seed oil;
d) in preparations for human dermal therapeutic use containing cold pressed neem seed
oil, when in a container fitted with a child-resistant closure and compliant with the
requirements of the Required Advisory Statements for Medicine Labels; or
e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed
oil.
AZAMETHIPHOS.
AZOBENZENE.
BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion

containing 2 per cent or less of antibiotic substances.
BARIUM SALTS except:

b) barium sulfate; or
c) in paints or tinters containing 5 per cent or less of barium calculated on the non-
BASIC BLUE 26 (CAS No. 2580-56-5) except when used as a colourant in cosmetics not
intended to be in contact with mucous membranes.
BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) except:
a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or

b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the
KEEP OUT OF REACH OF CHILDREN;
WARNING – This product contains ingredients which may cause skin irritation
to certain individuals. A preliminary test according to the accompanying
directions should be made before use. This product must not be used for dyeing
eyelashes or eyebrows; to do so may be injurious to the eye.

SCHEDULE 6
BASIC RED 76 (CAS No. 68391-30-0) in non-oxidative hair dye preparations and
eyebrow/eyelash colouring products containing 2 per cent or less of Basic Red 76 and
0.001 per cent or less of free o-anisidine.
BAY OIL except:
b) in medicines for human therapeutic use, when packed in containers having a nominal
capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant
closure and compliant with the requirements of the Required Advisory Statements for
Medicine Labels;
c) in preparations other than medicines for human therapeutic use, when packed in
insert and labelled with the warnings:
NOT TO BE TAKEN;
d) in preparations other than medicines for human therapeutic use, when packed in
insert and a child-resistant closure and labelled with the warnings:
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of bay oil.
BEAUVERIA BASSIANA except when included in Schedule 5.
BENDIOCARB:
a) in wettable powders containing 80 per cent or less of bendiocarb when packed in

containers or primary packs containing not less than 100 g of bendiocarb;
b) in wettable powders containing 20 per cent or less of bendiocarb and not less than
0.002 per cent of denatonium benzoate when packed in containers or primary packs
containing not less than 48 g of bendiocarb and labelled for use as a fly control
preparation;
c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or
d) when impregnated in plastic resin strip material containing 10 per cent or less of
bendiocarb,
BENQUINOX.

SCHEDULE 6
BENSULIDE.
BENZALKONIUM CHLORIDE except:

b) in preparations containing 5 per cent or less of benzalkonium chloride.
1,2-BENZENEDIOL.
BENZOVINDIFLUPYR.
6-BENZYLADENINE except in preparations containing 10 per cent or less of 6-benzyladenine.
BERYLLIUM.
BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin except

BETA-CYPERMETHRIN.
BHC (excluding lindane).
BICYCLOPYRONE except when included in Schedule 5.
BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin except in preparations

containing 0.5 per cent or less of bifenthrin.
BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing

3 per cent or less of total bifluorides except when included in Schedule 5.
BIOALLETHRIN except:

b) in preparations containing 1 per cent or less of bioallethrin.
1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE (including its salts) except when in hair dye

preparations containing 1.2 per cent or less of 1,3-bis(2,4-diaminophenoxy)propane after
mixing when the immediate container and primary pack are labelled with the following
statements:
WARNING - This product contains ingredients which may cause skin sensitisation to
be made before use. This product must not be used for dyeing eyelashes or eyebrows; to
do so may be injurious to the eye.

SCHEDULE 6
BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER except in rinse-off

cosmetic products containing 1 per cent or less of bis-isobutyl PEG/PPG-
20/35/amodimeticone copolymer when labelled with a warning to the following effect:
IF IN EYES, WASH OUT IMMEDIATELY WITH WATER.
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE
except in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-
(2.2.1)heptane-2,5-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-
(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-
2,6-dimethanamine, when labelled with statements to the effect of:
IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE
except in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-
(2.2.1)heptane-2,6-dimethanamine, or a combination of N,N-bis(phenylmethylene)-bicyclo-
(2.2.1)heptane-2,5-dimethanamine and N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-
2,6-dimethanamine, when labelled with statements to the effect of:
IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.
BITHIONOL for the treatment of animals.
BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF3)
BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.
BROFLANILIDE except when included in Schedule 5.

SCHEDULE 6
BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.
BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.
BROMOFORM except when included in Schedule 4.
BROMOPHOS.
BROMOPHOS-ETHYL.
BROMOXYNIL.
BROMUCONAZOLE except when included in Schedule 5.
BROTIANIDE.
BUNAMIDINE.
BUTACARB.
BUTOXYCARBOXIM except when included in Schedule 5.
2-BUTOXYETHANOL and its ACETATES except:
a) in plant growth regulator preparations containing 20 per cent or less of such substances;
or
b) in other preparations containing 10 per cent or less of such substances.
2-BUTOXY-2’-THIOCYANODIETHYL ETHER.
n-BUTYL ALCOHOL except:

b) in preparations containing 5 per cent or less of n-butyl alcohol; or
c) in preparations for cosmetic or therapeutic use other than in spray form.
BUTYRIC ACID in preparations for use as insect lures.
CACODYLIC ACID:
a) in animal feed premixes containing 4 per cent or less of arsenic; or

b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.
CADMIUM COMPOUNDS except:

b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-

SCHEDULE 6
CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated

cadusafos.
CAFFEINE except:

b) in divided preparations for internal human therapeutic use when labelled with a
maximum recommended daily dose of no greater than 600 mg of total caffeine; or
c) in undivided preparations for internal human therapeutic use with a concentration of
less than 5 per cent of total caffeine and when labelled with a maximum
recommended daily dose of no greater than 600 mg of total caffeine; or
d) in preparations for external use; or
e) in other preparations with a concentration of less than 5 per cent of caffeine.
CAJUPUT OIL except:
Medicine Labels;
NOT TO BE TAKEN;
NOT TO BE TAKEN;
e) in preparations containing 25 per cent or less of cajuput oil; or

f) in oils containing 25 per cent or less of cajuput oil.
CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.
CAMBENDAZOLE.

SCHEDULE 6
CAMPHOR except:
a) when included in Schedule 4 or 5;

b) when enclosed in an inhaler device which prevents ingestion of its contents;
c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;
d) in liquid preparations containing 2.5 per cent or less of camphor;
e) in essential oils when the camphor is present as a natural component of the oil:
i) in medicines for human therapeutic use, when packed in containers having a
nominal capacity of 15 mL or less fitted with a restricted flow insert and
compliant with the requirements of the Required Advisory Statements for
Medicine Labels;
ii) in medicines for human therapeutic use, when packed in containers having a
nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-
resistant closure and compliant with the requirements of the Required Advisory
Statements for Medicine Labels;
iii) in essential oils other than medicines for human therapeutic use, when packed in
containers having a nominal capacity of 15 mL or less fitted with a restricted
flow insert and labelled with the warnings:
NOT TO BE TAKEN; or
iv) in essential oils other than medicines for human therapeutic use, when packed in
containers having a nominal capacity of 25 mL or less fitted with a restricted
flow insert and a child-resistant closure and labelled with the warnings:
NOT TO BE TAKEN; or
f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.
CAPTAN.
CARBARYL except when included in Schedule 4 or 5.
CARBON DISULFIDE.
CARBAMIDE PEROXIDE except:

b) in other preparations containing 9 per cent or less of carbamide peroxide.
CARBETAMIDE.

SCHEDULE 6
CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for
cosmetic use except in wash-off preparations containing 1 per cent or less of castor oil,
monomaleate.
CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.
CHLORDANE.
CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr except when

included in Schedule 5.
CHLORFENETHOL.
CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine except:

b) in preparations containing 1 per cent or less of chlorhexidine; or
c) when in solid preparations.
CHLORINATING COMPOUNDS except:

b) when separately specified in these Schedules;
c) sodium hypochlorite preparations with a pH of less than 11.5;
d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent
of available chlorine when labelled with the statements:

e) in liquid preparations containing less than 2 per cent of available chlorine; or

f) in other preparations containing 4 per cent or less of available chlorine.
CHLORMEQUAT.
CHLOROACETAMIDE
a) in preparations for cosmetic use; or

b) in preparations for topical therapeutic use; or
c) in other preparations containing more than 0.3 per cent of chloroacetamide.
2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL except:
a) in non-oxidative hair dye preparations containing 3 per cent or less of 2-chloro-6-

(ethylamino)-4-nitrophenol after mixing for use when the immediate container and
primary pack are labelled with the following statements:

SCHEDULE 6

b) in oxidative hair dye preparations containing 1.5 per cent or less of 2-chloro-6-
(ethylamino)-4-nitrophenol after mixing for use when the immediate container and

CHLOROFORM except:

b) in preparations containing 10 per cent or less of chloroform.
ALPHA-CHLOROHYDRIN.
CHLOROPHACINONE.
(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-
3-OL (uniconazole-p) except in preparations containing 5 per cent or less of (E)-(S)-1-(4-
chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.
CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.
CHLOROTHALONIL except in water-based paint containing 0.5 per cent or less of

chlorothalonil.
2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE.
CHLORPYRIFOS except:

b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic
metre.
CHLORPYRIFOS-METHYL.
CHLORTHIAMID.

SCHEDULE 6
CHROMATES (including dichromates) except in paints or tinters containing 5 per cent or less
of chromium as the ammonium, barium, calcium, iron, potassium, sodium, strontium or
zinc chromate calculated on the non-volatile content of the paint or tinter.
CHROMIUM TRIOXIDE (excluding its salts and derivatives).
CHRYSOIDINE BASE except when in Schedule 10.
CINEOLE except:
Medicine Labels;
NOT TO BE TAKEN;
NOT TO BE TAKEN;
e) in preparations containing 25 per cent or less of cineole;

f) in oils containing 25 per cent or less of cineole; or
g) in rosemary oil or camphor oil (white).
CINNAMON LEAF OIL except:
Medicine Labels;

SCHEDULE 6
NOT TO BE TAKEN;
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of cinnamon leaf oil.
CLIMBAZOLE except:

b) in leave-on hair, face and foot cosmetic preparations containing 0.5 per cent or less of
climbazole; or
c) in other preparations (that are not leave-on cosmetic preparations) containing 2 per
cent or less of climbazole.
CLODINAFOP-PROPARGYL.
CLOMAZONE.
CLOSANTEL.
CLOTHIANIDIN except

b) when in gel preparations dispensed in sealed cartridges containing 1 per cent or less
of clothianidin.
CLOTRIMAZOLE for the external treatment of animals.
CLOVE OIL except:

c) in medicines for human therapeutic use, when packed in containers having a nominal

SCHEDULE 6
Medicine Labels;
NOT TO BE TAKEN;
e) in preparations other than medicines for human therapeutic use, when packed in
NOT TO BE TAKEN; or
f) in preparations containing 25 per cent or less of clove oil.
N-COCO-1,3-DIAMINOPROPANE.
COCOYL GLYCINATE in cosmetic preparations except:
a) in leave-on preparations containing 5 per cent or less of cocoyl glycinate; or

b) in wash-off preparations containing 30 per cent or less of cocoyl glycinate and, when
containing more than 5 per cent of cocoyl glycinate labelled with a warning to the
following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER.
COPPER ACETATE except:

b) in preparations containing 5 per cent or less of copper acetate.
COPPER COMPOUNDS except:

b) in preparations for human internal use containing 5 mg or less of copper per
recommended daily dose;
c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre
or less;
d) in feed additives containing 1 per cent or less of copper; or
e) in other preparations containing 5 per cent or less of copper compounds.
COPPER HYDROXIDE except:

SCHEDULE 6

b) in preparations containing 12.5 per cent or less of copper hydroxide.
COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in
sheep.
COPPER OXIDES except:

c) in marine paints; or
d) in other preparations containing 5 per cent or less of copper oxides.
COPPER OXYCHLORIDE except:

b) in preparations containing 12.5 per cent of less of copper oxychloride.
COPPER SULFATE except:

b) in preparations for internal use; or
c) in other preparations containing 5 per cent or less of copper sulfate.
COUMAPHOS:
a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of
coumaphos; or
b) in other preparations containing 5 per cent or less of coumaphos.
COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl except

CREOSOTE derived from wood other than beechwood except:

b) in preparations for human therapeutic use containing 10 per cent or less of creosote
derived from wood other than beechwood; or
c) in other preparations containing 3 per cent or less of phenols and homologues of
phenol boiling below 220°C.
CROTOXYPHOS.
CRUFOMATE.

SCHEDULE 6
CYANAMIDE.
CYANAZINE.
CYCLANILIDE.
N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM.
CYCLOSILAZANES, DI-ME, ME HYDROGEN, POLYMERS WITH DI-ME, ME

HYDROGEN SILAZANES, REACTION PRODUCTS WITH 3-(TRIETHOXYSILYL)-1-
PROPANAMINE (CAS 475645-84-2) when presented in a wipe and when packaged in a
container with a child-resistant closure, with chemical resistant gloves and labelled with the
following effect:
DO NOT USE WITHOUT PROTECTIVE GLOVES; and
KEEP OUT OF EYES.
CYFLUTHRIN except:

b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.
CYOMETRINIL.
CYPERMETHRIN except when included in Schedule 5.
CYPHENOTHRIN except when included in Schedule 5.
CYTHIOATE except when included in Schedule 5.
2,4-D except when included in Schedule 5.
DAZOMET.
DELTAMETHRIN:
a) in aqueous preparations containing 25 per cent or less of deltamethrin, when no

organic solvent, other than 10 per cent or less of a glycol, is present;
b) in wettable granular preparations containing 25 per cent or less of deltamethrin;
c) in water-dispersible tablets each containing 500 mg or less of deltamethrin;
d) in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a
solvent containing 40 per cent or less of acetophenone and 45 per cent or less of
liquid hydrocarbons; or
e) in other preparations containing 3 per cent or less of deltamethrin,
except:

SCHEDULE 6

b) in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or
c) in preparations containing 0.1 per cent or less of deltamethrin.
DERQUANTEL.
1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES except:
a) in cosmetic rinse-off preparations containing 8 per cent or less of 1-deoxy-1-

(methylamino)-D-glucitol N-coco acyl derivatives when labelled with the following
statement:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER, or
b) in household cleaning preparations, other than those intended to be sprayed,

containing 10 per cent or less of 1-deoxy-1-(methylamino)-D-glucitol N-coco acyl
derivatives when labelled with the following statement:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER.
2,4-DIAMINOPHENOXYETHANOL except when used in hair dye and eyebrow/eyelash

preparations at concentrations of 2 per cent or less of 2,4-diaminophenoxyethanol after
WARNING – This product contains ingredients which may cause skin sensitisation to
be made before use.
DIAZINON except when included in Schedule 5.
DICAMBA (including its salts and derivatives) except when included in Schedule 5.
DICHLOBENIL.
DICHLOFENTHION.
DICHLOFLUANID.
o-DICHLOROBENZENE.
DICHLOROETHYL ETHER.
DICHLOROISOCYANURIC ACID except:

SCHEDULE 6

b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent
of available chlorine when labelled with the statements:

c) in liquid preparations containing less than 2 per cent of available chlorine; or

d) in other preparations containing 4 per cent or less of available chlorine.
4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.
DICHLOROPHEN except:

b) in fabrics other than when:
i) for human therapeutic use; or
ii) as part of a registered pesticidal product.
1,2-DICHLOROPROPANE.
2,4-DICHLORPROP (including the R and S enantiomers).
DICHLORVOS in preparations containing 50 per cent or less of dichlorvos except when

DICLOFOP-METHYL.
DICYCLANIL except in preparations containing 6.5 per cent or less of dicyclanil.
DIDECYLDIMETHYLAMMONIUM SALTS except in preparations containing 1 per cent or

less of didecyldimethylammonium salts labelled with the statement:
DIELDRIN.
DIETHANOLAMINE (excluding its salts and derivatives) except:

b) in preparations containing 5 per cent or less of diethanolamine.
DIETHYLENE GLYCOL (excluding its salts and derivatives) except:

b) in paints or paint tinters;

SCHEDULE 6
c) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene

glycol; or
d) in other preparations containing 2.5 per cent or less of diethylene glycol.
DIETHYLENE GLYCOL MONOMETHYL ETHER.
DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.
DIFENZOQUAT.
DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.
5,6-DIHYDROXYINDOLINE.
DIMETHENAMID-P.
DIMETHIPIN.
DIMETHOATE.
2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE except when used in hair dye and

eyebrow/eyelash colouring products at a concentration of 0.25 per cent or less of 2,6-
dimethoxy-3,5-pyridinediamine after mixing for use when the immediate container and
certain individuals. A preliminary test according to the accompanying directions should be
made before use.
DIMETHYLACETAMIDE except when included in Schedule 5.
N,N-DIMETHYLDECANAMIDE.
DIMETHYLFORMAMIDE except:

b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.
4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL except:
a) in leave-on cosmetic preparations containing 0.1 per cent or less of 4,4-dimethyl-1-

cyclohexene-1-propanal;
b) in rinse-off cosmetic preparations containing 0.5 per cent or less of 4,4-dimethyl-1-
cyclohexene-1-propanal; or

SCHEDULE 6
c) in other preparations containing 1 per cent or less of 4,4-dimethyl-1-cyclohexene-1-

propanal.
3,7-DIMETHYL-2,6-OCTADIEN-1-OL and its isomers except in products containing 5 per

cent or less 3,7-dimethyl-2,6-octadien-1-ol and its isomers.
N,N-DIMETHYLOCTANAMIDE.
DIMETHYL SULFOXIDE (excluding dimethyl sulfone):
a) when not for therapeutic use; or

b) in cosmetic preparations; or
c) for the treatment of animals:
i) when combined with no other therapeutic substance(s);
ii) in liquid preparations containing copper salicylate and 1 per cent or less of
methyl salicylate as the only other therapeutic substances; or
iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide; or
d) in other preparations except when containing 10 per cent or less of dimethyl
sulfoxide.
DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such
compounds except:

DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such
compounds except:

DIOXACARB.
DIOXANE.
DIPHACINONE.
DIQUAT in preparations containing 20 per cent or less of diquat.
DIRECT RED 254 except when included in Schedule 5.
DISPERSE YELLOW 3 except when in Schedule 10.
DISULFIRAM except when included in Schedule 4.

SCHEDULE 6
DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.
DITHIANON.
DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment
of animals.
DIUREDOSAN.
N-(N-DODECYL)-2-PYRROLIDONE except:

b) in preparations containing 25 per cent or less of designated solvents.
DODINE.
DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per
cent or less of doramectin.
DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.
ECONAZOLE for the external treatment of animals.
EMAMECTIN in preparations containing 5 per cent or less of emamectin except when included
in Schedule 5.
EMODEPSIDE for the treatment of animals except when included in Schedule 5.
ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated

endosulfan.
ENDOTHAL in preparations containing 20 per cent or less of endothal.
EPRINOMECTIN for internal use in preparations containing 5 per cent or less of eprinomectin
EPTC.
ESBIOTHRIN except:

b) in pressurised spray packs containing 1 per cent or less of esbiothrin.
ESFENVALERATE except when included in Schedule 5.
ETHEPHON (excluding its salts and derivatives).
ETHER except:

SCHEDULE 6

b) in preparations containing 10 per cent or less of ether.
ETHIOFENCARB.
ETHOATE-METHYL.
ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2

per cent of linseed oil.
ETHYL BROMIDE.
ETHYLENE CHLOROHYDRIN.
ETHYLENE DICHLORIDE.
ETHYLENE GLYCOL (excluding its salts and derivatives) except:

b) in paints or paint tinters;
c) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol;
or
d) in other preparations containing 2.5 per cent or less of ethylene glycol.
ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, except:

b) in preparations containing 10 per cent or less of such substances.
ETHYL FORMATE when packed and labelled for use as a fumigant.
ETHYLHEXANEDIOL except in preparations containing 5 per cent or less of ethylhexanediol.
2-ETHYLHEXANOIC ACID and its alkyl esters except in preparations containing 5 per cent or
less calculated as 2-ethylhexanoic acid.
ETRIMFOS.
EUCALYPTUS OIL except:
Medicine Labels;

SCHEDULE 6
NOT TO BE TAKEN;
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of eucalyptus oil.
EUGENOL except:

c) in medicines for human therapeutic use, when packed in containers having a nominal
Medicine Labels;
NOT TO BE TAKEN;
e) in preparations other than medicines for human therapeutic use, when packed in
NOT TO BE TAKEN; or
f) in preparations containing 25 per cent or less of eugenol.
FAMPHUR in preparations containing 20 per cent or less of famphur.
FEBANTEL except:

SCHEDULE 6
a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or

b) in undivided preparations containing 10 per cent or less of febantel.
FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.
FENAZAFLOR.
FENBUTATIN OXIDE.
FENCHLORPHOS.
FENITROTHION.
FENOXACRIM in preparations for the treatment of carpets during manufacture.
FENPYROXIMATE.
FENTHION in preparations containing 60 per cent or less of fenthion except when included in
Schedule 5.
FENVALERATE.
FIPRONIL except:

b) in preparations containing 0.05 per cent or less of fipronil.
FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.
FLONICAMID.
FLUAZAINDOLIZINE except when included in Schedule 5.
FLUAZIFOP-BUTYL.
FLUAZIFOP-p-BUTYL.
FLUAZINAM.
FLUCOFURON in preparations for the treatment of carpets during manufacture.
FLUENSULFONE.
FLUMETHRIN except when included in Schedule 5.
FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.
FLUORIDES except:

SCHEDULE 6
b) in preparations for human use; or

c) in preparations containing 15 mg/kg or less of fluoride ion.
FLUPROPANATE.
FLUPYRADIFURONE.
FLUQUINCONAZOLE.
FLUSILAZOL.
FLUTRIAFOL except in fertilisers containing 0.5 per cent or less of flutriafol.
FLUVALINATE except when included in Schedule 5.
FOMESAFEN SODIUM.
FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more
of free formaldehyde except:
a) for human therapeutic use;

b) in oral hygiene preparations;
c) in nail hardener cosmetic preparations containing 5 per cent or more of free
formaldehyde;
d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free
formaldehyde when labelled with the statement:
PROTECT CUTICLES WITH GREASE OR OIL;
e) in all other cosmetic preparations; or

f) in other preparations containing 0.2 per cent or less of free formaldehyde when
labelled with the warning statement:
CONTAINS FORMALDEHYDE.
FORMOTHION.
FOSPIRATE except when included in Schedule 5.
FUMAGILLIN.
FURFURAL except in preparations containing 0.1 per cent or less of furfural.
GLUTARAL except:

SCHEDULE 6
b) in preparations containing 0.5 per cent or less of glutaral when labelled with the
statements:
IRRITANT; and
GLYCERYL THIOGLYCOLLATE in hair waving preparations except when labelled with

directions for use that include the statement:
Wear protective gloves when using. Keep out of eyes.
GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and
labelled for use as an agricultural chemical except:
a) in cosmetic preparations for salon use only, when labelled in accordance with
requirements under applicable jurisdictional Work Health and Safety laws, as
amended from time to time;
b) in preparations containing 5 per cent or less of glycolic acid; or
c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or
greater.
GUANIDINE except:

b) in preparations containing 1 per cent or less of guanidine.
GUAZATINE.
HALOXON.
HALOXYFOP.
HC VIOLET 1 except:
a) in non-oxidative hair dye preparations containing 0.28 per cent or less of HC Violet 1
after mixing when the immediate container and primary pack are labelled with the


SCHEDULE 6
b) in oxidative hair dye preparations containing 0.25 per cent or less of HC Violet 1
after mixing under oxidative conditions when the immediate container and primary
pack are labelled with the following statements:

HEPTACHLOR.
HEXACHLOROPHENE:
a) in preparations for the treatment of animals; or

HEXAZINONE except when included in Schedule 5.
HEXYLOXYETHANOL except in preparations containing 10 per cent or less of

hexyloxyethanol.
HYDRAMETHYLNON except when included in Schedule 5.
HYDRAZINE.
HYDROCHLORIC ACID (excluding its salts and derivatives) except:

b) in preparations for therapeutic use; or
c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).
HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate
hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride except
HYDROGEN PEROXIDE (excluding its salts and derivatives) except:

b) in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen
peroxide; or
c) in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.
HYDROQUINONE except:

SCHEDULE 6

b) in preparations containing 10 per cent or less of hydroquinone.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations

containing 1 per cent or less of hydrosilicofluoric acid (H2SiF6) except when included in
Schedule 5.
HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE (including its salts) except in

oxidative hair dye preparations containing 1.5 per cent or less of hydroxyethyl-3,4-
methylenedioxyaniline after mixing under oxidative conditions when the immediate container
be made before use. This product must not be used for dyeing eyelashes or eyebrows; to
do so may be injurious to the eye.
IMIDACLOPRID except:

b) in preparations containing 5 per cent or less of imidacloprid.
IMIDOCARB.
IMINOCTADINE TRIALBESILATE.
IMIPROTHRIN except:

b) in preparations containing 10 per cent or less of imiprothrin.
INDAZIFLAM.
INDOXACARB (includes the R and S enantiomers) except when included in Schedule 5.
IODINE (excluding its salts, derivatives and iodophors) except:

b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.
IODOPHORS except in preparations containing 1.5 per cent or less of available iodine.
3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) except:

SCHEDULE 6

b) in aqueous preparations not for cosmetic use containing 10 per cent or less of 3-iodo-
2-propynyl butyl carbamate (Iodocarb); or
c) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent
or less of 3-iodo-2-propynyl butyl carbamate.
IOXYNIL.
IPCONAZOLE except when included in Schedule 5.
IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient)
for the treatment of animals except:

b) in liquid or gel preparations containing 0.1 per cent or less of iron; or
c) in animal feeds or feed premixes.
ISOCONAZOLE for the external treatment of animals.
ISOCYANATES, free organic, boiling below 300° C, except in:
a) viscous polyurethane adhesives; or

b) viscous polyurethane sealants;
containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.
ISOEUGENOL except:

b) in preparations not intended for skin contact containing 10 per cent or less of
isoeugenol; or
c) in preparations intended for skin contact containing 0.02 per cent or less of
isoeugenol.
ISOPYRAZAM.
LAMBDA-CYHALOTHRIN:
a) in aqueous preparations containing 25 per cent or less of microencapsulated lambda-

cyhalothrin; or
b) in emulsifiable granule formulations containing 25 per cent or less lambda-
cyhalothrin; or
c) in other preparations containing 1.6 per cent or less of lambda-cyhalothrin

SCHEDULE 6
LASALOCID except in animal feeds containing 100 mg/kg or less of antibiotic substances.
LAURETH CARBOXYLIC ACIDS (excluding their salts and derivatives) except:
a) in leave-on preparations containing 1.5 per cent or less of laureth carboxylic acids;
b) in wash-off preparations containing 30 per cent or less of laureth carboxylic acids
and, if containing more than 5 per cent of laureth carboxylic acids, when labelled
with a warning to the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or
c) in other preparations containing 30 per cent or less of laureth carboxylic acids and, if
containing more than 5 per cent of laureth carboxylic acids, when labelled with

CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.
LAURYL ISOQUINOLINIUM BROMIDE.
LAURYL SULFATE SALTS (excluding their derivatives) except:
a) in wash-off preparations containing 30 per cent or less of lauryl sulfates and, if

containing more than 5 per cent of lauryl sulfates, when labelled with a warning to
the following effect:
IF IN EYES WASH OUT IMMEDIATELY WITH WATER;
b) in leave-on preparations containing 1.5 per cent or less of lauryl sulfates;

c) in toothpaste and oral hygiene preparations containing 5 per cent or less of lauryl
sulfates;
d) in other preparations for animal use containing 2 per cent or less of lauryl sulfates; or
e) in other preparations containing 30 per cent or less of lauryl sulfates and, if
containing more than 5 per cent of lauryl sulfates, when labelled with warnings to the
following effect:

CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.
LEAD COMPOUNDS except:

b) in paints, tinters, inks or ink additives;

SCHEDULE 6
c) in preparations for cosmetic use containing 100 mg/kg or less of lead;

d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster
paints/colours or coloured chalks containing 100 mg/kg or less of lead; or
e) in ceramic glazes when labelled with the warning statement:
CAUTION – Harmful if swallowed. Do not use on surfaces which contact food

or drink.
LEPTOSPERMUM SCOPARIUM OIL (manuka oil) except:
Medicine Labels;
NOT TO BE TAKEN;
insert and a child-resistant closure and labelled with the warnings;
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of Leptospermum scoparium oil.
LEVAMISOLE for the treatment of animals except:

b) in preparations for the treatment of ornamental birds or ornamental fish, in packs
containing 10 mg or less of levamisole.
LINDANE except when included in Schedule 2, 4 or 5.
MAFENIDE when packed and labelled for the treatment of ornamental fish only.
MALATHION except:

SCHEDULE 6

b) for human therapeutic use; or
c) in dust preparations containing 2 per cent or less of malathion.
MCPA except when included in Schedule 5.
MCPB.
MEBENDAZOLE for the treatment of animals except when included in Schedule 5.
MECOPROP except when included in Schedule 5.
MECOPROP-P.
MEFLUIDIDE.
MELALEUCA OIL (tea tree oil) except:
Medicine Labels;
NOT TO BE TAKEN;
NOT TO BE TAKEN; or
e) in preparations containing 25 per cent or less of melaleuca oil.
MELENGESTROL ACETATE when used as an animal feed additive.
MENAZON.
MERCAPTAMINE for cosmetic use except:

SCHEDULE 6

b) in preparations containing 1 per cent or less of mercaptamine.
MERCAPTOACETIC ACID and its salts, but excluding its derivatives, in cosmetic
preparations except:
a) when included in Schedule 5

b) in preparations containing 5 per cent or less of mercaptoacetic acid or its salts (as
mercapturic acid).
2-MERCAPTOETHANOL in preparations for use as insect lures.
MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.
MERCUROCHROME for the treatment of animals, in preparations for topical use.
METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION

PRODUCT for the treatment of animals.
METALAXYL except when included in Schedule 5.
METALDEHYDE except when included in Schedule 5.
METHACRIFOS in preparations containing 60 per cent or less of methacrifos.
METHAM.
METAMITRON.
METHANOL (excluding its derivatives) except:

b) in preparations containing 2 per cent or less of methanol.
METHIOCARB in preparations containing 20 per cent or less of methiocarb except when

METHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per
cent of denatonium benzoate as a bittering agent.
2-METHOXY-5-NITROPHENOL.
METHYLCHLOROISOTHIAZOLINONE except:
a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off

application containing 0.0015 per cent or less of methylchloroisothiazolinone and
methylisothiazolinone in total; or

SCHEDULE 6
b) in other preparations that are not intended for direct application to the skin containing
0.1 per cent or less of methylchloroisothiazolinone and methylisothiazolinone in
total.
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations

containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted
with a child-resistant closure.
METHYLDIBROMO GLUTARONITRILE except when in Schedule 10.
METHYLENE BISTHIOCYANATE except in preparations containing 1 per cent or less of

methylene bisthiocyanate.
METHYLEUGENOL except in preparations containing 1 per cent or less of methyleugenol.
METHYL ETHYL KETONE OXIME except:
a) in viscous silicone adhesives or viscous silicone sealants containing 2.5 per cent or
less of methyl ethyl ketone oxime; or
b) in other preparations conting 1 per cent or less of methyl ethyl ketone oxime.
p-METHYLAMINOPHENOL except when used in hair dye and eyebrow/eyelash colouring

products at a concentration of 1 per cent or less of p-methylaminophenol after mixing for
use when the immediate container and primary pack are labelled with the following
statements:
made before use.
METHYL ISOTHIOCYANATE.
METHYL METHACRYLATE (excluding its derivatives) except:
a) for cosmetic use; or

b) in preparations containing 1 per cent or less of methyl methacrylate as residual
monomer in a polymer.
METHYL NEODECANAMIDE except in liquid preparations containing 2 per cent or less of

methyl neodecanamide.
METHYLISOTHIAZOLINONE except:
a) in rinse-off cosmetic preparations or therapeutic goods intended for topical rinse-off

application containing 0.0015 per cent or less of methylisothiazolinone; or

SCHEDULE 6
b) in other preparations that are not intended for direct application to the skin containing
0.1 per cent or less of methylisothiazolinone
METHYLNORBORNYLPYRIDINE.
N-METHYL-2-PYRROLIDONE except:

2-METHYLRESORCINOL except:
a) in non-oxidative hair dye preparations containing 1.8 per cent or less of

2-methylresorcinol when the immediate container and primary pack are labelled with
the following statements:
WARNING – This product must not be used for dyeing eyelashes or eyebrows;
b) in oxidative hair dye preparations containing 1.8 per cent or less of 2-

methylresorcinol after mixing under oxidative conditions when the immediate
container and primary pack are labelled with the following statements:
WARNING – This product must not be used for dyeing eyelashes or eyebrows;
written in letter not less than 1.5 mm in height.
METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548-62-9)

and the following TRIARYLMETHANE DYES:
- Acid Violet 49 (CAS No. 1694-09-3),
- Ethyl Violet (CAS No. 2390-59-2),
- Basic Blue 7 (CAS No. 2390-60-5),
- Methylium, 4-(dimethylamino)phenylbis4-(ethylamino)-3-methylphenyl-, acetate (CAS

No. 72102-55-7),
except when included in Schedule 4 or Schedule 10.
METHYL SALICYLATE except:

SCHEDULE 6
b) in preparations for therapeutic use; or

c) in preparations containing 5 per cent or less of methyl salicylate.
METOFLUTHRIN except when included in Schedule 5.
METOSULAM.
METRAFENONE except when included in Schedule 5.
METRIBUZIN.
MICONAZOLE for the external treatment of animals.
MILBEMECTIN except when included in Schedule 5.
MOMFLUOROTHRIN except in preparations containing 0.2 per cent or less of

momfluorothrin.
MONENSIN:
a) in animal feed premixes containing 12.5 per cent or less of antibiotic substances; or
b) in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic
substances.
MONOETHANOLAMINE (excluding its salts and derivatives) except:

b) in preparations containing 5 per cent or less of monoethanolamine.
MORANTEL except:

b) in preparations containing 10 per cent or less of morantel.
MOXIDECTIN:
a) in preparations for external use containing 2.5 per cent or less of moxidectin when
packed in single dose tubes for the treatment of cats and dogs; or
b) in preparations for external use containing 2 per cent or less of moxidectin for the
treatment of animals; or
c) in preparations for internal use containing 10 per cent or less of moxidectin for the
treatment of sheep or cattle,
MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.

SCHEDULE 6
NALED except when included in Schedule 5.
NAPHTHALENE (excluding its derivatives) except in liquid hydrocarbons.
1,5-NAPHTHALENEDIOL except:
a) in non-oxidative hair dye preparations containing 1 per cent or less of 1,5-

naphthalenediol when the immediate container and primary pack are labelled with the

b) in oxidative hair dye preparations containing 1 per cent or less of 1,5-naphthalenediol


2,7-NAPHTHALENEDIOL except:
a) in non-oxidative hair dye preparations containing 1 per cent or less of 2,7-

naphthalenediol when the immediate container and primary pack are labelled with the

b) in oxidative hair dye preparations containing 1 per cent or less of 2,7-naphthalenediol


SCHEDULE 6

1-NAPHTHOL except in hair dye preparations containing 1 per cent or less of 1-naphthol after
mixing under oxidative conditions when the immediate container and primary pack are
made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so
may be injurious to the eye.
NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.
NARASIN in animal feed premixes containing 12 per cent or less of narasin.
NETOBIMIN for the treatment of animals except when included in Schedule 5.
NICKEL SULFATE.
NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed
for the treatment of animals.
NIMIDANE in preparations containing 25 per cent or less of nimidane.
NITENPYRAM except in divided preparations containing 100 mg or less of nitenpyram.
NITRIC ACID (excluding its salts and derivatives) except:

b) in preparations containing 0.5 per cent or less of nitric acid (HNO3).
NITROBENZENE except:
a) in solid or semi-solid polishes;

b) in soaps containing 1 per cent or less of nitrobenzene; or
c) in other preparations containing 0.1 per cent or less of nitrobenzene.
3-NITRO-p-HYDROXYETHYLAMINOPHENOL except

SCHEDULE 6
a) in non-oxidative hair dye preparations containing 1.85 per cent or less of 3-nitro-p-
hydroxyethylaminophenol after mixing when the immediate container and primary

b) in oxidative hair dye preparations containing 3 per cent or less of 3-nitro-p-

hydroxyethylaminophenol after mixing under oxidative conditions when the

NITROPHENOLS, ortho, meta and para, except when separately specified in these Schedules.
NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides except

NITROXYNIL.
NONOXINOL 9 except:

b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the
statements:
IRRITANT; and
c) in preparations containing 12.5 per cent or less of nonoxinol 9; or

d) in preparations for human use.
1-OCTEN-3-OL except in preparations containing 5 per cent or less of 1-octen-3-ol.

SCHEDULE 6
OCTHILINONE except in paints, jointing compounds and sealants containing 1 per cent or less
of octhilinone calculated on the non-volatile content.
N-(N-OCTYL)-2-PYRROLIDONE except:

OLAQUINDOX except in preparations containing 10 per cent or less of olaquindox.
N-OLEYL-1,3-DIAMINOPROPANE.
OMETHOATE in preparations containing 30 per cent or less of omethoate except when

OXADIAZON.
OXALIC ACID except
a) in dental care preparations, including mouthwashes, containing 3 per cent or less of

soluble salts of oxalic acid; or
b) its insoluble salts.
OXYCLOZANIDE.
PAECILOMYCES LILACINUS STRAIN 251.
PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent

or more of free formaldehyde except:
a) for human therapeutic use;

b) in oral hygiene preparations;
formaldehyde;
d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free
formaldehyde when labelled with the statement:
PROTECT CUTICLES WITH GREASE OR OIL;
e) in all other cosmetic preparations; or

f) in other preparations containing 0.2 per cent or less of free formaldehyde when
labelled with the warning statement:
PARATHION-METHYL in aqueous preparations containing 45 per cent or less of

microencapsulated parathion-methyl.

SCHEDULE 6
PARBENDAZOLE.
PEBULATE.
PENNYROYAL OIL except:
Medicine Labels;
NOT TO BE TAKEN; or
c) in preparations containing 4 per cent or less of D-pulegone.
PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of

pentachlorophenol.
PERACETIC ACID except when included in Schedule 5.
PERFLUIDONE.
PERMANGANATES except potassium permanganate in aqueous solutions containing 1 per

cent or less of potassium permanganate.
PERMETHRIN except:

b) in preparations for human therapeutic use containing 5 per cent or less of permethrin;
or
c) in preparations containing 2 per cent or less of permethrin.
2-PHENOXYETHANOL except:
a) in cosmetic preparations containing 1 per cent or less of 2-phenoxyethanol; or

b) in other preparations containing 15 per cent or less of 2-phenoxyethanol.
PHENOL, including cresols and xylenols and any other homologue of phenol boiling below
220°C, except:

b) in preparations containing 1 per cent or less of phenols, and in preparations
containing 3 per cent or less of cresols and xylenols and other homologues of phenol.

SCHEDULE 6
PHENOTHIAZINE (excluding its derivatives) except in preparations containing 10 per cent or

less of phenothiazine.
PHENOXYMETHYL OXIRANE.
PHENYLENEDIAMINES including alkylated, arylated, halogenated and nitro derivatives not

elsewhere specified in these Schedules:
a) in preparations packed and labelled for photographic purposes;

b) in preparations packed and labelled for testing water except tablets containing 10 mg
or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in
opaque strip packaging provided the directions for use include the statement, “Do not
discard testing solutions into the pool”;
c) in hair dye preparations except when the immediate container and primary pack are
WARNING ‒ This product contains ingredients which may cause skin irritation
d) in eyelash and eyebrow tinting products when the immediate container and primary
WARNING ‒ This product contains ingredients which may cause skin irritation
to certain individuals, and when used for eyelash and eyebrow tinting may
cause injury to the eye. A preliminary test according to the accompanying
directions should be made before use.
PHENYL METHYL PYRAZOLONE except when used in hair dye and eyebrow/eyelash
preparations at a concentration of 0.25 per cent or less after mixing for use when the immediate
container and primary pack are labelled with warning statements to the following effect:
be made before use.
PHOSALONE.

SCHEDULE 6
PHOSMET.
PHOSPHORIC ACID (excluding its salts and derivatives) except:

b) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);
c) in solid or semi-solid preparations; or
d) in professional dental kits.
PHOXIM.
o-PHTHALALDEHYDE except when included in Schedule 5.
PINDONE.
PINE OILs when packed and labelled as a herbicide except when included in Schedule 5.
PINOXADEN except when included in Schedule 5.
PIPEROPHOS.
PIRIMICARB except when included in Schedule 5.
PIRIMIPHOS-ETHYL.
PIRIMIPHOS-METHYL.
POLIHEXANIDE except:
a) in cosmetic preparations containing 0.3 per cent or less of polihexanide; or

b) when packed and labelled for therapeutic use; or
c) in other preparations containing 5 per cent or less of polihexanide.
POLIXETONIUM SALTS except:

b) in preparations containing 1 per cent or less of polixetonium salts.
POTASSIUM AZELOYL DIGLYCINATE except in preparations for cosmetic use containing

1 per cent or less of potassium azeloyl diglycinate.
POTASSIUM BROMATE except in preparations containing 0.5 per cent or less of potassium
bromate.
POTASSIUM CYANATE.
POTASSIUM HYDROXIDE (excluding its salts and derivatives) except:

SCHEDULE 6
a) when included in Schedule 5 or Schedule 10;

b) in preparations containing 5 per cent or less of potassium hydroxide being:
i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less;
or
ii) liquid or semi-solid preparations, the pH of which is 11.5 or less.
POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite

except:

b) in preparations containing 0.5 per cent or less of potassium nitrite;
c) when present as an excipient in preparations for therapeutic use; or
d) in aerosols containing 2 per cent or less of potassium nitrite.
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT except:

b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use”
aqueous solution is 2.5 or more, but not more than 11.5; or
c) in preparations containing 5 per cent or less of potassium peroxomonosulfate triple
salt being:
i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more;
or
ii) liquid or semi-solid preparations, the pH of which is 2.5 or more.
POTASSIUM PERSULFATE in hair preparations.
PRALLETHRIN (cis:trans=20:80) except:

b) in insecticidal mats containing 1 per cent or less of prallethrin.
PROCHLORAZ.
PROFENOFOS.
PROMACYL.
PROPACHLOR.
PROPARGITE.
PROPETAMPHOS.
PROPICONAZOLE except when included in Schedule 5.

SCHEDULE 6
PROPINEB.
PROPIONIC ACID (excluding its salts and derivatives) except:

b) in preparations containing 30 per cent or less of propionic acid; or
c) for therapeutic use.
PROPOXUR except when included in Schedule 5.
n-PROPYL ALCOHOL except:

b) in preparations containing 5 per cent or less of n-propyl alcohol; or
c) in preparations for cosmetic or therapeutic use other than in spray form.
PROQUINAZID.
PROSULFOCARB.
PROSULFURON.
PROTHIOFOS.
D-PULEGONE except in preparations containing 4 per cent or less of d-pulegone.
PYRACLOFOS.
PYRAZOPHOS.
PYRIDABEN except when included in Schedule 5.
PYRIDALYL.
PYRIDATE.
PYRIPROLE.
PYRITHIONE COPPER.
PYRITHIONE ZINC except:

b) for human use in preparations for the treatment of the scalp containing 2 per cent or
less of pyrithione zinc when compliant with the requirements of the Required
Advisory Statements for Medicine Labels;
c) in semi-solid hair preparations for animal use;

SCHEDULE 6
d) in shampoos for animal use containing 2 per cent or less of pyrithione zinc when
labelled with the statements “Keep out of eyes” and “If in eyes rinse well with
water”;
e) when immobilised in solid preparations containing 0.5 per cent or less of pyrithione
zinc; or
f) in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione
zinc calculated on the non-volatile content.
PYRIOFENONE except when included in Schedule 5.
PYROXASULFONE.
PYROXSULAM.
QUATERNARY AMMONIUM COMPOUNDS except:

b) when included in Schedule 5;
c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl
groups are derived from tallow or hydrogenated tallow or similar chain length
(C16/C18) sources; or
d) in preparations containing 5 per cent or less of such quaternary ammonium
compounds.
QUININE in cosmetic preparations except:
a) in rinse-off hair preparations containing 0.5 per cent or less of quinine calculated as
free base; or
b) in leave-on hair preparations containing 0.2 per cent or less of quinine calculated as
free base.
QUINOLINE and its salts (excluding other derivatives).
QUIZALOFOP ETHYL.
QUIZALOFOP-p-ETHYL except when included in Schedule 5.
QUIZALOFOP-p-TEFURYL.
RESMETHRIN except when included in Schedule 5.
RESORCINOL except:

b) in oxidative hair dye preparations containing 1.25 per cent or less of resorcinol after

SCHEDULE 6

c) in oxidative eyelash and eyebrow dye preparations containing 1.25 per cent or less of
resorcinol after mixing for use when the immediate container and primary pack are

d) in hair lotions/shampoo products containing 0.5 per cent or less of resorcinol when
the immediate container and primary pack are labelled with the following statement:

sensitisation to certain individuals.
ROTENONE except in solid or semi-solid preparations containing 2 per cent or less of

rotenone.
SAFROLE except:

b) in other preparations containing 1 per cent or less of safrole.
SAGE OIL (Dalmatian) except:
Medicine Labels;

SCHEDULE 6
NOT TO BE TAKEN; or
c) in preparations containing 4 per cent or less of thujone.
SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic

substances.
SAROLANER except when included in Schedule 5.
SASSAFRAS OIL except:

b) in other preparations containing 1 per cent or less of safrole.
SELENIUM:
a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:
i) for the blueing of gun barrels;
ii) for photographic purposes; or
iii) for the colouring of lead or lead alloys;
b) in coated granules containing 1 per cent or less of selenium for application to pasture
except in fertilisers containing 200 g/tonne or less of selenium; or
c) for the treatment of animals:
i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement
containing 0.5 per cent or less of selenium;
ii) in animal feed premixes containing 2 per cent or less of selenium for the
preparation of feeds containing 1 g/tonne or less of selenium;
iii) in controlled release bolus preparations containing 25 mg or less of selenium with
a release rate not greater than 0.25 mg/day; or
iv) as barium selenate in preparations for injection containing 5 per cent or less of
selenium.
SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or
less of antibiotic substances.
SILICOFLUORIDES except:

SILVER NITRATE except:
a) when included in or expressly excluded from Schedule 2; or

b) in preparations containing 1 per cent or less of silver.

SCHEDULE 6
SINBIOALLETHRIN except:

b) in preparations containing 1 per cent or less of sinbioallethrin.
SODIUM ALUMINATE (excluding its salts and derivatives) except:
a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

b) in liquid preparations, the pH of which is 11.5 or less.
SODIUM BROMATE except in preparations containing 0.5 per cent or less of sodium bromate.
SODIUM HYDROXIDE (excluding its salts and derivatives) except:
a) when included in Schedule 5 or Schedule 10;

b) in preparations containing 5 per cent or less of sodium hydroxide being:
i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less;
or
ii) liquid or semi-solid preparations, the pH of which is 11.5 or less.
SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite except:

b) in preparations containing 0.5 per cent or less of sodium nitrite;
d) in aerosols containing 2 per cent or less of sodium nitrite.
SODIUM PERCARBONATE (CAS No. 15630-89-4) except:

b) in preparations containing 15 per cent or less of sodium percarbonate.
SODIUM PERSULFATE:
a) in hair preparations; or
b) in products for the treatment of water for swimming pools and spas.
SODIUM SULFIDE in preparations for use as insect lures.
SPIROPIDION.
SPIROTETRAMAT.
SPIROXAMINE.

SCHEDULE 6
SULCOFURON in preparations for the treatment of carpets during manufacture.
SULFAMIC ACID (excluding its salts and derivatives) except when included in Schedule 5.
SULFLURAMID.
SULFOXAFLOR except when included in Schedule 5.
SULFURIC ACID (excluding its salts and derivatives) except:
a) in fire extinguishers; or
b) in preparations containing 0.5 per cent or less of sulfuric acid (H2SO4).
SULFURYL FLUORIDE.
SULPROFOS.
2,4,5-T.
N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE

ACETATES.
TAR ACIDS distilling within the range 230-290°C inclusive.
TCMTB (2-[thiocyanomethylthio]benzothiazole).
TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) except when included in Schedule 5.
TEBUFENPYRAD.
TEBUTHIURON.
TEMEPHOS except when in Schedule 5.
TERBUTHYLAZINE except in preparations containing 5 per cent or less of terbuthylazine.
TERPENES, CHLORINATED.
TESTOSTERONE in implant preparations for use in animals.
TETRACHLOROETHYLENE except:

b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed
into an inert solid; or
c) in preparations for the treatment of animals.
TETRACONAZOLE except when included in Schedule 5.

SCHEDULE 6
TETRADIFON.
2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations

containing 2 per cent or less of 2,2’,6,6’-tetraisopropyl-diphenyl-carbodiimide.
TETRAMISOLE in preparations for the treatment of animals.
THIACLOPRID.
THIAMETHOXAM except when included in Schedule 5.
THIAZAFLURON.
THIODICARB except when included in Schedule 5.
THIOMETON.
THIOPHANATE-METHYL except when included in Schedule 5.
THIOUREA AND ALKYL THIOUREAS except:

THIRAM except in paint containing 0.5 per cent or less of thiram.
THUJONE except in preparations containing 4 per cent or less of thujone.
THYMOL when packed and labelled for use as a pesticide.
TOLUENE (excluding its derivatives) except in preparations containing 50 per cent or less of
toluene or toluene and xylene.
TOLUENEDIAMINE not elsewhere specified in these Schedules:
a) in hair dye preparations except when the immediate container and primary pack are
b) in eyelash and eyebrow tinting products when the immediate container and primary

SCHEDULE 6
to certain individuals, and when used for eyelash and eyebrow tinting may
cause injury to the eye. A preliminary test according to the accompanying
directions should be made before use.
c) in nail polish preparations containing 2,5-toluenediamine except when labelled

‘avoid contact with skin’.
TOLYLFLUANID.
TRANSFLUTHRIN except:
a) in preparations containing 1 per cent or less of transfluthrin; or

b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per
cartridge.
TRIADIMEFON except:

b) in fertilisers containing 5 g/kg or less of triadimefon.
TRICHLORFON except metrifonate included in Schedule 4.
TRICHLOROACETIC ACID except:

b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid
for the treatment of warts other than anogenital warts.
TRICHLOROETHYLENE except when included in Schedule 4.
TRICHLOROPHENOL.
TRICLABENDAZOLE except in preparations containing 20 per cent or less of triclabendazole.
TRICLOPYR.
TRICLOSAN in cosmetic preparations for human use containing more than 0.3 per cent of
triclosan.
TRIDEMORPH.
TRIETHYL PHOSPHATE.
TRIFLUOROMETHANESULFONIC ACID.
TRINITROPHENOL (excluding its derivatives) except:

SCHEDULE 6

b) in preparations containing 5 per cent or less of trinitrophenol.
TRISODIUM NITRILOTRIACETATE except in preparations containing 20 per cent or less of

trisodium nitrilotriacetate.
VAMIDOTHION.
VINYL ACETATE MONOMER (excluding its derivatives) except:
a) in preparations for therapeutic use; or

b) in cosmetic preparations containing 0.01 per cent or less of vinyl acetate as residual
monomer in a polymer; or
c) in other preparations containing 1 per cent or less of vinyl acetate.
WARFARIN except when included in Schedule 4 or 5.
XYLENE (excluding its derivatives) except in preparations containing 50 per cent or less of
xylene or xylene and toluene.
ZERANOL in ear implants for use as a growth promotant in steer cattle.
ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.
ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.
ZINC CHLORIDE except:

b) in preparations containing 5 per cent or less of zinc chloride.
ZINC para-PHENOLSULFONATE except in preparations containing 5 per cent or less of zinc

para-phenolsulfonate.
ZINC LACTATE in toothpaste except in toothpaste preparations containing 2.5 per cent or less
of zinc lactate and labelled with the statement :
Not recommended for children under twelve years of age.
ZINC SULFATE except:
a) when included in or expressly excluded from Schedule 4; or

b) in other preparations containing 5 per cent or less of zinc sulfate.
ZIRAM in granular preparations.

SCHEDULE 7
SCHEDULE 7
ABAMECTIN except when included in Schedule 5 or 6.
ACIBENZOLAR-S-METHYL.
ACRIFLAVINIUM CHLORIDE for veterinary use except when in Schedule 5.
ACROLEIN.
ACRYLONITRILE.
ALACHLOR.
ALDICARB.
ALDOXYCARB.
ALLYL ALCOHOL except:
a) in preparations containing 5 per cent or less of allyl esters with 0.1 per cent or less of
free allyl alcohol by weight of allyl ester; or
ALPHA-CYPERMETHRIN except when included in Schedule 5 or 6.
AMINOACRIDINE for veterinary use except when included in Schedule 5.
AMINOCARB except when included in Schedule 6.
4-AMINOPROPIOPHENONE.
4-AMINOPYRIDINE except when included in Schedule 4.
AMITON.
ARPRINOCID.
ARSENIC except:

b) when included in Schedule 4 or 6;
c) as selenium arsenide in photocopier drums;
d) as 10,10’-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less
of arsenic;

SCHEDULE 7
e) as 10,10’-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane

extruded and moulded articles containing 160 mg/kg or less of arsenic other than
when included in articles:
i) in contact with food stuffs, animal feeds or potable water;
ii) of clothing and footwear in contact with the skin;
iii) used as infant wear; or
iv) intended for use as packaging materials;
f) in animal feeds containing 75 g/tonne or less of arsenic; or
g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile
content of the paint.
AZAFENIDIN.
AZINPHOS-ETHYL.
AZINPHOS-METHYL.
AZOCYCLOTIN.
AZO DYES that are derivatives by diazotisation of any of the following substances:
p-aminoazobenzene (CAS No. 60-09-3)
o-aminoazotoluene (CAS No. 97-56-3)
o-anisidine (CAS No. 90-04-0)
p-chloroaniline (CAS No. 106-47-8)
4-chloro-o-toluidine (CAS No. 95-69-2)
2,4-diaminoanisole (CAS No. 615-05-4)
6-methoxy-m-toluidine (p-cresidine) (CAS No. 120-71-8)
4,4-methylenedianiline (CAS No. 101-77-9)
2-naphthylamine (CAS No. 91-59-8)
5-nitro-o-toluidine (CAS No. 99-55-8)
2,4-toluenediamine (CAS No. 95-80-7)
o-toluidine (CAS No. 95-53-4)
2,4,5-trimethylaniline (CAS No. 137-17-7)

SCHEDULE 7
except for BASIC RED 76 (CAS No. 68391-30-0) when included in Schedule 6.
BENDIOCARB except when included in Schedule 5 or 6.
BENOMYL except in paints containing 0.5 per cent or less of benomyl.
BENZENE (excluding its derivatives) except:
a) preparations containing 15 mL/L or less of benzene; or

b) petrol containing 50 mL/L or less of benzene.
BENZIDINE-BASED AZO DYES being:
2,2'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[N-(4-chlorophenyl)-3-oxobutanamide]
(CAS No. 94249-03-3)
Acid Red 85 (Acid Fast Red A)
1,3-Naphthalenedisulfonic acid, 7-hydroxy-8-[[4'-[[4-[[(4-

methylphenyl)sulfonyl]oxy]phenyl]azo][1,1'-biphenyl]-4-yl]azo]-, disodium salt
(CAS No. 3567-65-5)
C.I Acid Black 29

(CAS No. 12217-14-0)
C.I. Direct Orange 1

(CAS No. 54579-28-1)
Direct Black 38
2,7-Naphthalenedisulfonic acid, 4-amino-3-[[4'-[(2,4-diaminophenyl)azo][1,1'-

biphenyl]-4-yl]azo]-5-hydroxy-6-(phenylazo)-, disodium salt
(CAS No. 1937-37-7)
Direct Blue 2
2,7-Naphthalenedisulfonic acid, 5-amino-3-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-

naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-4-hydroxy-, trisodium salt
(CAS No. 2429-73-4)
Direct Blue 6
2,7-Naphthalenedisulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[5-amino-4-

hydroxy-, tetrasodium salt
(CAS No. 2602-46-2)
Direct Brown 2

SCHEDULE 7
5-[[4'-[(7-amino-1-hydroxy-3-sulfo-2-naphthalenyl)azo][1,1'-biphenyl]-4-yl]azo]-2-
hydroxy- benzoic acid disodium salt
(CAS No. 2429-82-5)
Direct Brown 95
Cuprate(2-), [5-[[4'-[[2,6-dihydroxy-3-[(2-hydroxy-5-sulfophenyl)azo]phenyl]azo][1,1'-
biphenyl]-4-yl]azo]-2-hydroxybenzoato(4-)]-, disodium salt
(CAS No. 16071-86-6)
Direct Green 1
2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-3-[[4'-[(4-

hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-6-(phenylazo)-, disodium salt
(CAS No. 3626-28-6)
Direct Green 6
2,7-Naphthalenedisulfonic acid, 4-amino-5-hydroxy-6-[[4'-[(4-

hydroxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-3-[(4-nitrophenyl)azo]-, disodium salt
(CAS No. 4335-09-5)
Direct Red 28 (Congo Red)
1-Naphthalenesulfonic acid, 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(azo)]bis[4-amino-,

disodium salt
(CAS No. 573-58-0)
Direct Red 37
1,3-Naphthalenedisulfonic acid, 8-[[4'-[(4-ethoxyphenyl)azo][1,1'-biphenyl]-4-yl]azo]-

7-hydroxy-, disodium salt
(CAS No. 3530-19-6)
BENZIDINE-CONGENER (3,3’-disubstituted) AZO DYES.
BETACYFLUTHRIN except when included in Schedule 5 or 6.
BIFENTHRIN except:

b) in preparations containing 0.5 per cent or less of bifenthrin.
BIFLUORIDES (including ammonium, potassium and sodium salts) except when included in
Schedule 5 or 6.
BORON TRIFLUORIDE except when included in Schedule 5 or 6.
BRODIFACOUM except when included in Schedule 6.

SCHEDULE 7
BROMADIOLONE except when included in Schedule 6.
BROMETHALIN except when included in Schedule 6.
BROMINE (excluding its salts and derivatives).
BRUCINE except in alcohol containing 0.02 per cent or less of brucine as a denaturant.
CACODYLIC ACID except:

b) in animal feeds containing 75 g/tonne or less of arsenic.
CADUSAFOS except when included in Schedule 6.
CALCIFEROL for use as a rodenticide except when included in Schedule 6.
CAPTAFOL.
CARBADOX.
CARBENDAZIM except in paints, jointing compounds and sealants containing 0.1 per cent or
less of carbendazim.
CARBOFURAN.
CARBON TETRACHLORIDE except in chlorinated rubber based paint containing 1 per cent
or less of carbon tetrachloride.
CARBONYL SULFIDE when packed and labelled for use as a fumigant.
CARBOPHENOTHION.
CARBOSULFAN.
CHLORDECONE.
CHLORDIMEFORM.
CHLORFENAPYR except when included in Schedule 5 or 6.
CHLORFENVINPHOS.
CHLORINE (excluding its salts and derivatives).
CHLORHEXIDINE except:

b) in preparations containing 1 per cent or less of chlorhexidine; or

SCHEDULE 7
c) in solid preparations.
CHLOROMETHIURON.
5-CHLORO-3-METHYL-4-NITROPYRAZOLE.
4-CHLORO-o-TOLUIDINE.
CHLOROPICRIN except when included in Schedule 6.
CHLORTHIOPHOS.
COLECALCIFEROL for use as a rodenticide.
COUMAPHOS except when included in Schedule 6.
COUMATETRALYL except when included in Schedule 5 or 6.
CREOSOTE derived from coal.
CREOSOTE derived from beechwood.
CYANIDES, metallic except:
a) ferricyanides;
b) ferrocyanides; or
c) when separately specified in these Schedules.
CYANOGEN.

PROPANAMINE (CAS 475645-84-2) except when included in Schedule 6.
CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.
CYHEXATIN.
DELTAMETHRIN except:

b) in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or
c) in preparations containing 0.1 per cent or less of deltamethrin.
DEMETON.
DEMETON-O-METHYL.
DEMETON-S-METHYL.

SCHEDULE 7
DIALIFOS.
4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).
1,2-DIBROMO-3-CHLOROPROPANE.
1,3-DICHLOROPROPENE except in biocidal preparations containing 0.3 per cent or less of

1,3-dichloropropene.
DICHLORVOS except when included in Schedule 5 or 6.
DICROTOPHOS.
DIFENACOUM except when included in Schedule 6.
DIFETHIALONE except when included in Schedule 6.
DIMEFOX.
4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).
DIMETHYL SULFATE.
DIMETILAN.
DINITROCRESOLS except when included in Schedule 4 or 6.
DINITROPHENOLS except when included in Schedule 4, 6 or 10.
DINOCAP.
DINOSEB.
DIQUAT except when included in Schedule 6.
DISULFOTON except when included in Schedule 6.
DORAMECTIN except when included in Schedule 5 or 6.
DSMA except when included in Schedule 6.
EMAMECTIN except when included in Schedule 5 or 6.
ENDOSULFAN except when included in Schedule 6.
ENDOTHAL except when included in Schedule 6.
ENDRIN.
EPICHLOROHYDRIN.

SCHEDULE 7
EPIDERMAL GROWTH FACTOR except in preparations for human therapeutic use.
EPRINOMECTIN except when included in Schedule 5 or 6.
ETACONAZOLE.
ETHION.
ETHOPROPHOS except when included in Schedule 6.
2-ETHOXYETHANOL and its acetates except in preparations containing 0.5 per cent or less of
2-ethoxyethanol.
ETHYLENE DIBROMIDE.
ETHYLENE OXIDE.
FAMPHUR except when included in Schedule 6.
FENAMIPHOS except when included in Schedule 6.
FENOXACRIM except:

b) in treated carpets.
FENSULFOTHION.
FENTHION except when included in Schedule 5 or 6.
FENTHION-ETHYL.
FLOCOUMAFEN except when included in Schedule 6.
FLUCOFURON except:

FLUCYTHRINATE.
FLUMIOXAZIN except when included in Schedule 6.
FLUOROACETAMIDE.
FLUOROACETIC ACID.
FOLPET.
FORMETANATE.

SCHEDULE 7
FOSTHIAZATE.
FURATHIOCARB except when included in Schedule 5.
GAMMA-CYHALOTHRIN except when included in Schedule 5.
HALOFUGINONE except when included in Schedule 4.
HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.
HCB.
HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of

which boils above 350°C except:
a) when in solid polymers;

b) when containing 1 per cent or less of total polycyclic aromatic compounds as
measured by IP 346; or
c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.
HYDROCYANIC ACID except:

b) its salts and derivatives other than cyanides separately specified in this Schedule.
HYDROFLUORIC ACID (excluding its salts and derivatives) except when included in
Schedule 5 or 6.
HYDROGEN SULFIDE.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in
Schedule 5 or 6.
IODOMETHANE.
ISOCARBOPHOS.
ISOFENPHOS.
ISOPROTURON.
IVERMECTIN except when included in Schedule 4 or 5.
LAMBDA-CYHALOTHRIN except when included in Schedule 5 or 6.
LEPTOPHOS.
LITHIUM PERFLUOROOCTANE SULFONATE except in sealed bait stations containing 1

per cent or less of lithium perfluorooctane sulfonate.

SCHEDULE 7
MADURAMICIN except:

MALACHITE GREEN for veterinary use except when included in Schedule 5.
MAZIDOX.
MECARBAM.
2-METHOXYETHANOL and its acetates except in preparations containing 0.5 per cent or les
of 2-methoxyethanol.
MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or
horticultural purposes.
MERCURY except:

b) when included in Schedule 2, 4 or 6;
c) in preparations containing 0.01 per cent or less of mercury in organic form as a
preservative;
d) mercury (metallic) in scientific instruments;
e) dental amalgams; or
f) in a sealed device, for therapeutic use, which prevents access to the mercury.
METHACRIFOS except when included in Schedule 6.
METHAMIDOPHOS.
METHAPYRILENE.
METHAZOLE.
METHIDATHION.
METHIOCARB except when included in Schedule 5 or 6.
METHOMYL except when included in Schedule 6.
METHOXYETHYLMERCURIC ACETATE.
METHOXYETHYLMERCURIC CHLORIDE.
METHYL BROMIDE.

SCHEDULE 7
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL except:

b) when used in laboratory analysis; or
c) when packed for industrial use in containers with a nominal capacity of 100 L or
more.
4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA).
METHYLENE BLUE for veterinary use except when included in Schedules 4 or 5.
MEVINPHOS.
MIPAFOX.
MIREX.
MOLINATE.
MONOCROTOPHOS.
MOXIDECTIN except when included in Schedule 4, 5 or 6.
MSMA except when included in Schedule 6.
NAPHTHALOPHOS except when included in Schedule 6.
NICOTINE except:

b) in preparations for human therapeutic use; or
c) in tobacco prepared and packed for smoking.
NIMIDANE except when included in Schedule 6.
NITROFEN.
NITROPRUSSIDES except when included in Schedule 4 or 6.
2-NITROTOLUENE.
OMETHOATE except when included in Schedule 5 or 6.
OXAMYL.
OXYDEMETON METHYL.
PARAQUAT.

SCHEDULE 7
PARATHION.
PARATHION-METHYL except when included in Schedule 6.
PENTACHLOROPHENOL except when included in Schedule 6.
PHENYLMERCURIC ACETATE except in preparations containing 0.01 per cent or less of

mercury as a preservative.
PHORATE.
PHOSFOLAN.
PHOSPHIDES, METALLIC.
PHOSPHINE.
PHOSPHORUS, YELLOW (excluding its salts and derivatives).
POTASSIUM NITRITE except:

b) in preparations containing 0.5 per cent or less of potassium nitrite;
d) in aerosols containing 2 per cent or less of potassium nitrite.
PROCYMIDONE.
PROPYLENE OXIDE.
PYRINURON.
QUININE for veterinary use except when included in Schedule 5.
SAFLUFENACIL except when included in Schedule 5.
SCHRADAN.
SELENIUM except:

b) as selenium arsenide in photocopier drums;
c) in preparations for therapeutic use other than:
i) drench concentrates containing 2.5 per cent or less of selenium; or
ii) pour-on preparations containing 0.5 per cent or less of selenium;

SCHEDULE 7
d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-
volatile content of the paint or tinter; or
e) in fertilisers containing 200 g/tonne or less of selenium.
SEMDURAMICIN except:

SODIUM NITRITE except:
a) when included in Schedule 2, 5 or 6;

b) in preparations containing 0.5 per cent or less of sodium nitrite;
d) in aerosols containing 2 per cent or less of sodium nitrite.
STRYCHNINE except when included in Schedule 4.
SULCOFURON except:

SULFENTRAZONE.
SULFOTEP.
TEFLUTHRIN except when included in Schedule 5.
TEPP.
TERBUFOS.
TETRACHLOROETHANE.
2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE except when included in

Schedule 6.
THALLIUM.
THIOFANOX.
TIN ORGANIC COMPOUNDS, being dialkyl, trialkyl and triphenyl tin compounds where the
alkyl group is methyl, ethyl, propyl or butyl except:

b) in plastics;

SCHEDULE 7
c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the

dialkyl, trialkyl or triphenyl tin component; or
d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-
volatile content of the paint.
o-TOLIDINE except in solid-state diagnostic therapeutic reagents.
TRIAMIPHOS.
TRIAZBUTIL.
TRIBUFOS (S,S,S-tributylphosphorotrithioate).
VINCLOZOLIN.
VINYL CHLORIDE.
ZETA-CYPERMETHRIN except when included in Schedule 6.
ZIRAM except when included in Schedule 6.

SCHEDULE 8
(Substances marked # are listed in Appendix D.)
SCHEDULE 8
ACETYLDIHYDROCODEINE.
ACETYLMETHADOL.
ACETYLMORPHINES.
ALFENTANIL.
ALPHACETYLMETHADOL.
ALPHAPRODINE.
# ALPRAZOLAM.
AMFETAMINE.
AMOBARBITAL except when included in Schedule 4.
ANILERIDINE.
BENZYLMORPHINE.
BEZITRAMIDE.
BUPRENORPHINE.
BUTOBARBITAL.
BUTORPHANOL.
# CANNABIS (including seeds, extracts, resins and the plant, and any part of the plant) when
prepared or packed for human therapeutic use, when:
a) cultivated or produced, or in products manufactured1, in accordance with the Narcotic

Drugs Act 1967; and/or
b) for use in products manufactured in accordance with the Narcotic Drugs Act 1967;
and/or
c) imported as therapeutic goods, or for use in therapeutic goods, for supply, in
accordance with the Therapeutic Goods Act 1989; and/or
d) in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
except when:
1
“Cultivation”, “production” and “manufacture” have the same meaning as in the Narcotic Drugs Act 1967

SCHEDULE 8
i) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the

Therapeutic Goods Regulations 1990 applies; or
ii) separately specified in the NABIXIMOLS entry in this Schedule; or
iii) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3.
CARFENTANYL.
COCAINE.
CODEINE except when included in Schedule 4.
CODEINE-N-OXIDE.
CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into
a process for concentration of its alkaloids).
4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).
CYCLOBARBITAL.
DEXAMFETAMINE.
DEXTROMORAMIDE.
# DEXTROPROPOXYPHENE except when included in Schedule 4.
DIFENOXIN except when included in Schedule 4.
DIHYDROCODEINE except when included in Schedule 3 or 4.
DIHYDROMORPHINE.
DIPHENOXYLATE except when included in Schedule 3 or 4.
DIPIPANONE.
# DRONABINOL (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic

use.
DROTEBANOL.
ETHYLAMFETAMINE.
ETHYLMORPHINE except when included in Schedule 2 or 4.
FENTANYL.
# FLUNITRAZEPAM.

SCHEDULE 8
HYDROCODONE.
HYDROMORPHINOL.
HYDROMORPHONE.
KETAMINE.
LEVAMFETAMINE.
LEVOMETHAMFETAMINE.
LEVOMORAMIDE.
LEVORPHANOL (excluding its stereoisomers).
LISDEXAMFETAMINE.
METHADONE.
METAMFETAMINE.
METHYLDIHYDROMORPHINE.
METHYLPHENIDATE.
1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).
MORPHINE.
MORPHINE METHOBROMIDE.
MORPHINE-N-OXIDE.
NABILONE.
# NABIXIMOLS (botanical extract of Cannabis sativa which includes the following

cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol,
cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids,
tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol
(in approximately equal proportions) comprise not less than 90 per cent of the total
cannabinoid content) in a buccal spray for human therapeutic use.
NORCODEINE.
NORMETHADONE.
OPIUM except the alkaloids noscapine in Schedule 2 and papaverine when included in
Schedule 2 or 4.

SCHEDULE 8
OXYCODONE.
OXYMORPHONE.
PENTAZOCINE.
PENTOBARBITAL except when included in Schedule 4.
PETHIDINE.
PHENDIMETRAZINE.
PHENMETRAZINE.
PHENOPERIDINE.
4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).
PHOLCODINE except when included in Schedule 2 or 4.
PIRITRAMIDE.
PROPIRAM.
RACEMORAMIDE.
REMIFENTANIL.
SECBUTOBARBITAL.
SECOBARBITAL.
# SODIUM OXYBATE for human therapeutic use.
SUFENTANIL.
TAPENTADOL.
# TETRAHYDROCANNABINOLS when extracted from cannabis for human therapeutic use,

when:
a) included in products manufactured in accordance with the Narcotic Drugs Act 1967;
and/or
b) imported as therapeutic goods, or for use in therapeutic goods, for supply, in
accordance with the Therapeutic Goods Act 1989; and/or
c) in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
except when:

SCHEDULE 8
i) it is in a product to which item 4, 8, 10, 11 or 12 of Schedule 5A to the

Therapeutic Goods Regulations 1990 applies; or
ii) separately specified in the NABIXIMOLS entry in this Schedule; or
iii) captured by the CANNABIDIOL entry in Schedule 4 or Schedule 3.
THEBACON.
THEBAINE.
TILIDINE.

SCHEDULE 9
(Trivial or unofficial names are marked *)
SCHEDULE 9
ACETORPHINE.
ACETYL-ALPHA-METHYLFENTANYL.
ALKOXYAMFETAMINES and substituted alkoxyamfetamines except when separately

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines except when

ALKYLTHIOAMFETAMINES and substituted alkylthioamfetamines except when separately

ALLYLPRODINE.
ALPHAMEPRODINE.
ALPHA-METHYLFENTANYL.
ALPHA-METHYLTHIOFENTANYL.
ALPHAMETHADOL.
ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP).
2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).
5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans except when

BENZETHIDINE.
BENZOYLINDOLES except when separately specified in these Schedules.
BENZYLPIPERAZINE *(BZP).
BETACETYLMETHADOL.
BETA-HYDROXYFENTANYL.
BETA-HYDROXY-3-METHYLFENTANYL.
BETAMEPRODINE.
BETAMETHADOL.

SCHEDULE 9
BETAPRODINE.
1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE *(Bromo-
Dragonfly).
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).
BUFOTENINE.
CANNABIS (including seeds, extracts, resins, and the plant and any part of the plant when
packed or prepared), except:

b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinols and
hemp fibre products manufactured from such fibre; or
c) when in hemp seed oil for purposes other than internal human use containing 50
mg/kg or less of cannabinoids, including 20 mg/kg or less of tetrahydrocannabinols,
when labelled with either of the following warning statements:
i) Not for internal use; or
ii) Not to be taken.
CATHINONES except when separately specified in these Schedules.
CLONAZOLAM.
CLONITAZENE.
COCA LEAF.
CODOXIME.
4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE.
CYCLOHEXYLPHENOLS except:

b) in preparations containing 0.5 per cent or less of cyclohexylphenols.
DESCHLOROETIZOLAM.
DESOMORPHINE.
N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES except when separately

N,N-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES except when


SCHEDULE 9
DIAMPROMIDE.
DIBENZOPYRANS except when separately specified in these Schedules.
3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-
METHYLBENZAMIDE (U-47700).
3,4-DICHLORO-N-{[1- (DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE
*(AH-7921).
DICLAZEPAM.
DIETHYLTHIAMBUTENE.
N,N-DIETHYLTRYPTAMINE *(DET).
2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-B]INDOL-
1-ONE (SGT-151)
DIMENOXADOL.
DIMEPHEPTANOL.
2,5-DIMETHOXYAMFETAMINE *(DMA).
2,5-DIMETHOXY-4-BROMOAMFETAMINE *(DOB).
2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE *(DOET).
2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2).
2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I).
2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7).
3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-
6H-DIBENZO (b,d) PYRAN *(DMHP).
N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA).
N,N-DIMETHYLAMFETAMINE (Dimetamfetamine).
DIMETHYLTHIAMBUTENE.
N,N-DIMETHYLTRYPTAMINE *(DMT).
DIOXAPHETYL BUTYRATE.

SCHEDULE 9
ECGONINE.
N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL
MDA).
ETHYLMETHYLTHIAMBUTENE.
ETICYCLIDINE *(PCE).
ETONITAZENE.
ETORPHINE.
ETOXERIDINE.
FENETYLLINE.
4-FLUORO-N-METHYLAMFETAMINE.
FLUBROMAZEPAM.
FLUBROMAZOLAM.
1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE *(AM-694).
FURETHIDINE.
HARMALA ALKALOIDS except in herbs, or preparations, for therapeutic use:
a) containing 0.1 per cent or less of harmala alkaloids; or

b) in divided preparations containing 2 mg or less of harmala alkaloids per
recommended daily dose.
HEROIN.
3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d)
PYRAN *(PARAHEXYL).
4-HYDROXYBUTANOIC ACID and its salts except for sodium oxybate when in Schedule 8.
*(GAMMA HYDROXYBUTYRATE (GHB)).
2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL
*(Cannabicyclohexanol or CP 47,497 C8 homologue).
2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL *(CP
47,497).
HYDROXYPETHIDINE.

SCHEDULE 9
ISOMETHADONE.
KETOBEMIDONE.
LEVOMETHORPHAN (excluding its stereoisomers).
LEVOPHENACYLMORPHAN.
LYSERGIC ACID.
LYSERGIDE.
MECLONAZEPAM.
MECLOQUALONE.
METAZOCINE.
METHAQUALONE.
METHCATHINONE.
5-METHOXY- α –METHYLTRYPTAMINE *(5-MeO-AMT).
5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE *(MMDA).
4-METHOXY- α –METHYLPHENYLETHYLAMINE *(PMA).
2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE *(JWH-250).
METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-

DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-
CARBOXYLATE *(SALVINORIN A).
4-METHYLAMINOREX.
METHYLDESORPHINE.
3,4-METHYLENEDIOXYAMFETAMINE *(MDA).
3,4-METHYLENEDIOXYPYROVALERONE *(MDPV).
3-METHYLFENTANYL.
4-METHYLMETHCATHINONE *(MEPHEDRONE).
N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(N-
HYDROXY MDA).
N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB).

SCHEDULE 9
2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID

(Moramide intermediate).
METHYLONE *(MDMC).
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).
4-METHYLTHIOAMFETAMINE.
3-METHYLTHIOFENTANYL.
METOPON.
MITRAGYNA SPECIOSA.
MITRAGYNINE.
MORPHERIDINE.
(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE
*(JWH-200).
MUSCIMOL.
MYROPHINE.
NAPHTHOYLINDOLES except when separately specified in these Schedules.
NAPHTHYLMETHYLINDOLES except when separately specified in these Schedules.
NAPHTHOYLPYRROLES except when separately specified in these Schedules.
NAPHTHYLMETHYLINDENES except when separately specified in these Schedules.
NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE *(JWH-073).
NICOCODINE.
NICODICODINE.
NICOMORPHINE.
NIFOXIPAM.
NORACYMETHADOL.
NORLEVORPHANOL.
NORMORPHINE.

SCHEDULE 9
NORPIPANONE.
PARA-FLUOROFENTANYL.
1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. *(JWH-122).
1-PENTYL-3-(1-NAPHTHOYL)INDOLE *(JWH-018).
PHENADOXONE.
PHENAMPROMIDE.
PHENAZOCINE.
PHENCYCLIDINE *(PCP).
PHENIBUT.
N-PHENETHYL-4-PIPERIDONE.
PHENOMORPHAN.
PHENYLACETYLINDOLES except when separately specified in these Schedules.
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).
PIMINODINE.
PROHEPTAZINE.
PROPERIDINE.
PSILOCYBINE.
PYRAZOLAM.
RACEMETHORPHAN.
RACEMORPHAN.
ROLICYCLIDINE *(PHP or PCPY).
SALVIA DIVINORUM.
SYNTHETIC CANNABINOMIMETICS except when separately specified in these Schedules.
TENOCYCLIDINE *(TCP).
TETRAHYDROCANNABINOLS and their alkyl homologues, except:

SCHEDULE 9
a) when included in Schedule 4 or Schedule 8; or

b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinols, and
hemp fibre products manufactured from such fibre; or
c) in hemp seed oil for purposes other than internal human use containing 50 mg/kg or
less of total cannabinoids, including 20 mg/kg or less of tetrahydrocannabinols, when
labelled with either of the following warning statements:
i) Not for internal use; or
ii) Not to be taken.
THIOFENTANYL.
1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).
TRIMEPERIDINE.
3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE *(TMA).
3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally

derived from methoxy-phenylethylamine except:
a) methoxyphenamine; or
1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.

SCHEDULE 10
(Previously Appendix C)
SCHEDULE 10
SUBSTANCES OF SUCH DANGER TO HEALTH AS TO WARRANT PROHIBITION OF
SALE, SUPPLY AND USE
ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.
ACORUS CALAMUS (calamus) for human therapeutic use.
alone or in any combination for domestic use:
a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;
b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous
solution or mixture is more than 12.5; or
c) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more
than 12.5.
ALKYLAMINES WITH STIMULANT PROPERTIES except when separately specified in

these schedules.
ALLYLISOPROPYLACETYLUREA for therapeutic use.
AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.
AMYGDALIN for therapeutic use.
ANCHUSA OFFICINALIS for therapeutic use.
o-ANISIDINE (excluding derivatives) in preparations for skin colouration (including tattooing)

and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001 per cent
or less of o-anisidine.
ARISTOLOCHIA spp. for therapeutic use.
ARISTOLOCHIC ACID(S) for human therapeutic use.
ASARUM spp. containing aristolochic acid(s) for human therapeutic use.
AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for
human internal use except ‘debitterised neem seed oil’
BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in

preparations for skin colouration and dyeing of eyelashes or eyebrows.
1,2-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including

tattooing).

SCHEDULE 10
1,3-BENZENEDIAMINE in preparations for cosmetic use and skin colouration (including

tattooing).
BITHIONOL for human therapeutic use.
BORAGO OFFICINALIS (Borage) for therapeutic use except the fixed oil derived from the
seeds of Borago officinalis.
BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.
BUCLOSAMIDE for therapeutic use.
BUNIODYL SODIUM for therapeutic use.
1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for

domestic use.
BUTYL BENZYL PHTHALATE for cosmetic use.
CACALIA spp. for therapeutic use.
CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations
containing more than 18 per cent of carbamide peroxide except in preparations
manufactured for, and supplied solely by, registered dental practitioners as part of their
dental practice.
CARDARINE.
CHRYSOIDINE BASE in preparations for use in hair dyes.
CINCHOPHEN and its derivatives for therapeutic use.
CLIOQUINOL and other halogenated derivatives of oxyquinoline for human internal use
except or when being used solely for experimental purposes in humans and where such use:
a) is in accordance with:
i) an approval granted under paragraph 19(1)(b) of the Therapeutic Goods Act
1989, including any conditions specified in the notice of approval; and
ii) any conditions specified in the Therapeutic Goods Regulations 1990 for the
purposes of subsection 19(1A) of the Therapeutic Goods Act 1989; and
iii) any conditions specified in the Therapeutic Goods Regulations 1990 for the
purposes of subsection 19(4A) of the Therapeutic Goods Act 1989; or
b) is in accordance with the requirements of item 3 of Schedule 5A to the Therapeutic
Goods Regulations 1990.
COAL TAR for cosmetic use other than in therapeutic goods.

SCHEDULE 10
CONIUM MACULATUM (coniine) for therapeutic use.
COTARNINE for therapeutic use.
CROTALARIA spp. for therapeutic use.
CROTON TIGLIUM for therapeutic use.
CYNOGLOSSUM spp. for therapeutic use.
DIBUTYLPHTHALATE for cosmetic use.
DICOPHANE (DDT) for therapeutic use.
DIETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations

containing 0.25 per cent or less of diethylene glycol.
DIETHYLENE GLYCOL MONOMETHYL ETHER for cosmetic use.
DIETHYLHEXYL PHTHALATE for cosmetic use.
DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations

for human use except in preparations containing 0.5 per cent or less of diethylphthalate.
5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent
of 5,6-dihydroxyindoline.
DIIODOHYDROXYQUINOLINE (iodoquinol) for human internal use.
DIISOBUTYL PHTHALATE for cosmetic use.
1,3-DIMETHYLAMYLAMINE (DMAA).
1,3-DIMETHYLBUTYLAMINE (DMBA) except when separately specified in these schedules.
1-(1,1-DIMETHYLETHYL)-2-METHOXY-4-METHYL-3,5-DINITROBENZENE (musk
ambrette).
1,5-DIMETHYLHEXYLAMINE (DMHA) except when separately specified in these

schedules.
1,4-DIMETHYLPENTYLAMINE (DMPA).
DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations

for human use except in preparations containing 0.5 per cent or less of dimethylphthalate.
DI(METHYLOXYETHYL) PHTHALATE for cosmetic use.
2,4-DINITROPHENOL for human use.

SCHEDULE 10
DISPERSE YELLOW 3 for use in hair dyes.
DULCIN for therapeutic use.
ETHYLENE GLYCOL for use in toothpastes or mouthwashes except in preparations

containing 0.25 per cent or less of ethylene glycol.
EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.
FARFUGIUM JAPONICUM for therapeutic use.
FORMALDEHYDE (excluding its derivatives):
a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free
formaldehyde;
formaldehyde; or
d) in all other cosmetic preparations containing 0.05 per cent or more of free
formaldehyde except in preparations containing 0.2 per cent or less of free
formaldehyde when labelled with the warning statement:
GAMMA BUTYROLACTONE (excluding its derivatives) in non-polymerised form in

preparations for domestic and cosmetic use.
HELIOTROPIUM spp. for therapeutic use.
HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations
containing more than 6 per cent (20 volume) of hydrogen peroxide except in preparations
manufactured for, and supplied solely by, registered dental practitioners as part of their
dental practice.
ISOPROPYL NITRITE.
JUNIPERUS SABINE [savin(e)] for therapeutic use.
LEAD COMPOUNDS in paints, tinters, inks or ink additives except in preparations containing
0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or
ink additive.
LIGULARIA DENTATA for therapeutic use.
MELIA AZEDARACH including its extracts and derivatives.
METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the

skin, including cosmetic use..

SCHEDULE 10
METHYL METHACRYLATE for cosmetic use except in preparations containing 1 per cent or
less of methyl methacrylate as residual monomer in a polymer .
METHYLROSANILINIUM CHLORIDE (formerly known as crystal violet CAS No. 548-62-9)

and the following TRIARYLMETHANE DYES – for use in hair dyes:
- Acid Violet 49 (CAS No. 1694-09-3),
- Ethyl Violet (CAS No. 2390-59-2),
- Basic Blue 7 (CAS No. 2390-60-5),
- Basic Blue 26 (CI 44045) (CAS No. 2580-56-5).
NAPHTHALENE (excluding derivatives) in preparations in block, ball, disc, pellet or flake

form for domestic use except when enclosed in a device which, in normal use, prevents
removal or ingestion of its contents.
OXYPHENISATIN for therapeutic use.
PARAFORMALDEHYDE (excluding its derivatives):
a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;
b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free
formaldehyde;
formaldehyde;
d) in all other cosmetic preparations containing 0.05 per cent or more of free
formaldehyde except in preparations containing 0.2 per cent or less of free
formaldehyde when labelled with the warning statement:
PETASITES spp. for therapeutic use.
PHENPROMETHAMINE.
PHENYLENEDIAMINES, including alkylated, arylated, halogenated and nitro derivatives, in

preparations for skin colouration, tattooing and dyeing of eyelashes or eyebrows except
POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food
additive preparations, for domestic use, the pH of which is more than 11.5.
n-PROPYL NITRITE.
PTERIDIUM spp. for therapeutic use.

SCHEDULE 10
PULMONARIA spp. for therapeutic use.
SAFROLE for internal therapeutic use except in preparations containing 0.1 per cent or less of
safrole.
SANGUINARIA CANADENSIS (bloodroot) in preparations for human use except in

preparations containing 0.01 per cent or less of SANGUINARINE.
SENECIO spp. for therapeutic use.
SILICONES for injection or implantation except when included in Schedule 4.
SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food
additive preparations, for domestic use, the pH of which is more than 11.5.
SYMPHYTUM spp. (Comfrey) in preparations for human or animal use except when in
Schedule 5.
2,4-TOLUENEDIAMINE in preparations for skin colouration (including tattooing) and dyeing

of hair, eyelashes or eyebrows.
TOLUENEDIAMINES in preparations for skin colouration (including tattooing) and dyeing of

eyelashes or eyebrows except when included in Schedule 6.
o-TOLUIDINE (excluding derivatives) in preparations for skin colouration (including tattooing)

and dyeing of hair, eyelashes or eyebrows except in preparations containing 0.001 per cent
or less of o-toluidine.
1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.
TRICHODESMA AFRICANA for therapeutic use.
TRIPARANOL for therapeutic use.
TUSSILAGO FARFARA for therapeutic use.

PART 5 – THE APPENDICES
APPENDIX A
PART 5
THE APPENDICES
APPENDIX A – GENERAL EXEMPTIONS
This Standard does not apply to a poison in any of the following products:
ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the
definition of an agvet chemical product.
BACTERIAL CULTURE MEDIA containing antibiotics.
CERAMICS.
CHEMISTRY SETS for toy and educational use, when complying with the requirements of
Australian Standard AS 8124.4-2003 Safety of toys entitled Part 4: Experimental sets for
chemistry and related activities.
COPPER COMPOUNDS in paints.
DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES used as plasma

substitutes/blood volume expanders.
ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.
ELECTRONIC COMPONENTS.
ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.
EXPLOSIVES.
FOOD except:
a) food additives before incorporation into food; or

b) when used as a means of administering a poison for therapeutic use.
FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined

as a non-migratory component of glassy solid flakes or granules.
GLASS (including CRYSTAL WARE).
GLAZED POTTERY.
HUMAN BLOOD PRODUCTS including:
a) whole blood;

APPENDIX A
b) blood components including red cells, white cells, platelets and plasma (including
cryoprecipitate); and
c) the following plasma-derived therapeutic proteins; and their equivalent recombinant
alternatives:
i) albumin;
ii) anticoagulation complex;
iii) C1 esterase inhibitors;
iv) clotting factors;
v) fibrinogen;
vi) protein C;
vii) prothrombin complex concentrate (PCC) ; and
viii) thrombin.
IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent

or less of a poison included in Schedules 1 to 8.
INTRAOCULAR VISCOELASTIC PRODUCTS.
LUBRICANTS in preparations that provide a lubricating action between machinery parts,

except soluble oils and solvent-deposited lubricating agents.
MATCHES.
MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS.
MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to
the Therapeutic Goods (Medical Devices) Regulation 2002, except:
a) injectable tissue reconstructive, augmentation and restoration materials, including

collagen;
b) medical devices which include anticoagulants;
c) artificial tears;
d) urinary catheters; or
e) intra-articular fluids.
MOTOR, HEATING or FURNACE FUELS except:
a) when the contrary intention appears in any Schedule;

b) when containing methanol;
c) toy or hobby fuels; or
d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.

APPENDIX A
NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL

ADMINISTRATION.
PAPER except:
a) when prepared for pesticidal use; or

b) when containing a poison included in Schedule 8 or 9.
PHOTOGRAPHIC PAPER or FILM.
PIGMENTS when immobilised in a polymer.
PORCELAIN.
PRINTING INKS or INK ADDITIVES except:
a) when containing a pesticide; or

b) preparations containing more than 0.1 per cent of lead calculated on the non-volatile
content of the ink or ink additive.
RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.
RADIOISOTOPES for therapeutic use.
SEEDS treated with seed protectants.
SINGLE-USE TUBES for the estimation of alcohol content of breath.
TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the
relevant registration authority, and laminated between impervious sheeting.
TIMBER or WALLBOARD.
VITREOUS ENAMELS.
WRITING CORRECTION PENS which do not allow ingestion of the contents and which
contain no scheduled poison other than designated solvents included in Schedule 5.

APPENDIX B
APPENDIX B – SUBSTANCES CONSIDERED NOT TO REQUIRE

CONTROL BY SCHEDULING
(This Appendix should be read in conjunction with Appendix A.)
INTRODUCTION
Substances for which the available information suggests that inclusion in the Poisons Schedules
is not necessary, or not the most appropriate means of controlling the risk to public health, have
been considered at various times.
Listing in Appendix B indicates that a decision has been taken not to list substances anywhere
in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an
exhaustive, list i.e. there may be substances not included in the Schedules, and not included in
Appendix B, which may be hazardous or non-hazardous, but have not been considered in
relation to the need for scheduling.
Substances may be included in Appendix B because they have intrinsically low toxicity, or
where other factors suggest that the potential public health risk would be minimal. Factors
which are considered when determining an Appendix B entry include:
 the toxicology profile was adequately characterised and not consistent with inclusion in any
of the Schedules;
 the use, purpose or product presentation minimised any hazard to the public such as to not
require scheduling; or
 the public access was limited such that scheduling was inappropriate or unnecessary.
The list was developed from scheduling files and historical records. For transparency, where the
reason for entry and/or purpose or use for the substance was apparent in the consideration, this
has been included in the columns “Reason for Entry” and “Area of Use”.
Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where
adverse information becomes available about the Appendix B entry for that substance.
Applications are considered for scheduling. Applications for inclusion in Appendix B will not
be accepted.
PART 1 – REASONS FOR ENTRY
a Low Toxicity.
b Use pattern restricts hazard.

APPENDIX B
c Presentation/packaging restricts hazard.
d Industrial use only.
PART 2 – AREAS OF USE
1. Agriculture
1.1 Herbicide
1.2 Insecticide
1.2.1 Insecticide for codling moth
1.2.2 Termiticide
1.3 Fungicide
1.3.1 On seed fungicide
1.4 Bird Repellent
1.5 Fertiliser
1.6 Plant Growth Regulator
1.7 Insect Pheromone
1.8 Mushroom Bactericide
1.9 Acaricide
1.10 Biological control agent

APPENDIX B
1.11 Adjuvant in agricultural products
2 Veterinary
2.1 For animal use
2.2 Treatment of mastitis in cows
2.3 Coccidiostat
2.4 Feed additive
2.5 Antiseptic
2.6 Scabicide
2.7 Anthelmintic
2.8 Vitamin/Mineral
2.9 Growth Promotant
2.10 Ectoparasiticide
3 Domestic
3.1 Aromatherapy
3.2 Food additive
3.3 Cosmetic

APPENDIX B
3.4 Human use
3.5 Miticide
4. Industrial
4.1 Water treatment
4.2 Biological control agent
5. Environmental
5.1 Mosquito control
6. Human therapeutic use
6.1 Diagnostic agent
6.2 Medical device
6.3 Antiseptic
6.4 Sunscreen
6.5 External use
6.6 Laxative
6.7 Antiseborrheic
6.8 Cytoprotective

APPENDIX B
6.9 Vitamin/Mineral
6.10 Eye Drops
7. General
7.1 Any use
7.2 Excipient
7.3 Synergist
7.4 Flux
7.5 Pesticide
7.6 Insect repellent
7.7 Solvent
7.8 Disinfectant
7.9 Preservative
7.10 Antioxidant
7.11 Resin activator/accelerant
7.12 Sweetener artificial
7.13 Food additive

APPENDIX B
PART 3 – Substances considered not to require control by scheduling
SUBSTANCE DATE OF REASON AREA

ENTRY FOR OF
LISTING USE
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE Feb 2005 b 1.7
AFIDOPYROPEN Jun 2018 b 1.2
ALCOHOL, DEHYDRATED Aug 2000 b 6
ALUM May 1997 a 7.1
ALUMINIUM AMMONIUM SULFATE May 1997 a 7.1
ALUMINIUM POTASSIUM SULFATE May 1997 a 7.1
ALUMINIUM SILICATE Nov 1974 a 7.1
ALUMINIUM tris (ETHYLPHOSPHONATE) Aug 1986 a 1
AMETOCTRADIN May 2012 a 1.3
AMMONIUM PHOSPHATE Nov 1974 a 7.1
AMMONIUM THIOSULPHATE Nov 1974 a 7.1
AMPROLIUM Jun 1969 a 2.3
AMYL ACETATE Nov 1974 a 7.1
α -AMYLASE derived from Aspergillus niger Feb 2005 a 2.4

APPENDIX B
AMYL CINNAMALDEHYDE Feb 2017 a, b 3.3
ANDROSTENEDIONE ALBUMEN CONJUGATE Jun 2004 a 2.1

WITH DEA DEXTRAN ADJUNCT
ASPARTIC ACID - a 6
ASULAM May 1986 a 1
AUREOBASIDIUM PULLULANS (Strains DSM14940 Oct 2017 a 1.3

and DSM14941)
AZIMSULFURON Jun 2003 a 1.1
BACILLUS AMYLOLIQUEFACIENS Jun 2018 a 1.3
BACILLUS SPHAERICUS, STRAIN 2362 Feb 2003 a 5.1
BACILLUS THURINGIENSIS May 1992 a 5.1
(excluding endotoxin) Jun 2003 a 2.10
BACILLUS TOYOI Aug 1980 a 2.9
BACULOVIRUS CYDIA POMONELLA Jun 2006 a 1.2
BENFLURALIN - a 1.1
BENSULFURON-METHYL Aug 1987 a 1
BENTONITE Jun 2002 a 7.1
BENZYL BENZOATE Aug 1989 a 1.2

APPENDIX B
BETAINE HYDROCHLORIDE Nov 1974 a 7.1
BIFENAZATE Oct 2002 a 1.9
BISMUTH SUBNITRATE Nov 1999 b,c 2.1
BISTRIFLURON Feb 2014 a 1.2.2
BIURET Nov 1974 a 2.4
BIXLOZONE Feb 2020 a 1.1
BLAD (banda de Lupinus albus doce) Feb 2016 a 1.3
BOSCALID June 2003 a 1.3
BOVINE SOMATOTROPHIN May 1992 a 2
BROMACIL Aug 1987 a 1
BROMOPROPYLATE Nov 1994 a 1
BUPIRIMATE Nov 1990 a 1
BUTAFENACIL May 2000 a 1
BUTOXYPOLYPROPYLENE GLYCOL Nov 1974 a 7.7
n-BUTYL BUTYRATE - a 7.1
n-BUTYL LACTATE - a 7.1

APPENDIX B
CARBOXIN Aug 1987 a 1
CARFENTRAZONE-ETHYL Aug 1998 a 1
CELLULASE derived from Aspergillus niger Feb 2005 a 2.4
CETYL ALCOHOL Nov 1974 a 7.1
CHAMOMILE OIL Feb 2000 a 3.1
CHINA CLAY Sep 2008 a 1.2
CHLORANTRANILIPROLE Sep 2008 a 1.2
CHLORFLUAZURON Oct 2005 a 1.2.2
CHLORFLURENOL Feb 1974 a 1.6
CHLORIDAZON May 1988 a 1
CHLOROXYLENOLS Feb 1975 a 7.8
CITRONELLA OIL Feb 2000 a 7.1
CLARY SAGE OIL Feb 2000 a 7.1
CLITORIA TERNATEA EXTRACT Feb 2016 a 1.2
CLOPIDOL Nov 1974 d 2.3
COBALT NAPHTHENATE - d 7.1

APPENDIX B
CROSPOVIDONE Aug 1996 a 2
CULICINOMYCES CLAVOSPORUS Nov 1982 a 5.1
CYCLAMIC ACID Nov 1971 a 7.1
CYCLANILIPROLE Oct 2016 a 1.2
CYCLOHEXANE Nov 1974 a 7.7
CYCLOHEXANOL ACETATE - a 7.7
CYPRINID HERPESVIRUS-3 Oct 2018 a 1.10
CYROMAZINE Nov 1980 a 2
DICLAZURIL Nov 2001 a 2.3
DIETHYL CARBONATE - a 7.1
DIFLUFENICAN Feb 1987 a 1
DIKEGULAC-SODIUM Mar 1980 a 1.6
DIMETHYL ETHER Nov 1988 d 4
DIMETICONE - a 7.1
DIPHENYLAMINE Feb 1988 a 1
DIPROPYLENE GLYCOL MONOMETHYL ETHER Nov 1987 a 4

APPENDIX B
DIURON Nov 1987 a 1
DOCUSATE SODIUM (DIOCTYL SODIUM Feb 1970 a 7.1

SULFOSUCCINATE)
2,2-DPA Nov 1989 a 1
DROMETRIZOLE TRISILOXANE Oct 2003 a 6.4
DUDDINGTONIA FLAGRANS, STRAIN IAH 1297 Feb 2018 a 2.7
EPSIPRANTEL Nov 1991 a 2
ETHAMETSULFURON-METHYL Nov 2000 a 1.1
ETHOPABATE Jun 1969 d 2.3
ETHYL ACETATE Nov 1974 a 7.1
ETHYL ALCOHOL Nov 1974 a 7.1
ETHYLBUTYLACETYL AMINOPROPRIONATE Aug 2000 a 3.4
ETHYL BUTYRATE - a 7.1
ETHYL LACTATE - a 7.1
ETOFENPROX Jun 2018 a 1.2
ETOXAZOLE Oct 2003 a 1.2
EUBACTERIUM sp. strain DSM11798 Sep 2013 a 2.4

APPENDIX B
FENFURAM May 1977 a 1.3.1
FENHEXAMID Feb 1999 a 1
FENOXYCARB Feb 1988 a 1
FLORPYRAUXIFEN-BENZYL Feb 2018 a 1, 1.1
FLORYLPICOXAMID Feb 2021 a 1.3
FLUFENOXURON Feb 1997 a 1
FLUMETSULAM Feb 1992 a 1
FLUOMETURON Aug 1989 a 1
FLUOPICOLIDE Oct 2016 a 1.3
FLUTOLANIL Nov 2001 a 1.3
FLUROXYPYR May 1986 a, c 1
FORCHLORFENURON Feb 2005 a 1.6
FULLERS EARTH Nov 1974 a 7.1
FUNGAL PROTEASE derived from Aspergillus niger Feb 2005 a 2.4
GERANIUM OIL Feb 2000 a 7.1
GIBBERELLIC ACID Nov 1974 a 1.6

APPENDIX B
α-GLUCANASE derived from Aspergillus niger Feb 2005 a 2.4
HALAUXIFEN METHYL Oct 2014 a 1, 1.1
HEXAFLURON Nov 1988 a 1
HEXYL ACETATE - a 7.7
HEXYL CINNAMALDEHYDE Feb 2017 a, b 3.3
HEXYTHIAZOX Feb 1988 a 1
HUMAN OSTEOGENIC PROTEIN-1 (OP-1) Aug 2001 b 6.2
HYDROPRENE Feb 1988 a 1
HYDROXYPROPYL CELLULOSE Nov 1982 a 7.1
ICODEXTRIN Nov 2000 b 6
INDOLE-3-ACETIC ACID Feb 1985 b 1.6
ISOPRENE ALCOHOL - a 7.1
IPRODIONE Feb 1997 a 1
ISETHIONATE, as mixed ammonium and Jun 2016 a, b 1.11

ethanolamine salts of 2-hydroxyethanesulfonic acid
ISOFETAMID Feb 2018 a 1.3
ISOSTEARYL ALCOHOL ETHOXYLATE Nov 1999 a 5.1

APPENDIX B
KAOLIN Nov 1974 a 7.1
KRESOXIM-METHYL Aug 1999 a 1
KUNZEA OIL Feb 2000 a 7.1
LAURIC ACID Oct 2005 a 7.1
LAURYL ALCOHOL (1-DODECANOL) Nov 1974 a 7.1
LAVANDIN OIL Feb 2000 a 7.1
LAVENDER OIL Feb 2000 a 7.1
LEAD METALLIC - a 7.1
LEPIDOPTEROUS SEX PHEROMONES Nov 1990 a 1
LIMONENE (DIPENTENE) Jun 2002 a 7.1
LINOLEIC ACID Oct 2005 a 7.1
LINSEED FATTY ACIDS Aug 1990 a 2.1
LINURON Feb 1990 a 1
LIQUORICE, DEGLYCYRRHISINISED May 1999 a 7.1
MALEIC HYDRAZIDE Nov 1992 a 1
MANGANESE DIOXIDE May 1999 b 1

APPENDIX B
MEGASPHAERA ELSDENII strain 41125 Sep 2013 a 2.4
MESOSULFURON-METHYL Feb 2002 a 1.1
METARHIZIUM ANISOPLIAE Feb 2000 b 4.2
METARHIZIUM ANISOPLIAE Jun 2003 a 1.10
METCAMIFEN Feb 2020 a 1.1
METHOPRENE Aug 1987 a 1
METHOXYFENOZIDE Nov 2000 a 1
METHYL ACETATE - a 7.7
METHYL BENZOQUATE Nov 1974 d 2.3
1-METHYLCYCLOPROPENE Jun 2003 a 1.6
METHYL p-HYDROXYBENZOATE Nov 1974 a 7.9
METSULFURONMETHYL Nov 1985 a 1.1
MYRISTIC ACID Oct 2005 a 7.1
NAPROPAMIDE Aug 1987 a 1
NAPTHYL ACETAMIDE Nov 1974 a 1.6
NEROLI OIL Feb 2000 a 7.1

APPENDIX B
NICARBAZIN Jun 1969 d 2.3
NISIN Jun 2003 a 3.2
NORFLURAZON Nov 1983 a 1.1
NOVALURON Nov 2000 a 1
NUCLEAR POLYHEDROSIS VIRUS of Helicoverpa Feb 2004 a 1.2

armigera occlusion bodies
OCTYL ALCOHOLS Nov 1974 a 7.1
OLEIC ACID Oct 2005 a 7.1
ORANGE OIL, SWEET Aug 2000 a 7.1
OXABETRINIL Feb 1987 a 1
OXATHIAPIPROLIN Jun 2016 a 1.3
OXYFLUORFEN May 2001 a 1
PALMAROSA OIL Feb 2000 a 7.1
PALMITIC ACID Oct 2005 a 7.1
PATCHOULI OIL Feb 2000 a 7.1
PECTINASE derived from Aspergillus niger Feb 2005 a 2.4
PEGBOVIGRASTIM Jun 2017 a 2.1

APPENDIX B
PENCYCURON Aug 1994 a 1
PENTADECANOIC ACID Oct 2005 a 7.1
PEPPERMINT OIL Feb 2000 a 7.1
PHENMEDIPHAM May 1989 a 1.1
D-PHENOTHRIN Feb 1982 a 7.5, 1.2
PHYTASE Feb 1996 a 2.4
PICLORAM Aug 1987 a 1
PICOLINAFEN May 2000 a 1
PIMELIC ACID Oct 2005 a 7.1
PIPERONYL BUTOXIDE Aug 1991 a 7.5
POLOXALENE Nov 1974 a 7.1
POLY DIALLYL DIMETHYL AMMONIUM Nov 1997 a 4.1

CHLORIDE (PolyDADMAC)
POLYHEDROSIS VIRUS of Helico zea occlusion Nov 1996 a 1

bodies
POLY (GNRF) OVALBUMIN Feb 1990 a 2
POLYSORBATE 20 May 2001 a 1
PORCINE SOMATOTROPHIN Nov 1991 c 2

APPENDIX B
POTASSIUM SORBATE Oct 2004 a 1.3
POTASSIUM BICARBONATE Jun 2004 a 1
PROPYL ACETATES - a 7.1
PROPYLENE GLYCOL Nov 1974 a 7.1
2-PROPYLENE GLYCOL 1-MONOMETHYL Nov 1987 a 4

ETHER
PROTHIOCONAZOLE June 2005 a 1.3.1
PSEUDOMONAS FLUORESCENS May 1985 a 1.8
PYDIFLUMETOFEN Feb 2018 a 1.3
PYRIMETHANIL Feb 1996 a 1
PYRIPROXYFEN Aug 1994 a 1
QUASSIA Nov 1974 d 6, 2.1
QUINOXYFEN Nov 2001 a 1.3
RHIZOBIUM RHIZOGENES Nov 1989 b 1
ROSEMARY OIL Feb 2000 a 7.1
SAGE OIL (Spanish) Feb 2000 a 7.1
SANDALWOOD OIL Feb 2000 a 7.1

APPENDIX B
SEAWEED & UNFRACTIONED SEAWEED Feb 1985 d 1.5

EXTRACTS
SILVER OXIDE Jun 2018 b 7.14
SIMAZINE Nov 1987 a 1.1
SODIUM BICARBONATE Jun 2004 a 1
SODIUM PROPIONATE Oct 2004 a 1.3
STERIC ACID Oct 2005 a 7.1
STREPTOMYCES LYDICUS WYEC 108 Oct 2016 a 1.3
SUCRALFATE Aug 1982 a 6.8
SULESOMAB Jun 2002 b 6.1
SULFOSULFURON Feb 1998 a 1
SULPHATED POLYSACCHARIDES - a 7.1
TANNIC ACID Dec 1965 a 7.1
TANNIC ACID/BENZYL ALCOHOL PRODUCT Nov 1993 a 7.1
TERBACIL Aug 1987 a 1
THAUMATIN Nov 1990 a 3.2
THIDIAZURON Nov 1989 a 1

APPENDIX B
TIAFENACIL June 2019 a 1
TRIASULFURON Feb 1988 a 1
TRICHODERMA HARZIANUM May 1996 a 1
(Z)-9-TRICOSENE Aug 1991 a 1
TRIETHYLENE GLYCOL Nov 1974 a 7.1
TRIFLOXYSULFURON Feb 2002 a 1.1
TRIFLURALIN Aug 1990 a 1
TRIFORINE Aug 1987 a 1
ULOCLADIUM OUDEMANSII Oct 2003 a 1.10
UREA Nov 1974 a 7.1
13
C-UREA May 2001 a 6.1
VETIVER OIL Feb 2000 a 7.1
VINYL ETHER Nov 1987 b 6
VITAMIN K Jul 1963 a 6.9, 2.8
XANTHOPHYLL (lutein) Nov 1974 a 7.1
XYLANASE derived from Aspergillus niger Feb 2005 a 2.4

APPENDIX B
YLANG YLANG OIL Feb 2000 a 7.1
ZINC NAPHTHENATE - a 1.3

APPENDIX C
APPENDIX C (see SCHEDULE 10)

This Appendix is intentionally blank

APPENDIX D
APPENDIX D – ADDITIONAL CONTROLS ON POSSESSION OR

SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8
(The following controls apply to the substances listed only when included in Schedule 4 or
Schedule 8.)
1. Poisons available only from or on the prescription or order of an authorised

medical practitioner:
CANNABIS for human use.
CLOMIFENE for human use.
CLOZAPINE for human use.
CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use.
CYCLOFENIL for human use.
DINOPROST for human use.
DINOPROSTONE for human use.
FOLLITROPIN ALFA (recombinant human follicle-stimulating hormone) for human

use.
FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human

use.
FOLLITROPIN DELTA (recombinant human follicle-stimulating hormone) for human

use.
LUTEINISING HORMONE for human use.
NABIXIMOLS.

APPENDIX D
SODIUM OXYBATE for human use.
TETRAHYDROCANNABINOLS for human use.
TERIPARATIDE for human use.
UROFOLLITROPIN (human follicle-stimulating hormone) for human use.
2. Poisons available only from or on the prescription or order of a specialist physician

or a dermatologist and for which the prescriber must, where the patient is a
woman of child-bearing age:
(1) ensure that the possibility of pregnancy has been excluded prior to
commencement of treatment; and
(2) if the drug is -
(a) acitretin or etretinate, advise the patient to avoid becoming pregnant during
or for a period of 36 months after completion of treatment; or
(b) bexarotene, isotretinoin or thalidomide, advise the patient to avoid

becoming pregnant during or for a period of 1 month after completion of
treatment.
ACITRETIN for human use.
BEXAROTENE for human use.
ETRETINATE for human use.
ISOTRETINOIN for human oral use.
THALIDOMIDE for human use.

APPENDIX D
3. Poisons available only from or on the prescription or order of a medical

practitioner authorised or approved by the Secretary of the Commonwealth
Department of Health and Ageing under section 19 of the Therapeutic Goods Act
1989:
DRONABINOL (delta-9-tetrahydrocannabinol).
4. Poisons available only from or on the order of a specialist physician and for which
the prescriber must, where the patient is a woman of child bearing age:
(a) ensure that the possibility of pregnancy has been excluded prior to
(b) advise the patient to avoid becoming pregnant during or for a period of 1 month
after completion of treatment.
LENALIDOMIDE.
POMALIDOMIDE.
RIOCIGUAT for human use.
TRETINOIN for human oral use.
5. Poisons for which possession without authority is illegal (e.g. possession other than
in accordance with a legal prescription):
ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule

4.
ANDROGENIC STEROIDAL AGENTS, including those separately specified in

APPENDIX D
Schedule 4.
AOD-9604 (CAS No. 221231-10-3).
BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule

4 and Schedule 8.
CJC-1295 (CAS No. 863288-34-0).
DARBEPOETIN.
DEXTROPROPOXYPHENE.
EPHEDRINE.
EPOETINS.
ERYTHROPOIETIN.
ERYTHROPOIETINS except when separately specified in this Appendix.
FIBROBLAST GROWTH FACTORS.
FOLLISTATIN.
GLUTETHIMIDE.
GROWTH HORMONE RELEASING HORMONES (GHRHs) including those

separately specified in Schedule 4.
GROWTH HORMONE RELEASING PEPTIDES (GHRPs) including those separately

specified in Schedule 4.
GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6).

APPENDIX D
GROWTH HORMONE SECRETAGOGUES including those separately specified in

Schedule 4.
HEXARELIN.
IBUTAMOREN.
INSULIN-LIKE GROWTH FACTORS.
IPAMORELIN.
PERAMPANEL for human use.
PHENTERMINE.
PRALMORELIN ((GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2)).
SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those

separately specified in Schedule 4.
SOMATROPIN (human growth hormone).
STENABOLIC (SR9009) and other synthetic REV-ERB agonists.
TB-500.
THYMOSIN BETA 4 (THYMOSIN β4).
TIANEPTINE.
6. Poisons available only from or on the prescription or order of a specialist physician

and for which the prescriber must, where the patient is a woman of child-bearing

APPENDIX D
age:
(a) ensure that the possibility of pregnancy has been excluded prior to
(b) advise the patient to avoid becoming pregnant during and for a period of 3 months
after completion of treatment.
AMBRISENTAN for human use.
BOSENTAN for human use.
ENZALUTAMIDE for human use.
MACITENTAN for human use.
SITAXENTAN for human use.
7. Poisons available only from or on the prescription or order of a dermatologist:
ALEFACEPT for human use.
8. Poisons for which the initial treatment of a patient must be authorised by one of
the following specialist health practitioners:
(1) following the commencement of the Poisons Standard Amendment

(Hydroxychloroquine and Salbutamol) Instrument 2020—a medical
practitioner registered under State or Territory legislation that forms part of the
Health Practitioner Regulation National Law, as a specialist in any of the
following recognised specialties:
(a) dermatology;

APPENDIX D
(b) emergency medicine;
(c) intensive care medicine;
(d) paediatrics and child health;
(e) physician.
(2) following the commencement of the Poisons Standard Amendment

(Hydroxychloroquine) Instrument 2020—a dental practitioner registered under
State or Territory legislation that forms part of the Health Practitioner
Regulation National Law, as a specialist in the recognised specialty of oral
medicine.
HYDROXYCHLOROQUINE.
9. Poisons which must be stored in a locked container to prevent unauthorised

access:
PENTOBARBITAL in injectable preparations.

APPENDIX E
APPENDIX E – FIRST AID INSTRUCTIONS FOR POISONS

(other than agricultural and veterinary chemicals including pesticides registered by the
Australian Pesticides and Veterinary Medicines Authority and medicines for human use when
compliant with the requirements of the Required Advisory Statements for Medicine Labels.
Labelling is not required at concentrations below scheduled levels (see the Introduction to this
Appendix.))
INTRODUCTION
Directions for First Aid Attention
Under poisons legislation, scheduled substances and their preparations are required to be
labelled with appropriate directions for first aid attention in case of poisoning. It is the
responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the
first aid instructions included on the label of a poison are appropriate for a specific product. The
following code has been prepared as a guide for health authorities and manufacturers in drafting
suitable first aid directions for this purpose. Standard statements specified in this Appendix may
be varied provided that the intent is not changed.
The directions listed for any particular substance may require modification to take into account
combination of that substance with other substances, both toxic and non toxic, in a formulation,
as well as the physical form and presentation of the product. Any such modification should be
concise and readily understood.
These First Aid Instructions include action to be taken in case of eye contamination from
substances recognised as causing direct poisoning via the eye, causing severe eye damage or
requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is
recognised that many other substances or preparations will require a statement of varying nature
depending on the detailed formulation. While the necessity to flush the eyes in case of accident
will be so self-evident as not to justify label space in many instances, a statement such as “If in
eyes rinse well with water” may be appropriate.
Modified First Aid Instruction on Primary Pack
Where a primary pack contains two or more immediate containers of poisons each requiring
different first aid instructions:
a) each immediate container must be labelled with first aid instructions appropriate for
its contents; and
b) the primary pack must be labelled with the statement:
FIRST AID: See inner packs.
Exempt Preparations
This Appendix applies only to scheduled poisons. The directions are for substances and their
preparations at the concentrations at which the Schedules apply. If it is thought desirable to

APPENDIX E
show first aid instructions for a substance exempted from the schedules, it is the responsibility
of the manufacturer to ensure they are appropriate.
Poisons Information Centre Telephone Numbers
Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26;
New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the
national telephone numbers for Australia and New Zealand must meet the following criteria:
1. the poisons information service whose number is used must be attended by adequately trained
staff for 24 hour emergency poisons information; and
2. calls must be logged and submitted for incorporation into the official collection of poisoning
data.
PART 1 – STANDARD STATEMENTS
To be grouped together and prefaced with the words “FIRST AID” (see Part 2 Section 1.3(1)(p)
of this Standard).
Basic
A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New
Zealand 0800 764 766) or a doctor (at once).
Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g.
phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
General
G1 Urgent hospital treatment is likely to be needed.
(Note - the words ‘at once’ to be added to instruction A).
G2 If swallowed, give activated charcoal if instructed.
(Note - the words ‘at once’ to be added to instruction A).
G3 If swallowed, do NOT induce vomiting.
G4 Immediately give a glass of water.

APPENDIX E
G5 Avoid giving milk or oils.
G6 If sprayed in mouth, rinse mouth with water.
Eyes
E1 If in eyes wash out immediately with water.
E2 If in eyes, hold eyelids apart and flush the eye continuously with running water.
Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone
Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.
Respiratory system
R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.
R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if

not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use
air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.
Skin
S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with
running water.
S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with
running water. Continue flushing with water until advised to stop by a Poisons
Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a
doctor.
S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and
water, then methylated spirit if available. Contact a Poisons Information Centre (e.g.
phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.
S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated
spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running
water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11
26; New Zealand 0800 764 766) or a doctor.

APPENDIX E
S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under
running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons
Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).
Special Purpose
SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information

Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once.
Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated
charcoal may be advised. Give atropine if instructed.
PART 2 – FIRST AID INSTRUCTIONS
Standard statements in this Appendix apply to poisons other than agricultural and veterinary
chemicals (including pesticides) registered by the Australian Pesticides and Veterinary
Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the
Introduction to this Appendix).
POISON STANDARD STATEMENTS
ACETIC ACID A,G3,E2,S1
ACETIC ANHYDRIDE A,G3,E2,S1
ACETONE A,G3
ACROLEIN A,G1,G2,G3,E2,R2,S2
ALKALINE SALTS A,G3,E2,S1
ALKYL NITRITES A
AMIDOPROPYL BETAINES
 in cosmetic wash-off preparations when included E1

in Schedule 6

APPENDIX E
 in other preparations when included in Schedule 6 E1, S1
AMINES for use as curing agents A,G3,E1,S1
2-AMINO-6-CHLORO-4-NITROPHENOL A, E1
4-AMINO-m-CRESOL A, E1
2-AMINO-5-ETHYLPHENOL A
4-AMINO-2-HYDROXYTOLUENE A, E1
4-AMINO-3-NITROPHENOL A
2,2'-[(4-AMINO-3- E1
NITROPHENYL)IMINO]BISETHANOL
m-AMINOPHENOL A, S1
p-AMINOPHENOL A, S1
4-AMINOPYRIDINE A,G1,G2,E1,S1
AMMONIA
 5 per cent or less A
 above 5 per cent A,G3,E1,R1,S1
AMMONIUM COCOYL ISETHIONATE E1
AMMONIUM PERSULFATE A,G3,E2

APPENDIX E
AMMONIUM THIOCYANATE A
AMYL NITRITE A
ANHYDRIDES, organic acid, for use as curing agents for A,G3,E1,S1

epoxy resins
ANILINE A,E2,R1,S1
ANISE OIL A,G3
ANITMONY CHLORIDE A,E2,S2
ANTIMONY COMPOUNDS, except antimony chloride A
ARBUTIN when included in Schedule 6. A,G2,G3,E2,R2,S1
AZADIRACHTA INDICA (neem) including its extracts A,E1

and derivatives when included in Schedule 6.
AZO DYES (derivatives by diazotisation) A
BARIUM SALTS, except barium sulfate A
BASIC RED 76 A
BASIL OIL A,G3
BAY OIL A,G3
BENZALKONIUM CHLORIDE
 when included in Schedule 5 A,G3,E2

APPENDIX E
 when included in Schedule 6 A,G3,E2,S1
BENZENE A,G3,E1,R1,S1
1,2-BENZENEDIOL (Catechol) A, E1, S1
BENZOYL PEROXIDE
 above 20 per cent A,E2,S1
 above 10 per cent up to 20 per cent A,E1
BERGAMOT OIL A,G3
BIFLUORIDES (including ammonium, potassium and

sodium salts)
 when included in Schedule 5 A
 when included in Schedule 6 or 7 A,G3,E2,S5
1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE E1, S1
BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE A, E1
COPOLYMER
BORAX A
BORIC ACID A
BORON TRIFLUORIDE

APPENDIX E
BROMOFORM A,G3,E2,R1,S2
BRUCINE A,G1,G2,G3,R2
2-BUTOXYETHANOL and its acetates A,E2,S1
n-BUTYL ALCOHOL A, E1, S1
BUTYL NITRITE A
CADMIUM COMPOUNDS A
CAJUPUT OIL A,G3
CAMPHOR A,G1,G3,G5
CARBAMIDE PEROXIDE
 more than 9 per cent up to 60 per cent A,G3,E2,S1
 more than 60 per cent A,G1,G3,G4,E2,S1
CARBON DISULFIDE A,G3,E2,R1,S2
CARBON TETRACHLORIDE A,G3,E1,R1,S1
CASSIA OIL A,G3

APPENDIX E
CARBON DISULFIDE A,G3,E2,R1,S2
CARBON TETRACHLORIDE A,G3,E1,R1,S1
CASSIA OIL A,G3
CHLORINATING COMPOUNDS, except when
separately specified, containing
 above 4 per cent and below 10 per cent of available A,G3,E1,S1

chlorine
 10 per cent or more of available chlorine A,G3,E2,S1
CHLORIDE (gas) A,E1,R1
CHLOROACETAMIDE A
CHLOROCRESOL A,G3,E2,S2
2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL A, S1
CHLOROFORM A,G3,E1,R1,S1
CHROMATES A,G3,E2,S1
CHROMIUM TRIOXIDE A,G3,E2,S1
CHRYSOIDINE BASE A, S1,E1
CINEOLE A,G1,G3

APPENDIX E
CINNAMON BARK OIL A,G3
CINNAMON LEAF OIL A,G3
CLIMBAZOLE A
CLOVE OIL A,G1,G3,E2
COCOYL GLYCINATE E1
COPPER SULFATE A,G3,E2,S1
CREOSOTE A,G3,E2,S1
CRESOLS A,G3,E2,S3
CRESOLS in pressurised spray packs A,G6,E1,S1
CYANIDES A,G1,E1,R2
CYANOACRYLIC ACID ESTERS A
CYANURIC ACID A
CYCLOHEXANONE PEROXIDE A,G3,E2,S1
CYCLOSILAZANES, DI-ME, ME HYDROGEN, A, E2, S1

POLYMERS WITH DI-ME, ME HYDROGEN
SILAZANES, REACTION PRODUCTS WITH 3-
(TRIETHOXYSILYL)-1-PROPANAMINE (CAS 475645-
84-2)
CYCTEAMINE E1

APPENDIX E
1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N- E1
COCO ACYL DERIVATIVES
2,4-DIAMINOPHENOXYETHANOL A, E2, S1
o-DICHLOROBENZENE A,G3,E1,S1
para-DICHLOROBENZENE (PDB) A
DICHLOROETHYL ETHER A,G3,E1,R1,S1
DICHLOROISOCYANURATES A,G3,E1,S1
DICHLOROMETHANE (methylene chloride) A,G3,G5,E1,R1,S1
 in pressurised spray packs A,G6,S1
DICHROMATES A,G1,G3,E2,S1
DIDECYLDIMETHYLAMMONIUM SALTS A,G3
DIESEL (distillate) A,G3
DIETHANOLAMINE
 when included in Schedule 5 A,G3
DIETHYLENE GLYCOL MONOBUTYL ETHER A, E1, S1
5,6-DIHYDROXYINDOLINE E1

APPENDIX E
DIMETHYLFORMAMIDE
 less than 75 per cent A
 75 per cent or more A,E1,R1,S1
4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL A,E2
3,7-DIMETHYL-2,6-OCTADIEN-1-OL A, E1, S1
DIMETHYL SULFOXIDE A,G3,E1,S1
DINITROCRESOLS A,G1,E1,S1
DINITROPHENOLS A,G1,E1,S1
DIOXANE A,G3,E1,R1,S1
DISPERSE YELLOW 3 A, S1
DISTILLATE A,G3
N-(N-DODECYL)-2-PYRROLIDONE
EPOXY RESINS liquid A,G3,E2,S1
Essential oils containing CAMPHOR as natural component A,G3

unless otherwise specified.

APPENDIX E
ETHER A,G3,E1,R1
ETHYL BROMIDE A,E2,S1,R1
ETHYLENE GLYCOL A
ETHYLENE GLYCOL MONOALKYL ETHERS and A,G3,E2,S1

their acetates, except when separately specified
ETHYLENE OXIDE A,E2,R1
ETHYLHEXANEDIOL A, E2
2-ETHYLHEXANOIC ACID A
EUCALYPTUS OIL A,G1,G3
EUGENOL A,G1,G3,E2
FENNEL OIL A, G3
FLUORIDES except when separately specified
 when included in Schedule 6 A,G1,G3,E2,S1
FORMALDEHYDE (see also paraformaldehyde) A,G3,E2,R1,S1
FORMIC ACID A,G3,E2,S1
FURFURAL A,E1,S1

APPENDIX E
GLUTARAL
 below 5 per cent A,G3,E1
 5 per cent or more A,G3,E2,S1
GLYCOLIC ACID A,G3,E2
GUANIDINE when included in Schedule 6 A,G3,E2,S1
HC VIOLET 1 E1
HEXACHLOROPHENE when included in Schedule 6 A
HEXYLOXYETHANOL A,G3,E2,S1
HYDRAZINE A,G1,G3,E2,R1,S1
HYDROCARBONS, liquid A,G3
HYDROCHLORIC ACID A,G3,E2,S1
 when included in Schedule 5 A,G3
HYDROFLUORIC ACID and admixtures that generate

hydrofluoric acid
HYDROGEN PEROXIDE

APPENDIX E
 more than 3 per cent up to 20 per cent A,G3,E2,S1
 more than 20 per cent A,G1,G3,G4,E2,S1
HYDROQUINONE
 when included in Schedule 4 or 6 A,G2,G3,E2,R2,S1
HYDROSILICOFLUORIC ACID
2-HYDROXYETHYL METHACRYLATE A, E1, S1
HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE E1, S1
IODINE (excluding salts, derivatives and iodophors)
 2.5 per cent or more for human external use A,E2
 2.5 per cent or more for other uses A,E2,S1
 below 2.5 per cent A
IODOPHORS A
ISOAMYL NITRITE A

APPENDIX E
ISOBUTYL NITRITE A
ISOCYANATES, free organic A,E2,S1
ISOEUGENOL A, E1, S1
ISOPHORONE A,G3,E2,S1
KEROSENE A,G3
LAURETH CARBOXYLIC ACIDS
 leave-on or wash-off preparations above 5 per cent E1
 other preparations above 5 per cent E1,S1
LAURYL ISOQUINOLINIUM BROMIDE A,E1
LEAD COMPOUNDS
 in hair cosmetics A
 in other preparations A,S1
LEMON OIL A,G3
LEPTOSPERMUM SCOPARIUM OIL (manuka oil) A,G1,G3
LIME OIL A,G3
MAGNESIUM CHLORATE A

APPENDIX E
MALATHION at 20 per cent or less A
MARJORAM OIL A,G3
MELALEUCA OIL A,G1,G3
MERCAPTOACETIC ACID A, E1
MERCURIC CHLORIDE
 for external therapeutic use A
 for other uses A,G1,G3,E2,R2,S1
MERCURIC IODIDE A,G1,G3,E2,R2,S1
MERCURIC NITRATE A,G1,G3,E2,R2,S1
MERCURIC OXIDE A,G1,G3
MERCURIC POTASSIUM IODIDE A,G1,G3,E2,R2,S1
MERCURIC THIOCYANATE A,G1,G3,E2,R2,S1
MERCUROCHROME A
MERCUROUS CHLORIDE A
MERCURY metallic A
MERCURY, organic compounds A,S1

APPENDIX E
 in preparations for human external use A
METALDEHYDE A,E1,S1
METHANOL
 above 10 per cent A,G3
METHYLATED SPIRIT(S) A,G3
METHYLATED SPIRIT(S) when packed and labelled as a A,G3

'biofuel' suitable for use in 'spirit burners'.
METHYL ETHYL KETONE A,G3
METHYL ETHYL KETONE OXIME A,E1,S1
METHYL ETHYL KETONE PEROXIDE A,G3,E2,S1
METHYLEUGENOL A
METHYL ISOAMYL KETONE A,G3
METHYL ISOBUTYL KETONE A,G3
N-METHYL-2-PYRROLIDONE

APPENDIX E
2-METHYLRESORCINOL A, E1
METHYL SALICYLATE LIQUID when included in A,G3,E1

Schedule 5 or 6
MONOETHANOLAMINE
1,5-NAPHTHALENEDIOL A,E1,S1
2,7-NAPHTHALENEDIOL A,E1,S1
NAPHTHALENE A,G1,G3
1-NAPHTHOL A,E1,S1
NITRIC ACID A,G3,E2,S1
NITROBENZENE A,G3,E1,S1
3-NITRO-p-HYDROXYETHYLAMINOPHENOL E1
NITROPHENOL A,G3,E2,S1
NITROPRUSSIDES
 in aerosols A,G6,R1
 in other preparations A,G3

APPENDIX E
NONOXINOL 9 A,E2
NUTMEG OIL A,G3
OCTHILINONE A,G3,E2,S1
OCTYL NITRITE A
N-(N-OCTYL)-2-PYRROLIDONE
ORANGE OIL (bitter) A,G3
OXALIC ACID A,G3,E2,S1
PARAFORMALDEHYDE A,G3,E2,R1,S1
PENNYROYAL OIL A,G3
PERACETIC ACID
PETROL A,G3,R1
2-PHENOXYETHANOL A, E1

APPENDIX E
PHENOL when included in Schedule 6 A, E1
PHENOLS
 25 per cent and less A,G3,E2,S3
 above 25 per cent A,G3,E2,S4
PHENOLS in pressurised spray packs A,E1
PHENOXYMETHYL OXIRANE A, E1
PHENYLENEDIAMINES including alkylated, arylated,

halogenated and nitro derivatives
 in hair dyes. A,E1
 in preparations other than hair dyes. A,G1,G3,E1,S1
PHENYL METHYL KETONE as such, or in preparations A,G3,E1

of similar viscosity
PHENYL METHYL PYRAZOLONE A,S1
N,N-BIS(PHENYLMETHYLENE)-BICYCLO- A,E2,S1
(2.2.1)HEPTANE-2,5-DIMETHANAMINE
N,N-BIS(PHENYLMETHYLENE)-BICYCLO- A,E2,S1
o-PHENYLPHENOL A,G3,E2,S1
 in pressurised spray packs A,G6,E2,S1

APPENDIX E
PHOSPHONIC ACID A,G3,E2,S1
 neutralised to pH 6 (approx) A
 in spray packs A,E2,S1
PHOSPHORIC ACID A,G3,E2,S1
PHOSPHORUS, yellow A,G1,G3,E2,R2,S2
o-PHTHALALDEHYDE
 when included in Schedule 5 A,E1
PICRIC ACID A,G1,G3,E2,R1,S1
POLIHEXANIDE E1
POLYETHANOXY (15) TALLOW AMINE A,E2,S1
POLY(OXY-1,2-ETHANEDIYL), Α -[2-[(2- A,E1

HYDROXYETHYL)AMINO]-2-OXOETHYL]- Α -
HYDROXY-,MONO-C13-15-ALKYL ETHERS
POTASSIUM BROMATE A
POTASSIUM CHLORATE A
POTASSIUM CYANATE A,E1,S1
POTASSIUM HYDROXIDE A,G3,E2,S1

APPENDIX E
POTASSIUM METABISULPHITE A
POTASSIUM NITRITE
 when included in Schedule 7 A,G1,G3
 when included in Schedule 5 or 6 A,G3
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT
POTASSIUM PERSULFATE A,G3,E2
POTASSIUM SULFIDE A,G3,E2,S1
PROPIONIC ACID A,G3,E1,S1
n-PROPYL ALCOHOL A, E1
D-PULEGONE A,G3
PYRITHIONE ZINC A,E1
QUATERNARY AMMONIUM COMPOUNDS except

when separately specified
 above 20 per cent A,G3,E2
 20 per cent and below A,E2

APPENDIX E
 in pressurised spray packs A,E2,G6
QUINOLINE A, E1, S1
RESORCINOL A, E2, S1
SAFROLE A,G1,G3
SAGE OIL (Dalmatian) A,G3
SASSAFRAS OIL A,G1,G3
SELENIUM COMPOUNDS A,G1,E1,S1
SILICOFLUORIDES
 when included in Schedule 6 A,G1,G3,E2,S1
SILVER SALTS A,E2
SODIUM ALUMINATE A,G3,E2,S1
SODIUM BROMATE A,G1
SODIUM CHLORATE A
SODIUM DIACETATE A,G3,E2,S1
SODIUM DICHLOROISOCYANURATE A,G3,E1,S1

APPENDIX E
SODIUM DODECYLBENZENE SULFONATE A,G3,E2,S1
SODIUM HYDROGEN SULFATE A,G3,E1,S1
SODIUMHYDROSULFITE A,G3,E2,S1
SODIUM HYDROXIDE A,G3,E2,S1
SODIUM LAURETH-6 CABOXYLATE A
LAURYL SULFATE SALTS
 leave-on or wash-off preparations above 5 per cent E1
 other preparations above 5 per cent E1,S1
SODIUM METABISULPHITE A, G3
SODIUM NITRITE
 when included in Schedule 7 A,G1,G3
 when included in Schedule 5 or 6 A,G3
SODIUM PERCARBONATE
 when included in Schedule 5 A,G3,S1
SODIUM PERSULFATE A,G3,E2

APPENDIX E
SODIUM STANNATE A,E1
SODIUM SULFIDE A,G3,E2,S1
SODIUM TRICHLOROACETATE A
STRYCHNINE A,G1,G2,G3,R2
STYRENE A,G3,S1,E1
SULCOFURON A
SULFAMIC ACID A,G3,E2,S1
SULFURIC ACID A,G3,E2,S1
TERPENES, chlorinated A,G3
TETRACHLOROETHANE A,G3,E1,R1,S1
TETRACHLOROETHYLENE A,G3,E2,R1,S1
THIOUREA A
THUJONE A,G3
THYME OIL A,G3
o-TOLIDINE A
TOLUENE

APPENDIX E
 75 per cent and below A,G3
 in pressurised spray packs A
TOLUENEDIAMINES
 in hair dyes A,E1
 in other preparations A,G1,G3,E1,S1
TRICHLOROACETIC ACID A,G3,E2,S1
TRICHLOROACETIC ACID ALKALI SALTS A
1,1,1-TRICHLOROETHANE A,G3,E1,R1,S1
TRICHLOROETHYLENE A,G3,E1,R1,S1
TRICHLOROISOCYANURIC ACID A,G3,E1,S1
TRIETHYL PHOSPHATE A,E1
TRIFLUOROMETHANESULFONIC ACID A,G3,E2
TRIISOPROPANOLAMINE LAURYL ETHER A,E1,S1

SULFATE
TROLAMINE A,G3,E1,S1
TURPENTINE (mineral) A,G3

APPENDIX E
TURPENTINE OIL (vegetable) A,G3,E2
VINYL ACETATE MONOMER A, R1
WHITE SPIRIT A,G3
XYLENE
 75 per cent and below A,G3
 in pressurised spray packs A,G6,E1,S1
XYLENOLS
 in pressurised spray packs A,E1
ZINC CHLORIDE A,G3,E2,S1
ZINC SULFATE A,G3,E2,S1

APPENDIX F
APPENDIX F – WARNING STATEMENTS AND GENERAL

SAFETY DIRECTIONS FOR POISONS
(other than agricultural and veterinary chemicals including pesticides registered by the
Australian Pesticides and Veterinary Medicines Authority and medicines for human use when
compliant with the requirements of the Required Advisory Statements for Medicine Labels.
(where more than one statement or direction is required, they may be combined to form simple
sentences where appropriate.))
INTRODUCTION
Warning Statements and Safety Directions
It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure
that the purchaser or user of a product is given sufficient information to be able to use it
correctly and safely.
Under poisons legislation, scheduled substances, which may be harmful to the user, must be
labelled with appropriate warning statements and/or safety directions. The selection of warning
statements and safety directions will depend on the formulation of the product, and the use for
which it is sold or supplied. The following code has been prepared as a guide for this purpose.
The wording of warning statements and safety directions specified in this Appendix may be
varied provided that the intent is not changed. Additional statements also may be added to
ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid
any deleterious effects.
Poisons Information Centre Telephone Numbers
Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26;
New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.
Companies wishing to use a poisons information centre telephone number other than the
national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part
1 of this Appendix must meet the following criteria:
1. the poisons information service whose number is used must be attended by adequately trained
staff for 24 hour emergency poisons information; and
2. calls must be logged and submitted for incorporation into the official collection of poisoning
data.
PART 1 – WARNING STATEMENTS
1. Highly corrosive.

APPENDIX F
2. Corrosive.
3. Corrosive liquid.
4. Strongly alkaline.
5. Irritant.
6. May cause cancer.
7. WARNING – Causes birth defects.
8. WARNING – May be fatal to children.
9. Can be fatal to children if sucked or swallowed.
10. May produce severe burns.
11. WARNING – Vapour may be harmful.
12. Vapour is harmful to health on prolonged exposure.
13. May be fatal if inhaled, swallowed or absorbed through skin.
14. Dust will irritate and burn eyes, nose and skin.
15. Liquid will cause burns.
16. Forms dangerous gas near radiators or naked flames.
17. Contact with eyes even for short periods can cause blindness.

APPENDIX F
18. Product will irritate the eyes, nose, throat and skin.
19. WARNING – Skin contact may be dangerous. Take every precaution to avoid
contact – wash off after spillage and after use.
20. May give off dangerous gas if mixed with other products.
21. WARNING – This product contains ingredients which may cause skin irritation to
certain individuals. A preliminary test according to accompanying directions should
be made before use. This product must not be used for dyeing eyelashes or eyebrows;
22. Highly reactive oxidising chlorine compound.
23. May cause fire or explosion.
24. For external washing only. Rinse skin thoroughly after use.
25. Do not use on broken skin. Wash hands thoroughly after use.
26. (Powder) (and) (concentrated solutions) are dangerous if swallowed.
27. Not for therapeutic use.
28. (Over) (Repeated) exposure may cause sensitisation.
29. If congestion persists, consult your doctor or pharmacist.
30. WARNING – Do not use on face or on anal or genital areas.
31. WARNING – Do not use on face or on anal or genital areas except on doctor’s
advice.
32. This preparation should be part of an overall treatment plan regularly assessed with

APPENDIX F
your doctor.
33. Do not take for periods longer than four weeks except on medical advice.
34. WARNING – This medication may be dangerous when used in large amounts or for
a long time (period).
35. CAUTION – This preparation is for the relief of minor and temporary ailments and
should be used strictly as directed. Prolonged use without medical supervision could
be harmful.
or
CAUTION – This preparation is for the relief of minor and temporary ailments and
should be used strictly as directed. Prolonged or excessive use without medical
supervision could be harmful.
36. For use under medical supervision only.
37. Consult a doctor before giving this medication to children or teenagers with chicken
pox, influenza or fever.
38. CAUTION – Do not use for children under 2 years unless a doctor has told you to.
39. This medication may cause drowsiness. If affected do not drive a vehicle or operate
machinery. Avoid alcohol.
40. This medication may cause drowsiness and may increase the effects of alcohol. If
affected do not drive a motor vehicle or operate machinery.
41. Do not give to children under 12 years of age. Do not use beyond 48 hours or in
pregnancy or lactation except on doctor’s advice.
42. WARNING – Overuse may stain the skin or mouth.
43. Use of this product is not necessary in areas supplied with fluoridated water.

APPENDIX F
44. WARNING – May be dangerous, particularly to children, if you use large amounts
on the skin, clothes or bedding or on large areas of the body, especially if you keep
using it for a long time.
45. WARNING – If a pigmented spot or mole has recently become darker, changed
colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor
immediately. Do not use on children. Do not use near the eyes. Mild irritation may
occur; stop use if it becomes severe. If fading is not evident in three months, seek
doctor’s advice.
46. WARNING – Contains (name of substance) which causes birth defects in laboratory
animals. Women of child bearing age should avoid contact with (name of substance).
47. WARNING – This product contains (name of substance) which causes birth defects
in certain laboratory animals. Women of child bearing age are advised not to mix,
load or spray this product. They should keep out of crops being sprayed.
48. WARNING – This product forms cyhexatin which causes birth defects in certain
laboratory animals. Women of child bearing age are advised not to mix, load or spray
this product. They should keep out of crops being sprayed.
49. WARNING – Do not mix with other medication except on veterinarian’s advice.
50. Unless adequately fired, utensils glazed with this preparation must not be used as
containers for food or beverages; to do so may cause lead poisoning.
51. Irritant to skin, eyes, mucous membranes and upper respiratory tract.
52. Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.
53. CAUTION – (Name of substance) should not be used by pregnant women.
54. Seek medical advice before first course of treatment.
55. Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling,
irritation, redness or peeling occurs, discontinue use. If these persist, consult a
physician. Avoid excessive exposure to sunlight and other sources of ultra violet

APPENDIX F
light.
56. WARNING – Can cause elevated blood pressure and interact adversely with other
medication.
57. Not to be applied to infants under 12 months of age unless on doctor’s advice.
58. Highly reactive oxidising bromine and chlorine compound.
59. May cause allergy.
60. Do not mix with detergents or other chemicals.
61. WARNING - Can react with other medicines. Ask your doctor or pharmacist before
taking.
62. Do not use if pregnant.
63. See a doctor if you are pregnant or diabetic.
64. See a doctor (or) (dentist) if no better after (Insert number of days as per approved
Product Information) days.
65. If getting better, keep using for (Insert number of days as per approved Product
Information ) days.
66. See a doctor if problem returns.
67. Do not use if pregnant or likely to become pregnant.
68. If symptoms persist beyond 5 days consult a doctor (or) (dentist).
69. If symptoms recur within two weeks of completing the course, consult a doctor.

APPENDIX F
70. Use only under medical supervision if you are taking other medicines.
71. Do not use during the last three months of pregnancy.
72. Do not use in the eyes.
73. Do not use for acne.
74. Do not use under waterproof bandages unless a doctor has told you to.
75. Do not use for more than 7 days unless a doctor has told you to.
76. Do not become pregnant during use or within (Insert number of months as per
approved Product Information) month(s) of stopping treatment.
77. WARNING - May cause birth defects.
78. Attacks skin and eyes.
79. Will irritate eyes.
80. WARNING: Do not attempt to refill burner while it is in use or still warm; it could
lead to serious burn injury
81. (Intentionally blank)
82. (Intentionally blank)
83. This paint is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use on, in or around the home.

APPENDIX F
84. Breathing the vapour is dangerous.
Provide adequate ventilation during application.
Do not use in the presence of a naked flame.
Do not smoke.
85. This paint contains lead and is dangerous to health, even when dry.
For industrial use only.
Do not use on toys or furniture.
Do not use for painting any building or fixed structure.
Do not use where contact with food or drinking water is possible.
86. This tinter contains lead.
Do not add to any paint which is for application to any toy, furniture, building
(interior or exterior), fixed structure or to anything which may contact food or
drinking water.
87. (Insert brand name) remains in the body for many months after treatment has
stopped. Do not become pregnant or father a child before consulting your doctor.
88. This product is not recommended for dyeing eyelashes or eyebrows. To do so may be
injurious to the eye.
89. Application to skin may increase sensitivity to sunlight.
90. This preparation is to aid sleep. Drowsiness may continue the following day. If
affected do not drive or operate machinery. Avoid alcohol.
91. CAUTION – Total iodine intake may exceed recommended level when taking this
preparation.
92. WARNING – Contains iodine - do not take when pregnant except on physician’s
advice.

APPENDIX F
93. Causes severe burns, which are not likely to be immediately painful or visible.
94. WARNING – Contains nitrite. Substitution for table or cooking salt may be
dangerous, particularly for young children.
95. CAUTION – Do not use for children under 12 years unless a doctor has told you to.
96. CAUTION – This preparation is for the relief of minor and temporary ailments and
should be used strictly as directed. If symptoms persist or recur within two weeks,
consult a doctor.
97. Adults: Keep to the recommended dose. Don’t take this medicine for longer than a
few days at a time unless advised to by a doctor.
98. Children and adolescents: Keep to the recommended dose. Do not give this medicine
for longer than 48 hours at a time unless advised to by a doctor.
99. If an overdose is taken or suspected, ring the Poisons Information Centre (Australia
13 11 26; New Zealand 0800 764 766) or go to a hospital straight away even if you
feel well because of the risk of delayed, serious liver damage.
100. Do not take with other products containing paracetamol, unless advised to do so by a
doctor or pharmacist.
101. Don’t use [this product/name of the product]:
If you have a stomach ulcer.
In the last 3 months of pregnancy. [This statement may be omitted in preparations

used exclusively for the treatment of dysmenorrhoea.]
If you are allergic to (name of substance) or anti-inflammatory medicines.
102. Unless a doctor has told you to, don’t use [this product/name of the product]:
For more than a few days at a time.
With other medicines containing aspirin or other anti-inflammatory medicines.

APPENDIX F
If you have asthma.
In children under 12 years of age.
In children 12-16 years of age with or recovering from chicken pox, influenza or
fever.
If you are pregnant.
103. See a doctor before taking [this product/name of the product] for thinning the blood
or for your heart. [This statement may be omitted in products for inhibition of platelet
aggregation or with additional active ingredients.]
104. Unless a doctor has told you to, don’t use [this product/name of the product]:
For more than a few days at a time.
With other medicines containing (name of substance) or other anti-inflammatory

medicines.
If you have asthma.
If you are pregnant. [This statement may be omitted in preparations used exclusively
for the treatment of dysmenorrhoea.]
105. Do not use on the bedding or clothing of infants or in the bedrooms of children 3
years of age or less.
106. Contains formaldehyde.
107. Not recommended for children under twelve years of age.
108. Breathing of solder fumes is harmful and may cause asthma or sensitisation.
109. See your healthcare provider if you consider that you may be at risk of a Sexually
Transmitted Infection (STI).
110. See a doctor if you plan to become pregnant, or are breastfeeding or plan to
breastfeed.

APPENDIX F
111. Do not use if breastfeeding or planning to breastfeed.
PART 2 - SAFETY DIRECTIONS - GENERAL
To be grouped together and prefaced with the words “SAFETY DIRECTIONS” (see Part 2,
Section 1.3(1)(n) to this Standard).
1. Avoid contact with eyes.
2. Attacks eyes - protect eyes when using.
3. Wear eye protection when mixing or using.
4. Avoid contact with skin.
5. Wear protective gloves when mixing or using.
6. Wash hands after use.
7. Wash hands thoroughly after use.
8. Avoid breathing dust (or) vapour (or) spray mist.
9. Use only in well ventilated area.
10. Ensure adequate ventilation when using.
11. No smoking.
12. Do not allow product to come into contact with other chemicals, especially acids.
13. Do not allow product to come into contact with combustible materials such as paper,
fabric, sawdust or kerosene.

APPENDIX F
14. Do not allow to get damp.
15. Store under cover in a dry, clean, cool, well ventilated place away from sunlight.
16. Store and transport in an upright container.
17. Do not mix with other chemicals.
18. Do not mix with different types of chlorinating chemicals.
19. Use clean containers for dispensing.
20. Mix with water only.
21. Do not add water to product - add product to water, but in case of fire drench with
water.
22. In case of spillage flush with large quantities of water.
23. Keep away from heat, sparks and naked flames.
24. Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other
mucous membranes.
25. Avoid contact with food.
26. Avoid contact with clothing.
27. Wear a positive-pressure air-supplied full-face respirator whilst spraying and until
spray mist has been effectively dispersed.
28. Do not mix with hot water.

APPENDIX F
29. Obtain a supply of calcium gluconate gel.
30. (Intentionally blank.)
31. Do not use on broken skin.
32. Do not use under occlusive dressing.
33. Mix strictly according to instructions.
34. May cause fire if it comes into contact with other chemicals, paper or other flammable
materials.
35. Wash gloves thoroughly, immediately after use.
36. Protect cuticles with grease or oil.
37. Avoid breathing solder fumes.
PART 3 - POISONS (other than agricultural and veterinary chemicals) TO BE

LABELLED WITH WARNING STATEMENTS OR SAFETY DIRECTIONS
(Where more than one statement or direction is required, they may be combined to form simple
sentences where appropriate.)
POISON WARNING SAFETY

STATEMENTS DIRECTION
ACETIC ACID in concentrations of 80 per cent 2 or more 2 1,4,8

except when in Schedule 2.
ACETIC ANHYDRIDE 2 1,4,8
ACETONE in concentrations greater than 75 per cent. 1,4,8

APPENDIX F
ACITRETIN
a) for oral use. 7,62,76
b) for topical use. 62,77
ADAPALENE for topical use. 62,77
ALCLOMETASONE when included in Schedule 3. 38,72,73,74,75
ALKALINE SALTS. 4 1,4
AMBRISENTAN. 7,62,76
AMINES used as curing agents for epoxy resins. 1,3,4,5,8
2-AMINO-6-CHLORO-4-NITROPHENOL. 28
4-AMINO-m-CRESOL. 28
2-AMINO-5-ETHYLPHENOL. 21
4-AMINO-2-HYDROXYTOLUENE. 28
4-AMINO-3-NITROPHENOL. 28
2,2'-[(4-AMINO-3- 28
NITROPHENYL)IMINO]BISETHANOL.
m-AMINOPHENOL. 28 4, 8

APPENDIX F
p-AMINOPHENOL. 28
AMMONIA/AMMONIUM HYDROXIDE in 4 1,4,8

concentrations greater than 20 per cent ammonia
except in smelling salts.
AMMONIUM PERSULFATE. 5,21,25 1,5,23,33,34
ANHYDRIDES, organic acid, for use as curing 1,3,4,5,8

agents for epoxy resins.
ANILINE. 13 1,4,8
ANTIHISTAMINES not separately specified in this 39 or 40

Appendix except:
a) dermal, ocular, parenteral and paediatric

preparations;
b) oral preparations of astemizole,
azelastine, desloratadine, fexofenadine,
loratadine, terfenadine or cetirizine;
c) nasal preparations of azelastine; or
d) preparations for the treatment of animals.
ARBUTIN when included in Schedule 6. 45 1,4
AROMATIC EXTRACT OILS. 1,3,4,5,6
ASPIRIN
a) for inhibition of platelet aggregation. 36
b) in sustained release preparations

containing 650 mg or more of aspirin. 36

APPENDIX F
c) in other preparations. 101,102,103
ASTEMIZOLE. 61
ASTODRIMER SODIUM. 63,64,69,75,109,110
AZADIRACHTA INDICA including its extracts 67

and derivatives when included in Schedule 6.
AZOCYCLOTIN. 48
AZO DYES (derivatives by diazotisation) 6 5
BASIC RED 76. 5
BENOMYL. 46
BENZENE. 12 1,4,9
1,2-BENZENEDIOL (Catechol). 51,59 1,4,8
BENZOYL PEROXIDE when included in Schedule 55

2.
BENZOYL PEROXIDE when included in Schedule 1,4,8

5.
BERGAMOT OIL. 89
BERYLLIUM. 1,4,8
BEXAROTENE

APPENDIX F
a) for human use. 7,62,76
BIFLUORIDES (including ammonium, potassium

and sodium salts)
a) when included in Schedule 5. 1,4
b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35
1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE. 28, 79 1
BIS-ISOBUTYL PEG/PPG- 1
20/35/AMODIMETICONE COPOLYMER.
BITHIONOL for the treatment of animals. 1,4,8
BORIC ACID when used in Schedule 5 25, 26
BORON TRIFLUORIDE (including mixtures that

generate boron trifluoride)
a) when included in Schedule 5. 2 1,4
BOSENTAN. 7,62,76
BROMOFORM. 1,4,8
2-BUTOXY-2’-THIOCYANODIETHYL ETHER. 1,4,8

APPENDIX F
2-BUTOXYETHANOL and its acetates. 1,4,8
n-BUTYL ALCOHOL. 5 2, 4, 8
CAMPHOR
a) in block, ball, disc, pellet or flake form,

enclosed in a device which, in normal 9
use, prevents removal or ingestion of its
contents.
b) in other forms. 9 1
CANNABIDIOL when included in Schedule 3. 67, 111
CARBAMIDE PEROXIDE
a) more than 9 per cent up to 30 per cent. 5 1
b) more than 30 per cent up to 60 per cent. 5 2
c) more than 60 per cent. 2 2,4
CARBON DISULFIDE. 12 1,4,8,9,23
CARBON TETRACHLORIDE. 12 1,4,8,9
CASSIA OIL. 4
CHLORINATING COMPOUNDS
a) in household cleaning or bleaching

preparations. 20
b) in preparations containing less than 10

per cent of available chlorine. 11 1,4,10

APPENDIX F
c) in liquid preparations containing 10 per 3,18 1,4,6,8,10,

cent or more of available chlorine. 15,16, 17,18,
19,20,22,26
10,18,22,23 1,4,8,12,13,
d) in dry preparations containing 10 per cent 14,15,16,17,
or more of available chlorine. 18, 19,20,21,
22,26
e) in dry preparations containing 10 per cent

or more of available chlorine certified by 10,18,22 1,4,8,12,13,
a relevant State or Territory authority as 14,15,16,17,
not being a Dangerous Good of Class 5, 18,19,20,21,
Division 5.1: Oxidising substances, as 22,26
specified in the Australian Code for the
Transport of Dangerous Goods by Road
and Rail.
f) in compressed block or tablets containing
10 per cent or more of available chlorine 10,22,23 12,13,14,15,
except in preparations for use in toilet 17,18,19,21
cisterns only, containing 15 g or less of
trichloroisocyanuric acid.
g) in other compressed blocks or tablets
containing 10 per cent or more of 10,22 12,13,14,15,
available chlorine certified by a relevant 17,18,19,21
State or Territory authority as not being a
Dangerous Good of Class 5, Division
5.1: Oxidising substances, as specified in
the Australian Code for the Transport of
Dangerous Goods by Road and Rail
except in preparations for use in toilet
cisterns only, containing 15 g or less of
trichloroisocyanuric acid.
CHLOROACETAMIDE. 28 4
2-CHLORO-6-(ETHYLAMINO)-4- 28 4
NITROPHENOL.
CHLOROFORM when included in Schedule 6. 1,4,8
alpha-CHLOROHYDRIN. 13,51 1,4,8,9

APPENDIX F
CHROMATES (including dichromates) of alkali 1,4,8

metals or ammonia.
CHROMIUM TRIOXIDE. 2,14,15,23 1,4,8,13
CIMETIDINE when included in Schedule 3. 70,96
CINNAMON BARK OIL. 4
CLOBETASONE when included in Schedule 3. 72,73,74,75,95
CLOTRIMAZOLE in vaginal preparations when 54,63,64,66

CLOVE OIL. 1
CYANIDES when included in Schedule 7. 13 4,8
CYANURIC ACID. 1,4,8
CYCLOHEXANONE PEROXIDE. 1,4,8
CYCLOSILAZANES, DI-ME, ME HYDROGEN, 2, 10, 78 1, 4, 5, 35

POLYMERS WITH DI-ME, ME HYDROGEN
SILAZANES, REACTION PRODUCTS WITH 3-
(TRIETHOXYSILYL)-1-PROPANAMINE (CAS
475645-84-2).
CYCTEAMINE. 1
1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL 79 1
N-COCO ACYL DERIVATIVES.
4,4-DIAMINODIPHENYLMETHANE (methylene 1,4,8

dianiline).

APPENDIX F
2,4-DIAMINOPHENOXYETHANOL. 28, 79 1, 4
o-DICHLOROBENZENE. 1,4,8
para-DICHLOROBENZENE. 1,4
DICHLOROETHYLENE. 1,4,8
DICHLOEOETHYL ETHER. 1,4,8
DICHLOROISOCYANURATES
a) in household cleaning or bleaching

preparations. 20
b) in preparations containing less than 10

per cent of available chlorine. 11 1,4,10
c) in liquid preparations containing 10 per 3,18 1,4,6,8,10,

cent or more of available chlorine. 15,16,17,18,
19,20,22,26
d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,14,

or more of available chlorine. 15,16,17,18,19,
20,21,22,26
e) in dry preparations containing 10 per cent

or more of available chlorine certified by 10,18,22 1,4,8,12,13,14,
a relevant State or Territory authority as 15,16,17,18,19,
not being a Dangerous Good of Class 5, 20,21,22,26
Division 5.1: Oxidising substances, as
specified in the Australian Code for the
Transport of Dangerous Goods by Road
and Rail.
f) in anti-bacterial tablets containing 2.5 g
or less of sodium dichloroisocyanurate. 60
g) in other compressed blocks or tablets

containing 10 per cent or more of 10,22,23 12,13,14,15,
available chlorine except in preparations 17,18,19,21
containing 21 g or less of sodium

APPENDIX F
dichloroisocyanurate for use in toilet

cisterns only.
h) in other compressed blocks or tablets
containing 10 per cent or more of 10,22 12,13,14,15,17,
available chlorine certified by a relevant 18,19,21
Dangerous Goods by Road and Rail
except in preparations containing 21 g
less of sodium dichloroisocyanurate for
use in toilet cisterns only.
i) in other compressed blocks or tablets
containing 10 per cent or more of
available chlorine in preparations
containing 5 g or less of sodium
dichloroisocyanurate for use in toilet
bowls only:
10,22,23 12,13,14,15,17,
i) during storage.
18,21
ii) during use. 5 1,4,7,12
j) in other compressed blocks or tablets

containing 10 per cent or more of
available chlorine certified by a relevant
Dangerous Goods by Road and Rail in
preparations containing 5 g or less of
sodium dichloroisocyanurate for use in
toilet bowls only.
i) during storage.
10,22 12,13,14,15,17,
18,21
ii) during use.

5 1,4,7,12
DICHLOROMETHANE (methylene chloride)

APPENDIX F
a) in paint or lacquer removers. 12,16 1,4,8,11
b) other than in paint or lacquer removers. 1,4,8,25
DICLOFENAC. 101,104
DIENESTROL. 67
DIETHANOLAMINE when included in Schedule 5 1,4

5.
DIETHANOLAMINE when included in Schedule 2,11,18 1,4,8

6.
DIETHYLTOLUAMIDE for human use. 44
DIETHYLENE GLYCOL MONOBUTYL ETHER. 5 1, 4, 8, 9
5,6-DIHYDROXYINDOLINE. 21,28
2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE. 28
DIMETHYLFORMAMIDE. 1,4,8
4,4-DIMETHYL-1-CYCLOHEXENE-1- 5,28 1,2

PROPANAL.
3,7-DIMETHYL-2,6-OCTADIEN-1-OL. 5 1, 4
DIMETHYL SULFATE. 2 1,4,8
DIMETHYL SULFOXIDE.

APPENDIX F
a) when not packed and labelled for

therapeutic use. 27 1,4,5,8
b) when packed and labelled for the

treatment of animals. 49 1,4,5,8
DINITROCRESOLS (and their homologues) 1,4,8

except when for therapeutic use.
DINITROPHENOLS (and their homologues) 1,4,8

except when for therapeutic use.
DINOCAP. 47
DIOXANE. 1,4,8
DIPHENOXYLATE when included in Schedule 3. 39 or 40,41
DISPERSE YELLOW 3. 28 4
ECONAZOLE in vaginal preparations when 54,63,64,66

ENZALUTAMIDE. 7, 67,87
EPHEDRINE in nasal preparations for topical use. 29
EPICHLOROHYDRIN. 2 1,4,8
EPOXY RESINS, liquid. 1,3,4,5,8
ETHER when included in Schedule 5 or 6. 1,4,8
2-ETHOXYETHANOL. 77 1,4,8

APPENDIX F
ETHOXYETHYLMERCURIC CHLORIDE. 1,4
ETHYL BROMIDE. 1,4,8
ETHYLENE CHLOROHYDRIN. 1,4,8
ETHYLENE GLYCOL MONOALKYL ETHERS 1,4,8

and their acetates except when separately specified.
ETHYLENE OXIDE. 1,4,8
ETHYLHEXANEDIOL. 79 1
2-ETHYLHEXANOIC ACID. 53
ETHYLMERCURIC CHLORIDE. 1,4
ETHYL METHACRYLATE. 28 4,9,23
ETRETINATE. 7,62,76
EUGENOL. 1
FAMOTIDINE when included in Schedule 2. 96
FENTEROL in metered aerosols. 32
FLUCONAZOLE in oral preparations when 64

FLUORIDES (including silicofluorides) when 1,4

included in Schedule 5 or 6 except when separately
specified.

APPENDIX F
FORMALDEHYDE
a) in nail hardener cosmetics. 106 1,4,8,36
b) in other preparations. 106 1,4,8
FORMIC ACID. 1,4,8
FURFURAL. 5 1,4
Glazing preparations containing LEAD 50

COMPOUNDS.
GLUTARAL except when in Schedule 2
a) 25 per cent or less. 5,59 1,4,5
b) more than 25 per cent. 3,59 1,4,5,8
GLYCOLIC ACID. 79 1,5,6,31
HC VIOLET 1. 28
HEXACHLOROPHENE in preparations for skin 24

cleansing purposes containing 3 per cent or less of
hexachlorophene.
HEXYLOXYETHANOL. 2 1,4,8
HYDRAZINE. 1,4,8
HYDROCLORIC ACID

APPENDIX F
a) 30 per cent or less of HCl. 1,4
b) more than 30 per cent of HCl. 1,4,8
HYDROCORTISONE
a) for dermal use when included in

Schedule 2 or 3. 38,72,73,74,75
b) for topical rectal use when included in

Schedule 2 or 3. 38,75
HYDROCYANIC ACID when included in 13 4,8

Schedule 7.
HYDROFLUORIC ACID (including mixtures that

generate hydrofluoric acid)
HYDROGEN PEROXIDE
a) more than 3 per cent up to 10 per cent. 5 1
b) more than 10 per cent up to 20 per cent. 5 2
c) more than 20 per cent. 2 2,4
HYDROQUINONE
a) when in Schedule 2. 45
b) except when in Schedule 2 or 4. 1,4

APPENDIX F
HYDROSILICOFLUORIC ACID (including

mixtures that generate hydrosilicofluoric acid)
2-HYDROXYETHYL METHACRYLATE . 28 4
HYDROXYETHYL-3,4- 28
METHYLENEDIOXYANILINE.
IBUPROFEN. 101,104
IODINE
a) more than 20 per cent. 1,4,8
b) in preparations for human internal

therapeutic use containing 300 91,92
micrograms or more of iodine per
recommended daily dose.
IPRATROPIUM BROMIDE in metered aerosols. 32
ISOCYANATES (free organic)
a) when in paint. 28,52 1,5,8,10,27
b) other than in paint. 28,52 1,4,8
ISOEUGENOL. 19, 28, 79 1, 4
ISOPRENALINE in metered aerosols. 32

APPENDIX F
ISOTRETINOIN
a) for human oral use. 7,62,76
LEAD COMPOUNDS
a) in hair cosmetics. 25
b) when in Schedule 6. 1,4,8
LEFLUNOMIDE. 7,62,87
LEMON OIL. 89
LENALIDOMIDE. 7,62,76
LEVOCABASTINE
a) in eye or nasal preparations containing

0.5 mg/mL or less of levocabastine. 62
b) in other preparations. 62 and either 39 or

40
LIME OIL. 89
LOPERAMIDE when in Schedule 2. 41
MAGNESIUM CHLORATE. 1,4
MEFENAMIC ACID. 101,104

APPENDIX F
MERCAPTOACETIC ACID. 5, 28 1, 31
MERCURIC THIOCYANATE. 1,4
METACRESOLSULPHONIC ACID and 1,4

formaldehyde condensation product for the
METHANOL except in methylated spirit. 1,4,8
METHOXAMINE in nasal preparations for topical 29

use.
2-METHOXYETHANOL. 77 1,4,8
METHYLATED SPIRIT(S) when packed and 80

labelled as a 'biofuel' suitable for use in 'spirit
burners'.
p-METHYLAMINOPHENOL. 28
METHYL CHLORIDE. 1,4,8
METHYL ETHYL KETONE. 5 1,4,8
METHYL ETHYL KETONE OXIME. 5,28 1,4
METHYL ETHYL KETONE PEROXIDE. 2 2,3,4,6
METHYL ISOAMYL KETONE. 1,4,8
METHYL ISOBUTYL KETONE. 1,4,8
METHYL ISOTHIOCYANATE. 5,12 1,4,8

APPENDIX F
METHYL METHACRYLATE. 28 4,9,23
METHYLCHLOROISOTHIAZOLINONE. 28
METHYLDIBROMO GLUTARONITRILE. 28 1,4,7
METHYLENE BISTHIOCYANATE. 1,4
METHYLEUGENOL. 1,6
METHYLISOTHIAZOLINONE. 28
METHYLNORBORNYLPYRIDINE. 59
2-METHYLRESORCINOL. 1
1-(BETA-METHYL SULPHONAMIDOETHYL)- 1,4,8

2-AMINO-3-N,N-DIETHYLAMINOBENZENE.
MICONAZOLE in vaginal preparations when 54,63,64,66

MISOPROSTOL. 53
MONOETHANOLAMINE when included in 5 1,4

Schedule 5.
MONOETHANOLAMINE when included in 2,11,18 1,4,8

Schedule 6.
NAPHAZOLINE in nasal preparations for topical 29

use.
NAPHTHALENE

APPENDIX F
a) in block, ball, disc, pellet or flake form,

enclosed in a device which, in normal 9,105
use, prevents removal or ingestion of its
contents.
b) in other forms. 9,105 1
1,5-NAPHTHALENEDIOL. 28 1
2,7-NAPHTHALENEDIOL. 28 1,3
1-NAPHTHOL. 28 1
NAPROXEN. 101,104
NICOTINE except when in tobacco. 1,4
NITRIC ACID
a) 75 per cent or less HNO3. 2 1,4
b) more than 75 per cent HNO3. 2 1,4,8
NITROBENZENE. 1,4,8
3-NITRO-p-HYDROXYETHYLAMINOPHENOL. 28
NITROPHENOLS. 1,4
NITROPRUSSIDES in aerosols. 84 8
NIZATIDINE when included in Schedule 2. 96
NORADRENALINE in metered aerosols. 32

APPENDIX F
NYSTATIN in vaginal preparations when included 54,63,64,65,66

in Schedule 3.
ORANGE OIL (bitter). 89
ORCIPRENALINE in metered aerosols. 32
OXALATES, metallic. 4,8
OXALIC ACID. 2 4,8
OXYMETAZOLINE in nasal preparations for 29

topical use.
OXYQUINOLINE (including salts and derivatives) 33

when prepared for internal use.
PAINT
a) First Group paints. 83
b) Second Group paints. 84
PARACETAMOL. 97 and/or 98,99,100
PENTACHLOROPHENOL. 1,4,8
PERACETIC ACID. 2 1,4,8
PERMANGANATES. 2 24
2-PHENOXYETHANOL. 5 1

APPENDIX F
PHENOL and any other homologue of phenol. 1,4
PHENOL when included in Schedule 6 3, 51 2, 4, 8
PHENOLS. 5
PHENOXYMETHYL OXIRANE. 12, 28, 51 1, 3, 4, 5, 7, 8,

9
PHENYLENEDIAMINES including alkylated,

arylated, halogenated and nitro derivatives
a) in hair dyes. 21
b) in preparations other than hair dyes. 28 1,4,8
PHENYL METHYL PYRAZOLONE. 28 4
PHENYLEPHRINE in nasal preparations for 29

topical use.
POMALIDOMIDE. 7, 62, 76
N,N-BIS(PHENYLMETHYLENE)-BICYCLO- 5,28 1,4,5,10

o-PHENYLPHENOL except when in antiseptics. 1,4
PHENYLPROPANOLAMINE. 56
PHENYTOIN in pastes for the treatment of horses. 9
PHOSPHONIC ACID. 1,4

APPENDIX F
PHOSPHORIC ACID 1,4
PHOSPHORUS (yellow). 2 1,4
o-PHTHALADEHYDE
a) when included in Schedule 5. 51,52,59 1,4,5,8,10
b) when included in Schedule 6. 51,52,59 2,4,5,8,10
PICRIC ACID (more than 20 per cent). 1,4
PODOPHYLLIN
a) in preparations specifically for use on

anal or genital area. 36
b) in other liquid preparations when

included in Schedule 2 or Schedule 3. 31
c) in other solid or semi-solid preparations

when included in Schedule 2. 30
PODOPHYLLOTOXIN
a) in preparations specifically for use on

anal or genital area. 36
b) in other liquid preparations when

included in Schedule 2 or Schedule 3. 31
c) in other solid or semi-solid preparations

when included in Schedule 2. 30
POLIHEXANIDE. 28 1,4,8
POLYETHANOXY (15) TALLOW AMINE. 1,4

APPENDIX F
POLY(OXY-1,2-ETHANEDIYL), Α -[2-[(2- 5,88 1,5

HYDROXYETHYL)AMINO] -2-OXOETHYL]- Α
-HYDROXY-,MONO-C13-15 -ALKYL ETHERS
POTASSIUM HYDROXIDE
a) in preparations containing 0.5 per cent or

less of potassium hydroxide. 5 1,4,6
b) in solid preparations containing more

than 0.5 per cent of potassium hydroxide. 2,10,78 3,5,28
c) in liquid preparations containing more

than 0.5 per cent of potassium hydroxide. 2,10,78 3,5
POTASSIUM PERSULFATE. 5,21,25 1,5,23,33,34
POTASSIUM SULFIDE. 2 1,4
PROPIONIC ACID when in Schedule 6. 2 1,4
n-PROPYL ALCOHOL. 5 1, 9
QUININE. 28
QUINOLINE. 79 1, 4
RANITIDINE when included in Schedule 2. 96
RESORCINOL. 19,28,79 1,3,4
ROSIN. 108 37
SAFROLE
a) in preparations for therapeutic use. 1

APPENDIX F
b) other than for therapeutic use. 1,4
SALBUTAMOL in metered aerosols or in dry 32

powder formulations.
SALICYLAMIDE. 34 or 35
SASSAFRAS OIL
a) in preparations for therapeutic use. 1
b) other than for therapeutic use. 1,4
SELENIUM COMPOUNDS except when for 1,4,8

therapeutic use (human or animal).
SLIVER in smoking deterrents. 42
SITAXENTAN. 7,62,76
SODIUM ALUMINATE. 2 1,4
SODIUM CHLORATE. 1,4
SODIUM DODECYLBENZENE SULFONATE. 79 1
SODIUM FLUORIDE in preparations for human 43

ingestion when in Schedule 2.
SODIUM HYDROGEN SULFATE. 1,4,8
SODIUM HYDROSULFITE (more than 50 per 5,26 1,4,8

cent).

APPENDIX F
SODIUM HYDROXIDE
a) in preparations containing 0.5 per cent or

less of sodium hydroxide. 5 1,4,6
b) in solid preparations containing more

than 0.5 per cent of sodium hydroxide. 2,10,78 3,5,28
c) in liquid preparations containing more

than 0.5 per cent of sodium hydroxide. 2,10,78 3,5
SODIUM LAURETH-6 CARBOXYLATE. 79 1
SODIUM METABISULPHITE (more than 50 per 5,26 1,4

cent).
SODIUM NITRITE in pickling or curing salts. 94
SODIUM PERSULFATE. 5,21,25 1,5,23,33,34
SODIUM SULFIDE. 2 1,4
STYRENE. 1,4,8
SULFAMIC ACID. 2 1,4
SULFURIC ACID. 2 1,4
SYMPHYTUM SPP. (Comfrey) when included in 31,32

Schedule 5.
TAZAROTENE for topical use. 77,62
TERBUTALINE in metered aerosols or in dry 32

powder formulations.

APPENDIX F
TERFENADINE. 61
TERIFLUNOMIDE. 7,62,87
TERPENES, chlorinated. 1,4,8
TETRACHLOROETHANE. 12 8
TETRACHLOROETHYLENE when in Schedule 5 12,16 1,4,8,11

or 6.
TETRYZOLINE in nasal preparations for topical 29

use.
THALIDOMIDE. 7,62,76
THIOUREA. 1,4
TOLUENE. 1,4,8
TOLUENEDIAMINES
a) in hair dyes. 21
b) in preparations other than hair dyes. 1,4,8
TRAMAZOLINE in nasal preparations for topical 29

use.
TRETINOIN
a) for human oral use. 7,62,76

APPENDIX F
TRIAMCINOLONE when in topical preparations 64 or 68

for the treatment of mouth ulcers..
TRICHLOROACETIC ACID except when for 2 1,4

therapeutic use.
1,1,1-TRICHLOROETHANE. 8,9
TRICHLOROETHYLENE except when for 12 1,4,5,8,9

therapeutic use.
TRICHLOROPHENOL. 1,4,8
TRIETHYL PHOSPHATE. 1,4,8
TRIFLUOROMETHANESULFONIC ACID
a) more than 10 per cent. 1,17 1,4,8
b) 10 per cent or less. 1,4,8
TRIISOPROPANOLAMINE LAURYL ETHER 1,4,6

SULFATE.
3,6,9-TRIOXAUNDECANEDIOIC ACID. 5 1
TROLAMINE. 5 1,4
TYMAZOLINE in nasal preparations for topical 29

use.
VINCLOZOLIN. 46

APPENDIX F
VINYL ACETATE MONOMER. 11 8, 9
XYLENE. 1,4,8
XYLOMETAZOLINE in nasal preparations for 29

topical use.
ZINC CHLORIDE. 1,4
ZINC LACTATE. 107
ZINC SULFATE when in Schedule 6. 1,4

APPENDIX G
APPENDIX G – DILUTE PREPARATIONS

The requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix
at a concentration not more than that specified in Column 2 in respect of that poison.
Column 1 Column 2
Poison Concentration (quantity per litre or

kilogram)
ACETYLCHOLINE 1 mg
ALDOSTERONE 10 micrograms
ANTIMONY COMPOUNDS 1 mg
APOMORPHINE 1 mg
ARSENIC 1 mg
ATROPA BELLADONNA (belladonna) 300 micrograms
ATROPINE 300 micrograms
CANTHARIDIN 10 micrograms
CHLORINE 5 mg
CROTON TIGLIUM (croton oil) 1 mg
DIOXANE 100 mg
EPIDERMAL GROWTH FACTOR 2 mg

APPENDIX G
ERYSIMUM spp. 1 mg
ESTRADIOL 10 micrograms
ESTRONE 100 micrograms
FOLLICLE-STIMULATING HORMONE 100 micrograms
GELSEMIUM SEMPERVIRENS 1 mg
GLUCAGON 100 micrograms
GLYCERYL TRINITRATE 100 micrograms
GROWTH HORMONE 10 micrograms
HALOPERIDOL 1 mg
HYDROCYANIC ACID 1 microgram
HYOSCINE 300 micrograms
HYOSCYAMINE 300 micrograms
HYOSCYAMUS NIGER 300 micrograms
HYPOTHALAMIC RELEASING FACTORS 10 micrograms
INDOMETACIN 1 mg
MERCURY 1 mg

APPENDIX G
METHYLMERCURY 300 micrograms
NAPHTHALENE 1 mg
NERIUM OLEANDER 1 mg
OXYTOCIN 1 microgram
PHOSPHORUS 1 mg
PODOPHYLLUM RESIN (podophyllin) 1 mg
PROGESTERONE 1 mg
PROPRANOLOL 1 mg
SELENIUM 100 micrograms
STROPHANTHUS spp. 1 mg
STRYCHNINE 1 mg
TESTOSTERONE 1 mg
THYROXINE 10 micrograms

APPENDIX H
APPENDIX H – SCHEDULE 3 POISONS PERMITTED TO BE

ADVERTISED
ADRENALINE.
ASTODRIMER SODIUM for the treatment and relief of bacterial vaginosis.
BUTOCONAZOLE.
CICLOPIROX.
CLOBETASONE.
CLOTRIMAZOLE.
DICLOFENAC.
DIMENHYDRINATE for the prevention and relief of motion sickness.
DIPHENOXYLATE.
ECONAZOLE.
ELETRIPTAN.
ESOMEPRAZOLE.
FAMCICLOVIR.
FLUCONAZOLE.
FLUORIDES.

APPENDIX H
GLUCAGON.
GLYCERYL TRINITRATE.
HYDROCORTISONE.
HYOSCINE BUTYLBROMIDE.
IBUPROFEN.
ISOCONAZOLE.
KETOPROFEN.
LANSOPRAZOLE.
LEVONORGESTREL.
MICONAZOLE.
NALOXONE.
NAPROXEN
NYSTATIN.
OMEPRAZOLE.
OXICONAZOLE.
PANTOPRAZOLE.

APPENDIX H
PARACETAMOL.
PODOPHYLLOTOXIN.
PODOPHYLLUM EMODI (podophyllin).
PODOPHYLLUM PELTATUM (podophyllin).
RABEPRAZOLE.
RIZATRIPTAN.
SALICYLIC ACID.
SUMATRIPTAN.
TIOCONAZOLE.
TRIAMCINOLONE.
ULIPRISTAL for emergency post-coital contraception.
VITAMIN D.
ZOLMITRIPTAN.

APPENDIX I
APPENDIX I
This Appendix is intentionally blank

APPENDIX J
APPENDIX J – SCHEDULE 7 POISONS REQUIRING

ADDITIONAL CONTROLS ON AVAILABILITY AND USE
PART 1 – AUTHORISATION CONSIDERATIONS FOR AVAILABILITY AND USE
All poisons included in this Appendix are not to be available except to authorised or licensed
persons.
The use of a poison may be restricted for a particular purpose. Controls recommended for the
Schedule 7 poisons listed in the table below may be implemented through poisons controls or
other State or Territory legislation.
Authorisation considerations
a Poisons marked with ‘a’ are restricted to analytical or research purposes only.
p Poisons marked with ‘p’ have been identified as representing a significant risk to public
health. Additional restrictions on their possession and use must be applied through an
authorisation or licensing process which includes a case by case assessment of risks to
public health.
PART 2
A poison listed in this Appendix is to be available in accordance with the authorisations

considerations specified beside it in the “Authorisation Considerations” column.
POISONS AUTHORISATION
CONSIDERATIONS
ABAMECTIN
ACIBENZOLAR-S-METHYL
ACROLEIN
ACRYLONITRILE
ALACHLOR a

APPENDIX J
ALLYL ALCOHOL
4-AMINOPROPIOPHENONE p
4-AMINOPYRIDINE
ARPRINOCID a
ARSENIC p
AZOCYCLOTIN a
BENZENE
BIFLUORIDE
BORON TRIFLUORIDE
BRODIFACOUM
BROMADIOLONE
BROMINE
BRUCINE
CALCIFEROL
CAPTAFOL a
CARBADOX

APPENDIX J
CARBON TETRACHLORIDE
CARBONYL SULFIDE
CHLORDECONE a
CHLORDIMEFORM a
CHLORINE
CHLOROMETHIURON a
CHLOROPICRIN
4-CHLORO-o-TOLUIDINE a
COLECALCIFEROL
COUMATETRALYL
CYANOGEN
CYHEXATIN a
4,4-DIAMINODIPHENYLMETHANE
1,2-DIBROMO-3-CHLOROPROPANE a
1,3-DICHLOROPROPENE
DIFENACOUM

APPENDIX J
4-DIMETHYLAMINOAZOBENZENE a
DINITROCRESOLS a
DINITROPHENOLS a
DINOSEB a
EPICHLOROHYDRIN
EPIDERMAL GROWTH FACTOR
ETACONAZOLE a
ETHYLENE DIBROMIDE a
ETHYLENE OXIDE
FLUOROACETAMIDE p
FLUOROACETIC ACID p
FOLPET
HALOFUGINONE
HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS a
HCB a
HYDROCYANIC ACID AND CYANIDES p

APPENDIX J
HYDROFLUORIC ACID
IODOMETHANE
MADURAMICIN
MERCURY
METHACRIFOS
METHOXYETHYLMERCURIC ACETATE a
METHOXYETHYLMERCURIC CHLORIDE
METHYL BROMIDE
4,4’-METHYLENEBIS[2-CHLOROANILINE]
MIREX a
MOLINATE
NICOTINE
NITROFEN a
PHENYLMERCURIC ACETATE
PHOSPHIDE, metallic

APPENDIX J
PHOSPHINE
PROPYLENE OXIDE
PYRINURON a
STRYCHNINE p
SULCOFURON a
TETRACHLOROETHANE
2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE
THALLIUM p
o-TOLIDINE
VINYL CHLORIDE

APPENDIX K
APPENDIX K – DRUGS REQUIRED TO BE LABELLED WITH A

SEDATION WARNING
(see Part 2, Section 1.5.6)
ALIMEMAZINE
ALPRAZOLAM
AMISULPRIDE
AMITRIPTYLINE
AMOBARBITAL
ARIPIPRAZOLE
ASENAPINE
AZATADINE
BACLOFEN
BENZATROPINE
BREXPIPRAZOLE
BRIVARACETAM
BROMAZEPAM
BROMPHENIRAMINE

APPENDIX K
BUCLIZINE
BUPRENORPHINE
BUTOBARBITAL
CANNABIS except cannabidiol when included in Schedule 4 or Schedule 3
CETIRIZINE
CHLORAL HYDRATE
CHLORDIAZEPOXIDE
CHLORMETHIAZOLE
CHLORPHENAMINE
CHLORPROMAZINE
CLEMASTINE
CLOMIPRAMINE
CLONAZEPAM
CLONIDINE
CLORAZEPATE
CLOZAPINE

APPENDIX K
CODEINE.
CYCLIZINE
CYCLOBARBITAL
CYCLOSERINE
CYPROHEPTADINE
DANTROLENE
DESIPRAMINE
DEXCHLORPHENAMINE
DEXTROMORAMIDE
DEXTROPROPOXYPHENE
DIAZEPAM
DIFENOXIN
DIHYDROCODEINE
DIMENHYDRINATE
DIMETHINDENE
DIPHENHYDRAMINE

APPENDIX K
DIPHENOXYLATE
DIPHENYLPYRALINE
DOSULEPIN
DOXEPIN
DOXYLAMINE
DRONABINOL (delta-9-TETRAHYDROCANNABINOL)
DROPERIDOL
DULOXETINE
ETHYLMORPHINE
FENFLURAMINE
FENTANYL
FLUNITRAZEPAM
FLUPENTIXOL
FLUPHENAZINE
FLURAZEPAM
GABAPENTIN

APPENDIX K
GEMCITABINE
GLUTETHIMIDE
GUANFACINE
HALOPERIDOL
HYDROCODONE
HYDROMORPHONE
HYDROXYZINE
IMIPRAMINE
LAMOTRIGINE
LEVETIRACETAM
LEVOCABASTINE
LEVOCETIRIZINE
LORAZEPAM
LURASIDONE.
MAZINDOL
MEBHYDROLIN

APPENDIX K
MECLOZINE
MEDAZEPAM
MEPROBAMATE
MEPYRAMINE
MERCAPTAMINE
METHADONE
METHDILAZINE
METHOCARBAMOL
METHYLPHENOBARBITAL
MIANSERIN
MIDAZOLAM
MIRTAZAPINE
MORPHINE
NABIXIMOLS .
NALBUPHINE
NITRAZEPAM

APPENDIX K
NORMETHADONE
NORTRIPTYLINE
OLANZAPINE
OPIUM in any form except the alkaloids noscapine and papaverine.
OXAZEPAM
OXYCODONE
PALIPERIDONE
PAPAVERETUM
PENTAZOCINE
PENTOBARBITAL
PERAMPANEL
PERICIAZINE
PERPHENAZINE
PETHIDINE
PHENELZINE
PHENIRAMINE

APPENDIX K
PHENOBARBITAL
PHENOPERIDINE
PHENYLTOLOXAMINE
PHOLCODINE
PIMOZIDE
PIZOTIFEN
PRAZEPAM
PREGABALIN
PROCHLORPERAZINE
PROMAZINE
PROMETHAZINE
PROTRIPTYLINE
QUETIAPINE
RETIGABINE
RISANKIZUMAB
RISPERIDONE

APPENDIX K
ROTIGOTINE
RUFINAMIDE
RUPATADINE
SAFINAMIDE
SECBUTOBARBITAL
SECOBARBITAL
SELETRACETAM
SODIUM OXYBATE
STIRIPENTOL
SUVOREXANT
TAPENTADOL
TEMAZEPAM
TETRAHYDROCANNABINOLS except cannabidiol when included in Schedule 4 or Schedule

3
THENYLDIAMINE
THIETHYLPERAZINE
THIOPROPAZATE

APPENDIX K
THIORIDAZINE
THIOTHIXENE
TRAMADOL
TRANYLCYPROMINE
TRIFLUOPERAZINE
TRIMIPRAMINE
TRIPROLIDINE
ZIPRASIDONE
ZOLPIDEM
ZONISAMIDE
ZOPICLONE

APPENDIX L
APPENDIX L – REQUIREMENTS FOR DISPENSING LABELS

FOR HUMAN AND VETERINARY MEDICINES
PART 1 – GENERAL REQUIREMENTS FOR DISPENSING LABELS
(see Part 2, Controls on Medicines and Poisons Section 1.5.6(1)(a))
(1) All details, words and other required information on a label on a container of a substance for
therapeutic use must be in the English language in letters at least 1.5 millimetres in height.
(2) All symbols, numbers and words on a label must be in durable characters.
(3) The label on a container of a substance for therapeutic use must contain the following
details:
a) the name, address and telephone number of the dispenser supplying the substance;
b) the approved name of the substance and/or its proprietary name (unless it is a
preparation compounded in accordance with the dispenser’s own formula);
c) adequate directions for use;
d) the strength and form of the substance;
e) the total quantity of the goods in the container;
f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;
g) if the substance is intended for external use only, the word “POISON”, or the words
“FOR EXTERNAL USE ONLY”, in red on a white background;
h) if the substance is a medicine, the name of the person for whom it was dispensed; and
i) if the substance is a veterinary chemical, the species of animal, the name of the
animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.
(4) The label on a container of a medicine or veterinary chemical that is supplied on prescription
must also include:
a) the prescription reference number;

b) the date on which the prescription was supplied (unless that date is clear from the
prescription reference number); and
c) the directions for use set out in the prescription.
PART 2 - ADDITIONAL LABELLING REQUIREMENTS FOR CERTAIN HUMAN

MEDICINES
(see Part 2, Controls on Medicines and Poisons Section 1.5.6(1)(a))
Medicines required to be labelled with certain warning statements A substance listed in Column
1 of the following table must be labelled with the warning statement in Appendix F, Part 1, as
specified opposite in Column 2.

APPENDIX L
Column 1 Column 2
Substance Warning statement
ACITRETIN:
(i) for oral use. 7,62 and 76
(ii) for topical use. 62 and 77
ADAPALENE:
(i) for oral use. 7, 62 and 76
AMBRISENTAN. 7, 62 and 76
BEXAROTENE:
BOSENTAN. 7, 62 and 76
DIENESTROL. 67
ETRETINATE:

APPENDIX L
ENZALUTAMIDE. 7, 67 and 87
FINGOLIMOD. 76
ISAVUCONAZOLE. 53
ISOTRETINOIN:
LEFLUNOMIDE. 7, 62 and 87
LENALIDOMIDE:
LEVOCABASTINE. 62
MACITENTAN. 7, 62 and 76
MISOPROSTOL. 53
PLITIDEPSIN. 7, 62, 63, 76 and 87
POMALIDOMIDE. 7,62 and 76
RIOCIGUAT. 7, 62 and 76

APPENDIX L
RUFINAMIDE. 62, 76, 77
SAFINAMIDE. 62, 76, 77
SITAXENTAN. 7, 62 and 76
TERIFLUOMIDE. 7, 62 and 87
THALIDOMIDE:
TRETINOIN:

APPENDIX M
APPENDIX M – ADDITIONAL CONTROLS OR SUPPLY

REQUIREMENTS FOR POISONS INCLUDED IN SCHEDULE 3 TO
ALLOW THEM TO BE PROVIDED BY A PHARMACIST

INDEX
INDEX
A
ABACAVIR
Schedule 4
ABAMECTIN
Schedule 7
Schedule 6
Schedule 5
Appendix J, Part 2
ABATACEPT
Schedule 4
ABCIXIMAB
Schedule 4
ABEMACICLIB
Schedule 4
ABIRATERONE ACETATE
Schedule 4
ABRUS PRECATORIUS
cross reference: JEQUIRITY
Schedule 10
ABSCISIC ACID
Schedule 5
ACALABRUTINIB
Schedule 4
ACAMPROSATE CALCIUM
Schedule 4
ACARBOSE

INDEX
Schedule 4
ACEBUTOLOL
Schedule 4
ACEPHATE
Schedule 6
ACEPROMAZINE
Schedule 4
ACEQUINOCYL
Schedule 5
ACETAMIPRID
Schedule 6
ACETANILIDE
cross reference: ALKYL ACETANILIDES
Schedule 4
ACETARSOL
Schedule 4
ACETAZOLAMIDE
Schedule 4
ACETIC ACID
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
ACETIC ANHYDRIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ACETOHEXAMIDE

INDEX
Schedule 4
ACETONE
cross reference: DESIGNATED SOLVENT
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Part 1 – Interpretation
ACETORPHINE
Schedule 9
ACETYL-ALPHA-METHYLFENTANYL
Schedule 9
ACETYLCARBROMAL
Schedule 4
ACETYLCHOLINE
Schedule 4
Appendix G
ACETYLCYSTEINE
Schedule 4
Schedule 2
ACETYLDIGITOXIN
Schedule 4
ACETYLDIHYDROCODEINE
Schedule 8
ACETYL ISOVALERYLTYLOSIN
Schedule 4
ACETYLMETHADOL
Schedule 8
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE
Schedule 4

INDEX
ACETYLMORPHINES
Schedule 8
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE
Appendix B, Part 3
ACETYLSTROPHANTHIDIN
Schedule 4
ACIBENZOLAR-S-METHYL
Schedule 7
Appendix J, Part 2
ACICLOVIR
Schedule 4
ACIFLUORFEN
Schedule 6
ACINITRAZOLE
Schedule 6
ACIPIMOX
Schedule 4
ACITRETIN
Schedule 4
Appendix D, Item 2
Appendix F, Part 3
Appendix L, Part 2
ACLIDINIUM BROMIDE
Schedule 4
ACLONIFEN
Schedule 6
ACOKANTHERA OUABAIO
Schedule 4

INDEX
ACOKANTHERA SCHIMPERI
Schedule 4
ACONITUM spp.
Schedule 4
Schedule 2
ACORUS CALAMUS
cross reference: CALAMUS
Schedule 10
ACRIFLAVINE
cross reference: ACRIFLAVINIUM CHLORIDE
ACRIFLAVINUM CHLORIDE
Schedule 7
Schedule 5
ACRIVASTINE
Schedule 4
ACROLEIN
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
ACRYLONITRILE
Schedule 7
Appendix J, Part 2
ADALIMUMAB
Schedule 4
ADAPALENE
Schedule 4
Appendix F, Part 3
Appendix L, Part 2
ADEFOVIR
Schedule 4

INDEX
ADENOSINE
Schedule 4
ADIPHENINE
Schedule 4
ADONIS VERNALIS
Schedule 4
ADRAFINIL
Schedule 4
ADRENALINE
Schedule 4
Schedule 3
Appendix H
ADRENOCORTICAL HORMONES
Schedule 4
AFAMELANOTIDE
cross reference: MELANOCYTE STIMULATING HORMONE
Schedule 4
AFATINIB DIMALEATE
Schedule 4
AFIDOPYROPEN
Appendix B, Part 3
AFLIBERCEPT
Schedule 4
AFOXOLANER
Schedule 5
AGALSIDASE
Schedule 4

INDEX
AGLEPRISTONE
Schedule 4
AGOMELATINE
Schedule 4
AKLOMIDE
Schedule 5
ALACHLOR
Schedule 7
Appendix J, Part 2
ALANYLGLUTAMINE
Schedule 4
ALATROFLOXACIN MESILATE
cross reference: ALATROFLOXACIN MESYLATE
Schedule 4
ALBENDAZOLE
Schedule 6
Schedule 5
Schedule 4
ALCLOFENAC
Schedule 4
ALCLOMETASONE
Schedule 4
Schedule 3
Appendix F, Part 3
ALCOHOL, DEHYDRATED
Appendix B, Part 3
ALCURONIUM
Schedule 4

INDEX
ALDESLEUKIN
Schedule 4
ALDICARB
Schedule 7
ALDOSTERONE
Schedule 4
Appendix G
ALDOXYCARB
Schedule 7
ALDRIN
Schedule 6
ALECTINIB
Schedule 4
ALEFACEPT
Schedule 4
Appendix D, Item 7
ALEMTUZUMAB
Schedule 4
ALENDRONIC ACID
Schedule 4
ALFACALCIDOL
Schedule 4
ALFENTANIL
Schedule 8
ALFUZOSIN
Schedule 4
ALGICIDES

INDEX
Appendix A
ALGLUCERASE
Schedule 4
ALGLUCOSIDASE
Schedule 4
ALIMEMAZINE
cross reference: TRIMEPRAZINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
ALIROCUMAB
Schedule 4
ALISKIREN
Schedule 4
ALKALINE SALTS
cross reference: LYE WATER, POTASSIUM CARBONATE. POTASSIUM PHOSPHATE,
POTASSIUM SALTS, POTASSIUM SILICATE, SODIUM CARBONATE, SODIUM SALTS,
SODIUM SILICATE(S)
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
ALKOXYAMFETAMINES
cross reference: ALKOXYAMPHETAMINES
Schedule 9
ALKOXYLATED FATTY ALKYLAMINE POLYMER
Schedule 6
Schedule 5
ALKOXYPHENYLETHYLAMINES
Schedule 9

INDEX
ALKYLAMINES WITH STIMULANT PROPERTIES

cross reference: 1,3-dimethylbutylamine, DMBA, octodrine, 1-aminoisoheptane, DMHA, 1,5-
dimethylhexylamine, 4-methylhexane-2-amine, 1,3-dimethylamylamine, DMAA, 4-amino-2-
methylpentane citrate (AMP citrate), 1,4-dimethylpentylamine, DMPA, 1,4-
dimethylamylamine, DMAA.
Schedule 10
ALKYL NITRITES
Schedule 4
Appendix E, Part 2
ALKYLTHIOAMFETAMINES
cross reference: ALKYLTHIOAMPHETAMINES
Schedule 9
ALLERGENS
Schedule 4
ALLETHRIN
Schedule 6
Schedule 5
ALLOPURINOL
Schedule 4
ALLOXYDIM
Schedule 5
ALLYL ALCOHOL
Schedule 7
Appendix J, Part 2
ALLYL CYCLOHEXANEACETATE (CAS No. 4728-82-9)
Schedule 6
ALLYL CYCLOHEXANEPROPIONATE (CAS No. 2705-87-5)
Schedule 6
ALLYL ESTERS (excluding derivatives)
Schedule 6

INDEX
ALLYLESTRENOL
cross reference: ALLYLOESTRENOL
Schedule 4
ALLYL HEPTANOATE/ALLYL HEPTYLATE (CAS No. 142-19-8)
Schedule 6
ALLYL HEXANOATE (CAS No. 123-68-2)
Schedule 6
ALLYLISOPROPYLACETYLUREA
Schedule 10
ALLYL ISOVALERATE (CAS No. 2835-39-4)
Schedule 6
ALLYL NONANOATE (CAS No. 7493-72-3)
Schedule 6
ALLYL OCTANOATE (CAS No. 4230-97-1)
Schedule 6
ALLYLOESTRENOL
cross reference: ALLYLESTRENOL
ALLYL PHENYLACETATE (CAS No. 1797-74-6)
Schedule 6
ALLYLPRODINE
Schedule 10
ALLYL TRIMETHYLHEXANOATE (CAS No. 68132-80-9)
Schedule 6
ALOGLIPTIN
Schedule 4
ALOSETRON
Schedule 4

INDEX
ALOXIPRIN
Schedule 2
ALPELISIB
Schedule 4
ALPHACETYLMETHADOL
Schedule 8
ALPHA-CHLOROHYDRIN
Schedule 6
Appendix F, Part 3
ALPHA-CYPERMETHRIN
Schedule 7
Schedule 6
Schedule 5
ALPHADOLONE
Schedule 4
ALPHAMEPRODINE
Schedule 9
ALPHAMETHADOL
Schedule 9
ALPHA-METHYLFENTANYL
Schedule 9
ALPHA-METHYLTHIOFENTANYL
Schedule 9
ALPHAPRODINE
Schedule 8
ALPHA-PYRROLIDINOVALEROPHENONE *(ALPHA-PVP).
Schedule 9

INDEX
ALPHA1-PROTEINASE INHIBITOR (HUMAN)
Schedule 4
ALPHAXALONE
Schedule 4
ALPRAZOLAM
Schedule 8
Appendix D, Item 5 (Benzodiazepine group entry)
Appendix K
ALPRENOLOL
Schedule 4
ALPROSTADIL
Schedule 4
ALSEROXYLON
Schedule 4
ALTEPLASE
Schedule 4
ALTRENOGEST
Schedule 4
ALTRETAMINE
cross reference: HEXAMETHYLMELAMINE
Schedule 4
ALUM
Appendix B, Part 3
ALUMINIUM AMMONIUM SULFATE
Appendix B, Part 3
ALUMINIUM POTASSIUM SULFATE
Appendix B, Part 3

INDEX
ALUMINIUM SILICATE
Appendix B, Part 3
ALUMINIUM tris (ETHYLPHOSPHONATE)
Appendix B, Part 3
AMANTADINE
Schedule 4
AMBENONIUM CHLORIDE
Schedule 4
AMBRISENTAN
Schedule 4
Appendix D, Item 6
Appendix F, Part 3
Appendix L, Part 2
AMBUCETAMIDE
Schedule 4
AMBUTONIUM BROMIDE
Schedule 4
AMCINONIDE
Schedule 4
AMETOCTRADIN
Appendix B, Part 3
AMETRYN
Schedule 5
AMICARBAZONE
Schedule 6
AMIDITHION
Schedule 6

INDEX
AMIDOPROPYL BETAINES
Schedule 6
Appendix E, Part 2
AMIFOSTINE
Schedule 4
AMIKACIN
Schedule 4
AMILORIDE
Schedule 4
AMINACRINE
cross reference: AMINOACRIDINE
AMINES
cross reference: CURING AGENTS FOR EPOXY RESINS
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
AMINOACRIDINE
cross reference: AMINACRINE
Schedule 7
Schedule 5
AMINOCAPROIC ACID
Schedule 4
AMINOCARB
Schedule 7
Schedule 6
2-AMINO-6-CHLORO-4-NITROPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
4-AMINO-m-CRESOL

INDEX
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
5-AMINO-o-CRESOL
cross reference: 4-AMINO-2-HYDROXYTOLUENE
AMINOCYCLOPYRACHLOR
Schedule 5
2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE
cross reference: DOM, STP
Schedule 9
AMINOETHOXYVINYLGLYCINE
Schedule 6
2-AMINO-5-ETHYLPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AMINOGLUTETHIMIDE
Schedule 4
4-AMINO-2-HYDROXYTOLUENE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
5-AMINOLEVULINIC ACID
Schedule 4
1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE
Schedule 6
2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL
cross reference: HC VIOLET 1
AMINOMETRADINE
Schedule 4

INDEX
4-AMINO-3-NITROPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL
cross reference: HC RED 13
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AMINOPHENAZONE
cross reference: AMIDOPYRINE
Schedule 10
Schedule 4
m-AMINOPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
p-AMINOPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AMINOPHYLLINE
Schedule 4
Schedule 3
4-AMINOPROPIOPHENONE
cross reference: PARA-AMINOPROPIOPHENONE (PAPP)
Schedule 7
Appendix J, Part 2
5-(2-AMINOPROPYL)INDAN
Schedule 9
AMINOPTERIN
Schedule 4
AMINOPYRALID

INDEX
Schedule 6
Schedule 5
4-AMINOPYRIDINE
cross reference: FAMPRIDINE
Schedule 7
Schedule 4
Appendix E, Part 2
Appendix J, Part 2
AMINOREX
Schedule 4
AMINOSALICYLIC ACID
Schedule 4
AMIODARONE
Schedule 4
AMIPHENAZOLE
Schedule 4
AMISOMETRADINE
Schedule 4
AMISULBROM
Schedule 5
AMISULPRIDE
Schedule 4
Appendix K
AMITON
Schedule 7
AMITRAZ
Schedule 6
AMITRIPTYLINE

INDEX
Schedule 4
Appendix K
AMITROLE
Schedule 5
AMLODIPINE
Schedule 4
AMMI VISNAGA
Schedule 4
AMMONIA
cross reference: AMMONIUM HYDROXIDE, CHROMATES
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
AMMONIUM BROMIDE
Schedule 4
AMMONIUM COCOYL ISETHIONATE
Schedule 6
Appendix E, Part 2
AMMONIUM PERSULFATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AMMONIUM PHOSPHATE
Appendix B, Part 3
AMMONIUM THIOCYANATE
Schedule 5
Appendix E, Part 2
AMMONIUM THIOSULPHATE
Appendix B, Part 3

INDEX
AMOBARBITAL
Schedule 8
Schedule 4
Appendix K
AMODIAQUINE
Schedule 4
AMOROLFINE
Schedule 4
Schedule 2
AMOXAPINE
Schedule 4
AMOXICILLIN
Schedule 4
AMOXYCILLIN
cross reference: AMOXICILLIN
AMFETAMINE
cross reference: AMPHETAMINE
Schedule 8
AMPHOMYCIN
Schedule 4
AMPHOTERICIN
cross reference: AMPHOTERICIN B
AMPHOTERICIN B
Schedule 4
AMPICILLIN
Schedule 4
AMPRENAVIR
Schedule 4
AMPROLIUM

INDEX
Appendix B, Part 3
AMRINONE
Schedule 4
AMSACRINE
Schedule 4
AMYGDALIN 2
Schedule 10
AMYL ACETATE
Appendix B, Part 3
AMYL NITRITE
Schedule 4
Schedule 3
Appendix E, Part 2
α-AMYLASE derived from Aspergillus niger
Appendix B, Part 3
AMYL CINNAMALDEHYDE
Appendix B, Part 3
AMYLOBARBITAL
cross reference: AMOBARBITAL
AMYLOBARBITONE
cross reference: AMOBARBITAL
AMYLOCAINE
Schedule 4
ANABOLIC STEROIDAL AGENTS

cross reference: ANDROSTERONE, STEROIDAL AGENTS
Schedule 4
Appendix D, Item 5
ANAGRELIDE
Schedule 4

INDEX
ANAKINRA
Schedule 4
ANASTROZOLE
Schedule 4
ANCESTIM
Schedule 4
ANCHUSA OFFICINALIS
Schedule 10
ANCROD
Schedule 4
ANDROGENIC STEROIDAL AGENTS

cross reference: STEROIDAL AGENTS
Schedule 4
Appendix D, Item 5
ANDROISOXAZOLE
Schedule 4
Appendix D, Item 5 (Anabolic and/or androgenic steroidal agents)
ANDROSTANOLONE
Schedule 4
ANDROSTENEDIOL
Schedule 4
ANDROSTENEDIONE
Schedule 4
ANDROSTENEDIONE ALBUMEN
Appendix B, Part 3
ANECORTAVE

INDEX
Schedule 4
ANGIOTENSIN AMIDE
Schedule 4
ANHYDRIDES, ORGANIC ACID

cross reference: CURING AGENTS FOR EPOXY RESINS
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
ANIDULAFUNGIN
Schedule 4
ANILERIDINE
Schedule 8
ANILINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ANIRACETAM
cross reference: RACETAMS
Schedule 4
ANISE OIL
Schedule 5
Appendix E, Part 2, Part 4
o-ANISIDINE
Schedule 10
ANISTREPLASE
Schedule 4
ANTAZOLINE
Schedule 4
Schedule 2

INDEX
ANTIBIOTIC SUBSTANCES
cross reference: NISIN
Schedule 4
ANTIGENS
Schedule 4
ANTIHISTAMINES
cross reference: ASTEMIZOLE, AZELASTINE, BILASTINE, DESLORATADINE,
FEXOFENADINE, LORATADINE, TERFENADINE, CETIRIZINE
Schedule 4
Appendix F, Part 3
ANTIMONY
cross reference: ANTIMONY COMPOUNDS, ANTIMONY CHLORIDE, ANTIMONY
TITANATE
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix G
ANTISERA
cross reference: IMMUNOSERA
Schedule 4
AOD-9604 (CAS No. 221231-10-3)
Schedule 4
Appendix D, Item 5
APALUTAMIDE
Schedule 4
APIXABAN
Schedule 4
APOCYNUM spp.
Schedule 4
APOMORPHINE
Schedule 4
Appendix G

INDEX
APRACLONIDINE
Schedule 4
APRAMYCIN
Schedule 4
APREMILAST
Schedule 4
APREPITANT
Schedule 4
APRONAL
Schedule 4
APROTININ
Schedule 4
ARBUTIN (ALPHA)
Cross reference: ARBUTIN (BETA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ARBUTIN (BETA)
Cross reference: ARBUTIN (ALPHA); ARBUTIN (DEOXY OR OTHER DERIVATIVES)
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
ARBUTIN (DEOXY OR OTHER DERIVATIVES)

Cross reference: ARBUTIN (ALPHA); ARBUTIN (BETA)
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ARECOLINE
Schedule 4

INDEX
ARIPIPRAZOLE
Schedule 4
Appendix K
ARISTOLOCHIA spp.
Schedule 10
ARISTOLOCHIC ACID(S)
cross reference: ASARUM spp, BRAGANTIA
Schedule 10
ARPRINOCID
Schedule 7
Appendix J, Part 2
ARMODAFINIL
Schedule 4
ARSENIC
cross reference: ARSENIC TRIOXIDE, CACODYLIC ACID, TERMITE BARRIERS,
COPPER-CHROME-ARSENIC, SELENIUM ARSENIDE, THIACETARSAMIDE
Schedule 7
Schedule 6
Schedule 4
Appendix G
Appendix J, Part 2
ARTEMETHER
Schedule 4
ARTICAINE
Schedule 4
ASARUM spp
Schedule 10
ASENAPINE
Schedule 4
Appendix K
ASFOTASE ALFA

INDEX
Schedule 4
ASPARAGINASE
Schedule 4
ASPARTIC ACID
Appendix B, Part 3
ASPIRIN
cross reference: CAFFEINE, PARACETAMOL, SALICYLAMIDE
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix F, Part 3
ASTEMIZOLE
Schedule 4
Appendix F, Part 3
ASTODRIMER SODIUM
Schedule 3
Appendix F, Part 3
Appendix H
ASULAM
Appendix B, Part 3
ASUNAPREVIR
Schedule 4
ATAMESTANE
Schedule 4
ATAZANAVIR
Schedule 4
ATENOLOL
Schedule 4

INDEX
ATEZOLIZUMAB
Schedule 4
ATIPAMEZOLE
Schedule 4
ATOMOXETINE
Schedule 4
ATORVASTATIN
Schedule 4
ATOSIBAN
Schedule 4
ATOVAQUONE
Schedule 4
ATRACURIUM BESILATE
cross reference: ATRACURIUM BESYLATE
Schedule 4
ATRAZINE
Schedule 5
ATROPA BELLADONNA
cross reference: BELLADONNA
Schedule 4
Schedule 2
Appendix G
ATROPINE
Schedule 4
Schedule 2
Appendix G
ATROPINE METHONITRATE
Schedule 4
AURANOFIN

INDEX
Schedule 4
AUREOBASIDIUM PULLULANS (Strains DSM14940 and DSM14941)
Appendix B
AUROTHIOMALATE SODIUM
Schedule 4
AVELUMAB
Schedule 4
AVILAMYCIN
Schedule 4
AVIPTADIL
Schedule 4
AVOPARCIN
Schedule 4
AXITINIB
Schedule 4
AZACITIDINE
Schedule 4
AZACONAZOLE
Schedule 6
AZACYCLONOL
Schedule 4
AZADIRACHTA INDICA
cross reference: DEBITTERISED NEEM SEED OIL, NEEM
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
AZADIRACHTA INDICA EXTRACTS

INDEX
Schedule 5
AZAFENIDIN
Schedule 7
AZAMETHIPHOS
Schedule 6
AZAPERONE
Schedule 4
AZAPROPAZONE
Schedule 4
AZARIBINE
Schedule 4
AZATADINE
Appendix K
AZATADINE
Schedule 4
Schedule 3
AZATHIOPRINE
Schedule 4
AZELAIC ACID
Schedule 4
Schedule 2
AZELASTINE
Schedule 4
Schedule 2
AZIMSULFURON
Appendix B, Part 3
AZINPHOS-ETHYL

INDEX
Schedule 7
AZINPHOS-METHYL
Schedule 7
AZITHROMYCIN
Schedule 4
AZLOCILLIN
Schedule 4
AZOBENZENE
Schedule 6
AZOCYCLOTIN
Schedule 7
Appendix F, Part 3
Appendix J, Part 2
AZO DYES (derivatives by diazotisation)
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
AZOXYSTROBIN
Schedule 5
AZTREONAM
Schedule 4
BACAMPICILLIN
Schedule 4
BACILLUS AMYLOLIQUEFACIENS
cross reference: BACILLUS SUBTILIS, STRAIN QST 713; BACILLUS
AMYLOLIQUEFACIENS, STRAIN QST 713; BACILLUS AMYLOLIQUEFACIENS,
STRAIN MBI 600
Appendix B, Part 3

INDEX
BACILLUS SPHAERICUS, STRAIN 2362
Appendix B, Part 3
BACILLUS SUBTILIS, STRAIN QST 713

cross reference: BACILLUS AMYLOLIQUEFACIENS, STRAIN QST 713
BACILLUS THURINGIENSIS
cross reference: ENDOTOXIN
Appendix B, Part 3
BACILLUS THURINGIENSIS DELTA ENDOTOXIN
Schedule 5
BACILLUS TOYOI
Appendix B, Part 3
BACITRACIN
Schedule 4
BACLOFEN
Schedule 4
Appendix K
BACTERIAL CULTURE MEDIA

cross reference: ANTIBIOTIC SUBSTANCES
Appendix A
BACTERIOCIDES
Appendix A
BACULOVIRUS CYDIA POMONELLA
Appendix B, Part 3
BALOXAVIR MARBOXIL
Schedule 4
BALSALAZIDE
Schedule 4

INDEX
BAMBERMYCIN
cross reference: FLAVOPHOSPHOLIPOL
Schedule 6
Schedule 4
BAMBUTEROL
Schedule 4
BAMETHAN
Schedule 4
BAMIPINE
Schedule 4
BARBITURATES
Schedule 4
BARICITINIB
Schedule 4
BARIUM SALTS
cross reference: BARIUM METABORATE, BARIUM SULFATE
Schedule 6
Appendix E, Part 2
BARIUM SILICOFLUORIDE
Schedule 5
BASIC BLUE 26
Schedule 10
Schedule 6
BASIC ORANGE 31
Cross reference: 2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM,
CHLORIDE
Schedule 10
Schedule 6
BASIC RED 76 (CAS No. 68391-30-0)

cross reference: [7-HYDROXY-8-[(2- METHOXYPHENYL)AZO]-2-
NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0)

INDEX
Schedule 7
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BASIL OIL
cross reference: METHYL CHAVICOL
Schedule 5
Appendix E, Part 2
BASILIXIMAB
Schedule 4
BATTERIES
Appendix A
BAY OIL
Schedule 6
Appendix E, Part 2
BAZEDOXIFENE
Schedule 4
BEAUVERIA BASSIANA
Schedule 6
Schedule 5
BECAPLERMIN
Schedule 4
BECLAMIDE
Schedule 4
BECLOMETASONE
cross reference: BECLOMETHASONE
Schedule 4
Schedule 2
BECLOMETHASONE
cross reference: BECLOMETASONE
BELATACEPT

INDEX
Schedule 4
BELIMUMAB
Schedule 4
BEMEGRIDE
Schedule 4
BENACTYZINE
Schedule 4
BENALAXYL
Schedule 5
BENAZEPRIL
Schedule 4
BENDAMUSTINE
Schedule 4
BENDIOCARB
cross reference: DENATONIUM BENZOATE
Schedule 7
Schedule 6
Schedule 5
BENDROFLUAZIDE
Schedule 4
BENETHAMINE PENICILLIN
Schedule 4
BENFLURALIN
Appendix B, Part 3
BENOMYL
Schedule 7
Appendix F, Part 3
BENORYLATE

INDEX
Schedule 4
BENOXAPROFEN
Schedule 4
BENPERIDOL
Schedule 4
BENQUINOX
Schedule 6
BENRALIZUMAB
Schedule 4
BENSERAZIDE
Schedule 4
BENSULFURON-METHYL
Appendix B, Part 3
BENSULIDE
Schedule 6
BENTAZONE
Schedule 5
BENTONITE
Appendix B, Part 3
BENZALKONIUM CHLORIDE
Schedule 6
Schedule 5
Appendix E, Part 2
BENZATHINE PENICILLIN
Schedule 4
BENZENE

INDEX
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
1,2-BENZENEDIAMINE
Schedule 10
1,3-BENZENEDIAMINE
Schedule 10
1,2-BENZENEDIOL
cross reference: CATECHOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BENZETHIDINE
Schedule 9
BENZHEXOL
cross reference: TRIHEXYPHENIDYL
BENZIDINE-CONGENER (3,3'-disubstituted) AZO DYES
Schedule 7
BENZIDINE-BASED AZO DYES
Schedule 7
BENZILONIUM
Schedule 4
BENZOCAINE
Schedule 4
Schedule 2
BENZODIAZEPINE DERIVATIVES
Schedule 4
Appendix D, Item 5
BENZOFENAP

INDEX
Schedule 5
BENZOVINDIFLUPYR
Schedule 6
BENZOYL PEROXIDE
Schedule 5
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
BENZOYLINDOLES
Schedule 9
BENZPHETAMINE
Schedule 4
BENZTHIAZIDE
Schedule 4
BENZATROPINE
cross reference: BENZITROPINE
Schedule 4
Appendix K
BENZYDAMINE
Schedule 4
Schedule 2
6-BENZYLADENINE
Schedule 6
BENZYL BENZOATE
Appendix B, Part 3
BENZYLMORPHINE
Schedule 8
BENZYLPENICILLIN

INDEX
Schedule 4
BENZYLPIPERAZINE
cross reference: BZP
Schedule 9
BEPHENIUM SALTS
Schedule 2
BEPRIDIL
Schedule 4
BERACTANT
Schedule 4
BERGAMOT OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
BERYLLIUM
Schedule 6
Appendix F, Part 3
BESIFLOXACIN
Schedule 4
BETACETYLMETHADOL
Schedule 9
BETACYFLUTHRIN
Schedule 7
Schedule 6
Schedule 5
BETA-CYPERMETHRIN
Schedule 6
BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID
cross reference: PHENIBUT

INDEX
BETAHISTINE
Schedule 4
BETA-HYDROXY-3-METHYLFENTANYL
Schedule 9
BETA-HYDROXYFENTANYL
Schedule 9
BETAINE HYDROCHLORIDE
Appendix B, Part 3
BETAMEPRODINE
Schedule 9
BETAMETHADOL
Schedule 9
BETAMETHASONE
Schedule 4
1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3
Appendix F, Part 3
BETAPRODINE
Schedule 9
BETAXOLOL
Schedule 4
BETHANECHOL CHLORIDE
Schedule 4
BETHANIDINE
Schedule 4
BEVACIZUMAB
Schedule 4

INDEX
BEVANTOLOL
Schedule 4
BEXAROTENE
Schedule 4
Appendix D, Item 2
Appendix F, Part 3
Appendix L, Part 2
BEZAFIBRATE
Schedule 4
BEZITRAMIDE
Schedule 8
BEZLOTOXUMAB
Schedule 4
BHC
Schedule 6
BICALUTAMIDE
Schedule 4
BICTEGRAVIR
Schedule 4
BICYCLOPYRONE
Schedule 6
Schedule 5
BIFENAZATE
Appendix B, Part 3
BIFENTHRIN
Schedule 7
Schedule 6

INDEX
BIFLUORIDES
cross reference: AMMONIUM BIFLUORIDE, AMMONIUM SALTS, POTASSIUM SALTS,
SODIUM SALTS
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix J
BIFONAZOLE
Schedule 4
Schedule 2
BILASTINE
Schedule 4
BIMATOPROST
Schedule 4
BINIMETINIB
Schedule 4
BIOALLETHRIN
Schedule 6
Schedule 5
BIORESMETHRIN
Schedule 5
BIPERIDEN
Schedule 4
1,3-BIS(2,4-DIAMINOPHENOXY)PROPANE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BIS-ISOBUTYL PEG/PPG-20/35/AMODIMETICONE COPOLYMER

INDEX
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BISMUTH COMPOUNDS
cross reference: BISMUTH CITRATE, BISMUTH FORMIC IODIDE, BISMUTH
OXYCHLORIDE, BISMUTH SUBIODIDE
Schedule 4
BISMUTH SUBNITRATE
Appendix B, Part 3
BISOPROLOL
Schedule 4
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-
DIMETHANAMINE
cross reference: N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-
DIMETHANAMINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-
DIMETHANAMINE
cross reference: N,N-bIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-
DIMETHANAMINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BISPYRIBAC
Schedule 5
BISTRIFLURON
Appendix B, Part 3
BITHIONOL
Schedule 10
Schedule 6
Appendix F, Part 3
BIURET

INDEX
Appendix B, Part 3
BIVALIRUDIN
Schedule 4
BIXAFEN
Schedule 5
BIXLOZONE
Appendix B, Part 3
BLAD (banda de Lupinus albus doce)
Appendix B, Part 3
BLEOMYCIN
Schedule 4
BLINATUMOMAB
Schedule 4
BOCEPREVIR
Schedule 4
BOLANDIOL
Schedule 4
BOLASTERONE
Schedule 4
BOLAZINE
Schedule 4
BOLDENONE
cross reference: DEHYDROTESTOSTERONE
Schedule 4

INDEX
BOLENOL
Schedule 4
BOLMANTALATE
Schedule 4
BORAGO OFFICINALIS
cross reference: BORAGE
Schedule 10
BORIC ACID
cross reference: BORAX, SODIUM BORATE, POTASSIUM BORATE, MEA-BORATE,
MIPA-BORATE
Schedule 5
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
BORON
cross reference: BORATES, BORAX, BORIC ACID, BORON COMPOUNDS
Schedule 4
BORON TRIFLUORIDE
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
BORTEZOMIB
Schedule 4
BOSCALID
Appendix B, Part 3
BOSENTAN
Schedule 4
Appendix D, Item 6

INDEX
Appendix F, Part 3
Appendix L, Part 2
BOSUTINIB
Schedule 4
BOTULINUM TOXINS
Schedule 4
BOVINE SOMATOTROPHIN
Appendix B, Part 3
BRAGANTIA spp
Schedule 10
BRENTUXIMAB VEDOTIN
Schedule 4
BRETYLIUM TOSILATE
Schedule 4
BRETYLIUM TOSYLATE
cross reference: BRETYLIUM TOSILATE
BREXPIPRAZOLE
Schedule 4
Appendix K
BRIGATINIB
Schedule 4
BRIMONIDINE
Schedule 4
BRINZOLAMIDE
Schedule 4
BRIVARACETAM

INDEX
Schedule 4
Appendix K
BRODIFACOUM
Schedule 7
Schedule 6
Appendix J, Part 2
BROFLANILIDE
Schedule 6
Schedule 5
BROMACIL
Appendix B, Part 3
BROMADIOLONE
Appendix J, Part 2
BROMADIOLONE
Schedule 7
Schedule 6
BROMAZEPAM
Schedule 4
Appendix D, Item 5 (benzodiazepine derivatives)
Appendix K
BROMETHALIN
Schedule 7
Schedule 6
BROMHEXINE
Schedule 2
BROMIDES
Schedule 4
BROMINE
Schedule 7
Appendix J, Part 2

INDEX
1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE
cross reference: BROMO-DRAGONFLY
Schedule 9
BROMOCRIPTINE
Schedule 4
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE
cross reference: BDMPEA
Schedule 9
BROMOFORM
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
BROMOPHOS
Schedule 6
BROMOPHOS-ETHYL
Schedule 6
BROMOPROPYLATE
Appendix B, Part 3
BROMOXYNIL
Schedule 6
BROMPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
BROMUCONAZOLE
Schedule 6
Schedule 5
BROMVALETONE

INDEX
Schedule 4
BROTIANIDE
Schedule 6
BRUCINE
Schedule 7
Appendix E, Part 2
Appendix J, Part 2
BRUGMANSIA spp.
Schedule 4
BUCLIZINE
Appendix K
BUCLIZINE
Schedule 4
Schedule 3
BUCLOSAMIDE
Schedule 10
BUDESONIDE
Schedule 4
Schedule 2
BUFEXAMAC
Schedule 4
BUFOTENINE
Schedule 9
BUMETANIDE
Schedule 4
BUNAMIDINE
Schedule 6
BUNIODYL SODIUM

INDEX
Schedule 10
BUPHENINE
Schedule 4
BUPIRIMATE
Appendix B, Part 3
BUPIVACAINE
Schedule 5
Schedule 4
BUPRENORPHINE
Schedule 8
Appendix K
BUPROFEZIN
Schedule 5
BUPROPION
cross reference: AMFEBUTAMONE
Schedule 4
BUSERELIN
Schedule 4
BUSPIRONE
Schedule 4
BUSULPHAN
Schedule 4
BUTACAINE
Schedule 4
BUTACARB
Schedule 6
BUTAFENACIL

INDEX
Appendix B, Part 3
BUTAMBEN
cross reference: BUTYL AMINOBENZOATE
Schedule 4
1,4-BUTANEDIOL
Schedule 10
BUTHIDAZOLE
Schedule 5
BUTOBARBITAL
Schedule 8
Appendix K
BUTOBARBITONE
cross reference: BUTOBARBITAL
BUTOCONAZOLE
Schedule 4
Schedule 3
Appendix H
BUTORPHANOL
Schedule 8
BUTOXYCARBOXIM
Schedule 6
Schedule 5
2-BUTOXYETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
BUTOXYPOLYPROPYLENE GLYCOL
Appendix B, Part 3
2-BUTOXY-2’-THIOCYANODIETHYL ETHER

INDEX
Schedule 6
Appendix F, Part 3
BUTRACONAZOLE
Schedule 4
BUTRALIN
Schedule 5
BUTROXYDIM
Schedule 5
n-BUTYL ALCOHOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
BUTYL AMINOBENZOATE
cross reference BUTAMBEN
BUTYL BENZYL PHTHALATE
Schedule 10
n-BUTYL BUTYRATE
Appendix B, Part 3
n-BUTYL LACTATE
Appendix B, Part 3
BUTYL NITRITE
Schedule 4
Appendix E, Part 2
BUTYLCHLORAL HYDRATE
Schedule 4
BUTYRIC ACID
Schedule 6

INDEX
CABAZITAXEL
Schedule 4
CABERGOLINE
Schedule 4
CABOTEGRAVIR
Schedule 4
CABOZANTINIB
Schedule 4
CACALIA spp.
Schedule 10
CACODYLIC ACID
Schedule 7
Schedule 6
CADMIUM COMPOUNDS
cross reference: CADMIUM, CADMIUM ACETATE, CADMIUM CHLORIDE, CADMIUM
NITRATE
Schedule 6
Schedule 4
Appendix E, Part 2
CADUSAFOS
Schedule 7
Schedule 6
CAFFEINE
cross reference: PARACETAMOL, ASPIRIN, SALICYLAMIDE
Schedule 6
Schedule 4
CAJUPUT OIL
Schedule 6
Appendix E, Part 2

INDEX
CALCIFEDIOL
Schedule 4
CALCIFEROL
Schedule 7
Schedule 6
Appendix J, Part 2
CALCIPOTRIOL
Schedule 4
CALCITONIN SALMON
Schedule 4
CALCITRIOL
Schedule 4
CALCIUM CARBIMIDE
Schedule 4
CALCIUM HYDROXYLAPATITE
Schedule 4
CALCIUM POLYSTYRENE SULPHONATE
Schedule 4
CALOTROPIS GIGANTEA
Schedule 4
CALOTROPIS PROCERA
Schedule 4
CALUSTERONE
Schedule 4
CAMBENDAZOLE
Schedule 6

INDEX
CAMPHOR
cross reference: ESSENTIAL OILS, LAVANDIN OIL, ROSEMARY OIL, SHUI OIL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CAMPHORATED OIL
Schedule 4
CAMPHOTAMIDE
Schedule 4
CANAGLIFLOZIN
Schedule 4
CANAKINUMAB
Schedule 4
CANDESARTAN CILEXETIL
Schedule 4
CANDICIDIN
Schedule 4
CANINE TICK ANTI-SERUM
Schedule 4
CANNABICHROMENE
cross reference: NABIXIMOLS, CANNABIS, TETRAHYDROCANNABINOLS
CANNABIDIOL
Schedule 4
Schedule 3
Appendix F, Part 3
CANNABIDIOLIC ACID
CANNABIDIVAROL

INDEX
CANNABIGEROL
CANNABINOIDS
CANNABINOL
CANNABIS
cross reference: CANNABIS SATIVA, HEMP, HEMP SEED OIL,
TETRAHYDROCANNABINOLS
Schedule 9
Schedule 8
Appendix D, Item 1
Appendix K
CANTHARIDIN
Schedule 4
Appendix G
CAPECITABINE
Schedule 4
CAPREOMYCIN
Schedule 4
CAPTAFOL
Schedule 7
Appendix J, Part 2
CAPTAN
Schedule 6
CAPTODIAME
Schedule 4
CAPTOPRIL
Schedule 4
CAPURIDE
Schedule 4

INDEX
CARAMIPHEN
Schedule 4
CARBACHOL
Schedule 4
CARBADOX
Schedule 7
Appendix J, Part 2
CARBAMAZEPINE
Schedule 4
CARBAMIDE PEROXIDE
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CARBARYL
Schedule 6
Schedule 5
Schedule 4
CARBAZOCHROME
Schedule 4
CARBENDAZIM
Schedule 7
CARBENICILLIN
Schedule 4
CARBENOXOLONE
Schedule 4
CARBETAMIDE
Schedule 6

INDEX
CARBETAPENTANE
Schedule 2
CARBETOCIN
Schedule 4
CARBIDOPA
Schedule 4
CARBIMAZOLE
Schedule 4
CARBOCISTEINE
Schedule 2
CARBOCROMEN
Schedule 4
CARBOFURAN
Schedule 7
CARBON DISULFIDE
Schedule 6
Appendix E, Part 2
CARBON TETRACHLORIDE
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
CARBONYL SULFIDE
Schedule 7
Appendix J, Part 2
CARBOPHENOTHION
Schedule 7
CARBOPLATIN

INDEX
Schedule 4
CARBOPROST
Schedule 4
CARBOSULFAN
Schedule 7
CARBOXIN
Appendix B, Part 3
CARBROMAL
Schedule 4
CARBUTAMIDE
Schedule 4
CARBUTEROL
Schedule 4
CARDARINE
Schedule 10
CARFENTANYL
Schedule 8
CARFENTRAZONE-ETHYL
Appendix B, Part 3
CARFILZOMIB.
Schedule 4
CARGLUMIC ACID
Schedule 4
CARINDACILLIN
Schedule 4
CARIPRAZINE

INDEX
Schedule 4
CARISOPRODOL
Schedule 4
CARMUSTINE
Schedule 4
CARNIDAZOLE
Schedule 4
CARPROFEN
Schedule 4
CARVEDILOL
Schedule 4
CASPOFUNGIN
Schedule 4
CASSIA OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CASTOR OIL, MONOMALEATE
Schedule 6
CATHINE
Schedule 4
CATHINONES
cross reference: SYNTHETIC CATHINONES
Schedule 9
CATUMAXOMAB
Schedule 4
CEDAZURIDINE

INDEX
Schedule 4
CEFACETRILE
cross reference: CEPHACETRILE
Schedule 4
CEFACLOR
Schedule 4
CEFADROXIL
Schedule 4
CEFALEXIN
cross reference: CEPHALEXIN
Schedule 4
CEFALORIDINE
cross reference: CEPHALORIDINE
Schedule 4
CEFALOTIN
cross reference: CEPHALOTHIN, CEFALOTHIN
Schedule 4
CEFAMANDOLE
cross reference: CEPHAMANDOLE
Schedule 4
CEFAPIRIN
cross reference: CEPHAPIRIN
Schedule 4
CEFAZOLIN
cross reference: CEPHAZOLIN
Schedule 4
CEFEPIME
Schedule 4
CEFETAMET

INDEX
Schedule 4
CEFIXIME
Schedule 4
CEFODIZIME
Schedule 4
CEFONICID
Schedule 4
CEFOPERAZONE
Schedule 4
CEFOTAXIME
Schedule 4
CEFOTETAN
Schedule 4
CEFOTIAM
Schedule 4
CEFOVECIN
Schedule 4
CEFOXITIN
Schedule 4
CEFPIROME
Schedule 4
CEFPODOXIME
Schedule 4
CEFQUINOME
Schedule 4
CEFSULODIN

INDEX
Schedule 4
CEFTAROLINE FOSAMIL
Schedule 4
CEFTAZIDIME
Schedule 4
CEFTIBUTEN
Schedule 4
CEFTIOFUR
Schedule 4
CEFTRIAXONE
Schedule 4
CEFUROXIME
Schedule 4
CELECOXIB
Schedule 4
CELIPROLOL
Schedule 4
CELLULASE derived from Aspergillus niger
Appendix B, Part 3
CENEGERMIN
Schedule 4
CEPHAELIS ACUMINATA
cross reference: IPECACUANHA
Schedule 4
CEPHAELIS IPECACUANHA
cross reference: IPECACUANHA
Schedule 4

INDEX
CEPHALEXIN
cross reference: CEFALEXIN
CEPHALONIUM
Schedule 4
CEPHALOTHIN
cross reference: CEFALOTIN
CEPHRADINE
Schedule 4
CERAMICS
Appendix A
CERITINIB
Schedule 4
CERIVASTATIN
Schedule 4
CERLIPONASE ALFA
Schedule 4
CERTOLIZUMAB PEGOL
Schedule 4
CERULETIDE
Schedule 4
CETIRIZINE
Schedule 4
Schedule 2
Appendix K
CETRORELIX
Schedule 4
CETUXIMAB
Schedule 4

INDEX
CETYL ALCOHOL
Appendix B, Part 3
CHAMOMILE OIL
Appendix B, Part 3
CHEMISTRY SETS
Appendix A
CHENODEOXYCHOLIC ACID
Schedule 4
CHINA CLAY
Appendix B, Part 3
CHLOPHEDIANOL
Schedule 2
CHLORAL FORMAMIDE
Schedule 4
CHLORAL HYDRATE
Schedule 4
Appendix K
CHLORALOSE
cross reference: ALPHA-CHLORALOSE
Schedule 6
Schedule 4
CHLORAMBUCIL
Schedule 4
CHLORAMPHENICOL
Schedule 4
Schedule 3
CHLORANDROSTENOLONE

INDEX
Schedule 4
CHLORANTRANILIPROLE
Appendix B, Part 3
CHLORAZANIL
Schedule 4
CHLORBUTANOL
Schedule 3
Schedule 2
CHLORBUTOL
cross reference: CHLOROBUTANOL
CHLORCYCLIZINE
Schedule 4
CHLORDANE
Schedule 6
CHLORDECONE
Schedule 7
Appendix J, Part 2
CHLORDIAZEPOXIDE
Schedule 4
Appendix D, Item 5 (benzodiazepine derivative)
Appendix K
CHLORDIMEFORM
Schedule 7
Appendix J, Part 2
CHLORFENAC
Schedule 5
CHLORFENAPYR

INDEX
Schedule 7
Schedule 6
Schedule 5
CHLORFENETHOL
Schedule 6
CHLORFENSON
Schedule 5
CHLORFENVINPHOS
Schedule 7
CHLORFLUAZURON
Appendix B, Part 3
CHLORFLURENOL
Appendix B, Part 3
CHLORHEXIDINE
Schedule 7
Schedule 6
Schedule 5
CHLORIDAZON
Appendix B, Part 3
CHLORIDE
Appendix E, Part 2
CHLORINATING COMPOUNDS
cross reference: BLEACHES, BROMOCHLORODIMETHYLHYDANTOIN,
TRICHLOROISOCYANURIC ACID, CALCIUM HYPOCHLORITE, CHLORINE,
DICHLOROETHYL ETHER, SODIUM HYPOCHLORITE
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2

INDEX
CHLORINE
cross reference: CHLORINATING COMPOUNDS, DICHLOROISOCYANURATES,
DICHLOROISOCYANURIC ACID
Schedule 7
Appendix G
Appendix J, Part 2
CHLORMEQUAT
Schedule 6
CHLORMERODRIN
Schedule 4
CHLORMETHIAZOLE
Schedule 4
Appendix K
CHLORMEZANONE
Schedule 4
CHLORNIDINE
Schedule 5
CHLOROACETAMIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CHLOROCRESOL
Schedule 5
Appendix E, Part 2
2-CHLORO-6-(ETHYLAMINO)-4-NITROPHENOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CHLOROFORM
Schedule 6
Schedule 4
Schedule 2

INDEX
Appendix E, Part 2
Appendix F, Part 3
4-CHLOROMETHANDIENONE
Schedule 4
Appendix D, Item D (Anabolic and/or androgenic steroidal agents)
CHLOROMETHIURON
Schedule 7
Appendix J, Part 2
5-CHLORO-3-METHYL-4-NITROPYRAZOLE
Schedule 7
2-CHLORO-5-NITRO-N-HYDROXYETHYL-p-PHENYLENEDIAMINE
cross reference: PHENYLENEDIAMINES
CHLOROPHACINONE
Schedule 6
2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE
Schedule 4
CHLOROPICRIN
Schedule 7
Schedule 6
CHLOROPICRIN
Appendix J, Part 2
CHLOROQUINE
Schedule 4
CHLOROTHALONIL
Schedule 6
CHLOROTHIAZIDE
Schedule 4

INDEX
4-CHLORO-o-TOLUIDINE
Schedule 7
Appendix J, Part 2
CHLOROTRIANISENE
Schedule 4
2-CHLORO-6-(TRICHLOROMETHYL)-PYRIDINE
Schedule 6
CHLOROXYDIENONE
Schedule 4
CHLOROXYLENOLS
Appendix B, Part 3
CHLORPHENAMINE
cross reference: CHLORPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
CHLORPHENIRAMINE
cross reference: CHLORPHENAMINE
CHLORPHENTERMINE
Schedule 4
CHLORPROMAZINE
Schedule 4
Appendix K
CHLORPROPAMIDE
Schedule 4
CHLORPROPHAM
Schedule 5
CHLORPROTHIXENE

INDEX
Schedule 4
CHLORPYRIFOS
Schedule 6
Schedule 5
CHLORPYRIFOS-METHYL
Schedule 6
CHLORQUINALDOL
Schedule 4
CHLORSULFURON
Schedule 5
CHLORTALIDONE
Schedule 4
CHLORTETRACYCLINE
Schedule 5
Schedule 4
CHLORTHAL-DIMETHYL
Schedule 5
CHLORTHALIDONE
cross reference: CHLORTALIDONE
CHLORTHIAMID
Schedule 6
CHLORTHIOPHOS
Schedule 7
CHLORZOXAZONE
Schedule 4
CHOLECALCIFEROL
cross reference: COLECALCIFEROL

INDEX
Schedule 7
Appendix J, Part 2
CHOLERA VACCINE
Schedule 4
CHOLESTYRAMINE
cross reference: COLESTYRAMINE
CHOLIC ACID
Schedule 4
CHROMATES
cross reference: AMMONIUM CHROMATE, BARIUM CHROMATE, CHROMIUM,
COPPER-CHROME-ARSENIC, DICHROMATES, POTASSIUM CHROMATE, ZINC
CHROMATE SODIUM CHROMATE, STRONTIUM CHROMATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CHROMIUM TRIOXIDE
cross reference: CHROMIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CHRYSOIDINE BASE
Schedule 10
Schedule 6
Appendix E, Part 2
CHYMOPAPAIN
Schedule 4
CICLACILLIN
Schedule 4
CICLESONIDE
Schedule 4
CICLOPIROX

INDEX
Schedule 4
Schedule 3
Schedule 2
Appendix H
CICLOSPORIN
Schedule 4
CIDOFOVIR
Schedule 4
CILASTATIN
Schedule 4
CILAZAPRIL
Schedule 4
CILOSTAZOL
Schedule 4
CIMETIDINE
Schedule 4
Schedule 3
Appendix F, Part 3
CIMICOXIB
Schedule 4
CINACALCET
Schedule 4
CINCHOCAINE
Schedule 4
Schedule 2
CINCHOPHEN
Schedule 10
CINEOLE
cross reference: CAMPHOR OIL (white), ROSEMARY OIL

INDEX
Schedule 7
Appendix E, Part 2
CINMETHYLIN
Schedule 5
CINNAMEDRINE
Schedule 2
CINNAMON BARK OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CINNAMON LEAF OIL
Schedule 6
Appendix E, Part 2
CINNARIZINE
Schedule 4
CINOXACIN
Schedule 4
CIPROFLOXACIN
Schedule 4
CISAPRIDE
Schedule 4
CISATRACURIUM BESILATE
cross reference: CISATRACURIUM BESYLATE
Schedule 4
CISPLATIN
Schedule 4
CITALOPRAM
Schedule 4

INDEX
CITRONELLA OIL
Appendix B, Part 3
CJC-1295 (CAS No. 863288-34-0)
Schedule 4
Appendix D, Item 5
CLADRIBINE
Schedule 4
CLANOBUTIN
Schedule 4
CLARITHROMYCIN
Schedule 4
CLARY SAGE OIL
Appendix B, Part 3
CLAVULANIC ACID
Schedule 4
CLEMASTINE
Schedule 4
Schedule 3
Appendix K
CLEMIZOLE
Schedule 4
CLENBUTEROL
Schedule 4
CLETHODIM
Schedule 5
CLEVIDIPINE
Schedule 4

INDEX
CLIDINIUM BROMIDE
Schedule 4
CLIMBAZOLE
Schedule 6
Schedule 5
Appendix E, Part 2
CLINDAMYCIN
Schedule 4
CLIOQUINOL
cross reference: OXYQUINOLINE, CHLORQUINALDOL, HALQUINOL
Schedule 10
Schedule 4
CLITORIA TERNATEA EXTRACT
Appendix B, Part 3
CLOBAZAM
Schedule 4
CLOBETASOL
Schedule 4
CLOBETASONE
Schedule 4
Schedule 3
Appendix F, Part 3
Appendix H
CLOCORTOLONE
Schedule 4
CLODINAFOP-PROPARGYL
Schedule 6
CLODRONIC ACID
cross reference: SODIUM CLODRONATE
Schedule 4

INDEX
CLOFARABINE
Schedule 4
CLOFAZIMINE
Schedule 4
CLOFENAMIDE
Schedule 4
CLOFENTEZINE
Schedule 5
CLOFIBRATE
Schedule 4
CLOMAZONE
Schedule 6
CLOMIFENE
cross reference: CLOMIPHENE
Schedule 4
Appendix D, Item 1
CLOMIPHENE
cross reference: CLOMIFENE
CLOMIPRAMINE
Schedule 4
Appendix K
CLOMOCYCLINE
Schedule 4
CLONAZEPAM
Schedule 4
Appendix K
CLONAZOLAM
Schedule 9

INDEX
CLONIDINE
Schedule 4
Appendix K
CLONITAZENE
Schedule 9
CLOPAMIDE
Schedule 4
CLOPIDOGREL
Schedule 4
CLOPIDOL
Appendix B, Part 3
CLOPROSTENOL
Schedule 4
CLOPYRALID
Schedule 5
CLOQUINTOCET
Schedule 5
CLORAZEPATE
Schedule 4
Appendix K
CLOREXOLONE
Schedule 4
CLORPRENALINE
Schedule 4
CLORSULON
Schedule 5

INDEX
CLOSANTEL
Schedule 6
CLOSTEBOL
cross reference: 4-CHLOROTESTOSTERONE
Schedule 4
CLOTHIANIDIN
Schedule 6
Schedule 5
CLOTRIMAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
CLOVE OIL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CLOXACILLIN
Schedule 4
CLOZAPINE
Schedule 4
Appendix D, Item 1
Appendix K
COAL TAR
Schedule 10
COBALT
cross reference: DICOBALT EDETATE
Schedule 4
COBALT NAPHTHENATE

INDEX
Appendix B, Part 3
COBICISTAT
Schedule 4
COBIMETINIB
Schedule 4
COCA LEAF
Schedule 9
COCAINE
Schedule 8
N-COCO-1,3-DIAMINOPROPANE
Schedule 6
COCOYL GLYCINATE
Schedule 6
Appendix E, Part 2
COCOYL METHYL GLUCAMAIDE

cross reference: 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL
DERIVATIVES
CODEINE
Schedule 8
Schedule 4
Appendix K
CODEINE-N-OXIDE
Schedule 8
CO-DERGOCRINE
Schedule 4
CODOXIME
Schedule 9
COLASPASE
cross reference: ASPARAGINASE

INDEX
COLCHICINE
Schedule 4
COLCHICUM AUTUMNALE
Schedule 4
COLECALCIFEROL
cross reference: CHOLECALCIFEROL
Schedule 7
Appendix J, Part 2
COLESTIPOL
Schedule 4
COLESTYRAMINE
Schedule 4
COLFOSCERIL PALMITATE
Schedule 4
COLISTIN
Schedule 4
COLLAGEN
Schedule 4
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Schedule 4
COLURACETAM
Schedule 4
CONCENTRATE OF POPPY STRAW
Schedule 8
CONIUM MACULATUM
cross reference: CONIINE
Schedule 10

INDEX
CONVALLARIA KEISKI
Schedule 4
CONVALLARIA MAJALIS
Schedule 4
COPPER ACETATE
Schedule 6
Schedule 5
COPPER COMPOUNDS
cross reference: COPPER
Schedule 6
Schedule 5
Schedule 4
Appendix A
COPPER HYDROXIDE
Schedule 6
Schedule 5
COPPER NITRATE
cross reference: COPPER CHLORIDE
Schedule 6
COPPER OXIDES
Schedule 6
Schedule 5
COPPER OXYCHLORIDE
Schedule 6
Schedule 5
COPPER SULFATE
Schedule 6
Schedule 5
Appendix E, Part 2
CORIFOLLITROPIN ALFA
cross reference: FOLLICLE STIMULANT, RECOMBINANT

INDEX
Schedule 4
Appendix D, Item 1
CORONILLA spp.
Schedule 4
CORTICOSTERONE
Schedule 4
CORTICOTROPHIN
Schedule 4
CORTISONE
Schedule 4
COTARNINE
Schedule 10
CO-TRIMOXAZOLE
Schedule 4
COUMAPHOS
Schedule 7
Schedule 6
COUMARIN
Schedule 4
COUMATETRALYL
Schedule 7
Schedule 6
Schedule 5
Appendix J, Part 2
4-CPA
Schedule 5
CREOSOTE
cross reference: BEECHWOOD, PHENOL, WOOD

INDEX
Schedule 7
Schedule 6
Schedule 2
Appendix E, Part 2
CRESOLS
Appendix E, Part 2
CRISABOROLE
Schedule 4
CRIZOTINIB
Schedule 4
CROFELEMER
Schedule 4
CROSPOVIDONE
Appendix B, Part 3
CROTALARIA spp.
Schedule 10
CROTON TIGLIUM
cross reference: CROTON OIL
Schedule 10
Appendix G
CROTOXYPHOS
Schedule 6
CRUFOMATE
Schedule 6
CRYSTAL VIOLET
cross reference: METHYLROSANILINIUM CHLORIDE, GENTIAN VIOLET
CULICINOMYCES CLAVOSPORUS
Appendix B, Part 3
CUPRIMYXIN

INDEX
Schedule 4
CURARE
Schedule 4
13
C-UREA
Appendix B, Part 3
CYANAMIDE
Schedule 6
CYANATRYN
Schedule 5
CYANAZINE
Schedule 6
CYANIDES
cross reference: FERRICYANIDES, FERROCYANIDES
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
CYANOACRYLATE ESTERS
Schedule 5
CYANOACRYLIC ACID ESTERS
Appendix E, Part 2
4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE
cross reference: METHADONE INTERMEDIATE
Schedule 9
CYANOGEN
cross reference: ETHANEDINITRILE, OXALONITRILE
Schedule 7
Appendix J, Part 2
4-CYANO-1-METHYL-4-PHENYLPIPERIDINE
cross reference: PETHIDINE INTERMEDIATE A

INDEX
Schedule 8
CYANTRANILIPROLE
Schedule 5
CYANURIC ACID
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CYAZOFAMID
Schedule 5
CYCLAMIC ACID
Appendix B, Part 3
CYCLANDELATE
Schedule 4
CYCLANILIDE
Schedule 6
CYCLANILIPROLE
Appendix B
CYCLIZINE
Schedule 4
Schedule 3
Appendix K
CYCLOBARBITAL
Schedule 8
Appendix K
CYCLOBARBITONE
cross reference: CYCLOBARBITAL
CYCLOBENZAPRINE
Schedule 4
CYCLOFENIL

INDEX
Schedule 4
Appendix D, Item 1
CYCLOHEXANE
Appendix B, Part 3
CYCLOHEXANOL ACETATE
Appendix B, Part 3
CYCLOHEXANONE PEROXIDE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
CYCLOHEXIMIDE
Schedule 4
N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM
cross reference: K-HDO
Schedule 6
CYCLOHEXYLPHENOLS
Schedule 9
CYCLOPENTHIAZIDE
Schedule 4
CYCLOPENTOLATE
Schedule 4
CYCLOPHOSPHAMIDE
Schedule 4
CYCLOPROPANE
Schedule 4
CYCLOPROTHRIN
Schedule 5
CYCLOSERINE

INDEX
Schedule 4
Appendix J, Part 2

PROPANAMINE (CAS 475645-84-2)
Schedule 7
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
CYCLOSPORIN
cross reference: CICLOSPORIN
CYCLOTHIAZIDE
Schedule 4
CYCLOXYDIM
Schedule 5
CYCRIMINE
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
CYFLUFENAMID
Schedule 5
CYFLUTHRIN
Schedule 6
Schedule 5
CYHALOFOP-BUTYL
Schedule 5
CYHALOTHRIN
Schedule 7
CYHEXATIN
Schedule 7
CYMARIN

INDEX
Schedule 4
CYMIAZOLE
Schedule 5
CYNOGLOSSUM spp.
Schedule 10
CYOMETRINIL
Schedule 6
CYPERMETHRIN
cross reference: ALPHA-CYPERMETHRIN AND BETA-CYPERMETHRIN, ZETA-
CYPERMETHRIN
Schedule 6
Schedule 5
CYPHENOTHRIN
Schedule 6
Schedule 5
CYPRINID HERPESVIRUS-3
Appendix B, Part 3
CYPROCONAZOLE
Schedule 5
CYPRODINIL
Schedule 5
CYPROHEPTADINE
Schedule 4
Schedule 3
Appendix K
CYPROTERONE
Schedule 4
CYROMAZINE
Appendix B, Part 3

INDEX
CYSTEAMINE
cross reference: MERCAPTAMINE
CYTARABINE
Schedule 4
CYTHIOATE
Schedule 6
Schedule 5
2,4-D
Schedule 6
Schedule 5
DABIGATRAN
Schedule 4
DABRAFENIB MESILATE
Schedule 4
DACARBAZINE
Schedule 4
DACLATASVIR
Schedule 4
DACLIZUMAB
Schedule 4
DACTINOMYCIN
Schedule 4
DALFOPRISTIN
Schedule 4
DALTEPARIN
Schedule 4

INDEX
DAMINOZIDE
Schedule 5
DANAPAROID
Schedule 4
DANAZOL
Schedule 4
DANTHRON
Schedule 4
DANTROLENE
Schedule 4
Appendix K
DAPAGLIFLOZIN
Schedule 4
DAPOXETINE
Schedule 4
DAPSONE
Schedule 4
DAPTOMYCIN
Schedule 4
DARATUMUMAB
Schedule 4
DARBEPOETIN
Schedule 4
Appendix D, Item 5
DARIFENACIN
Schedule 4

INDEX
DAROLUTAMIDE
Schedule 4
DARUNAVIR
Schedule 4
DASABUVIR
Schedule 4
DASATINIB
Schedule 4
DATURA spp.
Schedule 4
Schedule 2
DATURA STRAMONIUM
cross reference: STRAMONIUM
Schedule 4
Schedule 2
DATURA TATULA
cross reference: STRAMONIUM
Schedule 4
Schedule 2
DAUNORUBICIN
Schedule 4
DAZOMET
Schedule 6
2,4-DB
Schedule 5
DEANOL
cross reference: 2-(DIMETHYLAMINO)ETHANOL, DMEA, DIMETHYL MEA
Schedule 4
DEBRISOQUINE

INDEX
Schedule 4
DECAMETHONIUM
Schedule 4
DECITABINE
Schedule 4
DECOQUINATE
Schedule 5
DEFERASIROX
Schedule 4
DEFERIPRONE
Schedule 4
DEFIBROTIDE
Schedule 4
DEFLAZACORT
Schedule 4
DEGARELIX
Schedule 4
DEHYDROCHLOROMETHYLTESTOSTERONE
cross reference: CHLOROMESTERONE
Schedule 4
DEHYDROCORTICOSTERONE
Schedule 4
DELAVIRDINE
cross reference: DELAVIRDINE MESILATE
DELAVIRDINE MESILATE
Schedule 4

INDEX
DELPHINIUM STAPHISAGRIA
cross reference: STAPHISAGRIA
Schedule 2
DELTAMETHRIN
Schedule 7
Schedule 6
Schedule 5
DEMBREXINE
Schedule 5
Schedule 4
DEMECARIUM
Schedule 4
DEMECLOCYCLINE
Schedule 4
DEMETON
Schedule 7
DEMETON-O-METHYL
Schedule 7
DEMETON-S-METHYL
Schedule 7
DENGUE VACCINE
cross reference: LIVE ATTENUATED CHIMERIC DENGUE VIRUS (SEROTYPES 1,2,3 &
4)
Schedule 4
DENOSUMAB
Schedule 4
DEOXYCHOLIC ACID
Schedule 4
DEOXYCORTONE

INDEX
Schedule 4
1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL N-COCO ACYL DERIVATIVES

cross reference: COCOYL METHYL GLUCAMAIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DEOXYRIBONUCLEASE
Schedule 4
DERACOXIB
Schedule 4
DERMATOPHAGOIDES PTERONYSSINUS AND DERMATOPHAGOIDES FARINAE

EXTRACT
Schedule 4
DERQUANTEL
Schedule 6
2,4-DES
Schedule 5
DESCHLOROETIZOLAM
Schedule 9
DESFERRIOXAMINE
Schedule 4
DESFLURANE
Schedule 4
DESIPRAMINE
Schedule 4
Appendix K
DESIRUDIN
Schedule 4

INDEX
DESLANOSIDE
Schedule 4
DESLORATADINE
Schedule 4
Schedule 2
DESLORELIN
Schedule 4
DESMOPRESSIN
cross reference: D.D.A.V.P.
Schedule 4
DESOGESTREL
Schedule 4
DESOMORPHINE
Schedule 9
DESONIDE
Schedule 4
DESOXYMETHASONE
Schedule 4
DESVENLAFAXINE
Schedule 4
DETOMIDINE
Schedule 4
DEXAMETHASONE
Schedule 4
DEXAMFETAMINE
cross reference: DEXAMPHETAMINE
Schedule 8

INDEX
DEXCHLORPHENAMINE
cross reference: DEXCHLORPHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
DEXCHLORPHENIRAMINE
cross reference: DEXCHLORPHENAMINE
DEXFENFLURAMINE
Schedule 4
DEXMEDETOMIDINE
Schedule 4
DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES
Appendix A
DEXTROMETHORPHAN
Schedule 4
Schedule 2
DEXTROMORAMIDE
cross reference: MORAMIDE
Schedule 8
Appendix K
DEXTROPROPOXYPHENE
Schedule 8
Schedule 4
Appendix D, Item 5
Appendix K
DEXTRORPHAN
Schedule 4
N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES

cross reference: 3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-
METHYLBENZAMIDE *(U-47700)
Schedule 9

INDEX
N,N-DIALKYLAMINOCYCLOHEXYLMETHYL ALKYL BENZAMIDES

Cross reference: 3,4-DICHLORO-N-{[1-
(DIMETHYLAMINO)CYCLOHEXYL]METHYL}BENZAMIDE *(AH-7921)
Schedule 9
4,4-DIAMINODIPHENYLMETHANE
cross reference: METHYLENE DIANILINE
Schedule 7
Appendix F, Part 3
Appendix J, Part 2
2,4-DIAMINO-5-METHYLPHENETOLE
cross reference: PHENYLENEDIAMINES
2,4-DIAMINOPHENOXYETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DIAFENTHIURON
Schedule 5
DIALIFOS
Schedule 7
N,N-DIALLYLDICHLOROACETAMIDE
Schedule 5
DIAMPROMIDE
Schedule 9
DIAMTHAZOLE
Schedule 4
DIAVERIDINE
Schedule 4
DIAZEPAM
Schedule 4
Appendix K

INDEX
DIAZINON
Schedule 6
Schedule 5
DIAZOXIDE
Schedule 4
DIBENZEPIN
Schedule 4
DIBENZOPYRANS
Schedule 9
DIBOTERMIN
Schedule 4
1,2-DIBROMO-3-CHLOROPROPANE
Schedule 7
Appendix J, Part 2
DIBROMOPROPAMIDINE
Schedule 4
Schedule 2
DIBUTYLPHTHALATE
Schedule 10
DICAMBA
Schedule 6
Schedule 5
DICLAZEPAM
Schedule 9
DICHLOBENIL
Schedule 6
o-DICHLOROBENZENE
Appendix F, Part 3

INDEX
DICHLOEOETHYL ETHER
Appendix F, Part 3
DICHLOFENTHION
Schedule 6
DICHLOFLUANID
Schedule 6
DICHLONE
Schedule 5
DICHLORALPHENAZONE
Schedule 4
DICHLOROBENZENE
Schedule 6
Schedule 5
Appendix E, Part 2
3,4-DICHLORO-N-[(1R,2R)-2-(DIMETHYLAMINO)CYCLOHEXYL]-N-
METHYLBENZAMIDE (U-47700)
cross reference: N,N-DIALKYLAMINOCYCLOHEXYL ALKYL BENZAMIDES
Schedule 9
DICHLOROETHYL ETHER
Schedule 6
Appendix E, Part 2
DICHLOROETHYLENE
Appendix F, Part 3
DICHLOROISOCYANURIC ACID
cross reference: CHLORINE, CHLORINATING COMPOUNDS,
DICHLOROISOCYANURATES, SODIUM DICHLOROISOCYANURATE
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3

INDEX
DICHLOROMETHANE
cross reference: METHYLENE CHLORIDE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
3,4-DICHLORO-N-{[1-DIMETHYLAMINO)CYCLOHEXYL]METHYL}
BENZAMIDE
cross reference: AH-7921
Schedule 9
4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE
Schedule 6
DICHLOROPHEN
Schedule 6
Schedule 5
Schedule 4
2,4-DICHLORPROP
Schedule 6
1,2-DICHLOROPROPANE
Schedule 6
1,3-DICHLOROPROPENE
Schedule 7
Appendix J, Part 2
DICHLORPHENAMIDE
Schedule 4
DICHLORVOS
Schedule 7
Schedule 6
Schedule 5
DICHROMATES
Appendix E, Part 2
DICLAZURIL

INDEX
Appendix B, Part 3
DICLOBUTRAZOL
Schedule 5
DICLOFENAC
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
DICLOFOP-METHYL
Schedule 6
DICLORAN
Schedule 5
DICLOXACILLIN
Schedule 4
DICOFOL
Schedule 5
DICOPHANE
cross reference: DDT
Schedule 10
DICROTOPHOS
Schedule 7
DICYCLANIL
Schedule 6
DICYCLOMINE
Schedule 4
DIDANOSINE
Schedule 4

INDEX
DIDECYLDIMETHYLAMMONIUM SALTS
Schedule 6
DIELDRIN
Schedule 6
DIENESTROL
Schedule 4
Appendix F, Part 3
Appendix L
DIENOGEST
Schedule 4
DIESEL
Appendix E, Part 2
DIETHANOLAMINE
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
DIETHAZINE
Schedule 4
DIETHYL CARBONATE
Appendix B, Part 3
DIETHYLCARBAMAZINE
Schedule 4
DIETHYLENE GLYCOL
Schedule 10
Schedule 6
Schedule 5
DIETHYLENE GLYCOL MONOBUTYL ETHER

INDEX
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
DIETHYLENE GLYCOL MONOMETHYL ETHER
Schedule 10
Schedule 6
DIETHYLHEXYL PHTHALATE
Schedule 10
DIETHYLPHTHALATE
Schedule 10
DIETHYLPROPION
Schedule 4
DIETHYLTHIAMBUTENE
Schedule 9
DIETHYLTOLUAMIDE (DEET)
Schedule 5
Appendix F, Part 3
N,N-DIETHYLTRYPTAMINE
cross reference: DET
Schedule 9
DIFENACOUM
Schedule 7
Schedule 6
Appendix J, Part 2
DIFENOCONAZOLE
Schedule 5
DIFENOXIN
Schedule 8
Schedule 4
Appendix K

INDEX
DIFENZOQUAT
Schedule 6
DIFETHIALONE
Schedule 7
Schedule 6
DIFLORASONE
Schedule 4
DIFLOXACIN
Schedule 4
DIFLUBENZURON
Schedule 5
DIFLUCORTOLONE
Schedule 4
DIFLUFENICAN
Appendix B, Part 3
DIFLUNISAL
Schedule 4
DIGITALIS LANATA
Schedule 4
DIGITALIS PURPUREA
Schedule 4
DIGITOXIN
Schedule 4
DIGOXIN
Schedule 4
DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab)

INDEX
Schedule 4
DIHYDRALAZINE
Schedule 4
DIHYDROCODEINE
Schedule 8
Schedule 4
Schedule 3
Appendix K
DIHYDROERGOTOXINE
Schedule 4
DIHYDROLONE
Schedule 4
2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-
B]INDOL-1-ONE (SGT-151)
cross reference: SGT-151, CUMYL-PEGACLONE
Schedule 9
DIHYDROMORPHINE
Schedule 8
DIHYDROSTREPTOMYCIN
Schedule 4
DIHYDROTACHYSTEROL
Schedule 4
5,6-DIHYDROXYINDOLINE
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DIIODOHYDROXYQUINOLINE
cross reference: IODOQUINOL

INDEX
Schedule 10
Schedule 4
Schedule 3
DI-IODOHYDROXYQUINOLINE
cross reference: DIIODOHYDROXYQUINOLINE
DIISOBUTYL PHTHALATE
Schedule 10
DIISOPROPYLAMINE DICHLOROACETATE
Schedule 4
DIKEGULAC-SODIUM
Appendix B, Part 3
DILTIAZEM
Schedule 4
DIMEFOX
Schedule 7
DIMENHYDRINATE
Schedule 4
Schedule 3
Schedule 2
Appendix H
Appendix K
DIMENOXADOL
Schedule 9
DIMEPHEPTANOL
Schedule 9
DIMERCAPROL
Schedule 4
DIMETHANDROSTANOLONE
Schedule 4

INDEX
DIMETHAZINE
Schedule 4
DIMETHENAMID-P
Schedule 6
DIMETHICODIETHYLBENZALMALONATE
cross reference: POLYSILICONE-15
Schedule 5
DIMETHICONE
cross reference: DIMETICONE
DIMETHINDENE
Schedule 4
Appendix K
DIMETHIPIN
Schedule 6
ambrette)
cross reference: Amber musk
Schedule 10
DI(METHYLOXYETHYL) PHTHALATE
Schedule 10
1,4-DIMETHYLPENTYLAMINE (DMPA)
cross reference: 1,4-DIMETHYLAMYLAMINE (DMAA)
Schedule 10
DIMETHIRIMOL
Schedule 5
DIMETHOATE
Schedule 6
DIMETHOMORPH

INDEX
Schedule 5
DIMETHOTHIAZINE
Schedule 4
DIMETHOXANATE
Schedule 4
2,5-DIMETHOXYAMFETAMINE
cross reference: 2,5-DIMETHOXYAMPHETAMINE, DMA
Schedule 9
2,5-DIMETHOXY-4-BROMOAMFETAMINE
cross reference: 2,5-DIMETHOXY-4-BROMOAMPHETAMINE, DOB
Schedule 9
2,5-DIMETHOXY-4-ETHYL-a-AMFETAMINE
cross reference: 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE, DOET
Schedule 9
2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE
cross reference: 2C-T-2
Schedule 9
2,5-DIMETHOXY-4-IODOPHENETHYLAMINE
cross reference: 2C-I
Schedule 9
2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE
cross reference: 2C-T-7
Schedule 9
2,6-DIMETHOXY-3,5-PYRIDINEDIAMINE
Schedule 6
Appendix F, Part 3
DIMETHYLACETAMIDE
Schedule 6
Schedule 5

INDEX
N,N-DIMETHYLAMFETAMINE
cross reference: N,N-DIMETHYLAMPHETAMINE, DIMETAMFETAMINE
Schedule 9
4-DIMETHYLAMINOAZOBENZENE
cross reference: MOCA, N,N-DIMETHYL-4-[PHENYLAZO]-BENZENAMINE
Schedule 7
Appendix J, Part 2
3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE
cross reference: PSILOCINE, PSILOTSIN
Schedule 9
1,3-DIMETHYLAMYLAMINE
cross reference: 4-METHYLHEXANE-2-AMINE, DMAA
Schedule 10
1,3-DIMETHYLBUTYLAMINE (DMBA)
cross reference: octodrine, 1-aminoisoheptane, DMHA, 1,5-dimethylhexylamine,
4-methylhexane-2-amine, 1,3-dimethylamylamine, DMAA, 4-amino-2-methylpentane Citrate
(AMP Citrate)
Schedule 10
4,4-DIMETHYL-1-CYCLOHEXENE-1-PROPANAL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
N,N-DIMETHYLDECANAMIDE
Schedule 6
DIMETHYL ETHER
Appendix B, Part 3
ambrette)
cross reference: Amber musk
Schedule 10
DIMETHYLFORMAMIDE

INDEX
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Part 1 - Interpretation
DIMETHYL FUMARATE
Schedule 4
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-
TRIMETHYL-6H-DIBENZO (b,d) PYRAN
cross reference: DMHP
Schedule 9
1,5-DIMETHYLHEXYLAMINE (DMHA)
cross reference: 1,3-dimethylbutylamine, DMBA, octodrine, 1-aminoisoheptane, DMHA,
4-methylhexane-2-amine, 1,3-dimethylamylamine, DMAA, 4-amino-2-methylpentane Citrate
(AMP Citrate)
Schedule 10
N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE
cross reference: 3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE,
MDMA
Schedule 9
3,7-DIMETHYL-2,6-OCTADIENAL
cross reference: CITRAL, NERAL, GERANIAL
Schedule 5
3,7-DIMETHYL-2,6-OCTADIEN-1-OL
cross reference: GERANIOL, NEROL, CITROL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
N,N-DIMETHYLOCTANAMIDE
Schedule 6
DIMETHYLPHTHALATE
Schedule 10
DIMETHYL SULFATE

INDEX
Schedule 7
Appendix F, Part 3
DIMETHYL SULFOXIDE
cross reference: COPPER SALICYLATE, METHYL SALICYLATE
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
DIMETHYLTHIAMBUTENE
Schedule 9
N,N-DIMETHYLTRYPTAMINE
cross reference: DMT
Schedule 9
DIMETICONE
cross reference: DIMETHICONE
Appendix B, Part 3
DIMETILAN
Schedule 7
DIMETRIDAZOLE
Schedule 4
DIMIRACETAM
Schedule 4
DINICONAZOLE
Schedule 5
2,4-DINITROCHLOROBENZENE
Schedule 4
DINITROCRESOLS
Schedule 7
Schedule 6
Schedule 4

INDEX
Appendix E, Part 2
Appendix J, Part 2
DINITRONAPHTHOLS
Schedule 4
DINITROPHENOLS
Schedule 10
Schedule 7
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
DINITROTHYMOLS
Schedule 4
DINOCAP
Schedule 7
Appendix F, Part 3
DINOPROST
Schedule 4
Appendix D, Item 1
DINOPROSTONE
Schedule 4
Appendix D, Item 1
DINOSEB
Schedule 7
Appendix J, Part 2
DINOTEFURAN
Schedule 5
DI-n-PROPYL ISOCINCHOMERONATE (previoiusly di-N propyl isocinchomeronate)
Schedule 5
DIOXACARB

INDEX
Schedule 6
DIOXANE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
Appendix G
DIOXAPHETYL BUTYRATE
Schedule 9
DIPERODON
Schedule 4
DIPHACINONE
Schedule 6
DIPHEMANIL
Schedule 4
DIPHENAMID
Schedule 5
DIPHENHYDRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
DIPHENIDOL
Schedule 4
DIPHENOXYLATE
Schedule 8
Schedule 4
Schedule 3
Appendix F, Part 3
Appendix H
Appendix K
DIPHENYLAMINE

INDEX
Appendix B, Part 3
DIPHENYLPYRALINE
Schedule 4
Appendix K
DIPHTHERIA TOXOID
Schedule 4
DIPIPANONE
Schedule 8
DIPIVEFRIN
Schedule 4
DIPROPYLENE GLYCOL
Appendix B, Part 3
DIPYRIDAMOLE
Schedule 4
DIQUAT
Schedule 7
Schedule 6
DIRECT RED 254

cross reference: 2-NAPHTHALENESULFONIC ACID, 7-AMINO-4-HYDROXY-3-[[p-[(p-
SULFOPHENYL)AZO]PHENYL]AZO]-, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-
SULFOPHENYL)DIAZENYL]PHENYL]HYDRAZINYLIDENE]NAPHTHALENE-2-
SULFONIC ACID, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-
SULFONIC ACID BIS(TRIETHANOLAMINE) SALT, (3Z)-7-AMINO-4-OXO-3-[[4-[(4-
SULFONIC ACID DISODIUM SALT
Schedule 6
Schedule 5
DIRITHROMYCIN
Schedule 4
DIRLOTAPIDE

INDEX
Schedule 4
DISOPHENOL
Schedule 4
DISOPYRAMIDE
Schedule 4
DISPERSE YELLOW 3
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
DISTIGMINE
Schedule 4
DISTILLATE
Appendix E, Part 2
DISULFIRAM
Schedule 6
Schedule 4
DISULFOTON
Schedule 7
Schedule 6
DISULPHAMIDE
Schedule 4
DITHIANON
Schedule 6
DITHIAZANINE
Schedule 6
Schedule 4
DITHIOPYR
Schedule 5

INDEX
DITHRANOL
Schedule 3
DITIOCARB
Schedule 4
DIUREDOSAN
Schedule 6
DIURON
Appendix B, Part 3
DOBUTAMINE
Schedule 4
DOCETAXEL
Schedule 4
DOCUSATE SODIUM
cross reference: DIOCTYL SODIUM SULFOSUCCINATE
Appendix B, Part 3
N-(N-DODECYL)-2-PYRROLIDONE
cross reference: DESIGNATED SOLVENT, N-(N-OCTYL)-2-PYRROLIDONE, N-METHYL-
2-PYRROLIDONE
Schedule 6
Schedule 5
Appendix E, Part 2
DODINE
Schedule 6
DOFETILIDE
Schedule 4
DOLASETRON
Schedule 4
DOLUTEGRAVIR

INDEX
Schedule 4
DOMPERIDONE
Schedule 4
DONEPEZIL
Schedule 4
DOPAMINE
Schedule 4
DOPEXAMINE
Schedule 4
DORAMECTIN
Schedule 7
Schedule 6
Schedule 5
DORAVIRINE
Schedule 4
DORIPENEM
Schedule 4
DORNASE
Schedule 4
DORZOLAMIDE
Schedule 4
DOSULEPIN
cross reference: DOTHIEPIN.
Schedule 4
Appendix K
DOTHIEPIN
cross reference: DOSULEPIN
DOXANTRAZOLE

INDEX
Schedule 4
DOXAPRAM
Schedule 4
DOXAZOSIN
Schedule 4
DOXEPIN
Schedule 4
Appendix K
DOXORUBICIN
Schedule 4
DOXYCYCLINE
Schedule 4
DOXYLAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
2,2-DPA
cross reference: SODIUM 2,2-DICHLOROPROPIONATE
Appendix B, Part 3
DROMETRIZOLE TRISILOXANE
Appendix B, Part 3
DRONABINOL
cross reference: DELTA-9-TETRAHYDROCANNABINOL, NABIXIMOLS
Schedule 8
Appendix D, Item 3
Appendix K
DRONEDARONE
Schedule 4
DROPERIDOL

INDEX
Schedule 4
Appendix K
DROSPIRENONE
Schedule 4
DROSTANOLONE
Schedule 4
DROTEBANOL
Schedule 8
DROTRECOGIN
Schedule 4
DSMA
Schedule 7
Schedule 6
DUBOISIA LEICHHARDTII
Schedule 4
Schedule 2
DUBOISIA MYOPOROIDES
Schedule 4
Schedule 2
DUDDINGTONIA FLAGRANS, STRAIN IAH 1297
Appendix B, Part 3
DULAGLUTIDE
Schedule 4
DULCIN
Schedule 10
DULOXETINE
Schedule 4
Appendix K

INDEX
DUPILUMAB
Schedule 4
DURVALUMAB
Schedule 4
DUTASTERIDE
Schedule 4
DYDROGESTERONE
Schedule 4
(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-
EN-3-OL
cross reference: UNICONAZOLE-P
Schedule 6
ECGONINE
Schedule 9
ECONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
ECOTHIOPATE
cross reference: ECOTHIOPATE IODIDE
Schedule 4
ECTYLUREA
Schedule 4
ECULIZUMAB
Schedule 4

INDEX
EDETIC ACID
cross reference: DICOBALT EDETATE
Schedule 4
EDOXUDINE
Schedule 4
EDROPHONIUM
Schedule 4
EFALIZUMAB
Schedule 4
EFAVIRENZ
Schedule 4
EFLORNITHINE
Schedule 4
EFORMOTEROL
cross reference: FORMOTEROL
ELBASVIR
Schedule 4
ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS
Appendix A
ELECTRONIC COMPONENTS
Appendix A
ELETRIPTAN
Schedule 4
Schedule 3
Appendix H
ELEXACAFTOR
Schedule 4
ELOSULFASE ALFA

INDEX
Schedule 4
ELOTUZUMAB
Schedule 4
ELTENAC
Schedule 4
ELTROMBOPAG
Schedule 4
ELUXADOLINE
Schedule 4
ELVITEGRAVIR
Schedule 4
EMAMECTIN
Schedule 7
Schedule 6
Schedule 5
EMEPRONIUM
Schedule 4
EMETINE
cross reference: CEPHAELIS ACUMINATA
Schedule 4
EMODEPSIDE
Schedule 6
Schedule 5
EMPAGLIFLOZIN
Schedule 4
EMTRICITABINE
Schedule 4
ENALAPRIL

INDEX
Schedule 4
ENASIDENIB
Schedule 4
ENCORAFENIB
Schedule 4
ENDOSULFAN
Schedule 7
Schedule 6
ENDOTHAL
Schedule 7
Schedule 6
ENDRIN
Schedule 7
ENESTEBOL
Schedule 4
ENFLURANE
Schedule 4
ENFUVIRTIDE
Schedule 4
ENHANCING AGENTS
cross reference: MAGNETIC RESONANCE IMAGING ENHANCING AGENTS,
ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING
Appendix A
ENOBOSARM
Schedule 4
Appendix D, Item 5 (SELECTIVE ANDROGEN RECEPTOR MODULATORS)
ENOXACIN
Schedule 4

INDEX
ENOXAPARIN
Schedule 4
ENOXIMONE
Schedule 4
ENPROSTIL
Schedule 4
ENROFLOXACIN
Schedule 4
ENTACAPONE
Schedule 4
ENTECAVIR
Schedule 4
ENTRECTINIB
Schedule 4
ENZALUTAMIDE
Schedule 4
Appendix D, Item 6
Appendix F, Part 3
Appendix L, Part 2
EPHEDRA spp.
Schedule 4
EPHEDRINE
cross reference: EPHEDRA
Schedule 4
Appendix D, Item 5
Appendix F, Part 3
EPICHLOROHYDRIN
Schedule 7
Appendix F, Part 3
Appendix J, Part 2

INDEX
EPICILLIN
Schedule 4
EPIDERMAL GROWTH FACTOR

cross reference: SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1
Schedule 7
Appendix G
Appendix J, Part 2
EPINASTINE
Schedule 4
EPINEPHRINE
cross reference: ADRENALINE
EPIRUBICIN
Schedule 4
EPITIOSTANOL
Schedule 4
EPLERENONE
Schedule 4
EPOETINS
cross reference: METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA
Schedule 4
Appendix D, Item 5
EPOPROSTENOL
Schedule 4
EPOXICONAZOLE
Schedule 5
EPOXY RESINS, LIQUID

cross reference: RESINS
Schedule 5
Appendix E, Part 2
Appendix F, Part 3

INDEX
EPRINOMECTIN
Schedule 7
Schedule 6
Schedule 5
EPROSARTAN
Schedule 4
EPSIPRANTEL
Appendix B, Part 3
EPTC
Schedule 6
EPTIFIBATIDE
Schedule 4
EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN

cross reference: IMMUNOGLOBULINSERGOMETRINE
Schedule 4
ERENUMAB
Schedule 4
ERGOT
Schedule 4
ERGOTAMINE
Schedule 4
ERGOTOXINE
Schedule 4
ERIBULIN MESILATE
cross reference: ERIBULIN MESYLATE
Schedule 4
ERLOTINIB
Schedule 4

INDEX
ERTAPENEM
Schedule 4
ERTUGLIFLOZIN
Schedule 4
ERYSIMUM spp.
Schedule 4
Appendix G
ERYTHRITYL TETRANITRATE
Schedule 3
ERYTHROMYCIN
Schedule 4
ERYTHROPOIETIN
Schedule 4
Appendix D, Item 5
ERYTHROPOIETINS
Schedule 4
Appendix D, Item 5
ESBIOTHRIN
Schedule 6
Schedule 5
ESCITALOPRAM
Schedule 4
ESFENVALERATE
Schedule 6
Schedule 5
ESMOLOL
Schedule 4
ESOMEPRAZOLE

INDEX
Schedule 4
Schedule 2
Appendix H
ESTRADIOL
Schedule 5
Schedule 4
Appendix G
ESTRAMUSTINE
Schedule 4
ESTRIOL
Schedule 4
ESTROGENS
Schedule 4
ESTRONE
Schedule 4
Appendix G
ESTROPIPATE
cross reference: PIPERAZINE ESTRONE SULFATE
Schedule 4
ETACONAZOLE
Schedule 7
Appendix J, Part 2
ETACRYNIC ACID
Schedule 4
ETAFEDRINE
Schedule 2
ETANERCEPT
Schedule 4
ETHACRYNIC ACID
cross reference: ETACRYNIC ACID

INDEX
ETHAMBUTOL
Schedule 4
ETHAMETSULFURON-METHYL
Appendix B, Part 3
ETHAMIVAN
Schedule 4
1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N-

METHYLMETHANAMINE
cross reference: N-METHYLMETHANAMINE
Schedule 5
ETHANOL
cross reference: ETHYL ALCOHOL
ETHANOLAMINE
cross reference: MONOETHANOLAMINE
ETHCHLORVYNOL
Schedule 4
ETHEPHON
Schedule 6
ETHER
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
ETHINAMATE
Schedule 4
ETHINYLESTRADIOL
Schedule 4
ETHINYLOESTRADIOL
cross reference: ETHINYLESTRADIOL

INDEX
ETHIOFENCARB
Schedule 6
ETHION
Schedule 7
ETHIONAMIDE
Schedule 4
ETHISTERONE
Schedule 4
ETHOATE-METHYL
Schedule 6
ETHOFUMESATE
Schedule 5
ETHOGLUCID
Schedule 4
ETHOHEPTAZINE
Schedule 4
ETHOPABATE
Appendix B, Part 3
ETHOPROPAZINE
Schedule 4
ETHOPROPHOS
cross reference: LINSEED OIL
Schedule 7
Schedule 6
ETHOSUXIMIDE
Schedule 4

INDEX
ETHOTOIN
Schedule 4
2-ETHOXYETHANOL
Schedule 7
Appendix F, Part 3
ETHOXYETHYLMERCURIC CHLORIDE
Appendix F, Part 3
ETHOXYQUIN
Schedule 5
ETHOXYSULFURON
Schedule 5
ETHOXZOLAMIDE
Schedule 4
ETHYL ACETATE
Appendix B, Part 3
ETHYL ALCOHOL
Appendix B, Part 3
ETHYL BROMIDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ETHYL BUTYRATE
Appendix B, Part 3
ETHYL CHLORIDE
Schedule 4
ETHYL FORMATE
Schedule 6

INDEX
ETHYL LACTATE
Appendix B, Part 3
ETHYL METHACRYLATE
Schedule 5
Appendix F, Part 3
ETHYLAMFETAMINE
cross reference: ETHYLAMPHETAMINE
Schedule 8
ETHYLBUTYLACETYL-
Appendix B, Part 3
ETHYLDIENOLONE
Schedule 4
ETHYLENE CHLOROHYDRIN
Schedule 6
Appendix F, Part 3
ETHYLENE DIBROMIDE
Schedule 7
Appendix J, Part 2
ETHYLENE DICHLORIDE
Schedule 6
ETHYLENE GLYCOL
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
ETHYLENE GLYCOL MONOALKYL ETHERS
Schedule 6
Appendix E, Part 2
Appendix F, Part 3

INDEX
ETHYLENE OXIDE
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
ETHYLESTRENOL
cross reference: ETHYLOESTRENOL
Schedule 4
ETHYLHEXANEDIOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
2-ETHYLHEXANOIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ETHYLMERCURIC CHLORIDE
Appendix F, Part 3
N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE
cross reference: N-ETHYL MDA
Schedule 9
ETHYLMETHYLTHIAMBUTENE
Schedule 9
ETHYLMORPHINE
Schedule 8
Schedule 4
Schedule 2
Appendix K
ETHYLOESTRENOL
cross reference: ETHYLESTRENOL
ETHYNODIOL
cross reference: ETYNODIOL

INDEX
ETICYCLIDINE
cross reference: PCE
Schedule 9
ETIDOCAINE
Schedule 4
ETIDRONIC ACID
cross reference: ETIDRONATE DISODIUM
Schedule 4
ETILEFRIN
Schedule 4
ETIPROSTON
Schedule 4
ETODOLAC
Schedule 4
ETOFENAMATE
Schedule 4
Schedule 2
ETOFENPROX
Appendix B, Part 3
ETONITAZENE
Schedule 9
ETONOGESTREL
Schedule 4
ETOPOSIDE
Schedule 4
ETORICOXIB
Schedule 4

INDEX
ETORPHINE
Schedule 9
ETOXAZOLE
Appendix B, Part 3
ETOXERIDINE
Schedule 9
ETRAVIRINE
Schedule 4
ETRETINATE
Schedule 4
Appendix D, Item 5
Appendix F, Part 3
Appendix L, Part 2
ETRIDIAZOLE
Schedule 5
ETRIMFOS
Schedule 6
ETYNODIOL
cross reference: ETHYNODIOL
Schedule 4
EUBACTERIUM sp. strain DSM11798
Appendix B, Part 3
EUCALYPTUS OIL
Schedule 6
Appendix E, Part 2
EUGENOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3

INDEX
EUPATORIUM CANNABINUM
cross reference: HEMP AGRIMONY
Schedule 10
EVEROLIMUS
Schedule 4
EXEMESTANE
Schedule 4
EXENATIDE
Schedule 4
EXPLOSIVES
Appendix A
EXTRACT OF LEMON EUCALYPTUS

cross reference: CORYMBIA CITRIODORA, OIL OF LEMON EUCALYPTUS
Schedule 5
EZETIMIBE
Schedule 4
FAMCICLOVIR
Schedule 4
Schedule 3
Appendix H
FAMOTIDINE
Schedule 4
Schedule 2
Appendix F, Part 3
FAMPHUR
Schedule 7
Schedule 6
FARFUGIUM JAPONICUM

INDEX
Schedule 10
FASORACETAM
Schedule 4
FEBANTEL
Schedule 6
FEBUXOSTAT
Schedule 4
FELBINAC
Schedule 4
Schedule 2
FELODIPINE
Schedule 4
FELYPRESSIN
Schedule 4
FENAMIPHOS
Schedule 7
Schedule 6
FENARIMOL
Schedule 5
FENAZAFLOR
Schedule 6
FENBENDAZOLE
Schedule 5
FENBUCONAZOLE
Schedule 5
FENBUFEN

INDEX
Schedule 4
FENBUTATIN OXIDE
Schedule 6
FENCAMFAMIN
Schedule 4
FENCHLORAZOLE-ETHYL
Schedule 5
FENCHLORPHOS
Schedule 6
FENCLOFENAC
Schedule 4
FENETYLLINE
Schedule 9
FENFLURAMINE
Schedule 4
Appendix K
FENFURAM
Appendix B, Part 3
FENHEXAMID
Appendix B, Part 3
FENITROTHION
Schedule 6
FENNEL OIL
Schedule 5
Appendix E, Part 2
FENOFIBRATE
Schedule 4

INDEX
FENOLDOPAM
Schedule 4
FENOPROFEN
Schedule 4
FENOPROP
Schedule 5
FENOTEROL
Schedule 4
FENOXACRIM
Schedule 7
Schedule 6
FENOXAPROP-ETHYL
Schedule 5
FENOXAPROP-p-ETHYL
Schedule 5
FENOXYCARB
Appendix B, Part 3
FENPIPRAMIDE
Schedule 4
FENPIPRANE
Schedule 4
FENPROPOREX
Schedule 4
FENPROSTALENE
Schedule 4
FENPYRAZAMINE

INDEX
Schedule 5
FENPYROXIMATE
Schedule 6
FENSON
Schedule 5
FENSULFOTHION
Schedule 7
FENTANYL
Schedule 8
Appendix K
FENTEROL
Appendix F, Part 3
FENTHION
Schedule 7
Schedule 6
Schedule 5
FENTHION-ETHYL
Schedule 7
FENVALERATE
Schedule 6
FERRIC DERISOMALTOSE
Schedule 4
FEXOFENADINE
Schedule 4
Schedule 2
FIBRINOLYSIN
Schedule 4
FIBROBLAST GROWTH FACTORS

INDEX
Schedule 4
Appendix D, Item 5
FIDAXOMICIN
Schedule 4
FILGOTINIB
Schedule 4
FILGRASTIM
Schedule 4
FINASTERIDE
Schedule 4
FINGOLIMOD
Schedule 4
Appendix L, Part 2
FIPRONIL
Schedule 6
Schedule 5
FIROCOXIB
Schedule 4
FLAMPROP-METHYL
Schedule 5
FLAMPROP-M-METHYL
Schedule 5
FLAVOXATE
Schedule 3
FLAZASULFURON
Schedule 5
FLECAINIDE

INDEX
Schedule 4
FLEROXACIN
Schedule 4
FLOCOUMAFEN
Schedule 7
Schedule 6
FLOCTAFENINE
Schedule 4
FLONICAMID
Schedule 6
FLORASULAM
Schedule 5
FLORFENICOL
Schedule 4
FLORPYRAUXIFEN-BENZYL
Appendix B, Part 3
FLORYLPICOXAMID
Appendix B, Part 3
FLUANISONE
Schedule 4
FLUAZAINDOLIZINE
Schedule 6
Schedule 5
FLUAZIFOP-BUTYL
Schedule 6
FLUAZIFOP-p-BUTYL
Schedule 6

INDEX
FLUAZINAM
Schedule 6
FLUAZURON
Schedule 5
FLUBENDAZOLE
Schedule 5
FLUBENDIAMIDE
Schedule 5
FLUBROMAZEPAM
Schedule 9
FLUBROMAZOLAM
Schedule 9
FLUCHLORALIN
Schedule 5
FLUCLOROLONE
Schedule 4
FLUCLOXACILLIN
Schedule 4
FLUCOFURON
Schedule 7
Schedule 6
FLUCONAZOLE
Schedule 4
Schedule 3
Appendix F, Part 3
Appendix H
FLUCYTHRINATE
Schedule 7

INDEX
FLUCYTOSINE
Schedule 4
FLUDARABINE
Schedule 4
FLUDIOXONIL
Schedule 5
FLUDROCORTISONE
Schedule 4
FLUENSULFONE
Schedule 6
FLUFENAMIC ACID
Schedule 4
FLUFENOXURON
Appendix B, Part 3
FLUMAZENIL
Schedule 4
FLUMETASONE
cross reference: FLUMETHASONE
Schedule 4
FLUMETHASONE
cross reference: FLUMETASONE
FLUMETHIAZIDE
Schedule 4
FLUMETHRIN
Schedule 6
Schedule 5
FLUMETSULAM

INDEX
Appendix B, Part 3
FLUMICLORAC PENTYL
Schedule 5
FLUMIOXAZIN
Schedule 7
Schedule 6
FLUNISOLIDE
Schedule 4
FLUNITRAZEPAM
Schedule 8
Appendix D, Item 5 (Benzodiazepine derivatives)
Appendix K
FLUNIXIN MEGLUMINE
Schedule 4
FLUOCINOLONE
Schedule 4
FLUOCINONIDE
Schedule 4
FLUOCORTIN
Schedule 4
FLUOCORTOLONE
Schedule 4
FLUOMETURON
Appendix B, Part 3
FLUOPICOLIDE
Appendix B, Part 3
FLUOPYRAM

INDEX
Schedule 5
FLUORESCEIN
Schedule 4
FLUORIDES
cross reference: SILICOFLUORIDES
Schedule 6
Schedule 5
Schedule 4
Schedule 3
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
Appendix H
FLUOROACETAMIDE
Schedule 7
FLUOROACETIC ACID
Schedule 7
Appendix J, Part 2
FLUOROMETHOLONE
Schedule 4
4-FLUORO-N-METHYLAMFETAMINE
cross reference: 4-FLUORO-N-METHYLAMPHETAMINE, 4-FLUORO-N-
METHAMFETAMINE
Schedule 9
1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE
cross reference: AM-694
Schedule 9
FLUOROURACIL
Schedule 4
FLUOXETINE
Schedule 4
FLUOXYMESTERONE

INDEX
Schedule 4
FLUPENTIXOL
cross reference: FLUPENTHIXOL
Schedule 4
Appendix K
FLUPHENAZINE
Schedule 4
Appendix K
FLUPROPANATE
cross reference: TETRAPION
Schedule 6
FLUPROSTENOL
Schedule 4
FLUPYRADIFURONE
Schedule 6
FLUQUINCONAZOLE
Schedule 6
FLURALANER
cross-reference: CARBAMOYL BENZAMIDE, PHENYL ISOXAZOLINE
Schedule 5
FLURANDRENOLONE
Schedule 4
FLURAZEPAM
Schedule 4
Appendix K
FLURBIPROFEN
Schedule 4
Schedule 2

INDEX
FLUOROACETAMIDE
Appendix J, Part 2
FLUROXENE
Schedule 4
FLUROXYPYR
Appendix B, Part 3
FLUSILAZOL
Schedule 6
FLUSPIRILENE
Schedule 4
FLUTAMIDE
Schedule 4
FLUTICASONE
cross reference: FLUTICASONE PROPIONATE, FLUTICASONE FUROATE
Schedule 4
FLUTICASONE FUROATE
cross reference FLUTICASONE
FLUTICASONE PROPIONATE
Schedule 4
Schedule 2
FLUTOLANIL
Appendix B, Part 3
FLUTRIAFOL
Schedule 6
FLUVALINATE
Schedule 6
Schedule 5
FLUVASTATIN

INDEX
Schedule 4
FLUVOXAMINE
Schedule 4
FLUXAPYROXAD
Schedule 5
FOLIC ACID
Schedule 4
Schedule 2
FOLINIC ACID
cross reference: CALCIUM FOLINATE
Schedule 4
Schedule 2
FOLLICLE-STIMULATING HORMONE
Schedule 4
Appendix D, Item 1
FOLLISTATIN
Schedule 4
Appendix D, Item 5
FOLLITROPIN ALFA
cross reference: FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN
Schedule 4
Appendix D, Item 1
FOLLITROPIN BETA
Schedule 4
Appendix D, Item 1
FOLLITROPIN DELTA
Schedule 4
Appendix D, Item 1
FOLPET

INDEX
Schedule 7
Appendix J, Part 2
FOMEPIZOLE
Schedule 4
FOMESAFEN SODIUM
Schedule 6
FOMIVIRSEN
Schedule 4
FONDAPARINUX
Schedule 4
FOOD
Appendix A
FORAMSULFURON
Schedule 5
FORCHLORFENURON
Appendix B, Part 3
FORMALDEHYDE
cross reference: FORMALDEHYDE CONDENSATION PRODUCT,
METACRESOLSULPHONIC ACID, FREE FORMALDEHYDE, METHYLENE GLYCOL
Schedule 10
Schedule 6
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
FORMALDEHYDE CONDENSATION PRODUCT
Schedule 6
FORMEBOLONE
Schedule 4
FORMESTANE

INDEX
Schedule 4
FORMETANATE
Schedule 7
FORMIC ACID
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
FORMOTEROL
Schedule 4
FORMOTHION
Schedule 6
FOSAMPRENAVIR
Schedule 4
FOSAPREPITANT
Schedule 4
FOSCARNET
Schedule 4
FOSFESTROL
cross reference: DIETHYLSTILBESTROL DIPHOSPHATE
Schedule 4
FOSFOMYCIN
Schedule 4
FOSINOPRIL
Schedule 4
FOSNETUPITANT
Schedule 4
FOSPHENYTOIN

INDEX
Schedule 4
FOSPIRATE
Schedule 6
Schedule 5
FOSTHIAZATE
Schedule 7
FOTEMUSTINE
Schedule 4
FRAMYCETIN
Schedule 4
FRITTED GLAZING OR ENAMELLING PREPARATIONS
Appendix A
FULLERS EARTH
Appendix B, Part 3
FULVESTRANT
Schedule 4
FUMAGILLIN
Schedule 6
FUNGAL PROTEASE derived from Aspergillus niger
Appendix B, Part 3
FURALAXYL
Schedule 5
FURALTADONE
Schedule 4
FURATHIOCARB
Schedule 7
Schedule 5

INDEX
FURAZABOL
Schedule 4
FURAZOLIDONE
Schedule 4
FURETHIDINE
Schedule 9
FURFURAL
cross reference: 2-FURANCARBOXALDEHYDE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
FUROSEMIDE
cross reference: FRUSEMIDE
Schedule 4
FUSIDIC ACID
Schedule 4
GABAPENTIN
Schedule 4
Appendix K
GALANTAMINE
Schedule 4
GALANTHUS spp.
Schedule 4
GALCANEZUMAB
Schedule 4
GALLAMINE
Schedule 4

INDEX
GALSULFASE
Schedule 4
GAMMA BUTYROLACTONE
Schedule 10
GAMMA HYDROXYBUTYRATE
cross reference: 4-HYDROXYBUTANOIC ACID, GHB, SODIUM OXYBATE
Schedule 9
GAMMA-CYHALOTHRIN
Schedule 7
Schedule 5
GANCICLOVIR
Schedule 4
GANIRELIX
Schedule 4
GATIFLOXACIN
Schedule 4
GEFITINIB
Schedule 4
GELSEMIUM SEMPERVIRENS
Schedule 2
Appendix G
GEMCITABINE
Schedule 4
Appendix K
GEMEPROST
Schedule 4
GEMFIBROZIL
Schedule 4

INDEX
GEMIFLOXACIN
Schedule 4
GEMTUZUMAB OZOGAMICIN
Schedule 4
GENTAMICIN
Schedule 4
GENTIAN VIOLET
cross reference: METHYLROSANILINIUM CHLORIDE, CRYSTAL VIOLET
GERANIUM OIL
Appendix B, Part 3
GESTODENE
Schedule 4
GESTONORONE
Schedule 4
GESTRINONE
Schedule 4
GHRH INJECTABLE PLASMID
Schedule 4
GIBBERELLIC ACID
Appendix B, Part 3
GILTERITINIB
Schedule 4
GITALIN
Schedule 4
GLASS
cross reference: CRYSTAL WARE

INDEX
Appendix A
GLATIRAMER ACETATE
Schedule 4
GLAZED POTTERY
Appendix A
GLECAPREVIR
Schedule 4
GLIBENCLAMIDE
Schedule 4
GLIBORNURIDE
Schedule 4
GLICLAZIDE
Schedule 4
GLIMEPIRIDE
Schedule 4
GLIPIZIDE
Schedule 4
GLISOXEPIDE
Schedule 4
GLUCAGON
Schedule 3
Appendix G
Appendix H
α-GLUCANASE derived from Aspergillus niger
Appendix B, Part 3
GLUFOSINATE-AMMONIUM
Schedule 5

INDEX
GLUTARAL
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
GLUTARALDEHYDE
cross reference: GLUTARAL
GLUTATHIONE
Schedule 4
GLUTETHIMIDE
Schedule 4
Appendix D, Item 5
Appendix K
GLYCERYL THIOGLYCOLLATE
Schedule 6
GLYCERYL TRINITRATE
Schedule 4
Schedule 3
Appendix G
Appendix H
GLYCOLIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
GLYCOPYRRONIUM
Schedule 4
Schedule 3
GLYCOSYLATED HYDROQUINONE
cross reference: HYDROQUINONE
GLYMIDINE
Schedule 4
GLYPHOSATE

INDEX
Schedule 5
GnRH VACCINE
Schedule 4
GOLIMUMAB
Schedule 4
GONADORELIN
Schedule 4
GONADOTROPHIC HORMONES
Schedule 4
GOSERELIN
Schedule 4
GRAMICIDIN
Schedule 4
GRANISETRON
Schedule 4
GRAPIPRANT
Schedule 4
GRAZOPREVIR
Schedule 4
GREPAFLOXACIN
Schedule 4
GRISEOFULVIN
Schedule 4
GROWTH HORMONE RELEASING HORMONES *(GHRHs)
Schedule 4
Appendix D, Item 5

INDEX
GROWTH HORMONE RELEASING PEPTIDE-6 (GHRP-6)
Schedule 4
Appendix D, Item 5
GROWTH HORMONE RELEASING PEPTIDE *(GHRPs)
Schedule 4
Appendix D, Item 5
GROWTH HORMONE SECRETAGOGUES *(GHSs)
Schedule 4
Appendix D, Item 5
GUAIFENESIN
cross reference: PARACETAMOL
Schedule 4
Schedule 2
GUAIPHENESIN
cross reference: GUAIFENESIN
GUANABENZ
Schedule 4
GUANACLINE
Schedule 4
GUANETHIDINE
Schedule 4
GUANFACINE
Schedule 4
Appendix K
GUANIDINE
Schedule 6
Schedule 4
Appendix E, Part 2
GUAZATINE
Schedule 6

INDEX
GUSELKUMAB
Schedule 4
HACHIMYCIN
Schedule 4
HAEMATIN
Schedule 4
HAEMOPHILUS INFLUENZAE VACCINE
Schedule 4
HALAUXIFEN METHYL
Appendix B, Part 3
HALCINONIDE
Schedule 4
HALOFANTRINE
Schedule 4
HALOFENATE
Schedule 4
HALOFUGINONE
Schedule 7
Schedule 4
Appendix J, Part 2
HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS

cross reference: DIBENZODIOXINS, HALOGENATED - DIBENZOFURANS,
HALOGENATED, DIOXINS
Schedule 7
Appendix J, Part 2
HALOPERIDOL
cross reference: BUTYPHENONES

INDEX
Schedule 4
Appendix G
Appendix K
HALOSULFURON-METHYL
Schedule 5
HALOTHANE
Schedule 4
HALOXON
Schedule 6
HALOXYFOP
Schedule 6
HARMALA ALKALOIDS
Schedule 9
HC RED 13
cross reference: 2,2'-[(4-AMINO-3-NITROPHENYL)IMINO]BISETHANOL
HC VIOLET 1
cross reference: 2-[(4-AMINO-2-METHYL-5-NITROPHENYL)AMINO]-ETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
HCB
Schedule 7
Appendix J, Part 2
HELIOTROPIUM spp.
Schedule 10
HEMEROCALLIS
Schedule 4
HEPARINS
Schedule 4

INDEX
HEPATITIS A VACCINE
Schedule 4
HEPATITIS B VACCINE
Schedule 4
HEPTACHLOR
Schedule 6
HEROIN
Schedule 9
HETACILLIN
Schedule 4
HEXACHLOROPHANE
cross reference: HEXACHLOROPHENE
HEXACHLOROPHENE
cross reference: HCB
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
HEXACONAZOLE
Schedule 5
HEXAFLURON
Appendix B, Part 3
HEXAMETHONIUM
Schedule 4
HEXARELIN
Schedule 4
Appendix D, Item 5
HEXAZINONE

INDEX
Schedule 6
Schedule 5
HEXETIDINE
Schedule 4
HEXLOXYETHANOL
Appendix F, Part 3
HEXOBENDINE
Schedule 4
HEXOCYCLIUM
Schedule 4
HEXOPRENALINE
Schedule 4
HEXYL ACETATE
Appendix B, Part 3
HEXYL AMINOLEVULINATE (AS HYDROCHLORIDE)
Schedule 4
HEXYL CINNAMALDEHYDE
Appendix B, Part 3
3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO
(b,d) PYRAN
cross reference: PARAHEXYL
Schedule 9
HEXYLOXYETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
HEXYTHIAZOX
Appendix B, Part 3

INDEX
HISTAMINE
Schedule 4
HMG-CoA REDUCTASE INHIBITORS

cross reference: STATINS
Schedule 4
HOMATROPINE
Schedule 4
HUMAN BLOOD PRODUCTS

cross reference: ALBUMIN, ANTICOAGULATION COMPLEX, C1 ESTERASE
INHIBITORS, CLOTTING FACTORS, CRYOPRECIPITATE, FIBRINOGEN, PLASMA,
PLATELETS, PROTEIN C, PROTHROMBIN COMPLEX CONCENTRATE (PCC), RED
CELLS, THROMBIN, WHOLE BLOOD, STEM CELLS
Appendix A
HUMAN CHORIONIC GONADATROPHIN
Schedule 4
HUMAN OSTEOGENIC PROTEIN-1 (OP-1)
Appendix B, Part 3
HUMAN PAPILLOMAVIRUS VACCINE
Schedule 4
HYALURONIC ACID
Schedule 4
HYALURONIC ACID AND ITS POLYMERS
Schedule 4
HYDRALAZINE
Schedule 4
HYDRAMETHYLNON
Schedule 6
Schedule 5
HYDRARGAPHEN

INDEX
Schedule 4
HYDRAZINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
HYDROCARBONS LIQUID AROMATIC

cross reference: AROMATIC EXTRACT OILS,
Schedule 7
Appendix F, Part 3
HYDROCARBONS, LIQUID
cross reference: BENZENE, DESIGNATED SOLVENT, DIESEL (DISTILLATE), DRY
CLEANING FLUID, KEROSENE, LAMP OIL, LIGHT MINERAL OILS, LIQUID
HYDROCARBONS, MINERAL OILS, MINERAL TURPENTINE, NAPHTHALENE,
PARAFFIN OILS, PETROL, PETROLEUM OILS, REDUCERS, THINNERS, TOLUENE,
WHITE SPIRIT, WHITE PETROLEUM SPIRIT, WHITE MINERAL OILS, XYLENE
Schedule 5
Appendix E, Part 2
HYDROCHLORIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
HYDROCHLOROTHIAZIDE
Schedule 4
HYDROCODONE
Schedule 8
Appendix K
HYDROCORTISONE
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
HYDROCORTISONE ACETATE

INDEX
Schedule 3
Schedule 2
HYDROCYANIC ACID
cross reference: CYANIDES
Schedule 7
Schedule 4
Appendix F, Part 3
Appendix G
Appendix J, Part 2
HYDROFLUMETHIAZIDE
Schedule 4
HYDROFLUORIC ACID
cross reference: HYDROGEN FLUORIDE
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
HYDROGEN PEROXIDE
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
HYDROGEN SULFIDE
Schedule 7
HYDROMORPHINOL
Schedule 8
HYDROMORPHONE
Schedule 8
Appendix K
HYDROPRENE
Appendix B, Part 3

INDEX
HYDROQUINONE
cross reference: ARBUTIN, GLYCOSYLATED HYDROQUINONE, MONOBENZONE
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
cross reference: FLUOROSILICIC ACID, HEXAFLUOROSILIC ACID,
HYDROFLUOSILICIC ACID, SILICOFLUORIC ACID
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
4-HYDROXYBUTANOIC ACID
Schedule 9
HYDROXYCARBAMIDE
Schedule 4
HYDROXYCHLOROQUINE
Schedule 4
Appendix D, Item 8
2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL
cross reference: CANNABICYCLOHEXANOL, CP 47,497 C8 HOMOLOGUE, CP 47,497
Schedule 9
HYDROXYEPHEDRINE
Schedule 4
4-[(2-HYDROXYETHYL)AMINO]-3-NITROPHENOL
cross reference: 3-NITRO-p-HYDROXYETHYLAMINOPHENOL
2-HYDROXYETHYL METHACRYLATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
HYDROXYETHYL-3,4-METHYLENEDIOXYANILINE

INDEX
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
[7-HYDROXY-8-[(2- METHOXYPHENYL)AZO]-2-
NAPHTHYL]TRIMETHYLAMMONIUM CHLORIDE (CAS No. 68391-30-0)
cross reference: BASIC RED 76 (CAS No. 68391-30-0)
HYDROXYPETHIDINE
Schedule 9
HYDROXYPHENAMATE
Schedule 4
HYDROXYPROGESTERONE
Schedule 4
HYDROXYPROPYL CELLULOSE
Appendix B, Part 3
2-HYDROXYPROPYL METHACRYLATE
Schedule 5
8-HYDROXYQUINOLINE
cross reference: OXYQUINOLINE
HYDROXYSTENOZOL
Schedule 4
HYDROXYUREA
cross reference: HYDROXYCARBAMIDE
HYDROXYZINE
Schedule 4, Appendix K
HYGROMYCIN
Schedule 4
HYOSCINE
cross reference: HYOSCINE BUTYLBROMIDE

INDEX
Schedule 4
Schedule 2
Appendix G
HYOSCINE BUTYLBROMIDE
Schedule 4
Schedule 3
Schedule 2
Appendix H
HYOSCYAMINE
Schedule 2
Appendix G
HYOSCYAMUS NIGER
Schedule 2
Appendix G
HYPOTHALAMIC RELEASING FACTORS
Schedule 4
Appendix G
HYPROMELLOSE
Schedule 4
IBAFLOXACIN
Schedule 4
IBANDRONIC ACID
Schedule 4
IBOGAINE
Schedule 4
IBRITUMOMAB
Schedule 4
IBRUTINIB
Schedule 4

INDEX
IBUFENAC
Schedule 4
IBUPROFEN
cross reference: PARACETAMOL
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
IBUTAMOREN
cross reference: MK-677, Nutrobal
Schedule 4
Appendix D, Item 5
IBUTEROL
Schedule 4
IBUTILIDE
Schedule 4
ICATIBANT
Schedule 4
ICODEXTRIN
Appendix B, Part 3
IDARUBICIN
Schedule 4
IDARUCIZUMAB
Schedule 4
IDEBENONE
Schedule 4
IDOXURIDINE
Schedule 4

INDEX
IDURSULFASE
Schedule 4
IFOSFAMIDE
Schedule 4
ILOPROST
Schedule 4
IMATINIB
Schedule 4
IMAZALIL
cross reference: ENILCONAZOLE
Schedule 5
IMAZAMOX
Schedule 5
IMAZAPIC
Schedule 5
IMAZAPYR
Schedule 5
IMAZETHAPYR
Schedule 5
IMEPITOIN
Schedule 4
IMIDACLOPRID
Schedule 6
Schedule 5
IMIDAPRIL
Schedule 4
IMIDOCARB

INDEX
Schedule 6
IMIGLUCERASE
Schedule 4
IMINOCTADINE TRIALBESILATE
Schedule 6
IMIPENIM
Schedule 4
IMIPRAMINE
Schedule 4
Appendix K
IMIPROTHRIN
Schedule 6
Schedule 5
IMIQUIMOD
Schedule 4
IMMUNOGLOBULINS
cross reference: EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
Schedule 4
IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS
Appendix A
INDACATEROL
Schedule 4
INDANAZOLINE
Schedule 2
INDAPAMIDE
Schedule 4
INDAZIFLAM

INDEX
Schedule 6
INDINAVIR
Schedule 4
INDOLE-3-ACETIC ACID
Appendix B, Part 3
INDOMETACIN
Schedule 4
Schedule 2
Appendix G
INDOMETHACIN
cross reference: INDOMETACIN
INDOPROFEN
Schedule 4
INDORAMIN
Schedule 4
INDOXACARB
Schedule 6
Schedule 5
INFLIXIMAB
Schedule 4
INFLUENZA AND CORYZA VACCINES

cross reference: H5N1 INFLUENZA VIRUS HAEMAGGLUTININ
Schedule 4
INGENOL MEBUTATE
Schedule 4
INOTUZUMAB OZOGAMICIN
Schedule 4
INOSITOL NICOTINATE

INDEX
Schedule 3
INSULIN DEGLUDEC
Schedule 4
INSULIN GLARGINE
Schedule 4
INSULIN-LIKE GROWTH FACTOR I
Schedule 4
INSULIN-LIKE GROWTH FACTORS
Schedule 4
Appendix D, Item 5
INSULINS
Schedule 4
INTERFERONS
Schedule 4
INTERLEUKINS
Schedule 4
INTRAOCULAR VISCOELASTIC PRODUCTS
Appendix A
IODINE
cross reference: IODOPHORS
Schedule 6
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
IODOMETHANE
Schedule 7
Appendix J, Part 2
IODOPHORS
cross reference: IODINE

INDEX
Schedule 6
Appendix E, Part 2
3-IODO-2-PROPYNYL BUTYL CARBAMATE

cross reference: IODOCARB
Schedule 6
Schedule 5
IODOSULFURON-METHYL-SODIUM
Schedule 5
IODOTHIOURACIL
Schedule 4
IOXYNIL
Schedule 6
IPAMORELIN
Schedule 4,
Appendix D, Item 5
IPCONAZOLE
Schedule 6
Schedule 5
IPILIMUMAB
Schedule 4
IPRATROPIUM
Schedule 4
Schedule 2
IPRATROPIUM BROMIDE
Appendix F, Part 3
IPRIFLAVONE
Schedule 4
IPRINDOLE
Schedule 4

INDEX
IPRODIONE
Appendix B, Part 3
IPRONIAZID
Schedule 4
IRBESARTAN
Schedule 4
IRINOTECAN
Schedule 4
IRON COMPOUNDS
cross reference: IRON OXIDES
Schedule 6
Schedule 5
Schedule 4
Schedule 2
ISAVUCONAZOLE
Schedule 4
Appendix L
ISETHIONATE
Appendix B, Part 3
ISOAMINILE
Schedule 4
ISOAMYL NITRITE
Schedule 4
Appendix E, Part 2
ISOBUTYL NITRITE
Schedule 4
Appendix E, Part 2
ISOCARBOPHOS
Schedule 7

INDEX
ISOCARBOXAZID
Schedule 4
ISOCONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2Appendix H
ISOCYANATES
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ISOETARINE
Schedule 4
ISOEUGENOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
ISOFENPHOS
Schedule 7
ISOFETAMID
Appendix B, Part 3
ISOFLURANE
Schedule 4
ISOMETHADONE
Schedule 9
ISOMETHEPTENE
Schedule 4
ISONIAZID
Schedule 4

INDEX
ISOPHORONE
Schedule 5
Appendix E, Part 2
ISOPRENALINE
Schedule 4
Appendix F, Part 3
ISOPRENE ALCOHOL
Appendix B, Part 3
ISOPRINOSINE
Schedule 4
ISOPROPAMIDE
Schedule 4
Schedule 2
ISOPROPYL NITRITE
Schedule 10
ISOPROTURON
Schedule 7
ISOPYRAZAM
Schedule 6
ISOSORBIDE DINITRATE
Schedule 4
Schedule 3
ISOSORBIDE MONONITRATE
Schedule 4
ISOSTEARYL ALCOHOL ETHOXYLATE
Appendix B, Part 3
ISOTRETINOIN

INDEX
Schedule 4
Appendix D, Item 5
Appendix F, Part 3
Appendix L, Part 2
ISOXABEN
Schedule 5
ISOXAFLUTOLE
Schedule 5
ISOXICAM
Schedule 4
ISOXSUPRINE
Schedule 4
ISRADIPINE
Schedule 4
ITRACONAZOLE
Schedule 4
IVABRADINE
Schedule 4
IVACAFTOR
Schedule 4
IVERMECTIN
Schedule 7
Schedule 5
Schedule 4
IXABEPILONE
Schedule 4
IXAZOMIB
Schedule 4

INDEX
IXEKIZUMAB
Schedule 4
JAPANESE ENCEPHALITIS VACCINE
Schedule 4
JUNIPERUS SABINE
cross reference: SAVIN(E)
Schedule 10
KANAMYCIN
Schedule 4
KAOLIN
Appendix B, Part 3
KEROSENE
Appendix E, Part 2
KETAMINE
Schedule 8
KETANSERIN
Schedule 4
KETAZOLAM
Schedule 4
KETOBEMIDONE
Schedule 9
KETOCONAZOLE
Schedule 4
Schedule 2

INDEX
KETOPROFEN
Schedule 4
Schedule 3
Appendix H
KETOROLAC
Schedule 4
KETOTIFEN
Schedule 4
Schedule 2
KHELLIN
Schedule 4
KITASAMYCIN
Schedule 5
Schedule 4
KRATOM
cross reference: MITRAGYNA SPECIOSA, MITRAGYNINE
KRESOXIM-METHYL
Appendix B, Part 3
KUNZEA OIL
Appendix B, Part 3
LABETALOL
Schedule 4
LACIDIPINE
Schedule 4
LACOSAMIDE
Schedule 4
LAMBDA-CYHALOTHRIN

INDEX
Schedule 7
Schedule 6
Schedule 5
LAMIVUDINE
Schedule 4
LAMOTRIGINE
Schedule 4
Appendix K
LANADELUMAB
Schedule 4
LANATOSIDES
Schedule 4
LANREOTIDE
Schedule 4
LANSOPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
LANTHANUM
Schedule 4
LAPATINIB
Schedule 4
LARONIDASE
Schedule 4
LAROPIPRANT
Schedule 4
LAROTRECTINIB
Schedule 4

INDEX
LASALOCID
Schedule 6
LASIODIPLODIA PSEUDOTHEOBROMAE
Schedule 5
LATAMOXEF
Schedule 4
LATANOPROST
Schedule 4
LAUDEXIUM
Schedule 4
LAURETH CARBOXYLIC ACIDS
Schedule 6
Appendix E, Part 2
LAURIC ACID
Appendix B, Part 3
LAUROMACROGOLS
cross reference: LAURETH-9
Schedule 4
LAURYL ALCOHOL
cross reference: 1-DODECANOL
Appendix B, Part 3
LAURYL ISOQUINOLINIUM BROMIDE
Schedule 6
Appendix E, Part 2
LAURYL SULFATE SALTS

cross reference: SODIUM LAURYL SULPHATE, DODECYL SULFATES
Schedule 6
Appendix E, Part 2

INDEX
LAVANDIN OIL
cross reference: CAMPHOR
Appendix B, Part 3
LAVENDER OIL
Appendix B, Part 3
LEAD
cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES,
SELENIUM
Schedule 4
LEAD COMPOUNDS
cross reference: GLAZING PREPARATIONS, PRINTING INKS or INK ADDITIVES,
SELENIUM
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
Appendix F, Part 3
LEAD METALLIC
Appendix B, Part 3
LEDIPASVIR
Schedule 4
LEFETAMINE
Schedule 4
LEFLUNOMIDE
Schedule 4
Appendix F, Part 3
Appendix L, Part 2
LEMON OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
LEMONGRASS OIL

INDEX
Schedule 5
LENALIDOMIDE
Schedule 4
Appendix D, Item 4
Appendix F, Part 3
Appendix L
LENOGRASTIM
Schedule 4
LENVATINIB
Schedule 4
LEPIDOPTEROUS SEX PHEROMONES
Appendix B, Part 3
LEPIRUDIN
Schedule 4
LEPTAZOL
Schedule 4
LEPTOPHOS
Schedule 7
LEPTOSPERMUM SCOPARIUM OIL

cross reference: MANUKA OIL
Schedule 6
Appendix E, Part 2
LERCANIDIPINE
Schedule 4
LESINURAD
Schedule 4
LETERMOVIR
Schedule 4

INDEX
LETROZOLE
Schedule 4
LEUPRORELIN
Schedule 4
LEVALLORPHAN
Schedule 4
LEVAMISOLE
Schedule 6
Schedule 5
Schedule 4
LEVAMFETAMINE
cross reference: LEVAMPHETAMINE
Schedule 8
LEVETIRACETAM
Schedule 4
Appendix K
LEVOBUNOLOL
Schedule 4
LEVOBUPIVACAINE
Schedule 4
LEVOCABASTINE
Schedule 4
Schedule 2
Appendix F, Part 3
Appendix L, Part 2
LEVOCETIRIZINE
Schedule 4
Schedule 2
Appendix K
LEVODOPA

INDEX
Schedule 4
LEVOMEPROMAZINE
cross reference: METHOTRIMEPRAZINE
Schedule 4
LEVOMETHAMFETAMINE
cross reference: LEVOMETHAMPHETAMINE
Schedule 8
LEVOMETHORPHAN
Schedule 9
LEVOMILNACIPRAN
Schedule 4
LEVOMORAMIDE
Schedule 8
LEVONORGESTREL
Schedule 4
Schedule 3
Appendix H
LEVOPHENACYLMORPHAN
Schedule 9
LEVORPHANOL
Schedule 8
LEVOSIMENDAN
Schedule 4
LIDOCAINE
Schedule 5
Schedule 4
Schedule 2
LIDOFLAZINE
Schedule 4

INDEX
LIFITEGRAST
Schedule 4
LIGNOCAINE
cross reference: LIDOCAINE
LIGULARIA DENTATA
Schedule 10
LIME OIL
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
LIMONENE
cross reference: DIPENTENE
Appendix B, Part 3
LINACLOTIDE
Schedule 4
LINAGLIPTIN
Schedule 4
LINCOMYCIN
Schedule 4
LINDANE
cross reference: BHC
Schedule 6
Schedule 5
Schedule 4
Schedule 2
LINEZOLID
Schedule 4
LINOLEIC ACID
Appendix B, Part 3
LINSEED FATTY ACIDS

INDEX
Appendix B, Part 3
LINURON
Appendix B, Part 3
LIOTHYRONINE
cross reference: TRIIODOTHYRONINE
Schedule 4
LIPEGFILGRASTIM
Schedule 4
LIQUORICE, DEGLYCYRRHISINISED
Appendix B, Part 3
LIRAGLUTIDE
Schedule 4
LISDEXAMFETAMINE
Schedule 8
LISINOPRIL
Schedule 4
LISURIDE
Schedule 4
LITHIUM
Schedule 4
Schedule 2
LITHIUM PERFLUOROOCTANE SULFONATE
Schedule 7
LIXISENATIDE
Schedule 4
LOBELIA INFLATA
Schedule 2

INDEX
LOBELINE
Schedule 2
LODOXAMIDE
Schedule 4
Schedule 2
LOFEXIDINE
Schedule 4
LOGIPARIN
Schedule 4
LOMEFLOXACIN
Schedule 4
LOMUSTINE
Schedule 4
LOPERAMIDE
Schedule 4
Schedule 2
Appendix F, Part 3
LOPINAVIR
Schedule 4
LOPRAZOLAM
Schedule 4
LORACARBEF
Schedule 4
LORATADINE
Schedule 4
Schedule 2
LORAZEPAM

INDEX
Schedule 4
Appendix K
LORLATINIB
Schedule 4
LORMETAZEPAM
Schedule 4
LOSARTAN
Schedule 4
LOTEPREDNOL
Schedule 4
LOTILANER
Schedule 5
LOXAPINE
Schedule 4
LUBRICANTS
Appendix A
LUFENURON
Schedule 5
LUMACAFTOR
Schedule 4
LUMEFANTRINE
Schedule 4
LUMIRACOXIB
Schedule 4
LURASIDONE

INDEX
Schedule 4
Appendix K
LUTEINISING HORMONE
Schedule 4
Appendix D, Item 1
LYMECYCLINE
Schedule 4
LYSERGIC ACID
Schedule 9
LYSERGIDE
Schedule 9
MACITENTAN
Schedule 4
Appendix D, Item 6
Appendix L, Part 2
MACROGOLS
Schedule 3
Schedule 2
MACROPHOMINA PHASEOLINA
Schedule 5
MADURAMICIN
Schedule 7
Schedule 5
Appendix J, Part 2
MAFENIDE
Schedule 6
Schedule 4
MAGNESIUM CHLORATE

INDEX
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
MAGNESIUM SULFATE
Schedule 3
MALACHITE GREEN
Schedule 7
Schedule 5
MALATHION
cross reference: MALDISON, ORGANOPHOSPHORUS COMPOUNDS
Schedule 6
Schedule 5
Schedule 3
Appendix E, Part 2
MALEIC HYDRAZIDE
Appendix B, Part 3
MANCOZEB
Schedule 5
MANDESTROBIN
Schedule 5
MANDIPROPAMID
Schedule 5
MANDRAGORA OFFICINARUM
Schedule 4
MANGANESE DIOXIDE
Appendix B, Part 3
MANNITYL HEXANITRATE
Schedule 3
MANNOMUSTINE

INDEX
Schedule 4
MAPROTILINE
Schedule 4
MARAVIROC
Schedule 4
MARBOFLOXACIN
Schedule 4
MARJORAM OIL
Schedule 5
Appendix E, Part 2
MAROPITANT
Schedule 4
MATCHES
Appendix A
MAVACOXIB
Schedule 4
MAZIDOX
Schedule 7
MAZINDOL
Schedule 4
Appendix K
MCPA
Schedule 6
Schedule 5
MCPB
cross reference: (4-(4-CHLORO-2-METHYLPHENOXY)BUTANOIC ACID
Schedule 6
MEASLES VACCINE

INDEX
Schedule 4
MEBANAZINE
Schedule 4
MEBENDAZOLE
Schedule 6
Schedule 5
Schedule 2
MEBEVERINE
Schedule 4
MEBHYDROLIN
Schedule 4
Appendix K
MEBOLAZINE
Schedule 4
MEBUTAMATE
Schedule 4
MECAMYLAMINE
Schedule 4
MECARBAM
Schedule 7
MECASERMIN
Schedule 4
MECILLINAM
Schedule 4
MECLOCYCLINE
Schedule 4
MECLOFENAMATE

INDEX
Schedule 4
MECLOFENAMIC ACID
Schedule 5
MECLOFENOXATE
Schedule 4
MECLONAZEPAM
Schedule 9
MECLOQUALONE
Schedule 9
MECLOZINE
Schedule 4
Schedule 2
Appendix K
MECOPROP
Schedule 6
Schedule 5
MECOPROP-P
Schedule 6
MEDAZEPAM
Schedule 4
Appendix K
MEDETOMIDINE
Schedule 4
MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS
Appendix A
MEDICAL DEVICES
cross reference: ANTICOAGULANT MEDICAL DEVICES, ARTIFICIAL TEARS,
COLLAGEN, INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND
RESTORATION MATERIALS, INTRA-ARTICULAR FLUIDS, URINARY CATHETERS

INDEX
Appendix A
MEDIGOXIN
cross reference: METHYLDIGOXIN
Schedule 4
MEDROXYPROGESTERONE
Schedule 4
MEDRYSONE
Schedule 4
MEFENAMIC ACID
Schedule 4
Schedule 2
Appendix F, Part 3
MEFENOREX
Schedule 4
MEFENPYR-DIETHYL
Schedule 5
MEFENTRIFLUCONAZOLE
Schedule 5
MEFLOQUINE
Schedule 4
MEFLUIDIDE
Schedule 6
MEFRUSIDE
Schedule 4
MEGASPHAERA ELSDENII strain 41125
Appendix B, Part 3
MEGESTROL

INDEX
Schedule 4
MELAGATRAN
Schedule 4
MELALEUCA OIL
cross reference: TEA TREE OIL
Schedule 6
Appendix E, Part 2
MELANOTAN II
cross reference: α–MELANOCYTE STIMULATING HORMONE
Schedule 4
MELATONIN
Schedule 4
MELENGESTROL
Schedule 4
MELENGESTROL ACETATE
Schedule 6
MELIA AZEDARACH
Schedule 10
MELOXICAM
Schedule 4
MELPHALAN
Schedule 4
MEMANTINE
Schedule 4
MENAZON
Schedule 6
MENINGOCOCCAL VACCINE

INDEX
Schedule 4
MENINGOCOCCAL GROUP B VACCINE

cross reference: Neisseria Meningitidis Serogroup B Recombinant LP2086 (MnB rLP2086)
Subfamily A Protein and Subfamily B Protein
Schedule 4
MENOTROPHIN
Schedule 4
MEPACRINE
Schedule 4
MEPENZOLATE
Schedule 4
MEPHENESIN
Schedule 4
MEPHENTERMINE
Schedule 4
MEPINDOLOL
Schedule 4
MEPIQUAT
Schedule 5
MEPITIOSTANE
Schedule 4
MEPIVACAINE
Schedule 4
MEPROBAMATE
Schedule 4
Appendix K
MEPTAZINOL

INDEX
Schedule 4
MEPYRAMINE
MEPYRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
MEQUITAZINE
Schedule 4
MERCAPTAMINE
cross reference: CYSTEAMINE
Schedule 6
Schedule 5
Schedule 4
Appendix K
MERCAPTOACETIC ACID
cross reference: THIOGLYCOLIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
2-MERCAPTOETHANOL
Schedule 6
MERCAPTOMERIN
Schedule 4
MERCAPTOPURINE
Schedule 4
MERCURIC CHLORIDE
cross reference: CALOMEL
Schedule 7
MERCURIC IODIDE
Appendix E, Part 2

INDEX
MERCURIC NITRATE
Appendix E, Part 2
MERCURIC OXIDE
Schedule 6
Appendix E, Part 2
MERCURIC POTASSIUM IODIDE
Appendix E, Part 2
MERCURIC THIOCYANATE
Appendix E, Part 2
Appendix F, Part 3
MERCUROCHROME
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
MERCUROUS CHLORIDE
cross reference: CORROSIVE SUBLIMATE
Appendix E, Part 2
MERCURY
cross reference: ETHOXYETHYLMERCURIC CHLORIDE, ETHOXYQUIN, PHENYL
MERCURIC CHLORIDE
Schedule 7
Schedule 4
Schedule 2
Appendix G
Appendix J, Part 2
MERCURY metallic
Appendix E, Part 2
MERCURY, organic compounds
Appendix E, Part 2
MEROPENEM
Schedule 4

INDEX
MERSALYL
Schedule 4
MERCURIC CHLORIDE
Appendix E, Part 2
MESABOLONE
Schedule 4
MESALAZINE
Schedule 4
MESNA
Schedule 4
MESOSULFURON-METHYL
Appendix B, Part 3
MESOTRIONE
Schedule 5
MESTANOLONE
cross reference: ANDROSTALONE
Schedule 4
MESTEROLONE
Schedule 4
MESTRANOL
Schedule 4
METACRESOLSULPHONIC ACID
Schedule 6
Appendix F, Part 3
METAFLUMIZONE

INDEX
Schedule 5
METALAXYL
Schedule 6
Schedule 5
METALDEHYDE
Schedule 6
Schedule 5
Appendix E, Part 2
METAMFETAMINE
cross reference: METHYLAMFETAMINE, METHYLAMPHETAMINE,
METHAMFETAMINE, METHAMPHETAMINE
Schedule 8
METAMITRON
Schedule 6
METANDIENONE
Schedule 4
METARAMINOL
Schedule 4
METARHIZIUM ANISOPLIAE
Appendix B, Part 3
METAZACHLOR
Schedule 5
METAZOCINE
Schedule 9
METCAMIFEN
Appendix B, Part 3
METENOLONE

INDEX
Schedule 4
METERGOLINE
Schedule 4
METFORMIN
Schedule 4
METHABENZTHIAZURON
Schedule 5
METHACHOLINE
Schedule 4
METHACRIFOS
Schedule 7
Schedule 6
Appendix J, Part 2
METHACYCLINE
Schedule 4
METHADONE
Schedule 8
Appendix K
METHALLENESTRIL
cross reference: METHALLENOESTRIL
Schedule 4
METHAM
cross reference: METHAM SODIUM
Schedule 6
METHAMIDOPHOS
Schedule 7
METHANDRIOL

INDEX
Schedule 4
METHANOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
METHANTHELINIUM
Schedule 4
METHAPYRILENE
Schedule 7
METHAQUALONE
Schedule 9
METHAZOLAMIDE
Schedule 4
METHAZOLE
Schedule 7
METHCATHINONE
Schedule 9
METHDILAZINE
Schedule 4
Schedule 3
Appendix K
METHENAMINE
cross reference: 1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE, HEXAMINE,
HEXAMETHYLENETETRAMINE
Schedule 5
METHENOLONE
Schedule 4

INDEX
METHICILLIN
Schedule 4
METHIDATHION
Schedule 7
METHIMAZOLE
cross reference: THIAMAZOLE
Schedule 4
METHIOCARB
Schedule 7
Schedule 6
Schedule 5
METHISAZONE
Schedule 4
METHIOZOLIN
Schedule 5
METHIXENE
Schedule 4
METHOCARBAMOL
Schedule 4
Appendix K
METHOFLUTHRIN
Schedule 5
METHOHEXITONE
Schedule 4
METHOIN
Schedule 4
METHOMYL

INDEX
Schedule 7
Schedule 6
METHOPRENE
Appendix B, Part 3
METHOTREXATE
Schedule 4
METHOXAMINE
Schedule 4
Schedule 2
Appendix F, Part 3
METHOXSALEN
Schedule 4
METHOXYCHLOR
Schedule 5
2-METHOXYETHANOL
Schedule 7
Appendix F, Part 3
METHOXYETHYLMERCURIC ACETATE
Schedule 7
Appendix J, Part 2
METHOXYETHYLMERCURIC CHLORIDE
Schedule 7
Appendix J, Part 2
METHOXYFENOZIDE
Appendix B, Part 3
METHOXYFLURANE
Schedule 4
5-METHOXY-3,4-METHYLENEDIOXYAMFETAMINE
cross reference: 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE, MMDA

INDEX
Schedule 9
4-METHOXY- α –METHYLPHENYLETHYLAMINE
cross reference: PMA
Schedule 9
5-METHOXY- α –METHYLTRYPTAMINE
cross reference: 5-MeO-AMT
Schedule 9
METHOXYPHENAMINE
Schedule 2
2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE
cross reference: JWH-250
Schedule 9
METHSUXIMIDE
Schedule 4
METHYCLOTHIAZIDE
Schedule 4
METHYL ACETATE
Appendix B, Part 3
METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-

DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-
CARBOXYLATE
cross reference: SALVINORIN A
Schedule 9
METHYL AMINOLEVULINATE
Schedule 4
p-METHYLAMINOPHENOL
Schedule 6
Appendix F, Part 3
4-METHYLAMINOREX

INDEX
Schedule 9
METHYLANDROSTANOLONE
Schedule 4
METHYLATED SPIRIT(S)
cross reference: DENATONIUM BENZOATE, ETHANOL, FLUORESCEIN
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
METHYL BENZOQUATE
Appendix B, Part 3
METHYL BROMIDE
Schedule 7
Appendix J, Part 2
METHYL CHLORIDE
Appendix F, Part 3
METHYLCHLOROISOTHIAZOLINONE
cross reference: METHYLISOTHIAZOLINONE
Schedule 6
Appendix F, Part 3
METHYLCLOSTEBOL
Schedule 4
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL
Schedule 7
Schedule 6
1-METHYLCYCLOPROPENE
Appendix B, Part 3
METHYLDESORPHINE
Schedule 9

INDEX
METHYLDIBROMO GLUTARONITRILE
Schedule 10
Schedule 6
Appendix F, Part 3
METHYLDIHYDROMORPHINE
Schedule 8
METHYLDOPA
Schedule 4
4,4’-METHYLENEBIS[2-CHLOROANILINE]
Schedule 7
Appendix J, Part 2
METHYLENE BISTHIOCYANATE
Schedule 6
Appendix F, Part 3
METHYLENE BLUE
Schedule 7
Schedule 5
Schedule 4
3,4-METHYLENEDIOXYAMFETAMINE
cross reference: 3,4-METHYLENEDIOXYAMPHETAMINE, MDA
Schedule 9
3,4-METHYLENEDIOXYPYROVALERONE
cross reference: MDPV
Schedule 9
METHYLEPHEDRINE
Schedule 2
METHYLERGOMETRINE
Schedule 4
METHYL ETHYL KETONE


INDEX
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
METHYL ETHYL KETONE OXIME
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
METHYL ETHYL KETONE PEROXIDE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
METHYLEUGENOL
Schedule 6
Appendix E, Part 2,
Appendix F, Part 3
3-METHYLFENTANYL
Schedule 9
METHYLPHENYLPIRACETAM
Schedule 4
METHYL p-HYDROXYBENZOATE
Appendix B, Part 3
METHYL ISOAMYL KETONE

Schedule 5
Appendix E, Part 2
METHYL ISOBUTYL KETONE

cross reference: DESIGNATED SOLVENT, METHYLATED SPIRIT(S)
Schedule 5
Appendix E, Part 2
METHYL ISOTHIOCYANATE

INDEX
Schedule 6
METHYLISOTHIAZOLINONE
cross reference: METHYLCHLOROISOTHIAZOLINONE
Schedule 6
Appendix F, Part 3
METHYLMERCURY
Schedule 4
Appendix G
METHYL METHACRYLATE
Schedule 10
Schedule 6
Appendix F, Part 3
4-METHYLMETHCATHINONE
cross reference: MEPHEDRONE
Schedule 9
N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE
cross reference: MBDB
Schedule 9
N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE
cross reference: N-HYDROXY MDA
Schedule 9
2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID

cross reference: MORAMIDE INTERMEDIATE
Schedule 9
METHYLNALTREXONE
Schedule 4
METHYL NEODECANAMIDE
Schedule 6
METHYLNORBORNYLPYRIDINE
Schedule 6

INDEX
METHYLONE *(MDMC)
Schedule 9
METHYLPENTYNOL
Schedule 4
METHYLPHENIDATE
Schedule 8
METHYLPHENOBARBITAL
cross reference: BARBITURATE METHYLPREDNISOLONE
Schedule 4
Appendix K
METHYLPHENOBARBITONE
cross reference: METHYLPHENOBARBITAL, BARBITURATE METHYLPREDNISOLONE
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE
cross reference: ACIDMPPP
Schedule 9
1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID
cross reference: PETHIDINE INTERMEDIATE C
Schedule 8
METHYLPREDNISOLONE
Schedule 4
N-METHYL-2-PYRROLIDONE
Schedule 6
Schedule 5
Appendix E, Part 2
2-METHYLRESORCINOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
METHYLROSANILINIUM CHLORIDE
cross reference: CRYSTAL VIOLET, GENTIAN VIOLET

INDEX
Schedule 10
Schedule 6
Schedule 4
METHYL SALICYLATE
Schedule 6
Schedule 5
Schedule 4
METHYL SALICYLATE LIQUID
Appendix E, Part 2
METHYLTESTOSTERONE
Schedule 4
4-METHYLTHIOAMFETAMINE
cross reference: 4-METHYLTHIOAMPHETAMINE
Schedule 9
3-METHYLTHIOFENTANYL
Schedule 9
2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5-
TRIAZINE
Schedule 5
METHYLTHIOURACIL
Schedule 4
METHYLTRIENOLONE
Schedule 4
METHYPRYLONE
Schedule 4
METHYSERGIDE
Schedule 4
METIRAM

INDEX
Schedule 5
METOCLOPRAMIDE
Schedule 4
Schedule 3
METOFLUTHRIN
Schedule 6
Schedule 5
METOLACHLOR
Schedule 5
METOLAZONE
Schedule 4
METOPON
Schedule 9
METOPROLOL
Schedule 4
METOSULAM
Schedule 6
METRAFENONE
Schedule 6
Schedule 5
METRIBOLONE
Schedule 4
METRIBUZIN
Schedule 6
METRIFONATE
cross reference: TRICHLORFON
Schedule 4

INDEX
METRONIDAZOLE
cross reference: BENZOYL METRONIDAZOLE
Schedule 4
METSULFURONMETHYL
Appendix B, Part 3
METYRAPONE
Schedule 4
MEVINPHOS
Schedule 7
MEXILETINE
Schedule 4
MEZLOCILLIN
Schedule 4
MIANSERIN
Schedule 4
Appendix K
MIBEFRADIL
Schedule 4
MIBOLERONE
Schedule 4
MICAFUNGIN
Schedule 4
MICONAZOLE
Schedule 6
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H

INDEX
MIDAZOLAM
Schedule 4
Appendix K
MIDODRINE
Schedule 4
MIDOSTAURIN
Schedule 4
MIFEPRISTONE
Schedule 4
MIGALASTAT
Schedule 4
MIGLITOL
Schedule 4
MIGLUSTAT
Schedule 4
MILBEMECTIN
Schedule 6
Schedule 5
MILNACIPRAN
Schedule 4
MILBEMYCIN OXIME
Schedule 5
Schedule 4
MILRINONE
Schedule 4
MINOCYCLINE
Schedule 4

INDEX
MINOXIDIL
Schedule 4
Schedule 2
MIPAFOX
Schedule 7
MIRABEGRON
Schedule 4
MIREX
Schedule 7
Appendix J, Part 2
MIRTAZAPINE
Schedule 4
Appendix K
MISOPROSTOL
Schedule 4
Appendix F, Part 3
Appendix L, Part 2
MITOBRONITOL
Schedule 4
MITOMYCIN
Schedule 4
MITOTANE
Schedule 4
MITOXANTRONE
Schedule 4
MITRAGYNA SPECIOSA
cross reference: KRATOM; MITRAGYNINE
Schedule 9

INDEX
MITRAGYNINE
cross reference: KRATOM; MITRAGYNA SPECIOSA
Schedule 9
MITRATAPIDE
Schedule 4
MIVACURIUM CHLORIDE
Schedule 4
MOCLOBEMIDE
Schedule 4
MODAFINIL
Schedule 4
MOLGRAMOSTIM
Schedule 4
MOLINATE
Schedule 7
Appendix J, Part 2
MOLINDONE
Schedule 4
MOMETASONE
Schedule 4
Schedule 3
Schedule 2
MOMFLUOROTHRIN
Schedule 6
MONENSIN
Schedule 6
Schedule 5
Schedule 4
MONEPANTEL

INDEX
Schedule 5
MONOBENZONE
cross reference: HYDROQUINONE
Schedule 4
MONOCLONAL ANTIBODIES
Schedule 4
MONOCROTOPHOS
Schedule 7
MONOETHANOLAMINE
Schedule 6
Schedule 5
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
MONTELUKAST
Schedule 4
MOPERONE
Schedule 4
MORANTEL
Schedule 6
Schedule 5
MORAZONE
Schedule 4
MORICIZINE
Schedule 4
MORPHERIDINE
Schedule 9
MORPHINE

INDEX
Schedule 8
Appendix K
MORPHINE METHOBROMIDE
Schedule 8
MORPHINE-N-OXIDE
Schedule 8
(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1- YLMETHANONE
Schedule 9
MOTOR, HEATING or FURNACE FUELS

cross reference: FUELS, FUELS, HOBBY - FUELS, TOY, KEROSENE, METHANOL,
PETROL
Appendix A
MOTRAZEPAM
Schedule 4
MOTRETINIDE
Schedule 4
MOXIDECTIN
Schedule 7
Schedule 6
Schedule 5
Schedule 4
MOXIFLOXACIN
Schedule 4
MOXONIDINE
Schedule 4
MSMA
Schedule 7
Schedule 6
MUMPS VACCINE

INDEX
Schedule 4
MUPIROCIN
Schedule 4
MURAGLITAZAR
Schedule 4
MUROMONAB
Schedule 4
MUSCIMOL
Schedule 9
MUSTINE
cross reference: NITROGEN MUSTARD
Schedule 4
MYCLOBUTANIL
Schedule 5
MYCOPHENOLIC ACID
cross reference: MYCOPHENOLATE MOFETIL
Schedule 4
MYRISTIC ACID
Appendix B, Part 3
MYROPHINE
Schedule 9
NAA
cross reference: NAPTHALENEACETIC ACID
Schedule 5
NABILONE
Schedule 8

INDEX
NABIXIMOLS
cross reference: CANNABICHROMENE, CANNABIDIOL, CANNABIDIOLIC ACID,
CANNABIDIVAROL, CANNABIGEROL, CANNABINOIDS, CANNABINOL, CANNABIS
SATIVA, TETRAHYDROCANNABINOLIC ACID, TETRAHYDROCANNABINOLS,
TETRAHYDROCANNABIVAROL
Schedule 8
Appendix D, Item 1
Appendix K
NABUMETONE
Schedule 4
NADOLOL
Schedule 4
NADROPARIN
Schedule 4
NAFARELIN
Schedule 4
NAFTIDROFURYL
Schedule 4
NALBUPHINE
Schedule 4
Appendix K
NALED
Schedule 6
Schedule 5
NALIDIXIC ACID
Schedule 4
NALMEFENE
Schedule 4
NALORPHINE
Schedule 4

INDEX
NALOXEGOL
Schedule 4
NALOXONE
Schedule 4
Schedule 3
Appendix H
NALTREXONE
Schedule 4
NANDROLONE
Schedule 4
NAPHAZOLINE
Schedule 2
Appendix F, Part 3
NAPHTHALENE
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
Appendix G
1,5-NAPHTHALENEDIOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
2,7-NAPTHALENEDIOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NAPHTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE
Schedule 9
NAPHTHALOPHOS

INDEX
Schedule 7
Schedule 6
1-NAPHTHOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NAPHTHOYLINDOLES
Schedule 9
NAPHTHOYLPYRROLES
Schedule 9
NAPHTHYLMETHYLINDENES
Schedule 9
NAPHTHYLMETHYLINDOLES
Schedule 9
NAPROPAMIDE
Appendix B, Part 3
NAPROXEN
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
NAPTALAM
Schedule 5
NAPTHYL ACETAMIDE
Appendix B, Part 3
NARASIN
Schedule 6
Schedule 4
NARATRIPTAN

INDEX
Schedule 4
NATALIZUMAB
Schedule 4
NATAMYCIN
cross reference: PIMARCIN
Schedule 4
NATEGLINIDE
Schedule 4
NEBACUMAB
Schedule 4
NEBIVOLOL
Schedule 4
NEBRACETAM
Schedule 4
NEDOCROMIL
Schedule 4
NEFAZODONE
Schedule 4
NEFIRACETAM
Schedule 4
NEFOPAM
Schedule 4
NELFINAVIR
Schedule 4
NEOMYCIN

INDEX
Schedule 4
NEOSCYTALIDIUM NOVAEHOLLANDIAE
Schedule 5
NEOSTIGMIN
Schedule 4
NEPAFENAC
Schedule 4
NERATINIB
Schedule 4
NERIUM OLEANDER
Schedule 4
Appendix G
NEROLI OIL
Appendix B, Part 3
NESIRITIDE
Schedule 4
NETILMICIN
Schedule 4
NETOBIMIN
Schedule 6
Schedule 5
NETUPITANT
Schedule 4
NEVIRAPINE
Schedule 4
NIALAMIDE
Schedule 4

INDEX
NICARBAZIN
Appendix B, Part 3
NICARDIPINE
Schedule 4
NICERGOLINE
Schedule 4
NICKEL SULFATE
Schedule 6
NICLOSAMIDE
Schedule 2
NICOCODINE
Schedule 9
NICODICODINE
Schedule 9
NICOFURANOSE
Schedule 4
NICOMORPHINE
Schedule 9
NICORANDIL
Schedule 4
NICOTINE
Schedule 7
Schedule 6
Schedule 4
Appendix F, Part 3
Appendix J, Part 2
NICOTINIC ACID
cross reference: NICOTINAMIDE

INDEX
Schedule 4
Schedule 3
NICOTINYL ALCOHOL
Schedule 3
NICOUMALONE
Schedule 4
NIFEDIPINE
Schedule 4
NIFENAZONE
Schedule 4
NIFOXIPAM
Schedule 9
NIKETHAMIDE
Schedule 4
NILOTINIB
Schedule 4
NILUTAMIDE
Schedule 4
NIMESULIDE
Schedule 4
NIMIDANE
Schedule 7
Schedule 6
NIMODIPINE
Schedule 4
NIMORAZOLE
Schedule 4

INDEX
NINTEDANIB
Schedule 4
NIRAPARIB
Schedule 4
NIRIDAZOLE
Schedule 4
NISIN
Appendix B, Part 3
NISOLDIPINE
Schedule 4
NITENPYRAM
Schedule 6
NITISINONE
Schedule 4
NITRAZEPAM
Schedule 4
Appendix K
NITRENDIPINE
Schedule 4
NITRIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
NITRIC OXIDE
Schedule 4
NITROBENZENE

INDEX
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NITROFEN
Schedule 7
Appendix J, Part 2
NITROFURANTOIN
Schedule 4
NITROFURAZONE
Schedule 4
3-NITRO-p-HYDROXYETHYLAMINOPHENOL
cross reference: 4-[(2-hydroxyethyl)amino]-3-nitrophenol
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NITROPHENOLS
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NITROPRUSSIDES
Schedule 7
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
NITROSCANATE
Schedule 5
2-NITROTOLUENE
Schedule 7
NITROUS OXIDE
Schedule 4
NITROXOLINE

INDEX
Schedule 4
NITROXYNIL
Schedule 6
NIVOLUMAB
Schedule 4
NIZATIDINE
Schedule 4
Schedule 2
Appendix F, Part 3
NOMEGESTROL
Schedule 4
NOMIFENSINE
Schedule 4
NONANOIC ACID
Schedule 5
NONOXINOL 9
Schedule 6
Schedule 5
Appendix E, Part 2
NORACYMETHADOL
Schedule 9
NORADRENALINE
Schedule 4
Appendix F, Part 3
19-NORANDROSTENEDIOL
Schedule 4
19-NORANDROSTENEDIONE

INDEX
Schedule 4
NORANDROSTENOLONE
Schedule 4
NORBOLETHONE
Schedule 4
NORBORMIDE
Schedule 5
NORCLOSTEBOL
Schedule 4
NORCODEINE
Schedule 8
NORELGESTROMIN
Schedule 4
NOREPINEPHRINE
cross reference: NORADRENALINE
NORETHANDROLONE
Schedule 4
NORETHISTERONE
Schedule 4
NORFLOXACIN
Schedule 4
NORFLURAZON
Appendix B, Part 3
NORGESTREL

INDEX
Schedule 4
NORIBOGAINE
Schedule 4
NORLEVORPHANOL
Schedule 9
NORMAL HUMAN IMMUNOGLOBULIN
Schedule 4
NORMETHADONE
Schedule 8
Appendix K
NORMETHANDRONE
Schedule 4
NORMORPHINE
Schedule 9
NORPIPANONE
Schedule 9
NORTRIPTYLINE
Schedule 4
Appendix K
NOSCAPINE
Schedule 2
NOVALURON
Appendix B, Part 3
NOVOBIOCIN
Schedule 4
NOXIPTYLINE

INDEX
Schedule 4
NUCLEAR POLYHEDROSIS VIRUS OF Helicoverpa armigera occlusion bodies
Appendix B, Part 3
NUSINERSEN
Schedule 4
NUTMEG OIL
Schedule 5
NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL

ADMINISTRATION
Appendix A
NYSTATIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
OBETICHOLIC ACID
Schedule 4
OCLACITINIB
Schedule 4
OCRELIZUMAB
Schedule 4
OCRIPLASMIN
Schedule 4
OCTAMYLAMINE
Schedule 4
OCTATROPINE

INDEX
Schedule 4
1-OCTEN-3-OL
Schedule 6
OCTHILINONE
Schedule 6
OCTREOTIDE
Schedule 4
OCTYL ALCOHOLS
Appendix B, Part 3
N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE
Schedule 5
OCTYL NITRITE
Schedule 4
Appendix E, Part 2
N-(N-OCTYL)-2-PYRROLIDONE
cross reference: DESIGNATED SOLVENT, N-(N-DODECYL)-2-PYRROLIDONE, N-
METHYL-2-PYRROLIDONE
Schedule 6
Schedule 5
Appendix E, Part 2
OESTRADIOL
cross reference: ESTRADIOL
OESTRIOL
cross reference: ESTRIOL
OESTROGENS
cross reference: ESTROGENS
OESTRONE
cross reference: ESTRONE
OFATUMUMAB
Schedule 4

INDEX
OFLOXACIN
Schedule 4
OLANZAPINE
Schedule 4
Appendix K
OLAPARIB
Schedule 4
OLAQUINDOX
Schedule 6
OLARATUMAB
Schedule 4
OLEANDOMYCIN
Schedule 5
Schedule 4
OLEANDRIN
Schedule 4
OLEIC ACID
Appendix B, Part 3
N-OLEYL-1,3-DIAMINOPROPANE
Schedule 6
OLMESARTAN
Schedule 4
OLODATEROL
Schedule 4
OLOPATADINE
Schedule 4
OLSALAZINE

INDEX
Schedule 4
OMBERACETAM
Schedule 4
OMBITASVIR
Schedule 4
OMALIZUMAB
Schedule 4
OMEGA-3-ACID ETHYL ESTERS
Schedule 4
OMEPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
OMETHOATE
Schedule 7
Schedule 6
Schedule 5
ONASEMNOGENE ABEPARVOVEC
Schedule 4
ONDANSETRON
Schedule 4
OPICAPONE
Schedule 4
OPIPRAMOL
Schedule 4
OPIUM
cross reference: NOSCAPINE, PAPAVERINE

INDEX
Schedule 8
Appendix K
ORANGE OIL (BITTER)
Schedule 5
Appendix E, Part 2
ORANGE OIL, SWEET
Appendix B, Part 3
ORBIFLOXACIN
Schedule 4
ORCIPRENALINE
Schedule 4
Appendix F, Part 3
ORGANOPHOSPHORUS COMPOUNDS
cross reference: MALATHION
Schedule 4
ORLISTAT
Schedule 4
Schedule 3
ORNIDAZOLE
Schedule 4
ORNIPRESSIN
Schedule 4
ORPHENADRINE
Schedule 4
ORTHOPTERIN
Schedule 4
OSELTAMIVIR
Schedule 4

INDEX
OSIMERTINIB
Schedule 4
OUABAIN
Schedule 4
OVANDROTONE
Schedule 4
OXABETRINIL
Appendix B, Part 3
OXABOLONE
Schedule 4
OXACILLIN
Schedule 4
OXADIARGYL
Schedule 5
OXADIAZON
Schedule 6
OXADIXYL
Schedule 5
OXALATES
Appendix F, Part 3
OXALIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
OXALIPLATIN
Schedule 4

INDEX
OXAMYL
Schedule 7
OXANDROLONE
Schedule 4
OXANTEL EMBONATE
Schedule 5
OXAPROZIN
Schedule 4
OXAZEPAM
Schedule 4
Appendix K
OXCARBAZEPINE
Schedule 4
OXATHIAPIPROLIN
Appendix B, Part 3
OXEDRINE
cross reference: SYNEPHRINE
Schedule 4
OXETACAINE
cross reference: OXETHAZAINE
Schedule 4
Schedule 2
OXFENDAZOLE
Schedule 5
OXIBENDAZOLE
Schedule 5
OXICONAZOLE

INDEX
Schedule 4
Schedule 3
Schedule 2
Appendix H
OXIRACETAM
Schedule 4
OXITROPIUM
Schedule 4
OXOLAMINE
Schedule 4
OXOLINIC ACID
Schedule 4
OXPENTIFYLLINE
cross reference: PENTOXIFYLLINE
OXPRENOLOL
Schedule 4
OXYBUPROCAINE
Schedule 4
OXYBUTYNIN
Schedule 4
OXYCARBOXIN
Schedule 5
OXYCLOZANIDE
Schedule 6
OXYCODONE
Appendix K
OXYCODONE

INDEX
Schedule 8
OXYDEMETON METHYL
Schedule 7
OXYFLUORFEN
Appendix B, Part 3
OXYMESTERONE
Schedule 4
OXYMETAZOLINE
Schedule 2
Appendix F, Part 3
OXYMETHOLONE
Schedule 4
OXYMORPHONE
Schedule 8
OXYPHENBUTAZONE
Schedule 4
OXYPHENCYCLIMINE
Schedule 4
OXYPHENISATIN
Schedule 10
OXYPHENONIUM
Schedule 4
OXYQUINOLINE
Schedule 2
Appendix F, Part 3
OXYTETRACYCLINE

INDEX
Schedule 5
Schedule 4
OXYTHIOQUINOX
Schedule 5
OXYTOCIN
Schedule 4
Appendix G
OZANIMOD
Schedule 4
PACLITAXEL
Schedule 4
PACLOBUTRAZOL
Schedule 5
PAECILOMYCES LILACINUS STRAIN 251
Schedule 6
PAINT
Appendix F, Part 3
PALBOCICLIB
Schedule 4
PALIFERMIN
Schedule 4
PALIPERIDONE
Schedule 4
Appendix K
PALIVIZUMAB
Schedule 4

INDEX
PALMAROSA OIL
Appendix B, Part 3
PALMITIC ACID
Appendix B, Part 3
PALONOSETRON
Schedule 4
PAMAQUIN
Schedule 4
PAMIDRONIC ACID
cross reference: PAMIDRONATE DISODIUM
Schedule 4
PANCREATIC ENZYMES
cross reference: LIPASE
Schedule 4
PANCURONIUM
Schedule 4
PANITUMUMAB
Schedule 4
PANOBINOSTAT
Schedule 4
PANTOPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
PAPAVERETUM
Appendix K
PAPAVERINE
cross reference: OPIUM

INDEX
Schedule 4
Schedule 2
PAPER
Appendix A
PARA-AMINOPROPIOPHENONE (PAPP)
cross reference: 4-AMINOPROPIOPHENONE
PARACETAMOL
cross reference: ASPIRIN, IBUPROFEN, METOCLOPRAMIDE, SALICYLAMIDE,
CAFFEINE
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
para-DICHLOROBENZENE
cross reference: PDB
Appendix F, Part 3
PARA-FLUOROFENTANYL
Schedule 9
PARAFORMALDEHYDE
cross reference: FREE FORMALDEHYDE
Schedule 10
Schedule 6
Schedule 2
Appendix E, Part 2
PARALDEHYDE
Schedule 4
PARAMETHADIONE
Schedule 4
PARAMETHASONE
Schedule 4
PARAQUAT

INDEX
Schedule 7
PARATHION
Schedule 7
PARATHION-METHYL
Schedule 7
Schedule 6
PARBENDAZOLE
Schedule 6
PARECOXIB
Schedule 4
PARICALCITOL
Schedule 4
PARITAPREVIR
Schedule 4
PAROMOMYCIN
Schedule 4
PAROXETINE
Schedule 4
PASIREOTIDE
Schedule 4
PATCHOULI OIL
Appendix B, Part 3
PATIROMER SORBITEX CALCIUM
Schedule 4
PAZOPANIB
Schedule 4

INDEX
PEBULATE
Schedule 6
PECAZINE
Schedule 4
PECTINASE derived from Aspergillus niger
Appendix B, Part 3
PEFLOXACIN
Schedule 4
PEGAPTANIB
Schedule 4
PEGASPARGASE
Schedule 4
PEGBOVIGRASTIM
Appendix B, Part 1
Appendix B, Part 2
PEGFILGRASTIM
Schedule 4
PEGINTERFERON
Schedule 4
PEGVISOMANT
Schedule 4
PERAMIVIR
Schedule 4
PHENOLS
Appendix E, Part 2
PEMBROLIZUMAB

INDEX
Schedule 4
PEMETREXED
Schedule 4
PEMOLINE
Schedule 4
PEMPIDINE
Schedule 4
PENBUTOLOL
Schedule 4
PENCICLOVIR
Schedule 4
PENCONAZOLE
Schedule 5
PENCYCURON
Appendix B, Part 3
PENDIMETHALIN
Schedule 5
PENETHAMATE
Schedule 4
PENFLUFEN
Schedule 5
PENICILLAMINE
Schedule 4
PENNYROYAL OIL
Schedule 6
Appendix E, Part 2

INDEX
PENTACHLOROPHENOL
Schedule 7
Schedule 6
Appendix F, Part 3
PENTADECANOIC ACID
Appendix B, Part 3
PENTAERYTHRITYL TETRANITRATE
Schedule 4
PENTAGASTRIN
Schedule 4
PENTAMETHONIUM
Schedule 4
PENTAMIDINE
Schedule 4
PENTAZOCINE
Schedule 8
Appendix K
PENTHIENATE
Schedule 4
PENTHIOPYRAD
Schedule 5
PENTOBARBITONE
cross reference: PENTOBARBITAL
PENTOBARBITAL
Schedule 8
Schedule 4
Appendix D, Item 9
Appendix K
PENTOLINIUM

INDEX
Schedule 4
PENTOSAN POLYSULFATE SODIUM
Schedule 4
PENTOXIFYLLINE
Schedule 4
1-PENTYL-3-(1-NAPHTHOYL)INDOLE
Schedule 9
1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE
Schedule 9
PEPPERMINT OIL
Appendix B, Part 3
PERACETIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PERAMPANEL
Schedule 4
Appendix D, Item 5
Appendix K
PERFLUIDONE
Schedule 6
PERGOLIDE
Schedule 4
PERHEXILINE
Schedule 4
PERICIAZINE

INDEX
Schedule 4
Appendix K
PERICYAZINE
cross reference: PERICIAZINE
PERINDOPRIL
Schedule 4
PERMANGANATES
cross reference: POTASSIUM PERMANGANATE
Schedule 6
Appendix F, Part 3
PERMETHRIN
Schedule 6
Schedule 5
Schedule 4
PERPHENAZINE
Schedule 4
Appendix K
PERTUSSIS ANTIGEN
Schedule 4
PERTUZUMAB
Schedule 4
PETASITES spp.
Schedule 10
PETHIDINE
Schedule 8
Appendix K
PETROL
Schedule 5
Appendix E, Part 2
PHEDRAZINE

INDEX
Schedule 2
PHENACEMIDE
Schedule 4
PHENACETIN
Schedule 4
PHENADOXONE
Schedule 9
PHENAGLYCODOL
Schedule 4
PHENAMPROMIDE
Schedule 9
PHENAZOCINE
Schedule 9
PHENAZONE
Schedule 5
Schedule 4
Schedule 2
PHENAZOPYRIDINE
Schedule 4
PHENCYCLIDINE
cross reference: PCP
Schedule 9
PHENDIMETRAZINE
Schedule 8
PHENELZINE
Schedule 4
Appendix K
N-PHENETHYL-4-PIPERIDONE

INDEX
Schedule 9
PHENETICILLIN
Schedule 4
PHENFORMIN
Schedule 4
PHENGLUTARIMIDE
Schedule 4
PHENIBUT
cross reference: BETA-PHENYL-GAMMA-AMINOBUTYRIC ACID
Schedule 9
PHENINDIONE
Schedule 4
PHENIRAMINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
PHENISATIN
Schedule 4
PHENISOPHAM
Schedule 5
PHENMEDIPHAM
Appendix B, Part 3
PHENMETRAZINE
Schedule 8
PHENOBARBITAL
Schedule 4
Appendix K

INDEX
PHENOBARBITONE
cross reference: PHENOBARBITAL
PHENOL
cross reference: CREOSOTE, PHENOLS, TAR, XYLENOLS
Schedule 6
Schedule 5
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
PHENOLPHTHALEIN
Schedule 4
PHENOMORPHAN
Schedule 9
PHENOPERIDINE
Schedule 8
Appendix K
PHENOTHIAZINE
Schedule 6
D-PHENOTHRIN
Appendix B, Part 3
PHENOXYBENZAMINE
Schedule 4
2-PHENOXYETHANOL
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
PHENOXYMETHYL OXIRANE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
PHENOXYMETHYLPENICILLIN

INDEX
Schedule 4
PHENPROMETHAMINE
Schedule 10
PHENSUXIMIDE
Schedule 4
PHENTERMINE
Schedule 4
Appendix D, Item 5
PHENTHIMENTONIUM
Schedule 4
PHENTOLAMINE
Schedule 4
PHENYLACETYLINDOLES
Schedule 9
PHENYLBUTAZONE
Schedule 4
PHENYLENEDIAMINES
cross reference: ALKYLATED, ARYLATED, HALOGENATED and NITRO-
PHENYLENEDIAMINES, DIETHYL-PARA-PHENYLENEDIAMINE, DIMETHYL-PARA-
PHENYLENEDIAMINE
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
PHENYLEPHRINE
cross reference: CODEINE, IBUPROFEN, PARACETAMOL
Schedule 4
Schedule 2
Appendix F, Part 3
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE
cross reference: PEPAP

INDEX
Schedule 9
PHENYLMERCURIC ACETATE
cross reference: MERCURY
Schedule 7
Appendix J, Part 2
PHENYL METHYL KETONE

Schedule 5
Appendix E, Part 2
o-PHENYLPHENOL
Appendix E, Part 2
Appendix F, Part 3
PHENYLPHENOL
Schedule 5
4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER

cross reference: PETHIDINE INTERMEDIATE B
Schedule 8
PHENYL METHYL PYRAZOLONE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
PHENYLPIRACETAM
Schedule 4
PHENYLPROPANOLAMINE
Schedule 4
PHENYLTOLOXAMINE
Schedule 4
Appendix K
PHENYTOIN

INDEX
Schedule 4
Appendix F, Part 3
PHLEUM PRATENSE POLLEN EXTRACT (Timothy-grass pollen extract)
Schedule 4
PHOLCODINE
Schedule 8
Schedule 4
Schedule 2
Appendix K
PHORATE
Schedule 7
PHOSALONE
Schedule 6
PHOSFOLAN
Schedule 7
PHOSMET
Schedule 6
PHOSPHIDES, METALLIC
cross reference: ALUMINIUM PHOSPHIDE, MAGNESIUM PHOSPHIDE, ZINC
PHOSPHIDE
Schedule 7
Appendix J, Part 2
PHOSPHINE
Schedule 7
Appendix J, Part 2
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Schedule 4
PHOSPHONIC ACID
cross reference: PHOSPHOURUS ACID

INDEX
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PHOSPHORIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PHOSPHORUS
Appendix F, Part 3
Appendix G
PHOSPHORUS,
Appendix E, Part 2
PHOSPHORUS, YELLOW
Schedule 7
PHOTOGRAPHIC PAPER or FILM
Appendix A
PHOXIM
Schedule 6
o-PHTHALADEHYDE
Appendix F, Part 3
o-PHTHALALDEHYDE
Appendix E, Part 2
PHTHALALDEHYDE
Schedule 6
Schedule 5
PHTHALYLSULFATHIAZOLE
Schedule 4
PHYSOSTIGMINE

INDEX
Schedule 4
PHYTASE
Appendix B, Part 3
PIBRENTASVIR
Schedule 4
PICARIDIN
Schedule 5
PICLORAM
Appendix B, Part 3
PICOLINAFEN
Appendix B, Part 3
PICRIC ACID
Appendix E, Part 2
Appendix F, Part 3
PICROTOXIN
Schedule 4
PIGMENTS
Appendix A
PILOCARPINE
Schedule 4
PIMECROLIMUS
Schedule 4
PIMELIC ACID
Appendix B, Part 3
PIMINODINE
Schedule 9

INDEX
PIMOBENDAN
Schedule 4
PIMOZIDE
Schedule 4
Appendix K
PINACIDIL
Schedule 4
PINDOLOL
Schedule 4
PINDONE
Schedule 6
PINE OILS
Schedule 6
Schedule 5
PINOXADEN
Schedule 6
Schedule 5
PIOGLITAZONE
Schedule 4
PIPECURONIUM
Schedule 4
PIPEMIDIC ACID
Schedule 4
PIPENZOLATE
Schedule 4
PIPER METHYSTICUM
cross reference: KAVA, KAVALACTONES
Schedule 4

INDEX
PIPERACILLIN
Schedule 4
PIPERAZNE
Schedule 5
Schedule 2
PIPERIDINE
Schedule 4
PIPERIDOLATE
Schedule 4
PIPERONYL BUTOXIDE
Appendix B, Part 3
PIPEROPHOS
Schedule 6
PIPOBROMAN
Schedule 4
PIPOTHIAZINE
Schedule 4
PIPRADROL
Schedule 4
PIRACETAM
Schedule 4
PIRBUTEROL
Schedule 4
PIRENOXINE
cross reference: CATALIN
Schedule 4

INDEX
PIRENZEPINE
Schedule 4
PIRETANIDE
Schedule 4
PIRFENIDONE
Schedule 4
PIRIMICARB
Schedule 6
Schedule 5
PIRIMIPHOS-ETHYL
Schedule 6
PIRIMIPHOS-METHYL
Schedule 6
PIRITRAMIDE
Schedule 8
PIROXICAM
Schedule 4
PIRPROFEN
Schedule 4
PITAVASTATIN
Schedule 4
PITUITARY HORMONES
Schedule 4
PIVAMPICILLIN
Schedule 4
PIZOTIFEN

INDEX
Schedule 4
Appendix K
PLASMID DNA (rE. coli DH5α pINGhT)

cross reference: VACCINES – PLASMID DNA
PLERIXAFOR
Schedule 4
PLICAMYCIN
Schedule 4
PLITIDEPSIN
Schedule 4
Appendix L
PNEUMOCOCCAL VACCINE
Schedule 4
PODOPHYLLOTOXIN
cross reference: PODOPHYLLIN
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
PODOPHYLLUM EMODI
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H
PODOPHYLLUM PELTATUM
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3
Appendix H

INDEX
PODOPHYLLUM RESIN
Appendix G
POLIHEXANIDE
cross reference: 1-(DIAMINOMETHYLIDENE)-2-HEXYLGUANIDINE, POLY

(IMINOCARBONIMIDOYLIMINOCARBONIMIDOYL IMINO-1,6-HEXANEDIYL),
POLYHEXAMETHYLENE BIGUANIDE (PHMB)
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
POLIOMYELITIS VACCINE
Schedule 4
POLIXETONIUM SALTS
Schedule 6
Schedule 5
POLOXALENE
Appendix B, Part 3
POLY (GNRF) OVALBUMIN
Appendix B, Part 3
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE

cross reference: POLYDADMAC
Appendix B, Part 3
POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-
OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS
Schedule 5
Appendix E, Part 2
POLYACRYLAMIDE
Schedule 4
POLYCAPROLACTONE
Schedule 4

INDEX
POLYESTRADIOL
Schedule 4
POLYETHANOXY (15) TALLOW AMINE
Schedule 5
Appendix E, Part 2
POLYHEDROSIS VIRUS of Helico zea occlusion bodies
Appendix B, Part 3
POLYLACTIC ACID
Schedule 4
POLYMYXIN
Schedule 4
POLYOXIN D ZINC SALT
Schedule 5
POLYSORBATE 20
Appendix B, Part 3
POLYSULFATED GLYCOSAMINOGLYCANS
Schedule 4
POLYTHIAZIDE
Schedule 4
POMALIDOMIDE
Schedule 4
Appendix D, Item 4
Appendix F, Part 3
Appendix L, Part 2
PORACTANT
Schedule 4
PORCELAIN
Appendix A

INDEX
PORCINE SOMATOTROPHIN
Appendix B, Part 3
POSACONAZOLE
Schedule 4
POTASSIUM AZELOYL DIGLYCINATE
Schedule 6
POTASSIUM BICARBONATE
Appendix B, Part 3
POTASSIUM BROMATE
Schedule 6
Appendix E, Part 2
POTASSIUM BROMIDE
Schedule 4
POTASSIUM CHLORATE
Schedule 5
Schedule 2
Appendix E, Part 2
POTASSIUM CHLORIDE
Schedule 4
POTASSIUM CYANATE
Schedule 6
Appendix E, Part 2
POTASSIUM HYDROXIDE
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
POTASSIUM METABISULPHITE

INDEX
Schedule 5
Appendix F, Part 3
POTASSIUM NITRITE
Schedule 7
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
POTASSIUM PERCHLORATE
Schedule 4
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT
Schedule 6
Schedule 5
POTASSIUM PERSULFATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
POTASSIUM SORBATE
Appendix B, Part 3
POTASSIUM SULFIDE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PRACTOLOL
Schedule 4
PRADOFLOXACIN
Schedule 4
PRALATREXATE
Schedule 4
PRALIDOXIME
Schedule 4

INDEX
PRALLETHRIN
Schedule 6
Schedule 5
PRALMORELIN (GROWTH HORMONE RELEASING PEPTIDE-2) (GHRP-2)
Schedule 4
Appendix D, Item 5
PRAMIPEXOLE
Schedule 4
PRAMIRACETAM
Schedule 4
PRAMOCAINE
Schedule 4
PRAMPINE
Schedule 4
PRASTERONE
cross reference: DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE
Schedule 4
PRASUGREL
Schedule 4
PRAVASTATIN
Schedule 4
PRAZEPAM
Schedule 4
Appendix K
PRAZIQUANTEL
Schedule 4

INDEX
PRAZOSIN
Schedule 4
PREDNISOLONE
Schedule 4
PREDNISONE
Schedule 4
PREGABALIN
Schedule 4
Appendix K
PREGNENOLONE
Schedule 4
PRENALTEROL
Schedule 4
PRENYLAMINE
Schedule 4
PRILOCAINE
Schedule 4
Schedule 2
PRIMAQUINE
Schedule 4
PRIMIDONE
Schedule 4
PRINTING INKS or INK ADDITIVES
Appendix A
PROBENECID
Schedule 4
PROBUCOL

INDEX
Schedule 4
PROCAINAMIDE
Schedule 4
PROCAINE
Schedule 4
PROCAINE BENZYLPENICILLIN
Schedule 4
PROCAINE PENICILLIN
cross reference: PROCAINE BENZYLPENICILLIN
PROCARBAZINE
Schedule 4
PROCHLORAZ
Schedule 6
PROCHLORPERAZINE
Schedule 4
Schedule 3
Appendix K
PROCYCLIDINE
Schedule 4
Schedule 2
PROCYMIDONE
Schedule 7
PROFENOFOS
Schedule 6
PROFOXYDIM
Schedule 5
PROGESTERONE

INDEX
Schedule 5
Schedule 4
Appendix G
PROGESTOGENS
Schedule 4
PROGLUMIDE
Schedule 4
PROGUANIL
Schedule 4
PROHEPTAZINE
Schedule 9
PROHEXADIONE CALCIUM
Schedule 5
PROLINTANE
Schedule 4
PROMACYL
Schedule 6
PROMAZINE
Schedule 4
Appendix K
PROMETHAZINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
PROMETRYN
Schedule 5
PROMOXOLANE
Schedule 4

INDEX
PROPACHLOR
Schedule 6
PROPAFENONE
Schedule 4
PROPAMIDINE
Schedule 4
Schedule 2
PROPAMOCARB
Schedule 5
PROPANIDID
Schedule 4
PROPANIL
Schedule 5
PROPANTHELINE
Schedule 4
PROPAQUIZAFOP
Schedule 5
PROPARGITE
Schedule 6
PROPENTOFYLLINE
Schedule 4
PROPERIDINE
Schedule 9
PROPETAMPHOS
Schedule 6
PROPETANDROL

INDEX
Schedule 4
PROPICONAZOLE
Schedule 6
Schedule 5
PROPINEB
Schedule 6
PROPIONIBACTERIUM ACNES
Schedule 4
PROPIONIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
PROPIRAM
Schedule 8
PROPOFOL
Schedule 4
PROPOXUR
Schedule 6
Schedule 5
PROPRANOLOL
Schedule 4
Appendix G
PROPYL ACETATES
Appendix B, Part 3
n-PROPYL ALCOHOL
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3

INDEX
n-PROPYL NITRITE
Schedule 10
PROPYLENE GLYCOL
Appendix B, Part 3
2-PROPYLENE GLYCOL 1-MONOMETHYL
Appendix B, Part 3
PROPYLENE OXIDE
Schedule 7
Appendix J, Part 2
PROPYLHEXEDRINE
Schedule 4
PROPYLTHIOURACIL
Schedule 4
PROPYPHENAZONE
Schedule 4
PROPYZAMIDE
Schedule 5
PROQUAZONE
Schedule 4
PROQUINAZID
Schedule 6
PROSCILLARIDIN
Schedule 4
PROSTAGLANDINS
Schedule 4
PROSTIANOL

INDEX
Schedule 4
PROSULFOCARB
Schedule 6
PROSULFURON
Schedule 6
PROTAMINE
Schedule 4
PROTHIOCONAZOLE
Appendix B, Part 3
PROTHIOCONAZOLE-DESCHLORO
Schedule 5
PROTHIOCONAZOLE-TRIAZOLIDINETHIONE
Schedule 5
PROTHIOFOS
Schedule 6
PROTHIONAMIDE
Schedule 4
PROTHIPENDYL
Schedule 4
PROTIRELIN
Schedule 4
PROTOVERATRINES
Schedule 4
PROTRIPTYLINE
Appendix K
PROTRIPTYLINE

INDEX
Schedule 4
PROXYMETACAINE
Schedule 4
PRUCALOPRIDE
Schedule 4
PSEUDOEPHEDRINE
Schedule 4
Schedule 3
PSEUDOMONAS FLUORESCENS
Appendix B, Part 3
PSILOCYBINE
Schedule 9
PTERIDIUM spp.
Schedule 10
D-PULEGONE
Schedule 6
Appendix E, Part 2
PULMONARIA spp.
Schedule 10
PYDIFLUMETOFEN
Appendix B, Part 3
PYMETROZINE
Schedule 5
PYRACLOFOS
Schedule 6
PYRACLOSTROBIN
Schedule 5

INDEX
PYRAFLUFEN-ETHYL
Schedule 5
PYRANTEL
Schedule 2
PYRASULFOTOLE
Schedule 5
PYRAZINAMIDE
Schedule 4
PYRAZOLAM
Schedule 9
PYRAZOPHOS
Schedule 6
PYRETHRINS
cross reference: CHRYSANTHEMIC ACID ESTERS, CINEROLONE, JASMOLONE,
PYRETHRIC ACIDS, PYRETHROLONE
Schedule 5
Schedule 2
PYRIDABEN
Schedule 6
Schedule 5
PYRIDALYL
Schedule 6
PYRIDATE
Schedule 6
PYRIDINOLCARBAMATE
Schedule 4
PYRIDOSTIGMINE
Schedule 4

INDEX
PYRIDOXAL
Schedule 4
PYRIDOXAMINE
Schedule 4
PYRIDOXINE
Schedule 4
PYRIFENOX
Schedule 5
PYRIMETHAMINE
Schedule 4
PYRIMETHANIL
Appendix B, Part 3
PYRINURON
Schedule 7
Appendix J, Part 2
PYRIOFENONE
Schedule 6
Schedule 5
PYRIPROLE
Schedule 6
PYRIPROXYFEN
Appendix B, Part 3
PYRITHIOBAC SODIUM
Schedule 5
PYRITHIONE COPPER
Schedule 6
PYRITHIONE ZINC

INDEX
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
PYROVALERONE
Schedule 4
PYROXASULFONE
Schedule 6
PYROXSULAM
Schedule 6
PYRVINIUM
cross reference: VIPRYNIUMA
Schedule 4
QUASSIA
Appendix B, Part 3
QUATERNARY AMMONIUM COMPOUNDS

cross reference: BENZALKONIUM CHLORIDE, DIALKYL and DIALKOYL
QUATERNARY AMMONIUM COMPOUNDS
Schedule 6
Schedule 5
Appendix E, Part 5
QUAZEPAM
Schedule 4
QUETIAPINE
Schedule 4
Appendix K
QUINAGOLIDE
Schedule 4

INDEX
QUINALBARBITONE
cross reference: SECOBARBITAL
QUINAPRIL
Schedule 4
QUINBOLONE
Schedule 4
QUINCLORAC
Schedule 5
QUINETHAZONE
Schedule 4
QUINIDINE
Schedule 4
QUININE
cross reference: QUININE (CAS No. 130-95-0), QUININE SULFATE (1:1) (CAS No. 549-56-
4), QUININE SULFATE (2:1) (CAS No. 804-63-7), QUININE SULFATE (2:1) DIHYDRATE
(CAS No. 6119-70-6), QUININE SULFATE (1:1) HEPTAHYDRATE (CAS No. 6183-68-2),
QUININE DIHYDROCHLORIDE (CAS No. 60-93-5), QUININE
MONOHYDROCHLORIDE (CAS No. 130-89-2), QUININE HYDROCHLORIDE
DIHYDRATE (CAS No. 6119-47-7), QUININE HYDROCHLORIDE (UNSPECIFIED) (CAS
No. 7549-43-1)
Schedule 7
Schedule 6
Schedule 5
Schedule 4
Appendix F, Part 3
QUINISOCAINE
cross reference: DIMETHISOQUINE
Schedule 4
QUINOLINE
cross reference: 2,3-BENZAPYRIDINE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3

INDEX
QUINOXYFEN
Appendix B, Part 3
QUINTOZENE
cross reference: PENTACHLORONITROBENZENE
Schedule 5
QUINUPRISTIN
Schedule 4
QUIZALOFOP ETHYL
cross reference: QUIZALOFOP ETHYL (D + ISOMER)
Schedule 6
QUIZALOFOP-p-ETHYL
Schedule 6
Schedule 5
QUIZALOFOP-p-TEFURYL
Schedule 6
RABEPRAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
RABIES VACCINE
Schedule 4
RACEMETHORPHAN
Schedule 9
RACEMORAMIDE
Schedule 8
RACEMORPHAN
Schedule 9

INDEX
RACETAMS
Schedule 4
RACTOPAMINE
Schedule 5
Schedule 4
RADIOGRAPHIC CONTRAST MEDIA

cross reference: RADIOPAQUES
Appendix A
RADIOISOTOPES
Appendix A
RALOXIFENE
Schedule 4
RALTEGRAVIR
Schedule 4
RALTITREXED
Schedule 4
RAMIPRIL
Schedule 4
RAMUCIRUMAB
Schedule 4
RANIBIZUMAB
Schedule 4
RANITIDINE
Schedule 4
Schedule 2
Appendix F, Part 3
RANOLAZINE
Schedule 4

INDEX
RAPACURONIUM
Schedule 4
RASAGILINE
Schedule 4
RASBURICASE
Schedule 4
RAUWOLFIA SERPENTINA
Schedule 4
RAUWOLFIA VOMITORIA
Schedule 4
RAZOXANE
Schedule 4
REBOXETINE
Schedule 4
RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
Schedule 4
RED YEAST RICE
Schedule 4
REGORAFENIB
Schedule 4
REMIFENTANIL
Schedule 8
REMDESIVIR
Schedule 4
REMOXIPRIDE
Schedule 4

INDEX
REPAGLINIDE
Schedule 4
RESERPINE
Schedule 4
RESLIZUMAB
Schedule 4
RESMETHRIN
Schedule 6
Schedule 5
RESORCINOL
cross reference: 1,3-benzenediol
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
RETAPAMULIN
Schedule 4
RETEPLASE
Schedule 4
RETIGABINE
Schedule 4
Appendix K
RHIZOBIUM RHIZOGENES
Appendix B, Part 3
RIBAVIRIN
Schedule 4
RIBOCICLIB
Schedule 4
RIDAFOROLIMUS

INDEX
Schedule 4
RIFABUTIN
Schedule 4
RIFAMPICIN
Schedule 4
RIFAMYCIN
Schedule 4
RIFAPENTINE
Schedule 4
RIFAXIMIN
Schedule 4
RILPIVIRINE
Schedule 4
RILUZOLE
Schedule 4
RIMEXOLONE
Schedule 4
RIMITEROL
Schedule 4
RIMONABANT
Schedule 4
RIMSULFURON
Schedule 5
RIOCIGUAT
Schedule 4
Appendix D, Item 5
Appendix L, Part 2

INDEX
RIPRETINIB
Schedule 4
RISANKIZUMAB
Schedule 4
RISEDRONIC ACID
Schedule 4
RISPERIDONE
Schedule 4
Appendix K
RITODRINE
Schedule 4
RITONAVIR
Schedule 4
RITUXIMAB
Schedule 4
RIVAROXABAN
Schedule 4
RIVASTIGMINE
Schedule 4
RIZATRIPTAN
Schedule 4
Schedule 3
Appendix H
ROBENACOXIB
Schedule 4
ROBENIDINE
Schedule 5

INDEX
ROFECOXIB
Schedule 4
ROFLUMILAST
Schedule 4
ROLICYCLIDINE
cross reference: PCPY, PHP
Schedule 9
ROLITETRACYCLINE
Schedule 4
ROLZIRACETAM
Schedule 4
ROMIDEPSIN
Schedule 4
ROMIFIDINE
Schedule 4
ROMIPLOSTIM
Schedule 4
ROMOSOZUMAB
Schedule 4
RONIDAZOLE
Schedule 4
ROPINIROLE
Schedule 4
ROPIVACAINE
Schedule 4
ROSEMARY OIL

INDEX
Appendix B, Part 3
ROSIGLITAZONE
Schedule 4
ROSIN
cross reference: COLOPHONY
Schedule 5
ROSOXACIN
Schedule 4
ROSUVASTATIN
Schedule 4
ROTENONE
cross reference: CUBE
Schedule 6
ROTIGOTINE
Schedule 4
Appendix K
ROXIBOLONE
Schedule 4
ROXITHROMYCIN
Schedule 4
RUBELLA VACCINE
Schedule 4
RUBOXISTAURIN
Schedule 4
RUFINAMIDE
Schedule 4
Appendix K
Appendix L, Part 2

INDEX
RUPATADINE
Schedule 4
Appendix K
RUXOLITINIB
Schedule 4
SACUBITRIL
Schedule 4
SAFINAMIDE
Schedule 4
SAFLUFENACIL
Schedule 7
Schedule 5
SAFROLE
cross reference: SASSAFRAS OIL
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SAGE OIL
cross reference: DALMATIAN, THUJONE
Schedule 6
Appendix E, Part 2
SAGE OIL (Spanish)

cross reference: CAMPHOR
Appendix B, Part 3
SALBUTAMOL
Schedule 4
Schedule 3
Appendix F, Part 3
SALCATONIN
cross reference: CALCITONIN SALMON

INDEX
SALICYLAMIDE
cross reference: ASPIRIN, CAFFEINE, PARACETAMOL
Schedule 4
Schedule 2
Appendix F, Part 3
SALICYLANILIDE
Schedule 5
SALICYLIC ACID
cross reference: CHOLINE SALICYLATE
Schedule 3
Appendix H
SALINOMYCIN
Schedule 6
Schedule 4
SALMETEROL
Schedule 4
SALVIA DIVINORUM
Schedule 9
SANDALWOOD OIL
Appendix B, Part 3
SANGUINARIA CANADENSIS (bloodroot)
Schedule 10
SANGUINARINE
cross reference: SANGUINARIA CANADENSIS (bloodroot)
SANTONIN
Schedule 3
SAPROPTERIN
Schedule 4
SAQUINAVIR

INDEX
Schedule 4
SARILUMAB
Schedule 4
SAROLANER
Schedule 6
Schedule 5
SARS-COV-2 (COVID-19) VACCINE
Schedule 4
SASSAFRAS OIL
cross reference: SAFROLE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SAXAGLIPTIN
Schedule 4
SCHOENOCAULON OFFICINALE
cross reference: SABADILLA
Schedule 4
SCHRADAN
Schedule 7
SCOPOLIA CARNIOLICA
Schedule 4
SEAWEED
Appendix B, Part 3
SEBELIPASE ALFA
Schedule 4
SECBUTOBARBITAL
Schedule 8
Appendix K

INDEX
SECBUTOBARBITONE
cross reference: SECBUTOBARBITAL
SECOBARBITAL
Schedule 8
Appendix K
SECUKINUMAB
Schedule 4
SEDAXANE
Schedule 5
SEEDS
Appendix A
SELAMECTIN
Schedule 5
SELECTIVE ANDROGEN RECEPTOR MODULATORS

cross reference: SARM
Schedule 4
Appendix D, Item 5
SELEGILINE
Schedule 4
SELENIUM
cross reference: BARIUM SELENATE, SELENIUM COMPOUNDS, SELENIUM
ARSENIDE, SELENIUM SULFIDE
Schedule 7
Schedule 6
Schedule 4
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
Appendix G
SELETRACETAM
Cross reference RACETAMS
Schedule 4
Appendix K

INDEX
SELEXIPAG
Schedule 4
SEMAGLUTIDE
Schedule 4
SEMDURAMICIN
Schedule 7
Schedule 6
SENECIO spp.
Schedule 10
SERELAXIN
Schedule 4
SERMORELIN
Schedule 4
SERTINDOLE
Schedule 4
SERTRALINE
Schedule 4
SETHOXYDIM
Schedule 5
SEVELAMER
Schedule 4
SEVOFLURANE
Schedule 4
SEX HORMONES
Schedule 4
SH-OLIGOPEPTIDE-1, RH-OLIGOPEPTIDE-1
cross reference: EPIDERMAL GROWTH FACTOR

INDEX
SIBUTRAMINE
Schedule 4
SIDURON
Schedule 5
SILANDRONE
Schedule 4
Appendix D, Item 5 (Anabolic steroidal agent)
SILDENAFIL
Schedule 4
SILICOFLUORIDES
cross reference: BARIUM SILICOFLUORIDE, FLUORIDES, FLUOROSILICATES,
HEXAFLUOROSILICATES MAGNESIUM FLUOSILICATE,
Schedule 6
Schedule 5
SILICONES
Schedule 10
Schedule 4
Appendix F, Part 3
SILODOSIN
Schedule 4
SILTUXIMAB
Schedule 4
SILVER
Schedule 2
SILVER NITRATE
cross reference: SILVER SALTS
Schedule 6
Appendix E, Part 2
SILVER OXIDE
Appendix B, Part 3

INDEX
SILVER SULFADIAZINE
Schedule 4
SIMAZINE
Appendix B, Part 3
SIMEPREVIR
Schedule 4
SIMVASTATIN
Schedule 4
SINBIOALLETHRIN
Schedule 6
Schedule 5
SINGLE-USE TUBES
Appendix A
SIPONIMOD
Schedule 4
SIROLIMUS
Schedule 4
SISOMICIN
Schedule 4
SITAGLIPTIN
Schedule 4
SITAXENTAN
Schedule 4
Appendix D, Item 6
Appendix F, Part 3
Appendix L, Part 2
SLIMICIDES
Appendix A

INDEX
SODIUM ALUMINATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SODIUM BICARBONATE
Appendix B, Part 3
SODIUM BROMATE
Schedule 6
Appendix E, Part 2
SODIUM BROMIDE
Schedule 5
Schedule 4
SODIUM CELLULOSE PHOSPHATE
Schedule 4
SODIUM CHLORATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM CROMOGLYCATE
Schedule 4
Schedule 2
SODIUM DIACETATE
Schedule 5
Appendix E, Part 2
SODIUM DICHLOROISOCYANURATE
Appendix E, Part 2
SODIUM DODECYLBENZENE SULFONATE
Schedule 5
Appendix E, Part 2, Part
Appendix F, Part 3
SODIUM FLUORIDE

INDEX
Appendix F, Part 3
SODIUM GLYCEROPHOSPHATE HYDRATE
Schedule 4
SODIUM HYDROGEN SULFATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM HYDROSULFITE
Schedule 5
Appendix F, Part 3
SODIUM HYDROXIDE
cross reference: LYE WATER
Schedule 10
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM LAURETH-6 CARBOXYLATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM METABISULPHITE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM MORRHUATE
Schedule 4
SODIUM NITRITE
Schedule 7
Schedule 6
Schedule 5
Schedule 2
Appendix E, Part 2
Appendix F, Part 3

INDEX
SODIUM NITROPRUSSIDE
Schedule 4
SODIUM OXYBATE
Schedule 8
Appendix D, Item 1
Appendix K
SODIUM PERCARBONATE
Schedule 6
Schedule 5
Appendix E, Part 2
SODIUM PERSULFATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SODIUM PHENYLBUTYRATE
Schedule 4
SODIUM PHOSPHATE
Schedule 4
Schedule 3
SODIUM PICOSULFATE
Schedule 3
SODIUM POLYSTYRENE SULPHONATE
Schedule 5
Schedule 4
SODIUM PROPIONATE
Appendix B, Part 3
SODIUM SALICYLATE
Schedule 4
SODIUM STANNATE

INDEX
Schedule 5,
Appendix E, Part 2
SODIUM SULFIDE
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SODIUM TETRADECYLSULFATE
Schedule 4
SODIUM TRICHLOROACETATE
Appendix E, Part 2
SODIUM ZIRCONIUM CYCLOSILICATE.
Schedule 4
SODIUMHYDROSULFITE
Appendix E, Part 2
SOFOSBUVIR
Schedule 4
SOLASODINE
Schedule 4
SOLIFENACIN
Schedule 4
SOMATOSTATIN
Schedule 4
SOMATOTROPIN EQUINE
Schedule 4
SOMATROPIN
cross reference: HUMAN GROWTH HORMONE

INDEX
Schedule 4
Appendix D, Item 5
Appendix G
SONIDEGIB
Schedule 4
SONTOQUINE
Schedule 4
SORAFENIB
Schedule 4
SOTALOL
Schedule 4
SPARFLOXACIN
Schedule 4
SPARTEINE
Schedule 4
SPECTINOMYCIN
Schedule 4
SPINETORAM
Schedule 5
SPINOSAD
Schedule 5
SPIRAMYCIN
Schedule 4
SPIRAPRIL
Schedule 4
SPIRONOLACTONE
Schedule 4

INDEX
SPIROPIDION
Schedule 6
SPIROTETRAMAT
Schedule 6
SPIROXAMINE
Schedule 6
SQUILL
Schedule 2
STANOLONE
Schedule 4
STANOZOLOL
Schedule 4
STAR ANISE OIL
Schedule 5
STAVUDINE
Schedule 4
STENABOLIC (SR9009) and other synthetic REV-ERB agonists

cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667
Schedule 4
Appendix D, Item 5
STENBOLONE
Schedule 4
STERIC ACID
Appendix B, Part 3
STEROID HORMONES

INDEX
Schedule 4
STILBESTROL
cross reference: STILBOESTROL, DIETHYLSTILBESTROL
Schedule 4
STIRIPENTOL
Schedule 4
Appendix K
STREPTODORNASE
Schedule 4
STREPTOKINASE
Schedule 4
STREPTOMYCES LYDICUS WYEC 108
Appendix B, Part 3
STREPTOMYCIN
Schedule 4
STRONTIUM RANELATE
Schedule 4
STROPHANTHINS
Schedule 4
STROPHANTHUS spp.
Schedule 4
Appendix G
STRYCHNINE
cross reference: NUX VOMICA
Schedule 7
Schedule 4
Appendix E, Part 2
Appendix G
Appendix J, Part 2
STRYCHNOS spp.

INDEX
Schedule 4
STYRAMATE
Schedule 4
STYRENE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SUCCIMER
Schedule 4
SUCRALFATE
Appendix B, Part 3
SUCROFERRIC OXYHYDROXIDE
Schedule 4
SUFENTANIL
Schedule 8
SUGAMMADEX
Schedule 4
SULBACTAM
Schedule 4
SULCOFURON
Schedule 7
Schedule 6
Appendix E, Part 2
Appendix J, Part 2
SULCONAZOLE
Schedule 4
Schedule 2
SULESOMAB

INDEX
Appendix B, Part 3
SULFACETAMIDE
Schedule 5
Schedule 4
Schedule 3
SULFADIAZINE
Schedule 5
Schedule 4
SULFADIMETHOXINE
Schedule 4
SULFADIMIDINE
Schedule 5
Schedule 4
SULFADOXINE
Schedule 4
SULFAFURAZOLE
Schedule 4
SULFAGUANIDINE
Schedule 4
SULFAMERAZINE
Schedule 5
Schedule 4
SULFAMETHIZOLE
Schedule 4
SULFAMETHOXAZOLE
Schedule 4
SULFAMETHOXYDIAZINE
Schedule 4

INDEX
SULFAMETHOXYPYRIDAZINE
Schedule 4
SULFAMETROLE
Schedule 4
SULFAMIC ACID
Schedule 6
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
SULFAMONOMETHOXINE
Schedule 4
SULFAMOXOLE
Schedule 4
SULFAPHENAZOLE
Schedule 4
SULFAPYRIDINE
Schedule 4
SULFAQUINOXALINE
Schedule 4
SULFASALAZINE
Schedule 4
SULFATHIAZOLE
Schedule 5
Schedule 4
SULFATROXAZOLE
Schedule 4
SULFENTRAZONE
Schedule 7

INDEX
SULFINPYRAZONE
Schedule 4
SULFLURAMID
Schedule 6
SULFOMETURON-METHYL
Schedule 5
SULFOMYXIN
Schedule 4
SULFONAMIDES
cross reference: SULFACETAMIDE, SULPHANILAMIDE
Schedule 4
SULFONMETHANE
cross reference: ALKYL SULFONALS, SULFONAL
Schedule 4
SULFOSULFURON
Appendix B, Part 3
SULFOTEP
Schedule 7
SULFOXAFLOR
Schedule 6
Schedule 5
SULFURIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
SULFURYL FLUORIDE
Schedule 6
SULINDAC

INDEX
Schedule 4
SULPHATED POLYSACCHARIDES
Appendix B, Part 3
SULPROFOS
Schedule 6
SULTAMICILLIN
Schedule 4
SULTHIAME
Schedule 4
SUMATRIPTAN
Schedule 4
Schedule 3
Appendix H
SUNIFIRAM
Schedule 4
SUNITINIB
Schedule 4
SUPROFEN
Schedule 4
SUTILAINS
Schedule 4
SUVOREXANT
Schedule 4
Appendix K
SUXAMETHONIUM
Schedule 4
SUXETHONIUM

INDEX
Schedule 4
SYMPHYTUM spp.
cross reference: COMFREY
Schedule 10
Schedule 5
Appendix F, Part 3
SYNTHETIC CANNABINOMIMETICS
Schedule 9
2,4,5-T
Schedule 6
TACRINE
Schedule 4
TACROLIMUS
Schedule 4
TADALAFIL
Schedule 4
TAFAMIDIS
Schedule 4
TAFENOQUINE SUCCINATE
Schedule 4
TAFLUPROST
Schedule 4
TALAZOPARIB
Schedule 4
TALIGLUCERASE ALFA
Schedule 4

INDEX
TALIMOGENE LAHERPAREPVEC
Schedule 4
TALLOW ALKYLAMINE ACETATES
Schedule 6
N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE
Schedule 6
TAMOXIFEN
Schedule 4
TAMSULOSIN
Schedule 4
TANACETUM VULGARE
cross reference: OIL OF TANSY, TANSY OIL
Schedule 4
TANNIC ACID
Appendix B, Part 3
TANNIC ACID/BENZYL ALCOHOL PRODUCT
Appendix B, Part 3
TAPENTADOL
Schedule 8
Appendix K
TAR ACIDS
Schedule 6
TASONERMIN
Schedule 4
TAZAROTENE
Schedule 4
Appendix F, Part 3

INDEX
TAZOBACTAM
Schedule 4
TB-500
Schedule 4
Appendix D, Item 5
2,3,6-TBA
Schedule 5
T-CELL RECEPTOR ANTIBODY
Schedule 4
TCMTB
cross reference: 2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE
Schedule 6
TDE
cross reference: 1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE
Schedule 6
Schedule 5
TEBUCONAZOLE
cross reference: TERBUCONAZOLE
Schedule 5
TEBUFENOZIDE
Schedule 5
TEBUFENPYRAD
Schedule 6
TEBUTHIURON
Schedule 6
TEDUGLUTIDE
Schedule 4
TEFLUTHRIN

INDEX
Schedule 7
Schedule 5
TEGAFUR
Schedule 4
TEGASEROD
Schedule 4
TEICOPLANIN
Schedule 4
TELAPREVIR
Schedule 4
TELBIVUDINE
Schedule 4
TELITHROMYCIN
Schedule 4
TELMISARTAN
Schedule 4
TELOTRISTAT ETHYL
Schedule 4
TEMAZEPAM
Schedule 4
Appendix K
TEMEPHOS
Schedule 6
Schedule 5
TEMOZOLOMIDE
Schedule 4
TEMSIROLIMUS

INDEX
Schedule 4
TENECTEPLASE
Schedule 4
TENIPOSIDE
Schedule 4
TENOCYCLIDINE
cross reference: TCP
Schedule 9
TENOFOVIR
Schedule 4
TENOXICAM
Schedule 4
TEPOXALIN
Schedule 4
TEPP
Schedule 8
TEPRALOXYDIM
Schedule 5
TERAZOSIN
Schedule 4
TERBACIL
Appendix B, Part 3,Part 3
TERBINAFINE
Schedule 4
Schedule 2
TERBUFOS
Schedule 7

INDEX
TERBUTALINE
Schedule 4
Schedule 3
Appendix F, Part 3
TERBUTHYLAZINE
Schedule 6
TERBUTRYN
Schedule 5
TERFENADINE
Schedule 4
Appendix F, Part 3
TERIFLUNOMIDE
Schedule 4
Appendix F, Part 3
Appendix L, Part 2
TERIPARATIDE
Schedule 4
Appendix D, Item 1
TERLIPRESSIN
Schedule 4
TERMITE BARRIERS
Appendix A
TERODILINE
Schedule 4
TEROPTERIN
Schedule 4
TERPENES, CHLORINATED
cross reference: CHLORINATED TERPENES

INDEX
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
TESTOLACTONE
Schedule 4
TESTOSTERONE
Schedule 6
Schedule 4
Appendix G
TETANUS ANTITOXIN
Schedule 4
TETANUS TOXOID
Schedule 4
1,3,5,7-TETRAAZATRICYLO[3.3.1.13,7] DECANE
cross reference: HEXAMINE, HEXAMETHYLENETETRAMINE, METHENAMINE
Schedule 5
TETRABENAZINE
Schedule 4
TETRACAINE
cross reference: AMETHOCAINE
Schedule 4
Schedule 2
TETRACHLOROETHANE
Schedule 7
Appendix E, Part 2
Appendix F, Part 3
Appendix J, Part 2
TETRACHLOROETHYLENE
Schedule 6
Schedule 5

INDEX
Schedule 2
Appendix E, Part 2
Appendix F, Part 3
TETRACHLORVINPHOS
Schedule 5
TETRACONAZOLE
Schedule 6
Schedule 5
TETRACOSACTIDE
Schedule 4
TETRACOSACTRIN
cross reference: TETRACOSACTIDE
TETRACYCLINE
Schedule 5
Schedule 4
TETRADIFON
Schedule 6
TETRAETHYLAMMONIUM
Schedule 4
TETRAHYDROCANNABINOLIC ACID
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS
TETRAHYDROCANNABINOLS
cross reference: CANNABIS, HEMP SEED OIL, NABIXIMOLS
Schedule 9
Schedule 8
Appendix D, Item 1
Appendix K
TETRAHYDROCANNABIDIVAROL
cross reference: NABIXIMOLS, TETRAHYDROCANNABINOLS, CANNABIS
TETRAHYDROZOLINE
cross reference: TETRYZOLINE

INDEX
2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE
cross reference: STABAXOL
Schedule 7
Schedule 6
Appendix J, Part 2
TETRAMETHRIN
Schedule 5
TETRAMISOLE
Schedule 6
TETRANILIPROLE
Schedule 5
TETROXOPRIM
Schedule 4
TETRYZOLINE
cross reference: TETRAHYDROZOLINE
Schedule 2
Appendix F, Part 3
TEZACAFTOR
Schedule 4
THALIDOMIDE
Schedule 4
Appendix D, Item 2
Appendix F, Part 3
Appendix L, Part 2
THALLIUM
cross reference: THALLIUM SULFATE
Schedule 7
Appendix J, Part 2
THAUMATIN
Appendix B, Part 3
THEBACON

INDEX
Schedule 8
THEBAINE
Schedule 8
THENYLDIAMINE
Schedule 4
Appendix K
THEOPHYLLINE
Schedule 4
Schedule 3
THEVETIA PERUVIANA
Schedule 4
THEVETIN
Schedule 4
THIABENDAZOLE
Schedule 5
Schedule 2
THIACETARSAMIDE
Schedule 4
THIACLOPRID
Schedule 6
THIAMBUTOSINE
Schedule 4
THIAMETHOXAM
Schedule 6
Schedule 5
THIAZAFLURON
Schedule 6
THIAZOPYR

INDEX
Schedule 5
THIAZOSULFONE
Schedule 4
THIDIAZURON
Appendix B, Part 3
THIETHYLPERAZINE
Schedule 4
Appendix K
THIFENSULFURON
Schedule 5
THIOACETAZONE
Schedule 4
THIOBENCARB
Schedule 5
THIOCARLIDE
Schedule 4
THIODICARB
Schedule 6
Schedule 5
THIOFANOX
Schedule 7
THIOFENTANYL
Schedule 9
THIOGUANINE
cross reference: TIOGUANINE
THIOMESTERONE
cross reference: TIOMESTERONE

INDEX
Schedule 4
THIOMETON
Schedule 6
THIOPENTAL
Schedule 4
THIOPENTONE
cross reference: THIOPENTAL
THIOPHANATE-METHYL
Schedule 6
Schedule 5
THIOPROPAZATE
Schedule 4
Appendix K
THIOPROPERAZINE
Schedule 4
THIORIDAZINE
Schedule 4
Appendix K
THIOSTREPTON
Schedule 4
THIOTEPA
cross reference: TRIETHYLENE THIOPHOSPHORAMIDE
Schedule 4
THIOTHIXENE
Schedule 4
Appendix K
THIOURACIL
Schedule 4

INDEX
THIOUREA
cross reference: ALKYL THIOUREAS
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
THIRAM
Schedule 6
THUJONE
Schedule 6
Appendix E, Part 2
THYME OIL
Schedule 5
Appendix E, Part 2
THYMOL
Schedule 6
THYMOSIN BETA 4 (THYMOSIN β4)
Schedule 4
Appendix D, Item 5
THYMOXAMINE
Schedule 4
THYROID
Schedule 4
THYROTROPHIN
cross reference: TSH
Schedule 4
THYROXINE
Schedule 4
Appendix G
TIAFENACIL

INDEX
Appendix B, Part 3
TIAGABINE
Schedule 4
TIAMULIN
Schedule 4
TIANEPTINE
Schedule 4
Appendix D, Item 5
TIAPROFENIC ACID
Schedule 4
TIARAMIDE
Schedule 4
TIBOLONE
Schedule 4
TICAGRELOR
Schedule 4
TICARCILLIN
Schedule 4
TICLOPIDINE
Schedule 4
TIEMONIUM
Schedule 4
TIENILIC ACID
Schedule 4
TIGECYCLINE
Schedule 4

INDEX
TIGILANOL TIGLATE
Schedule 4
TIGLOIDINE
Schedule 4
TILDIPIROSIN
Schedule 4
TILETAMINE
Schedule 4
TILIDINE
Schedule 8
TILMANOCEPT
Schedule 4
TILMICOSIN
Schedule 4
TILUDRONIC ACID
cross reference: DISODIUM TILUDRONATE
Schedule 4
TIMBER
cross reference: WALLBOARD
Appendix A
TIMOLOL
Schedule 4
TIMOTHY-GRASS POLLEN EXTRACT

cross reference: PHLEUM PRATENSE POLLEN EXTRACT
Schedule 4
TIN ORGANIC COMPOUNDS

cross reference: DIALKYL TIN COMPOUNDS, DIBUTYL TIN COMPOUNDS, DIETHYL
TIN COMPOUNDS, DIMETHYL TIN DICHLORIDE, DIMETHYL TIN COMPOUNDS,
DIPROPYL TIN COMPOUNDS, FENBUTATIN OXIDE, ORGANO TIN-COMPOUNDS,

INDEX
TBTO, TRIALKYL TIN COMPOUNDS, TRIBUTYL TIN COMPOUNDS, TRIETHYL TIN

COMPOUNDS, TRIMETHYL TIN COMPOUNDS, TRIPHENYL TIN COMPOUNDS,
TRIPROPYL TIN COMPOUNDS
Schedule 7
TINIDAZOLE
Schedule 4
TINZAPARIN
Schedule 4
TIOCARBAZIL
Schedule 5
TIOCONAZOLE
Schedule 4
Schedule 3
Schedule 2
Appendix H
TIOGUANINE
cross reference: THIOGUANINE
Schedule 4
TIOTROPIUM
Schedule 4
TIPEPIDINE
Schedule 4
TIPIRACIL
Schedule 4
TIPRANAVIR
Schedule 4
TIRILAZAD
Schedule 4
TIROFIBAN

INDEX
Schedule 4
TOBRAMYCIN
Schedule 4
TOCAINIDE
Schedule 4
TOCERANIB
Schedule 4
TOCILIZUMAB
Schedule 4
TOFACITINIB
Schedule 4
TOLAZAMIDE
Schedule 4
TOLAZOLINE
Schedule 4
TOLBUTAMIDE
Schedule 4
TOLCAPONE
Schedule 4
TOLCLOFOS-METHYL
Schedule 5
TOLFENAMIC ACID
Schedule 4
o-TOLIDINE
Appendix J, Part 2
TOLIDINE

INDEX
Schedule 4
Appendix E, Part 2
TOLMETIN
Schedule 4
TOLONIUM
Schedule 4
TOLPROPAMINE
Schedule 4
TOLRESTAT
Schedule 4
TOLTERODINE
Schedule 4
TOLTRAZURIL
Schedule 5
TOLUENE
cross reference: XYLENE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
2,4-TOLUENEDIAMINE
Schedule 10
TOLUENEDIAMINES
Schedule 10
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
o-TOLUIDINE
Schedule 10
TOLVAPTAN

INDEX
Schedule 4
TOLYLFLUANID
Schedule 6
TOPIRAMATE
Schedule 4
TOPOTECAN
Schedule 4
TOPRAMEZONE
Schedule 5
TORASEMIDE
Schedule 4
TOREMIFENE
Schedule 4
TOXOIDS
Schedule 4
TRALKOXYDIM
Schedule 5
TRAMADOL
Schedule 4
Appendix K
TRAMAZOLINE
Schedule 2
Appendix F, Part 3
TRAMETINIB DIMETHYL SULFOXIDE
Schedule 4
TRANDOLAPRIL
Schedule 4

INDEX
TRANEXAMIC ACID
cross reference: CETYL TRANEXAMATE
Schedule 4
TRANSFLUTHRIN
Schedule 6
TRANYLCYPROMINE
Schedule 4
Appendix K
TRASTUZUMAB
Schedule 4
TRASTUZUMAB EMTANSINE
Schedule 4
TRAVOPROST
Schedule 4
TRAZODONE
Schedule 4
TRENBOLONE
cross reference: TRIENBOLONE, TRIENOLONE
Schedule 5
Schedule 4
TREOSULPHAN
Schedule 4
TREPROSTINIL
Schedule 4
TRESTOLONE
Schedule 4
Appendix D, Item 5 (androgenic steroidal agents)
TRETAMINE

INDEX
Schedule 4
TRETINOIN
Schedule 4
Appendix D, Item 4
Appendix F, Part 3
Appendix L, Part 2
TRIACETYLOLEANDOMYCIN
Schedule 4
TRIADIMEFON
Schedule 6
Schedule 5
TRIADIMENOL
Schedule 5
TRI-ALLATE
Schedule 5
TRIAMCINOLONE
Schedule 4
Schedule 3
Schedule 2
Appendix F, Part 3, Part 2
Appendix H
TRIAMIPHOS
Schedule 7
TRIAMTERENE
Schedule 4
TRIASULFURON
Appendix B, Part 3
TRIAZBUTIL
Schedule 7
TRIAZIQUONE

INDEX
Schedule 4
TRIAZOLAM
Schedule 4
TRIBENURON-METHYL
Schedule 5
TRIBUFOS
cross reference: s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE
Schedule 7
TRICHLORFON
cross reference: METRIFONATE
Schedule 6
TRICHLORMETHIAZIDE
Schedule 4
TRICHLOROACETIC ACID
Schedule 6
Schedule 5
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
TRICHLOROACETIC ACID ALKALI SALTS
Schedule 5
Appendix E, Part 2
1,1,1-TRICHLOROETHANE
Schedule 10
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
TRICHLOROETHYLENE
cross reference: TRICHLOROETHENE

INDEX
Schedule 6
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
TRICHLOROISOCYANURIC ACID
cross reference: CHLORINATING COMPOUNDS
Appendix E, Part 2
TRICHLOROPHENOL
Schedule 6
Appendix F, Part 3
TRICHODERMA HARZIANUM
Appendix B, Part 3
TRICHODESMA AFRICANA
Schedule 10
TRICLABENDAZOLE
Schedule 6
TRICLOFOS
Schedule 4
TRICLOPYR
Schedule 6
TRICLOSAN
Schedule 6
TRICYCLAMOL
Schedule 4
TRIDEMORPH
Schedule 6
TRIDIHEXETHYL
Schedule 4

INDEX
TRIDIPHANE
Schedule 5
TRIENTINE
Schedule 4
TRIETAZINE
Schedule 5
TRIETHANOLAMINE
cross reference: TROLAMINE
TRIETHYL PHOSPHATE
Schedule 6
Appendix E, Part 2
TRIETHYLENE GLYCOL
Appendix B, Part 3
TRIFAROTENE
Schedule 4
TRIFLOXYSTROBIN
Schedule 5
TRIFLOXYSULFURON
Appendix B, Part 3
TRIFLUDIMOXAZIN
Schedule 5
TRIFLUMIZOLE
Schedule 5
TRIFLUMURON
Schedule 5
TRIFLUOPERAZINE

INDEX
Schedule 4
Appendix K
TRIFLUOROMETHANESULFONIC ACID
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE
cross reference: TFMPP
Schedule 9
TRIFLUPERIDOL
Schedule 4
TRIFLUPROMAZINE
Schedule 4
TRIFLURALIN
Appendix B, Part 3
TRIFLURIDINE
Schedule 4
TRIFORINE
Appendix B, Part 3
TRIHEXYPHENIDYL
cross reference: BENZHEXOL
Schedule 4
TRIISOPROPANOLAMINE LAURYL ETHER SULFATE
Schedule 5
Appendix E, Part 2
Appendix F, Part 3
TRILOSTANE
Schedule 4
TRIMEPERIDINE

INDEX
Schedule 9
TRIMEPRAZINE
cross reference: ALIMEMAZINE
TRIMETAPHAN
Schedule 4
TRIMETHOPRIM
Schedule 4
3,4,5-TRIMETHOXY- α –METHYLPHENYLETHYLAMINE
cross reference: TMA
Schedule 9
3,4,5-TRIMETHOXYPHENETHYLAMINE
cross reference: MESCALINE, METHOXYPHENAMINE, METHOXY-
PHENYLETHYLAMINE
Schedule 9
1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE
Schedule 9
TRIMIPRAMINE
Schedule 4
Appendix K
TRIMUSTINE
Schedule 4
TRINEXAPAC-ETHYL
Schedule 5
TRINITROPHENOL
Schedule 6
Schedule 4
3,6,9-TRIOXAUNDECANEDIOIC ACID
Schedule 5
Appendix F, Part 3

INDEX
TRIOXYSALEN
Schedule 4
TRIPARANOL
Schedule 10
TRIPELENNAMINE
Schedule 4
TRIPLE ANTIGEN VACCINE

cross reference: DIPHTHERIA TOXOID, PERTUSSIS ANTIGEN, TETANUS TOXOID
Schedule 4
TRIPROLIDINE
Schedule 4
Schedule 3
Schedule 2
Appendix K
TRIPTORELIN
Schedule 4
TRISODIUM NITRILOTRIACETATE
Schedule 6
TRITICONAZOLE
Schedule 5
TROGLITAZONE
Schedule 4
TROLAMINE
Schedule 5
Schedule 4
Appendix E, Part 2
Appendix F, Part 3
TROMETAMOL
Schedule 4

INDEX
TROPICAMIDE
Schedule 4
TROPISETRON
Schedule 4
TROVAFLOXACIN
Schedule 4
TROXIDONE
Schedule 4
TRYPTOPHAN
Schedule 4
TUAMINOHEPTANE
Schedule 2
TUCATINIB
Schedule 4
TUBERCULIN
Schedule 4
TUBOCURARINE
Schedule 4
TULATHROMYCIN
Schedule 4
TULOBUTEROL
Schedule 4
TURPENTINE OIL
cross reference: OIL OF TURPENTINE
Schedule 5
Appendix E, Part 2

INDEX
TUSSILAGO FARFARA
cross reference: COLTSFOOT
Schedule 10
TYLOSIN
Schedule 4
TYMAZOLINE
Schedule 4
Appendix F, Part 3
TYPHOID VACCINE
Schedule 4
ULIPRISTAL
Schedule 4
Schedule 3
Appendix H
ULOCLADIUM OUDEMANSII
Appendix B, Part 3
UMECLIDINIUM
Schedule 4
UNIFIRAM
Schedule 4
UNOPROSTONE
Schedule 4
UPADACITINIB
Schedule 4
URACIL
Schedule 4

INDEX
URAPIDIL
Schedule 4
UREA
Appendix B, Part 3
URETHANE
Schedule 4
UROFOLLITROPIN
cross reference: FOLLICLE-STIMULATING HORMONE, HUMAN
Schedule 4
Appendix D, Item 1
UROKINASE
Schedule 4
URSODEOXYCHOLIC ACID
Schedule 4
USTEKINUMAB
Schedule 4
VACCINES
Schedule 4
VACCINES – PLASMID DNA

cross reference: PLASMID DNA (rE. coli DH5α pINGhT)
Schedule 4
VACCINIA VIRUS VACCINE
Schedule 4
VALACICLOVIR
Schedule 4
VALDECOXIB

INDEX
Schedule 4
VALGANCICLOVIR
Schedule 4
VALNOCTAMIDE
Schedule 4
VALPROIC ACID
Schedule 4
VALSARTAN
Schedule 4
VAMIDOTHION
Schedule 6
VANCOMYCIN
Schedule 4
VANDETANIB
Schedule 4
VARDENAFIL
Schedule 4
VARENICLINE
Schedule 4
VARICELLA VACCINE
Schedule 4
VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN (RECOMBINANT)

cross reference: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
ANTIGEN
VASOPRESSIN
Schedule 4
VECURONIUM

INDEX
Schedule 4
VEDAPROFEN
Schedule 4
VEDOLIZUMAB
Schedule 4
VELAGLUCERASE ALFA
Schedule 4
VELPATASVIR
Schedule 4
VEMURAFENIB
Schedule 4
VENETOCLAX
Schedule 4
VENLAFAXINE
Schedule 4
VERAPAMIL
Schedule 4
VERATRUM
Schedule 4
VERNAKALANT
Schedule 4
VERNOLATE
Schedule 5
VERTEPORFIN
Schedule 4
VETIVER OIL

INDEX
Appendix B, Part 3
VIDARABINE
Schedule 4
VIGABATRIN
Schedule 4
VILANTEROL
Schedule 4
VILDAGLIPTIN
Schedule 4
VILOXAZINE
Schedule 4
VINBLASTINE
Schedule 4
VINCAMINE
Schedule 4
VINCLOZOLIN
Schedule 6
Appendix F, Part 3
VINCRISTINE
Schedule 4
VINDESINE
Schedule 4
VINFLUNINE
Schedule 4
VINORELBINE
Schedule 4

INDEX
VINYL ACETATE MONOMER
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
VINYL CHLORIDE
Schedule 7
Appendix J, Part 2
VINYL ETHER
Schedule 4
VIRGINIAMYCIN
Schedule 5
Schedule 4
VISMODEGIB
Schedule 4
VISNADINE
Schedule 4
VITAMIN A
Schedule 4
VITAMIN D
cross reference: COLECALCIFEROL, ERGOCALCIFEROL
Schedule 4
Schedule 3
Appendix H
VITAMIN K
cross reference: PHYTOMENADIONE
Appendix B, Part 3
VITREOUS ENAMELS
Appendix A
VORAPAXAR
Schedule 4

INDEX
VORETIGENE NEPARVOVEC
Schedule 4
VORICONAZOLE
Schedule 4
VORINOSTAT
Schedule 4
VORTIOXETINE
Schedule 4
VOXILAPREVIR
Schedule 4
WALLBOARD
cross reference: TIMBER
Appendix A
WARFARIN
Schedule 6
Schedule 5
Schedule 4
WRITING CORRECTION PENS
Appendix A
XAMOTEROL
Schedule 4
XANTHINOL NICOTINATE
Schedule 4
XANTHOPHYLL
cross reference: LUTEIN
Appendix B, Part 3

INDEX
XIMELAGATRAN
Schedule 4
XIPAMIDE
Schedule 4
XYLANASE derived from Aspergillus niger
Appendix B, Part 3
XYLAZINE
Schedule 4
XYLENE
cross reference: TOLUENE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
XYLOMETAZOLINE
Schedule 2
Appendix F, Part 3
YLANG YLANG OIL
Appendix B, Part 3
YOHIMBINE
cross reference: ASPIDOSPERMA QUEBRACHO
Schedule 4
(Z)-9-TRICOSENE
cross reference: TRICOSENE
Appendix B, Part 3
ZAFIRLUKAST
Schedule 4
ZALCITABINE

INDEX
Schedule 4
ZALEPLON
Schedule 4
ZANAMIVIR
Schedule 4
ZERANOL
Schedule 6
Schedule 4
ZETA-CYPERMETHRIN
Schedule 7
Schedule 6
ZIDOVUDINE
Schedule 4
ZILPATEROL
Schedule 4
ZIMELDINE
Schedule 4
ZINC BORATE
Schedule 6
ZINC CHLORIDE
Schedule 4
Appendix E, Part 2
ZINC COMPOUNDS
Schedule 4
ZINC LACTATE
Schedule 6
Appendix F, Part 3
ZINC NAPHTHENATE

INDEX
Appendix B, Part 3
ZINC para-PHENOLSULFONATE
Schedule 6
ZINC SULFATE
Schedule 6
Appendix E, Part 2
Appendix F, Part 3
ZINEB
cross reference: DITHIOCARBAMATES, MANCOZEB, PROPINEB, THIRAM
Schedule 5
ZIPRASIDONE
Schedule 4
Appendix K
ZIRAM
Schedule 7
Schedule 6
ZOLAZEPAM
Schedule 4
ZOLEDRONIC ACID
Schedule 4
ZOLMITRIPTAN
Schedule 4
Schedule 3
Appendix H
ZOLPIDEM
Schedule 4
Appendix K
ZONISAMIDE
Schedule 4
Appendix K

INDEX
ZOPICLONE
Schedule 4
Appendix K
ZOXAZOLAMINE
Schedule 4
ZUCLOPENTHIXOL
Schedule 4

Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or
will amend) the compiled law. The information includes commencement details for amending
laws and details of any application, saving or transitional provisions that are not included in this
compilation.
The amendment history in endnote 4 provides information about amendments at the provision
(generally section or equivalent) level. It also includes information about any provision of the
compiled law that has been repealed in accordance with a provision of the law.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment
to be made. If, despite the misdescription, the amendment can be given effect as intended, the
amendment is incorporated into the compiled law and the abbreviation “(md)” added to the
details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not
incorp)” is added to the details of the amendment included in the amendment history.

Endnote 2—Abbreviation key
ad = added or inserted o = order(s)

am = amended Ord = Ordinance
amdt = amendment orig = original
c = clause(s) par = paragraph(s)/subparagraph(s)
C[x] = Compilation No. x /sub-subparagraph(s)
Ch = Chapter(s) pres = present
def = definition(s) prev = previous
Dict = Dictionary (prev…) = previously
disallowed = disallowed by Parliament Pt = Part(s)
Div = Division(s) r = regulation(s)/rule(s)
exp = expires/expired or ceases/ceased to have reloc = relocated
effect renum = renumbered
F = Federal Register of Legislation rep = repealed
gaz = gazette rs = repealed and substituted
LA = Legislation Act 2003 s = section(s)/subsection(s)
LIA = Legislative Instruments Act 2003 Sch = Schedule(s)
(md) = misdescribed amendment can be given Sdiv = Subdivision(s)
effect SLI = Select Legislative Instrument
(md not incorp) = misdescribed amendment SR = Statutory Rules
cannot be given effect Sub-Ch = Sub-Chapter(s)
mod = modified/modification SubPt = Subpart(s)
No. = Number(s) underlining = whole or part not
commenced or to be commenced

Endnote 3—Legislation history
Name Registration Commencement Application,

saving and
transitional
provisions
Poisons Standard February 2021 24 Dec 2020 1 Feb 2021 

(F2020L01716)
Poisons Standard Amendment (Boric Acid and Picramic 25 Jan 2021 1 Feb 2021 
Acid) Instrument 2021 (F2021L00070)

Endnote 4—Amendment history
Provision affected How affected
s 2...................................................
rep LA s 48D
s 5...................................................
rep LA s 48C
Schedule 1
Part 4, Schedule 5...........................
am F2021L00070
Part 4, Schedule 6...........................
am F2021L00070
Part 5, Appendix E .........................
am F2021L00070
Part 5, Appendix F .........................
am F2021L00070
Index ..............................................
am F2021L00070
Schedule 2
Schedule 2 ......................................
rep LA s 48C

SUSMP Feb 21 F2021C00098

Uploaded by

Copyright:

Available Formats

SUSMP Feb 21 F2021C00098

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

SUSMP Feb 21 F2021C00098

Uploaded by

Copyright:

Available Formats

Poisons Standard February 2021

made under subsection 52D(2) of the

Therapeutic Goods Act 1989

Compilation date: 1 February 2021

Includes amendments up to: F2021L00070

Prepared by the Department of Health, Canberra

Authorised Version F2021C00098 registered 01/02/2021

If the operation of a provision or amendment of the compiled law is affected by an application,

Authorised Version F2021C00098 registered 01/02/2021

4 Current Poisons Standard

Poisons Standard February 2021 i

Compilation No. 1 Compilation date: 1/2/21

Authorised Version F2021C00098 registered 01/02/2021

Poisons Standard February 2021 ii

Compilation No. 1 Compilation date: 1/2/21

Authorised Version F2021C00098 registered 01/02/2021

Poisons Standard February 2021 iii

Compilation No. 1 Compilation date: 1/2/21

Authorised Version F2021C00098 registered 01/02/2021

Further inquiries in relation to this document should be directed to:

Media Liaison Unit

Poisons Standard February 2021 iv

Compilation No. 1 Compilation date: 1/2/21

Authorised Version F2021C00098 registered 01/02/2021

CONTROL ON MEDICINES AND POISONS _______________________ 11

SECTION ONE LABELS __________________________________________ 11

SECTION TWO CONTAINERS _____________________________________ 23

SECTION THREE STORAGE ______________________________________ 29

SECTION FOUR DISPOSAL _________________________________________ 30

SECTION FIVE RECORD KEEPING ________________________________ 30

SECTION SIX SALE, SUPPLY, POSSESSION, or USE __________________ 31

SECTION SEVEN/Appendix I PAINT OR TINTERS ____________________ 32

MISCELLANEOUS REGULATIONS ______________________________ 34

SECTION ONE ADVERTISING ____________________________________ 34

SECTION TWO SALE OR SUPPLY _________________________________ 34

SECTION THREE STORAGE ______________________________________ 35

THE SCHEDULES ______________________________________________36

SCHEDULE 5 ____________________________________________________ 165

Poisons Standard February 2021 v

Compilation No. 1 Compilation date: 1/2/21

Authorised Version F2021C00098 registered 01/02/2021

SCHEDULE 7 ____________________________________________________ 259

SCHEDULE 8 ____________________________________________________ 273

SCHEDULE 9 ____________________________________________________ 278

SCHEDULE 10 ___________________________________________________ 286

THE APPENDICES _____________________________________________292

APPENDIX A – GENERAL EXEMPTIONS ____________________________ 292

APPENDIX B – SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL

APPENDIX C (see SCHEDULE 10) __________________________________ 316

APPENDIX D – ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF

APPENDIX E – FIRST AID INSTRUCTIONS FOR POISONS _____________ 324

APPENDIX F – WARNING STATEMENTS AND GENERAL SAFETY

APPENDIX G – DILUTE PREPARATIONS____________________________ 393

APPENDIX H – SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED396

APPENDIX I _____________________________________________________ 399

APPENDIX J – SCHEDULE 7 POISONS REQUIRING ADDITIONAL

APPENDIX K – DRUGS REQUIRED TO BE LABELLED WITH A SEDATION

APPENDIX L – REQUIREMENTS FOR DISPENSING LABELS FOR HUMAN

APPENDIX M – ADDITIONAL CONTROLS OR SUPPLY REQUIREMENTS

Endnotes ______________________________________________________ 769